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Electronic Nicotine 
Delivery Systems (ENDS) 
are addictive and not 
without harm.
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ENDS should be 
strictly regulated for 
maximum protection 
of public health.
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Children and adolescents 
who use ENDS can double 
their risk of smoking 
cigarettes.







Monitor tobacco use and prevention policies
Protect people from tobacco smoke
Offer help to quit tobacco use
Warn about the dangers of tobacco
Enforce bans on tobacco advertising, promotion and sponsorship
Raise taxes on tobacco
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WHO report on the global tobacco epidemic, 2021: 
Addressing new and emerging products is the eighth 
in a series of WHO reports that tracks the status of 
the tobacco epidemic and interventions to combat it.
Tobacco control efforts 
must remain focused on 
reducing tobacco use 
and avoid distractions 
created by tobacco and 
related industries.
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“Despite the challenges of the COVID-19 pandemic, 
over the past year many countries have persisted in 
advancing tobacco control as a key health priority.”
Dr Tedros Adhanom Ghebreyesus, Director-General, World Health Organization
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“We must remain vigilant to the challenges posed 
by new products such as electronic nicotine delivery 
systems and heated tobacco products.”
5.3 billion people are now covered by at least one MPOWER 
measure at the highest level of achievement 
Since the last WHO report on the global 
tobacco epidemic in 2019, the world 
has changed immeasurably. Despite the 
challenges of the COVID-19 pandemic, 
over the past year many countries have 
persisted in advancing tobacco control 
as a key health priority. The progress 
presented in this report is testament to 
that perseverance. 
Tobacco-attributable diseases include 
lung and heart diseases, chronic 
respiratory diseases, cancers, and 
diabetes – all of which may increase 
the severity of COVID-19. Protecting 
populations from the harms of tobacco 
has never been more important. 
The implementation of the WHO 
Framework Convention on Tobacco 
Control is a recognized global 
development priority with a dedicated 
target in the Sustainable Development 
Goals. Reducing tobacco use is 
critical to reducing the burden of 
noncommunicable diseases, which 
account for 71% of deaths globally.
Today, 75% of countries and 5.3 
billion people are protected by at 
least one tobacco control measure at 
best-practice level and 50% by at least 
two measures. And globally, smoking 
prevalence among people aged over 15 
years has fallen from 22.7% to 17.5%.
This is encouraging progress. At the 
same time, we must remain vigilant to 
the challenges posed by new products 
such as electronic nicotine delivery 
systems and heated tobacco products. 
The WHO report on the global tobacco 
epidemic 2021: addressing new 
and emerging products highlights 
how these products are promoted 
aggressively as “safer” or “smoke-free” 
alternatives to conventional cigarettes. 
Although their full risks remain 
unknown, the impact of nicotine 
delivery devices is clear. 
While framing these products as a 
contribution to global tobacco control, 
the tobacco and related industries 
employ the same old marketing 
tactics to promote new tools to hook 
children on nicotine and circumvent 
tobacco legislation. At the same time, 
they continue to fight measures and 
legislation designed to protect people 
from the many harms of tobacco across  
the globe. 
Tobacco is one of the world’s largest 
preventable causes of premature 
death, accounting for more than 8 
million deaths and costing the global 
economy US$ 1.4 trillion each year. 
This disproportionately affects people 
in low- and middle-income countries. 
Political leaders must stand up to the 
powerful vested interests that profit 
from tobacco. 
All countries have the obligation to 
protect the health of their people by 
beating back the scourge of tobacco, 
whatever form it takes. 
Dr Tedros Adhanom Ghebreyesus
Director-General 
World Health Organization
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“Fighting tobacco use is truly a team effort, and 
as far as we have come, much more progress is 
still needed.” 
Michael R. Bloomberg, WHO Global Ambassador for Noncommunicable Diseases and Injuries 
Founder of Bloomberg Philanthropies
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Despite a global pandemic, 24 countries have now adopted one 
or more best-practice MPOWER measures since the last report 
Since the first WHO report on the 
global tobacco epidemic was published 
13 years ago, it has served as a 
critical resource in the fight to save 
lives from tobacco use. The data it 
contains help leaders identify policies 
that work, and it helps the public to 
hold elected officials accountable 
for protecting people’s health. And 
while the last year has been marked 
by more promising steps forward, 
the COVID-19 pandemic has also 
underlined the urgent need to do more, 
faster, to end the tobacco epidemic. 
Evidence shows that cigarette smokers 
are more likely to be hospitalized 
or die from COVID-19, a respiratory 
illness that attacks the lungs. The 
virus poses heightened risks to people 
with noncommunicable diseases like 
heart disease, cancer, and high blood 
pressure – all of which are associated 
with smoking. 
Tobacco is the single biggest cause of 
preventable death, killing 8.7 million 
people each year and leading tens of 
millions more to suffer from avoidable 
illnesses. The good news is: We know 
how to tackle this killer. 
Since WHO launched the first report 
13 years ago, cigarette sales had been 
steadily climbing for decades, and 
in most of the world, there were no 
measures in place to protect the public. 
Driven by the spread of MPOWER 
tobacco control measures, global 
cigarette sales began declining in 2012 
and have continued ever since, even 
as the global population has grown. 
MPOWER measures have saved more 
than 37 million lives, a number that 
increases every day, as more smokers 
quit, more people decide never to start 
using tobacco, and more of the public 
is protected from the deadly effects of 
second-hand smoke. 
Today, 75% of all countries – that 
together are home to more than 5.3 
billion people – have at least one 
MPOWER measure in place. Half of all 
countries have two or more. Over the 
past 2 years, despite the challenges 
of the pandemic, five more countries 
passed national smoke-free policies and 
eight more countries began requiring 
health warnings on tobacco packaging. 
But we are far from victory. More than 
1 billion people around the world still 
smoke. And as cigarette sales have 
fallen, tobacco companies have been 
aggressively marketing new products 
– like e-cigarettes and heated-tobacco 
products – and lobbying governments 
to limit their regulation. Their goal is 
simple: to hook another generation on 
nicotine. We cannot let that happen. 
This report brings a special focus to 
these new products and what we can 
do to protect kids from them. Around 
80 countries have taken steps to 
address the dangers of e-cigarettes,  
but they still remain unregulated in 
much of the world. 
This report is a call to action and an 
outline for building on the progress 
we have made. Fighting tobacco use 
is truly a team effort, and as far as we 
have come, much more progress is still 
needed. Together, we can keep pushing 
forward, and save many more lives. 
Michael R. Bloomberg
WHO Global Ambassador for 
Noncommunicable Diseases and Injuries 
Founder, Bloomberg Philanthropies
“As cigarette sales have fallen, tobacco companies have been 
aggressively marketing new products – like e-cigarettes and 
heated-tobacco products – and lobby governments to limit their 
regulation. Their goal is simple: to hook another generation on 
nicotine. We cannot let that happen.” 
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“Tobacco control is an integral part of the 
development agenda, contributing not only to 
Sustainable Development Goal 3 (target 3.a calls 
for strengthening implementation of the WHO 
FCTC in all countries) but also to the achievement 
of other targets, directly or indirectly impacted  
by tobacco growth and use.”
Dr Adriana Blanco Marquizo, Head of the WHO FCTC Secretariat
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In 2020 the WHO FCTC and the Protocol both increased  
the number of Parties 
The Secretariat of the WHO Framework 
Convention on Tobacco Control 
(WHO FCTC) and the Protocol to 
Eliminate Illicit Trade in Tobacco 
Products (Protocol) welcome the 
publication of the WHO report on 
the global tobacco epidemic, 2021. 
The report is published during one 
of the worst health emergencies in 
history: the COVID-19 pandemic.  
The pandemic has not only cost  
millions of lives globally, but has 
profoundly affected economies, 
exposed and exacerbated inequalities 
among and within countries, and 
potentially reversed the gains made  
by decades-long efforts to improve 
human health and well-being,  
especially for vulnerable populations. 
The data provided in this report 
demonstrate some good news: a 
growing percentage of the world’s 
population is now covered by at  
least one or two fully implemented  
WHO FCTC measures, and in 2020  
the WHO FCTC increased its number  
of Parties to 182 and the Protocol  
to 62.
Unfortunately, the endless interference 
of the tobacco industry has also grown. 
During the COVID-19 pandemic, the 
industry (and those who work to 
further its interests) have increased 
their “corporate social responsibility” 
efforts, offering to help governments 
save the lives of those worst-affected 
by COVID-19: these are often the 
same people that the tobacco 
industry helped put into danger in 
the first place. Smokers have worse 
outcomes from COVID-19, as have 
all people with noncommunicable 
diseases, for which tobacco is a 
common and major risk factor. 
While the advances shown in the  
report are encouraging, there is a  
need to accelerate implementation 
of the WHO FCTC and its Protocol. 
Tobacco control is an integral 
part of the development agenda, 
contributing not only to Sustainable 
Development Goal 3 (Target 3.a calls 
for strengthening implementation of 
the WHO FCTC in all countries) but  
also to the achievement of other 
targets, directly or indirectly impacted 
by tobacco growth and use. 
And while pandemics caused by  
viruses are difficult to prevent, the 
stealthy and ever-growing pandemic 
caused by tobacco is wholly and  
morally preventable. Unlike the 
COVID-19 pandemic, where scientists 
worked around the clock to find 
medicines to treat it and vaccines  
to prevent it, the solution for the 
“tobacco pandemic” is in plain sight: 
WHO FCTC and its Protocol.
Finally, new challenges lie ahead. 
Electronic nicotine delivery systems 
– also known as e-cigarettes – and 
novel tobacco products are promoted 
as healthier alternatives to smoking 
by their manufacturers (mainly the 
tobacco industry) and their supporters. 
Until independent research shows 
the real risk profile of these products, 
governments should be cautious. 
Science-based evidence, not marketing, 
should guide their actions. 
I call on governments who are party to 
the WHO FCTC and its Protocol to pull 
together in their efforts to strengthen 
implementation, and to build a new 
future for their populations, where 
not only COVID-19 has been defeated, 
but also the harms caused by tobacco 
use. There has never been a more 
pressing time to support populations 
to quit tobacco use, and to raise taxes 
on tobacco products – not only to 
curb tobacco consumption, but also to 
raise much-needed revenues to fund 
pandemic-recovery efforts.
Dr Adriana Blanco Marquizo 
Head of the WHO FCTC Secretariat
“Until independent research shows the real risk profile of 
[ENDS], governments should be cautious. Science-based 
evidence, not marketing, should guide their actions.”
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Since the publication of the first WHO 
report on the global tobacco epidemic 
in 2008, the steady progress made by 
countries on tobacco control has been 
demonstrated in biennial updates, of 
which this report is the latest. Despite 
the exceptional challenges brought on 
by the COVID-19 pandemic in 2020, 
that progress continues. Latest results 
show that, as of 2020, more than 5.3 
billion people – 69% of the world’s 
population – are covered by at least 
one MPOWER measure at the highest 
level. Inspiringly, 98 countries are 
now covered by at least two adopted 
MPOWER policies.
The number of countries adopting 
MPOWER measures continues to rise 
year-on-year. The number of countries 
with at least one MPOWER measure 
in place has tripled since 2007 – from 
44 to 146 countries – and since the 
last WHO report on the global tobacco 
epidemic, the number of countries with 
at least two MPOWER policies in place 
at the highest level of achievement 
has increased from 84 to 98 (just 
over half of all countries). In addition, 
the number of people now living in 
countries with at least two MPOWER 
measures in place rose from 3.5 billion 
in 2018 to 4.4 billion in 2020 – up from 
45% of the world’s population to 56% 
in just 2 years. 
Of the 49 countries that have not 
yet adopted any MPOWER measure 
at the highest level, 38 have 
provisions in place that are just one 
level below best-practice for one 
or more MPOWER measures.
Progress has been steady since the 
last report, with seven countries that 
previously had no best-practice measures 
in place (Cook Islands, Côte d’Ivoire, 
Ethiopia, Iraq, Morocco, Paraguay, and 
Tonga) taking action to reach the highest 
level on one or more measures. 
SUMMARY
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Total population: 7.8 billion Total number of countries: 195
Three quarters of countries and 5.3 billion 
people are now covered by at least one MPOWER 
measure at the highest level of achievement.
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Total population: 7.8 billion Total number of countries: 195
More than half the world 
is now covered by two 
MPOWER measures 
at the highest level of 
achievement
Of the 98 countries now covered 
by at least two measures, 31 have 
three measures at the highest level 
of achievement, and five countries 
have four measures at the highest 
level of achievement (Jordan, Ireland, 
Madagascar, New Zealand, Spain). 
Meanwhile, the number of countries 
that have adopted all MPOWER 
measures at best-practice level  
remains at two, Brazil and Turkey.
ENDS need to be regulated
This is the first time that the WHO 
report on the global tobacco epidemic 
has included data on electronic nicotine 
delivery systems (ENDS), and it reveals 
that a total of 111 countries regulate 
ENDS in some way. Thirty two of these 
countries (covering 2.4 billion people) 
ban the sale of ENDS, and the other 79 
countries have adopted one or more 
legislative measures to regulate ENDS, 
covering 3.2 billion people. 
Of the countries that have banned 
the sale of ENDS, 18 are middle-
income countries, nine are high-
income countries and the remaining 
five are low-income countries. The 
current regulatory options taken by 
79 countries include a wide range 
of measures with no common 
approach to address these products. 
Eighty-four countries still have no 
bans or regulations to address 
ENDS, leaving them particularly 
vulnerable to the activities of the 
tobacco and related industries.
Using ENDS in public places where 
smoking is banned may re-normalize 
smoking in public. However, only 
30 countries completely ban the use 
of ENDS in all indoor public places, 
workplaces and public transport. 
Only eight countries mandate the 
appearance of large graphic health 
warnings on ENDS packaging. 
Twenty-two countries completely 
ban the advertising, promotion 
and sponsorship of ENDS devices, 
e-liquids or both (only 15 countries 
have adopted advertising, sponsorship 
and promotion bans on both).
Monitoring ENDS use among children 
and adolescents, as well as adults, 
through nationally representative 
surveys is increasingly conducted 
globally. Eighty-seven countries have 
now collected data on the prevalence 
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of ENDS use among adolescents and 
56 countries have collected data on the 
prevalence of ENDS use among adults. 
Of the 86 countries where data 
are available on ENDS taxation, 
more than one-third do not impose 
any excise tax on e-liquids. Where 
taxes have been applied, tax rates 
are generally low, with only three 
countries taxing ENDS e-liquids at 
75% or more of the retail price.
Age restrictions to ENDS sale 
and purchase are applied in only 
42% of countries where ENDS 
are not banned, and regulations 
applied on ENDS flavours can be 
found in only nine countries.
Progress in tobacco control 
continues despite the global 
COVID-19 pandemic
Countries continued to make progress 
despite the COVID-19 pandemic. In 
particular, health warning laws and 
regulations at the highest level of 
achievement have now been adopted 
by 101 countries. This means that 4.7 
billion people (or 60% of the world’s 
population) are now protected by large 
graphic pack warnings featuring all 
recommended characteristics, making 
it the MPOWER measure with both 
the highest population coverage and 
the most countries covered. It is also 
important to note that by the end 
of 2020, 17 countries had adopted 
legislation mandating plain packaging 
of tobacco products and had issued 
regulations with implementation 
deadlines. A handful of other countries 
have required plain packaging by 
law but have not yet issued the 
implementing rules.
While cessation measures have made 
progress during most years since 2007, 
cessation service policies remain scarce, 
with only 26 countries providing these 
services at best-practice level. Although 
this measure is adopted by the fewest 
countries, those countries nevertheless 
contain 2.5 billion people, or one third 
of the world’s population, making it 
the second most adopted MPOWER 
measure in terms of population covered. 
Complete smoke-free indoor public 
places, workplaces and public transport 
now cover 1.8 billion people living in 67 
countries, making it the second most 
adopted MPOWER measure in terms  
of countries covered.
Although tobacco advertising, 
promotion and sponsorship (TAPS)  
bans remain an under-adopted 
measure, 1.6 billion people in 
57 countries are protected by 
comprehensive bans on TAPS. Low- 
and middle-income countries have 
made particularly strong progress in 
TAPS bans. Twelve countries that have 
adopted comprehensive TAPS  
bans are low-income countries 
(41% of all low-income countries), 
31 are middle-income countries 
(30% of middle-income countries) 
and 14 are high-income (23% 
of high-income countries).
Monitoring tobacco use, unfortunately, 
was significantly affected by the 
COVID-19 pandemic. Data collection 
efforts were hindered in most countries 
during 2020, as was the release of 
results for surveys completed during 
2018 and 2019. 
Raising prices through taxation is the 
most effective way to reduce tobacco 
use and yet it remains the policy with 
the lowest population coverage. While 
a large increase in population coverage 
was observed between 2016 and 2018 
(from 8% in 2016 to 13% in 2018), the 
proportion of the world’s population 
protected by taxes at best-practice level 
has since remained at 13%.
Countries in all regions 
are adopting MPOWER 
measures
Each MPOWER measure has been 
adopted at best-practice level by new 
countries since the last report:  
■	 Five countries (Bolivia (Plurinational 
State of), Ethiopia, Jordan, Paraguay, 
Saint Lucia) newly adopted complete 
smoke-free laws covering all indoor 
public places, workplaces and public 
transport.
■	 Five countries (Austria, Cook 
Islands, Jordan, Philippines, Tonga) 
advanced to best-practice level with 
their tobacco use cessation services. 
However, during the same period, 
three other countries dropped from 
the highest group, resulting in a net 
gain of only two countries.
■	 Eight countries (Ethiopia, Gambia, 
Mauritania, Montenegro, Niger, 
Nigeria, Qatar, United States of 
America) adopted large graphic 
pack warnings. 
■	 Five countries (Côte d’Ivoire, 
Ethiopia, Iraq, Jordan, Venezuela 
(Bolivarian Republic of)) 
introduced comprehensive 
bans on tobacco advertising, 
promotion and sponsorship, 
including at point-of-sale.
■	 Six countries (Denmark, Georgia, 
Morocco, Netherlands, Portugal, Sri 
Lanka) moved to the best-practice 
group by levying taxes that comprise 
at least 75% of retail prices. 
4.4 billion people, in 98 countries, are covered 
by at least two MPOWER measures at the 
highest level of achievement.
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Some countries have  
yet to adopt a single 
MPOWER measure
All countries can adopt and implement 
comprehensive tobacco control 
measures to prevent the immense 
burden caused by tobacco use and 
exposure to second-hand smoke. Yet,  
in 2020, 49 countries had not yet 
adopted a single MPOWER measure at 
best-practice level, leaving 2.4 billion 
people vulnerable to the tobacco 
industry’s tactics and marketing. 
Furthermore, the pace of progress 
of certain MPOWER measures is 
slower than others. The adoption 
of complete TAPS bans, the 
adoption of comprehensive 
cessation services and the raising 
of tobacco taxes to sufficiently 
high levels must be accelerated.
No known data, or 
no recent data or 
data that are not 

















































































































































Refer to Technical 
Note I for category 
definitions.
Note: Brunei Darussalam 
is excluded from R 
because no retail sale of 
cigarettes or renewal of 
cigarette import licenses 
have been reported 
since May 2014.
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There are 49 countries that have yet to adopt a single MPOWER 
measure at the highest level of achievement.
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Introduction to the WHO 
FCTC and the Protocol 
The WHO Framework Convention on 
Tobacco Control (WHO FCTC) is an 
evidence-based treaty that reaffirms 
the right of all people to the highest 
standard of health. Adopted in 2003 
by WHO Member States, it provides a 
framework for tobacco control measures 
to be implemented by its Parties in order 
to reduce continually and substantially 
the prevalence of tobacco use and the 
exposure to tobacco smoke. It is among 
the most widely embraced treaties in 
the UN’s history, with 182 Parties that 
together comprise more than 90% of 
the world’s population. Since its entry  
into force in 2005, the WHO FCTC has 
been an unambiguous success and 
remains the organizing principle for 
progress and cooperation on tobacco 
control locally, nationally, regionally,  
and globally. 
In becoming a Party to the WHO 
FCTC, countries assume mutually 
reinforcing obligations to reduce 
the demand for, and supply of, 
tobacco products. The MPOWER 
technical package – developed by 
WHO – helps countries implement 
most of these demand-reduction 
measures by providing a measurable 
gold standard for their achievement 
and monitoring progress towards 
it. While the MPOWER package’s 
cost-effectiveness justifies this focus, 
supply-reduction measures are also 
needed for a comprehensive, synergistic 
approach and for supporting the 
political economy of tobacco control.
The Convention also contains general 
obligations that are crucial to these 
demand- and supply-reduction 
measures (and especially those in the 
MPOWER package). Article 5 provides 
the basis for the governance of 
tobacco control, with Paragraph 1 and 
Paragraph 2 calling for a multisectoral, 
whole-of-government approach 
and the development of appropriate 
national legislation and strategies. 
Paragraph 3 of Article 5, together with 
the guidelines for implementation of 
Article 5.3, provides the basis  
for protecting tobacco control public 
health policies from the influence of  
the tobacco industry and those who 
work to further its interest. Those 
measures, together with Article 19  
on tobacco industry liability, make the 
Convention innovative in its ability to 
target an industry known for using 
deceptive means to prioritize profits 
over public health. 
The WHO FCTC governing body, the 
biennial Conference of the Parties 
(COP), is the leading global forum for 
discussing and reaching consensus 
on Convention implementation and 
any emerging tobacco control issues, 
and is the sole body for authoritative 
interpretations of the Convention’s 
provisions. In 2012, at the Fifth Session 
of the COP in the Republic of Korea, 
Parties adopted a new international 
treaty: the Protocol to Eliminate Illicit 
Trade in Tobacco Products. The Protocol 
builds on Article 15 of the Convention 
that addresses illicit trade in tobacco 
products, but the complexity of 
transboundary cooperation to prevent 
illicit trade required a more extensive 
and finely tuned set of obligations. 
Illicit trade in tobacco products poses 
a significant threat to key demand-
reduction measures, in particular price 
measures and health warnings. 
The Protocol came into force in 
September 2018 and currently counts 
63 Parties as of 25 May 2021. It aims 
at the elimination of all forms of 
illicit trade in tobacco products and 
its obligations encompass tools for 
preventing illicit trade, and numerous 
mechanisms for promoting cooperation 
between countries. Parties to the 
Protocol assume substantive obligations 
to: control the supply chain for tobacco 
products; make it an offence to have 
any involvement with illicit trade; and 
cooperate with other countries in the 
prevention of illicit trade. The Protocol 
also has its own governing body, the 
Meeting of the Parties (MOP), which, 
like the COP, convenes biennially. 
The WHO FCTC also mandated the COP 
to establish a Convention Secretariat 
to provide policy support to Parties 
in implementing the Convention, as 
well as to support the functioning of 
the COP and other subsidiary body 
meetings. The Protocol established 
that the Convention Secretariat is also 
its Secretariat, with similar functions. 
WHO cooperates with the Convention 
Secretariat to support Parties to the 
WHO FCTC and to the Protocol in their 
substantive and reporting requirements, 
and also advocates to increase the 
number of Parties to the WHO FCTC 
and the Protocol.
THE WHO FRAMEWORK CONVENTION  
ON TOBACCO CONTROL AND THE 
PROTOCOL TO ELIMINATE ILLICIT  
TRADE IN TOBACCO PRODUCTS 
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Demand-reduction 
measures
Article 6: Price and tax measures to reduce the demand for tobacco 
Article 8:  Protection from exposure to tobacco smoke 
Article 9:  Regulation of the contents of tobacco products
Article 10:  Regulation of tobacco product disclosures
Article 11: Packaging and labelling of tobacco products
Article 12:  Education, communication, training and public awareness
Article 13:  Tobacco advertising, promotion and sponsorship
Article 14: Demand-reduction measures concerning tobacco dependence and cessation
Supply-reduction 
measures
Article 15: Illicit trade in tobacco products
Article 16: Sales to and by minors
Article 17: Provision of support for economically viable alternative activities
General obligations Article 4: Guiding principles
Article 5: General obligations 
■	 5.1: Comprehensive multisectoral national tobacco control strategies,  
 plans and programmes
■	 5.2: National coordinating mechanism or tobacco control focal point
■	 5.3: Protecting tobacco control policies from the tobacco industry’s  
 commercial and vested interests
Other measures Article 18: Protection of the environment and the health of persons
Article 19: Liability
Article 20: Research, surveillance and exchange of information
Article 21: Reporting and exchange of information
Article 22: Cooperation in the scientific, technical and legal fields and provisions of 
related expertise
KEY WHO FCTC PROVISIONS
The Conference of the Parties has provided 
guidance on the regulation of novel and emerging 
tobacco products and nicotine products since 2008.
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COVID-19’s effect on 
WHO FCTC / Protocol 
Implementation 
The devastation caused by the COVID-19 
pandemic starkly illustrates the need for 
accelerated implementation of the WHO 
FCTC and the Protocol, with a particular 
focus on scaling up achievement using 
the MPOWER technical package. There is 
irrefutable evidence of a deadly interplay 
between COVID-19 and tobacco use, 
both past and present: those infected 
with the virus and who are tobacco 
users have suffered more severe disease 
progression than non-tobacco users; 
the vulnerability of health systems has 
been exacerbated; and tobacco use 
has increased the pandemic’s human 
and economic costs (1–6). Accordingly, 
global and national efforts to build back 
better will be incomplete unless the 
“tobacco pandemic”, alongside other 
vulnerabilities underlying the crisis,  
are addressed. 
More broadly, the COVID-19 pandemic 
and accompanying global economic 
recession have disrupted political 
agendas. This has, in certain cases, 
come at the expense of activities such 
as tobacco control, that may appear 
less pressing or uneconomical. This has 
challenged progress on implementation 
of the WHO FCTC and the Protocol. 
Most strikingly, the Ninth Session of the 
COP (COP9) and the Second Session of 
the MOP (MOP2), originally scheduled 
for November 2020, were postponed 
until November 2021. 
But the COVID-19 pandemic has also 
provided opportunities for advancing 
tobacco control measures. For 
example, 17 countries in the Eastern 
Mediterranean Region have banned the 
use of waterpipes (shishas) in public 
places, and South Africa temporarily 
banned tobacco sales under a general 
ban on the sale of “non-essential” 
products during the country’s pandemic 
response. Similarly, other countries 
such as South Africa and the Russian 
Federation have raised tobacco taxes in 
an effort to save lives while mobilizing 
revenue to fight the pandemic and its 
associated economic crisis.
The tobacco industry has taken 
advantage of the situation by muddying 
the science on tobacco’s link with 
COVID-19 and positioning itself as an 
economic and development partner 
for national COVID-19 recovery efforts. 
Many of the major tobacco industry 
actors have – under the banner of 
so-called corporate social responsibility 
– used a small portion of their immense 
resources on heavily publicized COVID-
19-related charity programmes. As 
the Guidelines for implementation of 
Article 13 of the WHO FCTC note, these 
activities are a form of sponsorship.
The COP9 (8–13 November 2021) 
and MOP2 (15–18 November 2021)
The COVID-19 pandemic means that 
the forthcoming sessions of the COP 
and MOP will be held virtually. At 
the sessions, delegates will note the 
implementation progress attained 
and identify challenges and possible 
opportunities for advancing and 
strengthening the comprehensive 
implementation of the respective 
treaties. Parties will adopt new 
decisions to guide the future direction 
of implementation for both treaties by, 
inter alia, establishing new subsidiary 
bodies, clarifying the interpretation 
of obligations and requesting the 
Convention Secretariat and/or inviting 
WHO to undertake some tasks and 
report on specific matters. 
After nearly 2 years of pandemic-
related disruption to the tobacco 
control agenda and despite an abridged 
Provisional Agenda, both COP9 and 
MOP2 will feature important items 
for consideration, such as a proposed 
investment fund for the WHO FCTC 
and the Protocol – an innovative 
financing mechanism that aims to 
provide much-needed resources for  
the implementation of both treaties. 
A highlight of the MOP2 Provisional 
Agenda is the consideration of a report 
from a subsidiary body established by 
MOP1 on tracking and tracing systems 
for tobacco products. Under Article 
8 of the Protocol, Parties agreed to 
establish a global tracking and tracing 
regime by September 2023. This global 
regime will comprise national and 
regional systems intended to ensure 
that Parties can secure the supply 
chain of tobacco products, and a 
global information-sharing focal point 
located at the Convention Secretariat 
that will enable Parties to exchange 
information in order to better tackle 
illicit trade. The MOP’s deliberation on 
this matter will be crucial for guiding 
and promoting timely implementation 
of this technically complex obligation.
Novel and emerging 
tobacco products and 
nicotine products 
The COP has provided guidance on 
the regulation of novel and emerging 
tobacco products and nicotine products 
since 2008, with a particular focus 
on heated tobacco products (HTPs), 
electronic nicotine delivery systems 
(ENDS) and electronic non-nicotine 
delivery systems (ENNDS) (7). The 
COP has defined the landscape as 
follows. HTPs are tobacco products, 
which produce aerosols containing 
nicotine and other chemicals, by 
heating tobacco units; they are subject 
to the provisions of the WHO FCTC. 
By contrast, ENDS and ENNDS do not 
contain tobacco and instead vaporize 
a solution composed of numerous 
compounds, which include nicotine 
in the case of ENDS, or may not 
contain nicotine in the case of ENNDS. 
Regarding the latter products, COP6 
invited Parties “to consider prohibiting 
or regulating ENDS/ENNDS, including as 
tobacco products, medicinal products, 
consumer products, or other categories, 
as appropriate, taking into account 
a high level of protection for human 
health”(8). At COP7, Parties were also 
invited to apply regulatory measures 
to prohibit or restrict the manufacture, 
import, distribution, presentation, 
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sale and use of ENDS/ENNDS, as 
appropriate (9). As noted in a WHO 
report submitted to COP8, the tobacco 
industry’s promotion of products in 
each category can be considered a 
response to declining sales of cigarettes 
in high-income countries (10).
Work on addressing ENDS  
at the COP to date
At COP3, the Convention Secretariat 
was requested to invite WHO to submit 
a report to COP4, identifying best 
practices in reporting to regulators 
on the contents, emissions, and 
product characteristics, including for 
electronic systems. Since then, multiple 
reports and decisions have addressed 
the matter.
The most relevant decisions are from 
COP6, which set out basic objectives 
that Parties were invited to pursue 
when addressing ENDS/ENNDS, 
including: (a) preventing initiation by 
non-smokers and youth with special 
attention to vulnerable groups; (b) 
minimizing as far as possible potential 
health risks to users and protecting 
non-users from exposure to emissions; 
(c) preventing unproven health claims 
being made about ENDS/ENNDS; 
and (d) protecting tobacco-control 
activities from all commercial and 
other vested interests related to these 
products, including interests of the 
tobacco industry. Parties were also 
invited to consider prohibiting or 
regulating ENDS/ENNDS, including as 
tobacco products, medicinal products, 
consumer products, or other categories 
as appropriate, taking into account 
a high level of protection for human 
health (8). 
This was followed, in 2016, by a 
COP7 decision inviting Parties to 
consider prohibiting or restricting the 
manufacture, import, distribution, 
presentation, sale and use of ENDS/
ENNDS, as appropriate to their national 
laws and public health objectives. Parties 
that have not totally banned those 
products were invited to follow a non-
exhaustive list of regulatory options for 
pursuing the objectives set out in the 
COP6 decision – provided in a report 
prepared by WHO – that were endorsed 
for consideration by the Parties (8). Such 
regulation entails the application of most 
of the WHO FCTC demand and supply 
reduction measures to ENDS/ENNDS, 
as well as the concerted application of 



















Decisions by the COP
The Secretariat and WHO 
are requested to report on 
Parties experience of ENDS
WHO is invited to identity 
options for controlling 
ENDS and examine the 
evidence-base on harms
Parties are invited to pursue 
certain objectives in their 
regulation of ENDS such as 
preventing initiation, minimizing 
health risks and preventing 
second-hand exposure
COP endorses the policy options 
set out in the WHO report and 
invites the Parties to consider 
applying these measures to 
prohibit or restrict presentation, 
sale and use of ENDS
Emerging regulatory gap 
on ENDS identified
The Secretariat and 
WHO identify 
divergence in regulatory 
approaches to ENDS
WHO sets out regulatory 
options and describes the 
evidence on ENDS as weak 
and characterized by 
uncertain as to their risk to 
health and cessation potential
WHO emphasizes the threat 
to health and tobacco control 
posed by ENDS and sets out 
a non-exhaustive list of 
options for pursuing the 
objectives detailed by COP-6
Progress report on the 
ENDS regulatory measures 
undertaken by Parties
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Work on addressing HTPs  
at the COP to date
Since their emergence, HTPs have been 
marketed with health and cessation 
claims that are not supported by 
independent, solid evidence (12). 
Cessation is defined in the Guidelines 
for implementation of Article 14 of the 
WHO FCTC as “the process of stopping 
the use of any tobacco product…” 
and it is, therefore, implausible to 
claim this may be done by switching 
to another tobacco product. In 2016, 
the COP7 requested the Convention 
Secretariat to invite WHO to report on 
specific questions related to HTPs at the 
subsequent session (13). 
Following this report, in 2018, COP8 
defined HTPs as tobacco products, and 
“therefore subject to the provisions 
of the WHO FCTC”. Parties were 
invited to prioritize certain measures 
in addressing the challenges posed 
by novel and emerging tobacco 
products such as HTPs, and the 
devices designed for consuming such 
products. Such measures included: 
(a) preventing initiation into use 
of novel and emerging tobacco 
products; (b) protecting people 
from exposure to their emissions 
and explicitly extending the scope 
of smoke-free legislation to these 
products in accordance with Article 
8 of the WHO FCTC; (c) preventing 
health claims from being made 
about these products; (d) applying 
measures regarding the advertising, 
promotion and sponsorship of these 
products in accordance with Article 
13 of the WHO FCTC; (e) regulating 
the contents and the disclosure of 
the contents of these products in 
accordance with Articles 9 and 10 
of the WHO FCTC; (f) protecting 
tobacco-control policies and activities 
from all commercial and other vested 
interests related to these products, 
including interests of the tobacco 
industry, in accordance with Article 
5.3 of the WHO FCTC; (g) regulating – 
including restriction or prohibition, as 
appropriate – the manufacture, import, 
distribution, presentation, sale and 
use of these products, as appropriate 
to their national laws, taking into 
account a high level of protection for 
human health; (h) applying, where 
appropriate, the above measures to  
the devices designed for consuming 
such products (9).
In 2018 the Convention Secretariat, 
WHO, and the WHO Tobacco 
Laboratory Network were also invited 
by the COP to report on various 
characteristics of novel and emerging 
tobacco products, in particular 
HTPs, as well as to monitor market 
developments and the use of these 
products. Despite HTPs unambiguously 
being tobacco products, some of their 
product characteristics pose regulatory 
challenges for their definition and 
classification, as well as for the 
comprehensive application of the 
WHO FCTC. For that reason, the COP 
requested the Convention Secretariat 
and invited WHO to provide more 
information on novel tobacco products, 
in particular HTPs, to COP9 (9).
Contextualizing the WHO  
report on the global tobacco 
epidemic, 2021
The focus of this report – addressing 
new and emerging products – is 
important at a time when the tobacco 
industry is using new strategies to 
position itself as a development partner. 
The foundation for the regulation of 
ENDS and HTPs, laid down by the COP, 
has been crucial for translating technical 
recommendations into political action 
at the national level.
The documents analysed in this chapter 
are the political decisions made by 
Parties to the WHO FCTC in relation to 
the regulation of ENDS and HTPs. Until 
solid and independent science present 
a different scenario for consideration of 
the Parties, these provide the regulatory 
options that Parties to the WHO FCTC 
are invited to follow. 
They are markers of global sentiment 
capable of cutting through the 
commercially interested noise and 
tobacco industry obfuscation that 
surrounds these products. Such 
decisions are influential in national 
regulation and can also contain legally 
authoritative interpretations  
of the WHO FCTC’s provisions.
In 2018, COP8 defined heated tobacco products 
as tobacco products, and are therefore subject 
to the provisions of the WHO FCTC.
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Global tobacco control efforts have made significant strides in reducing tobacco 
use and ensuring people in many parts of the world are protected from the harms 
of tobacco. However, in recent years, newer and emerging nicotine and tobacco 
products, like electronic nicotine delivery systems (ENDS), have proliferated in 
many markets. While the tobacco industry implies that ENDS are safer because 
they do not contain tobacco, ENDS continue to grow the industry’s customer base, 
including through attracting younger users.
Some of the nicotine and tobacco 
products fast emerging in different 
markets – including ENDS, heated 
tobacco products (HTPs) and nicotine 
pouches – pose serious health 
concerns. HTPs have been recognized 
by the eighth conference of the parties 
to the WHO FCTC as tobacco products 
and should be subject to the provisions 
of the WHO FCTC. They will therefore 
not be addressed in detail in the report. 
This report focuses mainly on electronic 
delivery systems, and the increasingly 
prominent role they play in the 
strategies of the tobacco and related 
industries.1
What are electronic  
delivery systems? 
For the purposes of this report, there are 
two types of electronic delivery systems: 
ENDS and ENNDS. These systems heat a 
liquid to create aerosols that are inhaled 
by the user. These “e-liquids” may 
or may not contain nicotine (but not 
tobacco)2 and other additives, flavours 
and chemicals that can be toxic to 
people’s health. ENNDS are essentially 
the same as ENDS but the e-liquids used 
are marketed as nicotine-free.
The most common ENDS are 
“electronic cigarettes”, also known as 
“e-cigarettes”, “vapes”, or “vape pens”. 
Other categories of ENDS include 
“e-hookahs”, “e-pipes” and “e-cigars”. 
Some of the products resemble their 
conventional tobacco counterparts; 
others are shaped like pens, USB 
memory sticks, or basic cylinders. 
Why electronic non-nicotine 
delivery systems ENNDS are 
included in this report 
ENNDS can be almost indistinguishable 
from ENDS: they often have enhanced 
flavours that appeal to young people 
and are often perceived as “safer” and 
non-addictive. However, while ENNDS, 
by definition, should not contain 
nicotine, in practice many e-liquids 
marked as containing “zero-nicotine” 
have been found to contain nicotine 
when tested (14). Further, depending 
on the device used, the user can choose 
e-liquids that either contain nicotine or 
not, and can add nicotine to an e-liquid 
that was formulated as nicotine-free. 
Therefore, it can be almost impossible to 
distinguish between ENDS and ENNDS. 
Even where ENNDS are nicotine-free 
there are other concerns related to the 
e-liquid they use, which contains harmful 
and potentially harmful constituents, 
which when inhaled may have long-term 
health impacts (15). In addition, as with 
ENDS, the act of using ENNDS mimics 
the use of conventional cigarettes, which 
is a behavioural pattern that can prevent 
those trying to quit tobacco from 
doing so successfully – and it may even 
contribute to non-smokers (particularly 
children and adolescents) taking up 
the use of conventional cigarettes. 
For policy-makers, the presence and 
availability of a non-nicotine electronic 
delivery system further complicates and 
confuses regulatory mechanisms that 
are intended to protect people from 
the harms of tobacco and nicotine, 
potentially generating loopholes that can 
be exploited by commercial interests.
For all the reasons above, ENNDS 
should be regulated and monitored  
in the same way as ENDS.
NEW AND EMERGING PRODUCTS: 
ADDRESSING ELECTRONIC NICOTINE  
DELIVERY SYSTEMS
1 “Industries” here refers to the tobacco industry, ENDS manufacturers, and any organizational body with commercial interests in ENDS or ENNDS.
2  Most ENDS use nicotine derived from tobacco, which leads some countries, including the United States, to classify them as tobacco products.
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New and emerging products should be included in a comprehensive approach  
to tobacco control
The rationale for addressing ENDS as part of tobacco control strategies includes the following: 
■	 Article 5.2 of the WHO FCTC 
obliges Parties to implement 
effective measures aimed at 
preventing and reducing tobacco 
consumption, nicotine addiction 
and exposure to tobacco smoke, 
and decision FCTC/COP7(9) 
invites Parties to consider applying 
regulatory measures (such as those 
referred to in document FCTC/
COP/7/11) to prohibit or restrict the 
manufacture, import, distribution, 
presentation, sale and use of ENDS, 
as appropriate to their national laws 
and public health objectives. 
■	 ENDS contain nicotine, which is 
the highly addictive component 
of tobacco. Using ENDS poses the 
risk of nicotine addiction, including 
among children and adolescents. 
Research findings show that ENDS 
users are more likely to become 
cigarette smokers, exposing them to 
the harmful effects of smoking (16).
■	 ENDS are harmful. For example, 
nicotine can have deleterious 
impacts on brain development, 
leading to long-term consequences 
for children and adolescents in 
particular (15).
■	 ENDS are marketed in thousands 
of flavours, which can increase the 
palatability of the product and help 
them be targeted specifically at 
children and young adults.
■	 In many social contexts, smoking 
tobacco has been “denormalized”, 
particularly in indoor public areas. 
The use of ENDS mimics the hand 
to mouth action associated with 
conventional smoked tobacco 
products. The use of ENDS, 
therefore, may risk renormalizing 
smoking behaviour, particularly 
among younger populations (17–19). 
■	 The tobacco and related industries 
and ENDS advocates have tried to 
undermine indoor smoking bans 
by lobbying for an exception for 
the use of ENDS. ENDS generate 
an aerosol that looks similar to 
tobacco smoke – an association 
further complicated by the difficulty 
in distinguishing these devices 
from HTPs, which, like cigarettes, 
contain tobacco. Therefore, it is 
often difficult to tell if a person is 
smoking a tobacco product or using 
an ENDS. 
■	 ENDS are marketed and promoted by 
the tobacco and related industries, 
employing many established tactics 
(see “Tobacco industry interference” 
chapter) to target their products at 
young people.
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ENDS were first developed by 
companies independent of the 
tobacco industry, but tobacco 
manufacturers have since 
entered the ENDS market
The early growth of the ENDS market 
was driven largely by companies 
independent of traditional tobacco 
companies, such as Pax Labs which 
developed the Juul e-cigarette. 
However, almost all major multinational 
tobacco companies, such as British 
American Tobacco, Philip Morris 
International and Altria have purchased 
shares in ENDS companies and/or 
developed their own brands (20, 21). 
There are now more than 30 000 ENDS 
(devices and e-liquids) brands sold in 
the EU (20).
In 2014, ENDS generated US$ 2.76 
billion in global sales, rising to US$ 15 
billion in 2019. The total market value 
of ENDS and heated tobacco products 
sales in 2018 was less than 2.2% of the 
total market value, while cigarette sales 
alone accounted for 91% of the same 
total market value (22). Consumers 
in Western European and other 
countries (including the United States 
of America (the United States) and 
Canada) comprise the largest portion 
of this market, followed by those in 
Asia-Pacific countries. According to 
2015–2018 data and projections, ENDS 
use is expected to recover from a brief 
period of decline (2019–2020) and 
continue increasing globally (20). Some 
evidence from the tobacco industry 
itself suggests that, given the market 
growth in recent years, there has been 
an increase in total nicotine users (new 
users) over recent years (23).
ENDS devices vary greatly  
and are evolving rapidly
ENDS devices vary in shape, size 
and functionality. New designs are 
continuously being developed. There  
is also a variety of “generations” 
of ENDS that differ according to 
technology and how they are designed  
to be used. 
Open systems have refillable tanks 
and can be modified, whereas 
closed systems are not meant to be 
modified and use pre-filled cartridges 
or pods, or come pre-filled, as in the 
case of disposable ENDS. Over time, 
developments have included increasing 
the electrical power generated. The 
electrical power generated in the 
device and the temperature to which 
the solution is heated can increase the 
amount of nicotine in the aerosol and 
therefore delivered to the user. Some 
ENDS have increased to more than 
250W (earlier models were powered 
at about 10W), thereby increasing 
the risk of users’ exposure to harmful 
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ENDS SALES, CURRENT AND PROJECTED, BY UNITED NATIONS REGIONS 
Source: (7) 
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Examples of ENDS 
 Cig-a-likes
 These are disposables that have 
the look and feel of conventional 
cigarettes. This may renormalize 
smoking. 
      Disposables
 These are the latest version of ENDS, 
often shaped like pods, but are meant 
to be discarded after the e-liquid has 
been used. They are available in a  
wide variety of flavours and are also 
easily concealable.
 Vape-pens
 These enable users to vary e-liquid 
formulations according to their 
preferences. Some use pre-filled 
cartridges while others allow users  
to refill them.
 Tank systems
 These enable users to vary almost  
every element of the user experience, 
including e-liquid formulations  
and battery power.
 Pods
 These are a newer generation of ENDS. 
Because this generation often uses 
nicotine salts, they provide higher 
doses of nicotine without a harsh 
sensation. The devices often look like 
USB sticks allowing users (e.g. young 
people or students) to conceal them.
There is a huge diversity in 
e-liquids and their contents
Liquids differ greatly in their contents. 
In addition to variable levels of nicotine, 
they often contain a wide variety of 
flavourings, water, propylene glycol, 
usually glycerine and other compounds. 
In addition, the aerosols generated by 
these products after aerosolization of 
the liquid contain compounds, some 
of which are toxic. Examples include 
formaldehyde, which is a cancer-causing 
agent (27). Some of the most common 
liquids components are as follows:
Nicotine 
Nicotine is a highly addictive 
substance contained in all ENDS and 
has reportedly been found in some 
products marketed as ENNDS (14). 
The nicotine contained in ENDS is 
often derived from tobacco, but some 
products use synthetic nicotine. The 
nicotine content of ENDS can range 
from 0 mg/ml to over 66 mg/ml or 
more (at least twice the nicotine 
content of a standard cigarette). Several 
factors other than concentration can 
determine the amount of nicotine to 
which the user will be exposed. The 
electrical power generated in the 
device, the puffing style of the user 
and the inclusion of ingredients in the 
e-liquid have the potential to increase 
users’ nicotine uptake (28). 
The nicotine used in e-liquids may exist 
in different forms. Free-base nicotine is 
a modified form of nicotine present in 
varying concentrations in conventional 
cigarettes and can make cigarettes 
more addictive by delivering nicotine 
rapidly to the brain. More recently, 
ENDS manufacturers have developed 
nicotine salt formulations that deliver 
higher levels of nicotine to the user 
while masking its harshness (29). 
There are approximately 16 000 unique 
flavours available in some markets,  
many of them appealing to children.
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Flavours 
There are approximately 16 000 unique 
flavours available in some markets, 
many of them appealing to children  
(17, 18, 30, 31). These flavours can 
mask the harshness of nicotine and play 
a role in a person’s decision to try using 
ENDS for the first time (32). Flavours 
can make the use of the product more 
pleasurable, the inhalation of aerosols 
easier, and change the perceived risk 
associated with their use (33). For 
example, flavours such as menthol 
contribute to promoting and sustaining 
the use of tobacco products, while 
flavours such as cinnamon can improve 
the palatability of products (34, 35). 
The figure below illustrates a flavour 
wheel for e-liquids in which more 
than half of the flavours are those that 
appeal to children and adolescents (36), 
while other fruity and menthol flavours 
may also appeal to specific adult 
populations (e.g. women or certain 
ethnic groups) and non-smokers  
(32, 37).
Propylene glycol (PG) and glycerol 
These compounds are present in almost 
all ENDS as carriers of nicotine and some 
flavourings used in these products. The 
ratio of these two compounds often 
determines the e-cigarette experience as 
they can affect the smoothness, “throat 
hit” and the plume (cloud) generated 
during use. PG is frequently used as an 
additive in some foods and is “generally 
recognized as safe” when ingested 
orally. However, its effects when inhaled 
have not been well studied. 
E-liquid flavour wheel 
With so many flavours available on the market, researchers have proposed this tool to classify e-liquid flavours  
and provide a shared and comparable vocabulary.
E-liquid
Flavour Wheel
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Studies in the United States of America show how flavours play a major role in 
e-cigarette use amongst children and adolescents: 
■	 Since 2011 the use of e-cigarettes amongst high school students in the United States has increased from 1.5% to 
19.6% in 2020 (Graph 1). While there has been a recent dip in the prevalence of users, the rates continue to be 
worryingly high.
■	 From 2014 to 2020, the proportion of current e-cigarette users using flavoured e-cigarettes increased from 
65.1% to 84.7%. 
■	 Among high school students who currently used any type of flavoured e-cigarette, the most commonly used 
flavour types were fruit (73%), mint (56%), menthol (37%), and candy, desserts, or other sweets (37%)  
(Graph 2). 
■	 70% of current youth (ages 12–17) e-cigarette users say they use e-cigarettes “because they come in flavours  
I like”.
GRAPH 1: 
CURRENT E-CIGARETTE USE (PAST 30 DAYS) 
AMONG HIGH SCHOOL STUDENTS
IN THE UNITED STATES
GRAPH 2: 
FLAVOURS USED BY HIGH SCHOOL STUDENTS
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Diversity of ENDS presents a 
challenge to understanding, 
monitoring, and regulating them
ENDS have evolved differently 
depending on the regulatory 
environment of a given region, and 
demographic contexts and markets. 
In addition to the diversity of ENDS 
designs, product types and variants, 
interchangeable parts, and the wide 
variety of e-liquids and flavour types that 
the user can themselves mix, many ENDS 
are also customizable by the user post-
sale, and some can even be manipulated 
remotely by the manufacturer (41). 
Customizable devices mean that they 
can be manipulated by changing 
different aspects of the products, such 
as the battery power, the heating coil 
and the temperature that the heating 
component reaches. This can have a 
significant impact on the emissions to 
which users and bystanders are exposed.
There is growing evidence of 
harmful effects of ENDS
Tobacco and related industries 
market and promote ENDS as “safer” 
alternatives to conventional cigarettes 
and many users perceive them to 
be significantly “less harmful” than 
tobacco products, especially cigarettes 
(42). However, even though many of 
the long-term health effects of ENDS 
use are still unknown, there is growing 
evidence to demonstrate that these 
products are not harmless (43). For 
example, recent studies suggest that 
ENDS have negative acute effects on 
cardiovascular health, including heart 
rate and blood pressure (44–46), and 
that daily ENDS use has been shown 
to be associated with increased risk 
of myocardial infarction. In addition, 
studies on the impact of ENDS use on 
respiratory health show measurable 
adverse effects on organ and cellular 
health in humans, in animals, and in 
vitro, and is likely to be associated 
with asthma and chronic obstructive 
pulmonary disease (47, 48). 
The health impacts on users of these 
products are also likely to depend 
on the many factors associated with 
the range of ENDS design and how 
they are used, as well as on other 
products that the user is consuming 
at the same time, and the quantity 
or pattern of that consumption. For 
example, ENDS are often used as 
complements to cigarette smoking 
and not as substitutes, especially in 
the smoke-free environments where 
ENDS use is not banned. This means 
many ENDS users use both ENDS and 
conventional cigarettes (dual use) 
(49) – a pattern of use that may in 
fact have more deleterious effects on 
users’ health than the use of ENDS 
or conventional cigarettes alone. In 
the United States, almost 70% of 
adult ENDS users also currently smoke 
cigarettes (50). Dual use of ENDS and 
cigarettes may also sustain nicotine 
dependence. Some studies suggest that 
dual use is associated with increased 
risk of respiratory and cardiovascular 
conditions relative to single product use 
(51–53). 
Nicotine is deleterious to 
adolescent brain development 
and poses risks during pregnancy
Nicotine is highly addictive. A  
non-smoker who uses ENDS may 
become addicted to nicotine and find 
it difficult to stop using ENDS and/
or become addicted to conventional 
tobacco products. Given that many 
ENDS are marketed to be attractive 
to youth, they have been taken up 
by adolescents and children in large 
numbers in some countries. Nicotine 
addiction is generally established in 
adolescence, creating a very real risk 
of young users becoming nicotine 
dependent (54). Young people who 
experiment with ENDS are two to three 
times as likely to progress to regular 
use of conventional cigarettes than 
those who do not (55). If an ENDS 
user transitions to the use of tobacco 
products they will become vulnerable 
to the health outcomes associated 
with tobacco use, such as cancer, 
cardiovascular disease, respiratory 
diseases and hypertension. 
Nicotine also poses health risks to 
children, adolescents and pregnant 
women. The consumption of 
nicotine in children and adolescents 
has deleterious impacts on brain 
development, leading to long-term 
consequences for brain development 
and potentially leading to learning and 
anxiety disorders (56–58). Nicotine 
exposure in pregnant women can have 
similar consequences for the brain 
development of the fetus (59, 60).
Other e-liquid components can 
also be harmful to health 
Aside from nicotine, some of the 
common components of e-liquids are 
known to have health effects, while 
little is known about many more  
(25, 61). Some of the flavours used in 
ENDS and ENNDS, for example, have 
been shown to increase the toxicity 
of their aerosols (62). Aldehydes 
like vanilla and cinnamaldehyde 
flavouring, for example, have been 
shown to contribute to toxicity and 
the component used to bring about 
buttery flavours is known for causing 
bronchiolitis obliterans (sometimes 
called “popcorn lung”) (47). 
The outbreak of electronic-cigarette 
or vaping product use-associated 
lung injury (EVALI) in the United 
States in 2019–2020 highlights the 
potential dangers associated with these 
products. According to the most recent 
data from the Centers for Disease 
Many of the long-term health effects of ENDS use 
are still unknown, there is growing evidence to 
demonstrate that these products are not harmless.
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Control, EVALI resulted in a total of 
2807 cases and 60 deaths (63). While 
the cause of these deaths has not been 
conclusively determined, vitamin E 
acetate (VEA), a common additive in 
ENDS that contains cannabis (or THC), 
is thought to have played a significant 
role in these cases of lung injury (64). 
While VEA is safe when consumed 
orally in foods and when used on the 
skin, the impact of inhaling VEA is not 
fully understood. This is an example 
of why ENDS should be regulated and 
some jurisdictions, such as Canada, the 
United Kingdom of Great Britain and 
Northern Ireland (the United Kingdom), 
and some states in the United States, 
currently prohibit this additive (41, 65).
Electronic delivery systems have 
also been linked to a number of 
physical injuries, including burns from 
explosions or malfunctions, when 
the products are not of the expected 
standard or are tampered with by 
users. Accidental exposure to the high 
nicotine concentrations in e-liquid can 
also be very dangerous and even cause 
death. Cases of accidental ingestion of 
the poisonous e-liquid by children are 
particularly concerning, with one study 
finding over 8000 exposures among 
children under the age of 6 years over 
a 5-year period in the United States 
of America. Amongst these cases, 
eight children suffered major health 
consequences and one 1-year old boy 
died (65–68). 
Second-hand emissions have the 
potential to harm bystanders 
Studies show that ENDS use raises 
airborne concentrations of particulate 
matter above background levels when 
measured indoors (69–71). The levels 
of nicotine, particulate matter and 
potential carcinogens in second-hand 
aerosols (SHA) exceed the maximum 
recommended levels set out in the 
WHO FCTC Guidelines (72–74). This 
is of concern, as human exposure 
to particulate matter generated 
during the use of ENDS – including 
fine and ultrafine particles (which 
may penetrate the alveoli), volatile 
organic compounds, heavy metals and 
nicotine (75) – have been shown to 
be associated with increased risk of 
heart and lung disorders. Although the 
health risks associated with SHA from 
ENDS are not yet well understood, 
a systematic review concluded that 
ENDS “vapour” has the potential to 
cause harm to bystanders (71). Further 
research is needed to fully understand 
the health effects of second-hand 
exposure to ENDS aerosols.
Children and adolescents that use ENDS are more 
than twice as likely to use conventional cigarettes.
38 | WORLD HEALTH ORGANIZATION
Prevalence of adult ENDS use is 
low, but varies and fluctuates 
greatly across countries 
While reliable data are not available 
for all countries, current ENDS use 
among adults varies greatly across 
the countries that monitor it, from 
11% in Estonia (2018) to 0.2% in 
Uruguay (2016-17) – see Annex II 
and Annex XI. ENDS use rates can 
also change rapidly in a population 
over a short period of time (41): in 
Great Britain, the prevalence of adult 
ENDS use rose to 7.1% in 2017 and 
decreased to 6.3% in 2020 (49). 
Increasingly, population-level surveys 
include questions about the use of 
ENDS (as well as ENNDS) among 
both adults and adolescents. 
Questions have been incorporated 
into Tobacco Questions for Surveys 
(TQS) (76). The diversity of products 
and nomenclature, however, pose 
a real challenge for monitoring and 
surveillance of these and other novel 
and emerging nicotine and tobacco 
products. In addition, the conflation 
of the ENDS product category with 
that of HTPs (23) makes it difficult 
to know which products people are 
using and how they are using them. 
Surveillance criteria must be particularly 
stringent and meticulous to capture 
the current and evolving nuances 
that exist among these products and 
patterns of use across countries. 
ENDS use among children and 
adolescents must be prevented
A recent systematic review found 
that the prevalence of ENDS ever-use 
among children and adolescents across 
all countries and territories that had 
data (50 out of the total 67 countries 
that reported on ENDS use in some 
dimension) was estimated to be 19.9%. 
For current use of ENDS (use in the last 
30 days) the pooled estimate across 60 
countries was 8.8% (77). And in the 
United States, the extent of e-cigarette 
use among children and adolescents 
led the US Surgeon General to declare 
the problem an epidemic in 2019 (78). 
More recent surveys have observed a 
decline in the prevalence of e-cigarettes 
use in this population but trends must 
be carefully monitored (79).
ENDS use among children 
and adolescents increases 
the chances they will use 
conventional cigarettes and 
other tobacco products
ENDS use among children and 
adolescents under the age of 20 years 
is of concern in many countries, not 
only because of the detrimental effects 
of nicotine in this age group but also 
because most young ENDS users are 
non-tobacco users, and ENDS use 
may lead to future consumption and 
addiction to tobacco products  
(67, 80). In other words, ENDS 
may act as a “gateway” to tobacco 
consumption (81). A global systematic 
review recently found that those 
children and adolescents that use 
ENDS, even when experimental in 
nature, are more than twice as likely 
to later use conventional cigarettes 
(both ever and current use) (82). 
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Evidence on the potential  
role for ENDS in cessation  
is still inconclusive
To date, evidence on the use of ENDS 
as a cessation aid is inconclusive. A 
recent Cochrane Review suggests that 
e-cigarettes can help smokers quit 
(83). This review compared ENDS to 
behavioural support and other nicotine 
replacement therapy (NRT) and pooling 
the results of four studies found a small 
but significant increase in quitting rates 
among ENDS users. The results suggested 
that out of 100 people using NRTs, six of 
them are likely to quit successfully, while 
10 out of 100 people using e-cigarettes 
to quit are likely to be successful. 
There are a number of caveats to this 
conclusion. Firstly, the authors note that 
the certainty of these findings is low (for 
the comparison to behavioural support) 
to moderate (for the comparison to 
NRTs). Secondly, the studies included 
used a single product type in a 
therapeutic environment, and this is not 
considered comparable to the current 
real-world context of e-cigarette use. 
Thirdly, and perhaps most significantly, 
there is the question of defining 
cessation. Cessation may be seen to 
be the quitting of smoked tobacco 
products, the quitting of any tobacco 
product or the quitting of any nicotine 
product. In the Cochrane Review, 
cessation was considered successful 
if people quit smoking any tobacco 
product. In other words, a person could 
move from conventional cigarettes to 
ongoing use of ENDS and be considered 
to have successfully “quit”. This leaves 
open the question about the duration 
for which a person would be expected 
to continue using ENDS as a cessation 
device, especially since longer-term use 
may entail increased exposure to the 
potential health risks associated with 
ENDS. NRTs are designed such that 
nicotine content is progressively reduced 
throughout the treatment so as to 
reduce dependence on nicotine. 
The US Surgeon General’s Report on 
Cessation concluded, “The evidence is 
inadequate to infer that e-cigarettes, in 
general, increase smoking cessation” 
(84). In addition, the European 
Union’s Scientific Committee on 
Health, Environmental and Emerging 
Risks (SCHEER) Opinion on electronic 
cigarettes concluded, “There is a 
lack of robust longitudinal data on 
the effect of electronic cigarettes on 
smoking cessation. Until such research 
is available, electronic cigarettes 
should only be considered to support 
smoking cessation for a limited time 
and under supervision” (85). Indeed, 
some research has suggested that, 
in some cases, ENDS could hinder 
cessation in some individuals by 
prolonging or increasing addiction to 
nicotine (86).Given the diverse nature 
of ENDS, more evidence is needed to 
inform a conclusive statement on the 
potential of any specific ENDS product 
as a cessation tool. At this time, 
there are still a number of unknown 
factors which mean that ENDS cannot 
be recommended as cessation aids 
at the population level. Currently 
available cessation treatments such 
as NRTs (gums and patches), and 
pharmacotherapies (Bupropion and 
Varenicline), must be approved by 
each country’s regulatory authority 
before they can be marketed and made 
available in that country and comply 
with regulatory requirements (87). 
ENDS are not currently subject to this 
regulatory approach in most countries 
where they are sold, and consequently 
do not benefit from the same quality 
assurance and oversight guaranteed 
for other cessation treatments.
ENDS by prescription: the unique case of Australia
On 1 October 2021 Australia 
will become the first country in 
the world to ban the purchase 
or import of ENDS by consumers 
unless they have a valid doctor’s 
prescription to do so. The main 
reason a doctor may provide a 
prescription is to help the user quit.
As there are currently no 
approved nicotine e-cigarettes 
on the Australian Register of 
Therapeutic Goods (ARTG), 
doctors themselves may need to 
apply to the Therapeutic Goods 
Administration (a regulatory agency 
of the Australian Government) for 
access to the unapproved product 
before they issue a prescription.
Patient access to these products 
is restricted to certain pathways 
available for ‘unapproved’ 
prescription medicines. Further 
information is available at:  
https://www.tga.gov.au/nicotine 
-e-cigarettes.
The tightened ENDS regulations 
aim to stem the increase in the 
use of nicotine e-cigarettes by 
young people in Australia. Between 
2016 and 2019, the proportion of 
young people aged 18–24 years 
who reported using e-cigarettes 
daily, weekly, monthly or less 
than monthly at the time of being 
surveyed nearly doubled, from 
2.8% to 5.3%. The regulations also 
provide an opportunity for current 
smokers to receive appropriate 
advice from a medical doctor on 
the benefits of smoking cessation 
and the risks associated with ENDS.
Source: (88)
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Potential impact of ENDS on the 
wider population who do not 
currently use tobacco or ENDS 
Apart from the question of whether 
ENDS can help tobacco users quit, there 
are many other questions raised by 
ENDS in relation to patterns of tobacco 
consumption (89). For example, to what 
extent do people, in particular adults, 
reduce their tobacco use (if at all) when 
they start using ENDS? And how does 
this differ between the type of ENDS or 
ENNDS used? At the population level, 
does the availability of ENDS on the 
market increase or decrease cessation 
attempts? Are ENDS attractive to 
former smokers and do long-term 
former smokers start using ENDS (90)? 
And, if indeed ENDS help people to quit 
smoking, how does this health benefit 
compare to the risks of increasing 
numbers of children and adolescents 
initiating the use of these products 
(89)? Many of these questions have 
no quick answer, and answers might 
not be generalizable to all countries, 
but ensuring ENDS are adequately 
regulated to protect population health 
can be achieved immediately. If they are 
not appropriately regulated, they may 
undermine current measures intended 
to protect people’s health.
ENDS present important  
threats and challenges to 
tobacco control 
Tobacco control has made significant 
progress over the last two to three 
decades. This report finds that the 
global prevalence of smoking has 
reduced in just the past 12 years from 
22.7% in 2007 to 17.5% in 2019, and 
with the adoption of measures like 
smoke-free environments in many 
countries, at national, provincial 
and city levels, tobacco use has 
been denormalized (91). Legal 
restrictions have protected children 
and adolescents from the harms of 
tobacco by restricting the age of 
purchase and ensured bans against 
advertising of tobacco products. 
Today, over 5.3 billion people are 
protected from the harms of tobacco 
by at least one MPOWER measure. 
The emergence of ENDS in 
many countries may undermine 
tobacco control progress
ENDS proponents argue that the 
presence of “less-harmful” alternatives 
can help reduce the prevalence of 
tobacco use and improve the health of 
the population. But while innovation in 
cessation products is to be welcomed, 
ENDS are currently marketed to attract 
new users (i.e., not limited to tobacco 
users wanting to quit) and misinform 
the public about the risks associated 
with their use in the absence of robust 
evidence (or indeed in the face of 
growing evidence to the contrary).  
ENDS currently pose significant 
challenges to public health and could 
undermine some of the hard-won 
progress in tobacco control achieved  
to date.
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How ENDS challenge tobacco control and effective public health implementation 
Legislation and regulatory 
mechanisms struggle to 
keep pace with changing 
product characteristics
Because ENDS often do not have the same characteristics as conventional 
products and are constantly evolving, they may not be covered under existing 
laws and can fall between regulatory cracks. In particular, open-system 
(modifiable) ENDS are difficult to regulate (92) and regulations are often not 
able to keep pace with changing product characteristics. 
ENDS use among children 
and adolescents may act as 
a gateway to tobacco use
ENDS are aggressively marketed towards children and adolescents, including 
through the use of flavouring and promotional strategies (93, 94) and their use 
could lead young people to take up more harmful forms of nicotine or tobacco 
consumption. The advent of high-concentration nicotine solutions and nicotine 
salts may increase a new user’s dependence on nicotine and increase their 
likelihood of moving on to conventional tobacco cigarettes (95, 96). 
ENDS subvert tobacco 
control laws and thereby 
undermine tobacco control 
achievements
Many ENDS users cite the ability to get around smoke-free restrictions as a 
major motivation for using these products (97). If ENDS are not banned in 
smoke-free spaces, people will not only be exposed to second-hand emissions 
but existing bans on tobacco products such as HTPs (which can be difficult to 
differentiate from ENDS) may be more difficult to implement, thus undermining 
the measures in place to protect by-standers. 
ENDS are renormalizing 
smoking in society
ENDS use mimics the behaviour of smoking by the hand to mouth movement, 
with the aerosol generated bearing close resemblance to tobacco smoke. Where 
regulations do not exist to restrict it, the use of ENDS in public spaces may 
make people more comfortable around those using them and may increase 
acceptance of smoking (98, 99). 
ENDS may entice former 
smokers to take up ENDS
ENDS may remind people of smoking and result in former smokers taking up 
ENDS or relapsing to use tobacco products again (100).
ENDS may discourage 
smokers from fully quitting 
by prolonging dual use 
or continuing their use of 
nicotine products
It is still unclear if ENDS use is likely to eventually lead to cessation. Switching 
from tobacco to ENDS or dual use may prolong the use of tobacco products 
beyond what would have been the case had users been relying on NRTs or other 
evidence-based interventions to quit (86, 101, 102).
Regulating ENDS must not 
distract from work to strengthen 
tobacco control in general
One of the major concerns associated 
with ENDS is that they are a deliberate 
distraction from work to prevent the 
more than 8 million deaths each year 
that result from tobacco use (103). The 
exact harm or level of risk that ENDS 
will have on population health in the 
future is not known, but currently the 
number of people using these products 
is only a fraction of the number 
exposed to the known harms of 
tobacco (54). While a close eye must be 
maintained on these products, the main 
goals of tobacco control cannot be 
neglected. Where tobacco control laws 
are firmly in place, it will be possible to 
leverage more effective responses to 
ENDS and other novel and emerging 
nicotine and tobacco products.
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There are many regulatory 
mechanisms and options to 
protect populations against ENDS
This report finds that a total of 32 
countries currently ban ENDS. Where 
ENDS are not banned, they should be 
regulated, and there are a number of 
different approaches that countries have 
taken to do so (104). Given the speed at 
which ENDS markets are growing and 
its products are evolving, it is necessary 
to apply regulatory controls on ENDS 
immediately. This may mean temporarily 
banning these products or temporarily 
classifying them according to an existing 
category such as tobacco products, 
pharmaceutical products or consumer 
products. But in the long-term, countries 
should ensure that their tobacco control 
laws and regulations are comprehensive 
enough to regulate all forms of novel 
and emerging nicotine and tobacco 
products, thereby ensuring that the 
relevant industries do not exploit any 
regulatory or legal loopholes to sell and 
market these products (for example, 
classifying ENDS as smokeless tobacco 
may mean that they can be used in 
indoor public spaces).
Effective adoption and implementation 
of regulatory measures will depend 
on a number of factors including: 
the country’s achievements to date 
to implement the WHO FCTC and 
MPOWER at the highest level; the 
regulatory authority over these products; 
the country’s tobacco control policy 
goals; the available resources and 
capacity to regulate a highly complex set 
of products in a changing environment; 
and the size of the existing ENDS market 
in that country (50). Effective policy 
toolkits already exist (such as MPOWER) 
that should be applied productively 
to ENDS, as well as ENNDS (see table 
below). Guidance provided by the WHO 
report to the 2014 Conference of the 
Parties (FCTC/COP/6/10 Rev.1) and 
further elaborated in WHO’s 2016 report 
to the seventh session of the Conference 
of the Parties (outlined on facing page) 
remain relevant.
HOW MPOWER CAN BE APPLIED TO ENDS
Demand Reduction Measures
M Governments are recommended to use their existing tobacco surveillance and monitoring systems to assess developments in ENDS and nicotine use by sex and age.
P ENDS non-users should be protected from exposure to ENDS emissions. Indoor smoke-free places should  never exempt ENDS (or ENNDS or HTPs) from a ban.  
O
Evidence on the use of ENDS as a potential tobacco use cessation aid is still under debate and there is 
insufficient evidence to support their use at the population level, as compared to proven approaches.  
Countries should also use evidence-based approaches to support ENDS users who want to quit (105).
W Strong graphic health warnings should be mandated for all ENDS products, in line with overall tobacco  control strategies to deter use by young people. 
E
Given that the same promotional elements that make ENDS attractive to adult smokers could make them 
attractive to children and non-smokers, effective banning on ENDS advertising, promotion and sponsorship 
should be enforced. Further recommendations on the regulation of advertising, promotion and sponsorship  
of ENDS can be found in FCTC/COP/6/10 Rev.1 (106)
R
ENDS on their own carry health risks. Therefore, taxes should be applied to these products, in line with 
national standards, to prevent uptake, particularly among children and adolescents (see WHO’s Technical 
Manual on Tobacco Tax Policy and Administration for more information) (22).
Other policy approaches beyond MPOWER should also be applied. A ban on flavours, as has been implemented in Finland, 
can reduce the attractiveness of ENDS, particularly to minors. Furthermore, like tobacco, banning the sale and distribution of 
ENDS to minors should be adopted globally and Internet and other remote sales should be banned to avoid the potential use 
of this service to circumvent age restrictions and other regulations. 
“…each Party shall, in accordance with its capabilities, adopt and implement effective 
legislative, executive, administrative and/or other measures and cooperate, as 
appropriate, with other Parties in developing appropriate policies for preventing and 
reducing tobacco consumption, nicotine addiction and exposure to tobacco smoke.”
Article 5.2 WHO FCTC
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Objectives and options for regulating ENDS and ENNDS  
(based on the COP Decision FCTC/COP6/10/rev)
OBJECTIVE: 
Prevent the initiation of ENDS and ENNDS use  
by non-smokers and youth, with special attention 
to vulnerable groups
Measures may include banning the sale and distribution, 
as well as the possession of, ENDS and ENNDS by minors; 
banning or restricting advertising, promotion and 
sponsorship of ENDS/ENNDS; taxing ENDS/ENNDS at a 
level that makes the devices and e-liquids unaffordable 
to minors; banning or restricting the use of flavours; 
regulating places, density and channels of sales.
OBJECTIVE: 
Minimize as far as possible potential health risks  
to ENDS and ENNDS users and protect non-users 
from exposure to their emissions
a. To minimize health risks to users: Testing heated 
and inhaled flavourings used in the e-liquids for safety 
and banning or restricting the amount of those found 
to be of serious toxicological concern; requiring the 
use of ingredients that are not a risk to health and are, 
when allowed, of the highest purity.
b. To minimize health risks to non-users: 
Prohibiting by law the use of ENDS and ENNDS in 
indoor spaces; requiring health warnings about 
potential health risks deriving from their use. Health 
warnings may additionally inform the public about the 
addictive nature of nicotine in ENDS; and reducing the 
risk of accidental acute nicotine intoxication.
OBJECTIVE: 
Prevention of unproven health claims being  
made about ENDS and ENNDS
Measures may include prohibiting implicit or explicit 
claims about the effectiveness of ENDS/ENNDS 
as smoking cessation aids unless a specialized 
governmental agency has approved them; prohibiting 
implicit or explicit claims that ENDS/ENNDS are 
innocuous or that ENDS/ENNDS are not addictive; 
and prohibiting implicit or explicit claims about the 
comparative safety or addictiveness of ENDS with 
respect to any product unless these have been 
approved by a specialized governmental agency.
OBJECTIVE: 
Protect tobacco control activities from all 
commercial and other vested interests related  
to ENDS and ENNDS, including the interests of  
the tobacco industry
Measures to do this are outlined in detail in the next 
chapter. Briefly, measures may include rejecting 
partnerships with the industry; raising awareness about 
potential industry interference with Parties’ tobacco 
control policies; treating state-owned industry in the 
same way as any other industry; banning activities 
described as “socially responsible” by the industry and 
taking measures to prevent conflicts of interest for 
government officials and employees.
Recommendations 
Countries should:
■	 Ensure continued focus on comprehensive evidence-based 
tobacco control measures to reduce nicotine addiction 
and tobacco use through all provisions of the WHO FCTC 
and full implementation of MPOWER. This is a priority. 
■	 Where manufacture, sale and distribution of ENDS is 
not prohibited, adopt appropriate regulatory options to 
achieve the key objectives of protecting the population 
from potential health risks; preventing unproven claims 
being made about ENDS; and protecting tobacco control 
activities from commercial interests (107). See box below 
for a summary of regulatory options. 
■	 Consider prohibiting the sale of ENDS that the user can 
modify (either its features or e-liquid ingredients) (50).
■	 Where a ban on manufacture, sale and distribution of ENDS 
is the preferred regulatory approach to protect the health 
of a country’s population (in the wider context of tobacco 
control, and based on the specific domestic regulatory 
environment), countries should strictly implement the ban 
without any interference from the industry to ensure a high 
degree of protection for children and adolescents.
■	 Monitor the use of ENDS and ensure that data 
are disaggregated by age and sex. National 
representative surveys must capture use of all forms 
of novel and emerging products such as ENDS so 
that researchers can perform rigorous analyses, 
and regulatory approaches are well-informed.
■	 All these recommendations should also be applied  
to ENNDS.
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Despite the more than 8 million tobacco 
use-related deaths each year (103), 
the tobacco industry continues to 
aggressively market its products 
worldwide and to undermine 
implementation of the WHO FCTC 
and the MPOWER package. But 
implementation of the WHO FCTC 
benefits from strong governmental 
commitment to eliminate this 
interference. Parties to the Convention 
are legally obliged (under Article 
5.3) to “protect these policies from 
commercial and other vested interests 
of the tobacco industry in accordance 
with national law” (108). However, the 
tobacco industry invests considerable 
resources to oppose strong tobacco 
control measures, both at national 
and international levels. Following 
failed attempts to prevent, delay, or 
derail negotiation of the WHO FCTC 
(as well as to weaken it), the tobacco 
industry now strives to subvert its 
comprehensive implementation by 
deploying a wide variety of strategies 
to obstruct tobacco control measures. 
Some of these strategies are public 
while others are more covert. Overall, 
however, the goal is to weaken 
effective tobacco control.
The many faces of tobacco industry interference 
Tobacco industry tactics to thwart tobacco cessation are not new (109).  
The Stopping Tobacco Organizations and Products (STOP) partnership has 
identified nine common tobacco and related industries’ tactics (90, 110):
TACTIC 1
Building alliances and front groups  
to represent its case – the “third  
party technique” 
TACTIC 2 
Attempting to fragment and weaken 
the public health community
TACTIC 3 
Disputing and suppressing public  
health information
TACTIC 4 
Producing and disseminating  
misleading research and information
TACTIC 5 
Directly lobbying and influencing  
policy-making
TACTIC 6 
Influencing “upstream” policies, 
including trade treaties, to make it 
harder to pass public health regulations
TACTIC 7
Litigating or threatening litigation 
TACTIC 8 
Facilitating and causing confusion 
around tobacco smuggling, using  
it to fight tobacco control
TACTIC 9 
Seeking to manage and enhance its 
own reputation in order to increase  
its ability to influence policy
Countering tobacco industry tactics
Countering industry interference  
is fundamental to effective  
WHO FCTC implementation. In 2008, 
the Conference of Parties (COP) to the 
WHO FCTC adopted guidelines for the 
implementation of Article 5.3. These 
were based on both scientific evidence 
and the experiences of Parties, and 
aimed to assist Parties in achieving their 
legal obligations under the WHO FCTC. 
These guidelines continue to be 
instrumental in combatting industry 
interference and should be applied in 
the context of both conventional and 
emerging nicotine and tobacco products. 
The tobacco industry attempts to present 
itself as a partner in tobacco control, 
while simultaneously blocking regulatory 
efforts. Therefore, partnerships with 
tobacco and related industries should 
be rejected, and there should be clear 
rules regarding conflicts of interest for 
government officials and government 
employees working on tobacco control. 
TOBACCO INDUSTRY INTERFERENCE: 
STRENGTHENING RESPONSE IN  
THE FACE OF EVOLVING TACTICS
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Government action to counter tobacco industry interference should include  
the following:
■	 Requiring disclosure of, and clearly 
communicating, funding sources for 
research institutions, academics, and 
scientific studies to prevent unseen 
biases in science on which policy 
may be based, as well as to clarify 
the motivations of nongovernmental 
organizations, business and trade 
associations, consumer groups, think 
tanks, professional associations and 
others seeking involvement or input 
in tobacco control policies.
■	 Rejecting partnerships and  
non-binding or non-enforceable 
agreements with the tobacco 
industry and those working in its 
interests, including financial support, 
incentives and endorsement of 
tobacco industry activities related  
to tobacco control.
■	 Raising awareness about the known 
addictive and harmful properties 
of tobacco and nicotine-containing 
products, and about tobacco 
industry interference with tobacco 
control policies.
■	 Denormalizing and, to the extent 
possible, regulating and banning 
publicity around activities described 
as “socially responsible” by the 
tobacco industry.
■	 Prohibiting the dissemination of 
misleading information relevant  
to tobacco control policies.
■	 Requiring that information from 
the tobacco industry on marketing, 
lobbying and philanthropic activities 
is disclosed and that the information 
provided by them be transparent 
and accurate, with regular, truthful, 
complete and precise information 
on tobacco industry activities. All 
government interactions with the 
industry should be recorded and 
made available to the public.
■	 Putting in place and enforcing 
effective conflict of interest 
policies for policy-makers and 
officials engaged in developing, 
implementing and enforcing 
tobacco control policies.
■	 Treating state-owned tobacco 
enterprises the same as other 
tobacco companies. No government 
privileges or influence should 
be afforded to any tobacco and 
nicotine companies.
■	 Ensuring that non-health agencies 
take the same action, adhering 
to Article 5.3 and applying the 
Guidelines for Implementation.
■	 Blocking interaction between 
government and front groups that 
are funded by tobacco and related 
industries “purporting to work for  
a smoke-free world” (speech by  
Dr Tedros Ghebreyesus) (111).
Governments should encourage and empower civil society to play a role in 
preventing and addressing tobacco industry interreference. Effective advocacy 
against the tobacco and nicotine industries requires skills training, capacity  
building and longer-term investments from donors to ensure sustainability (112). 
Tobacco and related 
industry interference  
and ENDS
“Whenever tobacco companies 
have faced a major threat, they have 
introduced new products promising 
they would be less harmful (than 
conventional cigarettes). They used 
these products to protect their 
sales and position themselves as 
part of the solution and re-connect 
with policymakers. Ultimately, 
they just undermined progress 
while providing the industry with 
a new way to make money.”
STOP Initiative (113) 
The tobacco and related nicotine 
industries1 use a number of strategies 
to sell their products. The following 
outlines some of the key tactics 
identified regarding novel and 
emerging products. 
Attracting new customers and 
sustaining existing customers 
ENDS are aimed at attracting 
new, young users
Tobacco and ENDS companies use 
product design features that increase 
the attractiveness of the products, 
especially to young users. The products 
look like sleek new technology and 
are often sold in stores that are 
glamorous and hyper modern. Some 
of the designs associated with ENDS 
look like small USB sticks and are small 
enough to hide from others, making 
them particularly useful in the school 
Whenever tobacco companies have faced a major threat, 
they have introduced new products promising they 
would be less harmful than conventional cigarettes. 
Ultimately, they just undermined progress while 
providing the industry with a new way to make money.
1 “Nicotine industry” means manufacturers, wholesale distributors and importers of nicotine and non-nicotine products, including associations or other entities, 
as well as industry lobbyists.
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environment where students can keep 
them concealed from teachers and 
other authorities (114). Furthermore, 
the products are promoted at youth-
friendly events such as music festivals, 
and manufacturers use social media 
influencers that appeal to young 
audiences to promote them (115). Other 
product characteristics that attract 
new users are the use of an enormous 
range of flavours that particularly 
appeal to children and adolescents. 
Sustaining addiction among  
the customer base 
E-liquid contents are also designed to 
keep people coming back for more. For 
years tobacco companies have included 
additives in conventional cigarettes, 
such as acids and ammonia, to make 
cigarettes more palatable, decrease 
the harshness of nicotine and enhance 
nicotine delivery to the brain (116). 
Similarly, in some ENDS, nicotine salts 
(see page 33) for example not only  
help increase the palatability of product 
use, they also deliver larger amounts  
of nicotine to the user which is likely  
to increase their addictiveness. 
Dissemination of misinformation 
and interference with scientific 
research 
Misinformation about ENDS,  
as well as HTPs
HTPs, ENDS and ENNDS are often 
promoted by the industry as “safer” 
alternatives to conventional tobacco. 
They are also promoted or indirectly 
framed as cessation products that can 
help tobacco users quit conventional 
smoking. Such activities have 
ramifications for proven interventions 
to assist tobacco cessation, as they have 
the potential to misinform and mislead 
consumers. Based upon misinformation, 
individuals who want to quit may opt 
for the use of products with which they 
have a lower chance of success. 
A significant amount of research 
is funded by the tobacco and 
nicotine industries
Despite unquestionable and inevitable 
conflicts of interest, a substantial 
amount of the available literature 
on novel and emerging nicotine 
and tobacco products is funded by 
product manufacturers including the 
tobacco industry (117). This creates 
many challenges when interpreting 
the evidence, as selective and 
favourable results are more likely to 
be reported and presented to the 
public. For example, there are serious 
concerns around the scientific research 
conducted by Philip Morris International 
(PMI) on HTP aerosols and the failure 
of the company to make available data 
from longer term studies (118). 
Conflation of product categories
Blurring the lines between ENDS 
and HTPs and creating confusion 
over their associated risks 
When expedient, such as to benefit 
from lighter regulation, tobacco 
companies pitch HTPs as electronic 
products “similar to ENDS”. Yet, where 
ENDS are banned, HTPs are pitched 
as tobacco products that do not fall 
within existing categories (119). This 
creates confusion about these product 
categories, both among the general 
public and for regulatory purposes. 
HTPs are tobacco products and should 
be regulated as such, with application 
of the WHO FCTC, but by blurring the 
difference between HTPs and ENDS 
the industry attempts to circumvent 
strict regulation (120). HTPs are often 
promoted, especially to regulators, 
as smoking cessation aids. However, 
there is no reliable tobacco industry 
independent evidence on the impact 
of HTP use on conventional smoking 
cessation. HTP use is tobacco use. 
Indeed, more generally, there is limited 
evidence on the long-term health 
impacts of HTPs. 
Tobacco and ENDS companies use product 
design features that increase the attractiveness 
of the products, especially to young users.
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Manipulating public opinion 
to gain “respectability” while 
undermining public health 
functions and progress
Promoting ENDS in the name  
of public health while  
opposing effective tobacco 
control measures
The tobacco industry increasingly 
positions itself as a legitimate partner 
and stakeholder in tobacco control, 
but its interests are fundamentally at 
odds with control efforts. The tobacco 
industry simultaneously portrays 
themselves as working towards a 
“smoke-free” future, while at the same 
time promoting – and making most 
of their profits from – conventional 
smoked tobacco across the world. 
The British American Tobacco Annual 
report, 2019 (122) demonstrates that 
most of the profits generated through 
the sale of ENDS come not from 
customers who have replaced their 
tobacco consumption with ENDS, but 
rather from dual users who sustain the 
use of conventional tobacco while also 
using ENDS. The industry, therefore, 
continues to reap profits from all 
possible avenues while acting as if 
it is working to improve population 
health. Furthermore, there is emerging 
evidence from prospective studies 
to suggest that dual use may indeed 
be more harmful than conventional 
cigarette use alone (123). 
Controversies about “harm 
reduction” that divide public 
health communities
Harm reduction is a public health 
approach that aims to reduce the  
harm caused by substances or 
behaviours that are otherwise difficult 
to eliminate. Some have endorsed the 
idea that ENDS can be used as part 
of a harm-reduction approach, while 
others have warned of the importance 
of evidence to quantify the risk over the 
long-term, the risk associated with dual 
use of ENDS and cigarettes (a common 
pattern of use) and the risk of initiation 
among children and adolescents (124). 
The commercialization and marketing 
of ENDS currently practiced by the 
PMI International exploits confusion over HTP classification
HTPs and ENDS
HTPs and ENDS are sometimes 
conflated by companies. In its 
“Hold my light” campaign, Philip 
Morris International (PMI) has 
itself described HTPs as being 
“like e-cigarettes”. This is deeply 
problematic because HTPs are 
tobacco products, which means 
they have different risks. 
HTPs help to hook  
new consumers
Recent investigations have 
shown that PMI has sought to 
expand its market by aiming to 
attract consumers who are not 
current smokers. To do this they 
use marketing pricing strategies 
that establish their HTP product 
(IQOS) as an aspirational brand, 
and not a product designed to 
attract smokers who want to 
quit (23). PMI’s business model 
and tactics are representative of 
those being pursued by other 
tobacco industry actors. 
PMI exploits the confusion 
over the FDA decision 
To support their claim that HTPs 
are safer products, PMI submitted 
an application to the United States 
Food and Drug Administration 
(FDA) to classify HTPs as a 
“modified risk tobacco product”. 
On 7 July 2020, the FDA granted 
an “exposure modification” order 
but denied the “risk modification” 
order for which PMI had applied. In 
other words, reducing exposure to 
harmful chemicals in HTPs does not 
render them harmless, nor does it 
translate to reduced risk to human 
health (121).
Indeed, the FDA statement noted 
that, “Even with this action, these 
products are neither safe nor 
‘FDA approved’. The exposure 
modification orders also do not 
permit the company to make any 
other modified risk claims or any 
express or implied statements that 
convey or could mislead consumers 
into believing that the products are 
endorsed or approved by the FDA, 
or that the FDA deems the products 
to be safe for use by consumers.”
On 27 July 2020 WHO issued a 
statement reminding Member 
States that are Parties to the 
WHO FCTC that HTPs are tobacco 
products, meaning that the 
WHO FCTC fully applies to these 
products. Specifically, Article 
13.4(a) obliges Parties, to prohibit 
“all forms of tobacco advertising, 
promotion and sponsorship that 
promote a tobacco product by any 
means that are false, misleading 
or deceptive or likely to create 
an erroneous impression about 
its characteristics, health effects, 
hazards or emissions”.
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tobacco and related industries is not 
aligned with the cause of public health. 
While the tobacco industry claims to 
be committed to harm reduction, their 
duplicity is demonstrated by how they 
simultaneously aggressively promote 
tobacco products where they can, and 
especially in low- and middle-income 
countries (23) continue to circumvent 
and undermine legislation to regulate 
conventional tobacco products (125, 
126), and take advantage of legislative 
loopholes for promotion and sale of 
novel products (127).
Industry tactics that interfere 
with the public health endeavour 
in tobacco cessation
Guidelines for Implementation of 
Article 14 of the WHO FCTC define 
the phrase “tobacco cessation” as 
“the process of stopping the use of 
any tobacco product, with or without 
assistance”. Nicotine replacement 
therapies (NRTs) are designed to help 
people quit tobacco, and eventually 
stop using NRTs as well. Switching from 
tobacco use to HTPs such as IQOS does 
not constitute cessation of tobacco use.
PMI’s “unsmoke” campaign (primarily 
focused on HTPs) encourages people 
“who don’t quit cigarettes” to “change 
to a better alternative” and is in line 
with PMI’s goal to “replace cigarettes 
with the smoke-free products we’re 
developing and selling”. The campaign 
undermines tobacco cessation initiatives 
by presenting a tempting and easy 
“alternative” to breaking a nicotine 
addiction, and undermining successful 
tobacco control initiatives (which 
have denormalized smoking in many 
countries) by portraying this form of 
tobacco use as socially acceptable.
Interference to undermine 
current tobacco control measures 
ENDS have created new ways for 
the tobacco industry to sidestep 
laws governing advertisments 
ENDS have been openly advertised. 
After decades of marketing restrictions, 
the tobacco industry is once again 
using media channels such as television, 
which were previously used to target 
youth and young adults. Without 
appropriate legislation in place to 
prevent it, advertising can then use 
brand names of tobacco products, 
hence helping to sell not only the ENDS 
product but also the original branded 
tobacco product. 
Interfering in legislative processes 
in countries, directly and through 
front groups like Foundation for  
a Smoke Free World
Over past years the tobacco 
industry has interfered with tobacco 
control legislation at country level 
by attempting to slow tobacco 
control or by preventing outright 
the advancement of tobacco control 
measures. For example, PMI and groups 
funded by PMI, like the Foundation for 
a Smoke Free World, use promotion 
and other tactics to try pressure 
governments to allow these products 
into domestic markets and exempt 
them from tobacco control regulation 
(in particular TAPS bans, taxes and 
smoke free laws), thereby undermining 
tobacco control initiatives and 
weakening WHO FCTC implementation 
(23, 128).
Disappearing into regulatory gaps: the battle to regulate ENDS in Israel
While the Israeli government was 
developing legislation to govern 
ENDS, a manufacturer called E-Cig 
Ltd applied for permission to import 
and market an e-cigarette. The 
government rejected the request on 
grounds that the efficacy and safety 
of the product were not proven, 
and that importing it contravened 
the country’s laws surrounding 
pharmaceuticals. The company 
challenged the decision on the 
grounds that ENDS were recreational 
products and not pharmaceuticals, 
and the court agreed. 
However, in December 2018, the 
Israeli legislature passed a new law 
governing both tobacco products 
and ENDS, and which restricted 
ENDS advertising and required plain 
packaging for ENDS products. JUUL 
Labs and the Tel Aviv Chamber of 
Commerce (Chamber) challenged 
these provisions on the grounds that 
vaping products are less harmful 
than cigarettes and could encourage 
regular smokers to switch to 
ENDS. They argued that therefore, 
prohibitions and restrictions on 
the advertising of vaping products 
violated the rights of the Members  
of the Chamber. 
In the end, Israel successfully 
amended its tobacco legislation 
to implement plain packaging 
for smoking products, including 
e-cigarettes, but the case shows 
how companies want ENDS to  
fall within regulatory gaps.
Sources: (110, 119, 129)
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Countering the tobacco industry to overturn ENDS regulation in Thailand
When Thailand banned the import and sale of all types of ENDS in 2015, 
pro-ENDS groups lobbied the government to lift the ban after PMI began 
promoting its IQOS in 2017. ENDS Cigarette Smoking Thailand (ECST), a 
pro-ENDS group in Thailand, worked in parallel with Philip Morris Thailand 
Limited (PMTL) to oppose the ban, using six tactics:
■	 Creating front groups
■	 Lobbying decision-makers 
■	 Running public relations 
campaigns
■	 Seeking to discredit tobacco 
control advocates
■	 Funding tobacco-harm 
reduction research
■	 Pitching government sectors 
against each other
Despite strong opposition to the ban, the commitment of the Thai 
government and Thai tobacco control organizations (helped by tobacco 
workers union, which opposed the involvement of transnational tobacco 
companies in the Thai tobacco industry in order to protect the public from 
harmful tobacco products) has ensured that ENDS remain illegal (as of 
January 2021). 
As the tobacco companies 
continue to press into more low- 
and middle-income countries, 
more attention should be given 
to past industry use of legal and 
administrative influences/measures 
to prevent this influence and 
establish science-based regulatory 
frameworks. Health advocates 
should also persuade non-health 
agencies to maintain policies in 
accordance with the WHO FCTC.
Source: (130)
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The question of tobacco’s role in 
COVID-19 cases and deaths arose early 
in the pandemic and many studies 
have attempted to better understand 
the relationship between tobacco and 
COVID-19. 
While most cases of COVID-19 result in 
no symptoms or only mild symptoms, in 
some individuals COVID-19 can trigger 
life-threatening pneumonia (131–134) 
and other severe outcomes. People 
suffering from obesity (135, 136) and 
those with underlying conditions such 
as cardiovascular diseases, diabetes, 
and chronic obstructive pulmonary 
disease (COPD) are at higher risk of 
more severe COVID-19 outcomes, 
including admission to intensive care 
units, the need for a ventilator, and in 
some cases death (137). Tobacco is a 
known risk factor for these diseases 
as well as for infectious respiratory 
diseases such as pneumonia and 
tuberculosis (TB).
Tobacco’s role in infectious 
respiratory diseases is  
well established
Tobacco compromises lung function, 
and COVID-19 primarily affects the 
lungs. Smoking tobacco is also a 
known risk factor for severe disease 
from many respiratory infections (54), 
including coronaviruses SARS (first 
identified in 2003) and MERS-CoV (first 
documented in June 2012) (138–140). 
Smoking also impairs the immune 
system and previous studies have 
established that tobacco use is linked 
with poorer outcomes for people with 
TB (141) and pneumonia (142). Indeed, 
smoking increases pneumococcal, 
legionella, and mycoplasma pneumonia 
by three- to five-fold (143).
Smoking worsens  
COVID-19 outcomes 
Current evidence indicates that smokers 
(current and former) are more likely 
to suffer more severe outcomes of 
COVID-19 (144). Multiple systematic 
reviews and meta-analyses conducted 
on this issue provide evidence of a 
direct association between cigarette 
smoking and COVID-19 severity, with 
smokers having a substantially increased 
risk of COVID-19 progression and death 
(144–147) compared to non-smokers. 
Furthermore, severe forms of COVID-19 
or deaths due to COVID-19 are more 
frequent in people with comorbidities 
related to tobacco use, including COPD, 
lung cancer, and cardiovascular diseases 
(131–134). There is currently only 
limited information on COVID-19 in 
relation to other tobacco products (e.g. 
heated tobacco products, waterpipe, 
cigars) and electronic nicotine delivery 
systems (e.g. e-cigarettes), although 
these products are thought to play an 
unfavourable role in COVID-19 severity 
(148, 149).
Evidence on the biological 
mechanisms linking 
COVID-19 and tobacco  
use is growing 
Some evidence suggests biological 
mechanisms involved in the viral 
infection may make smokers more 
vulnerable to COVID-19 (150). While 
these findings provide a plausible 
explanation for the observed association 
between smoking and COVID-19 
outcomes, they are not undisputed. At 
the same time, some have hypothesized 
that nicotine might be protective against 
COVID-19 through anti-inflammatory 
effects and the inhibition of cytokine 
storms. A clinical trial is underway to 
investigate the specific role nicotine 
plays in COVID-19 (151), but until more 
information is available no conclusions 
should be drawn. 
TOBACCO AND THE  
COVID-19 PANDEMIC: 
THE LINKS
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WHO European Regional Office media campaign launch in early 2020 to help keep people informed about the risks 
associated with tobacco in the context of the COVID-19 pandemic
TOBACCO INFORMATION CAMPAIGNS DURING COVID-19
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South-East Asia Regional Office media campaign launched in the early months of 2020 to inform people of the risks associated 
with tobacco, e-cigarettes, sheesha and smokeless tobacco and betel nut use during the COVID-19 pandemic
TOBACCO INFORMATION CAMPAIGNS DURING COVID-19
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Evidence and misinformation on the risk of contracting COVID-19
At the start of the pandemic there 
was a great deal of confusion 
about the potential link between 
smoking and COVID-19, due in part 
to misinformation in the media. 
Some early studies claimed that the 
prevalence of smokers identified 
among hospitalized COVID-19 
patients was lower than among 
the general population, leading 
some to claim that smoking, 
and nicotine in particular, may 
be acting as a protective factor 
against COVID-19.* The quality 
of the data and data analysis 
have been a major concern in 
these investigations, as well as 
the conflict of interest inherent in 
some of the researchers involved 
in these studies. While research is 
still ongoing to better quantify the 
risk of acquiring COVID-19 as a 
smoker, it is important to recognize 
that there are many challenges 
associated with interpreting these 
data, especially at a time of global 
emergency (130, 152). Here are 
some key challenges: 
Self-reported tobacco  
use in hospital settings
At the start of the pandemic in 
particular, smoking status was 
rarely reported in published 
 reports from clinical settings. 
Self-reported tobacco use is 
difficult to collect, particularly in 
emergency settings. In the hospital 
setting, where people are admitted 
in varying states of health, the 
collection of smoking status is not 
often high on the priority list for  
health-care workers and if 
someone is unconscious upon 
admission, this data may never be 
collected. Information about past 
smoking status and time since 
quitting is often not collected and 
those in intensive care are often 
not even included in the published 
case-series studies. 
Furthermore, depending on the 
context, some people would prefer 
not to share information about their 
tobacco use (young people who 
are hiding their consumption from 
adults for example, or contexts 
where women feel it is socially 
unacceptable), especially with their 
doctor. Furthermore, given the 
context of a respiratory disease 
outbreak, some smokers may have 
recently stopped smoking when 
they began to feel ill and reported 
that they no longer smoke.  
Representativeness  
of study populations
Many of the studies informing  
our understanding of the link 
between smoking and COVID-19  
were conducted on selected 
populations, such as health-care 
workers or people with  
co-morbidities. These populations 
can exhibit very different smoking 
prevalence trends compared to 
the general population. People 
who are admitted to hospital are 
also often not representative of 
the overall population. There are a 
number of factors that may make 
them different from the general 
population. For example, people 
admitted to hospital with COVID-19 
during the first wave were more 
likely to be older and suffer from 
underlying noncommunicable 
diseases. It is also likely that these 
people have better access to 
the hospital, whether by virtue 
of geography or socioeconomic 
context. Importantly, the 
majority of studies examining the 
association between smoking and 
COVID-19 outcomes do not adjust 
for relevant confounders such as 
age, making the interpretation 
of results easily fallible.
Testing biases in population-
based cohort studies
Some studies have suggested that 
of those tested for COVID-19, 
results among smokers show lower 
rates of positives and this has been 
taken to mean that smokers are 
less likely to acquire the disease. 
However, given smokers are more 
likely to present with respiratory 
symptoms like coughing, they are 
also more likely to be tested as 
suspected cases. If proportionately 
more smokers take the test than 
non-smokers, it will appear that 
smokers have a lower risk of 
contracting COVID-19, whether 
true or not. 
In order to overcome these potential 
sources of bias, the best study 
design is a large prospective cohort 
study that follows a population 
that is representative of the 
general population over time 
(and for whom we have complete 
data on smoking history as well 
as confounders such as age and 
other underlying conditions) to 
see if they contract COVID-19 
or not, and to what degree of 
severity. At the time of writing, 
the evidence is not conclusive 
with regards to the relationship 
between smoking and the risk 
of contracting COVID-19 (153).
* Investigative journalists have revealed that authors of some controversial papers suggesting smokers are less likely to get COVID-19 are linked with the 
tobacco industry. One notable paper claiming was retracted from the European Respiratory Journal because of undisclosed conflicts of interest with the 
tobacco industry among the authors (154).
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COVID-19 drives bold 
tobacco-control measures
Since the start of the COVID-19 
pandemic, most governments have 
attempted to restrict movement and 
slow the spread of the disease through 
actions such as curfews, quarantines, 
and stay-at-home orders. Under these 
conditions, some countries have applied 
“essential goods lists” to restrict the 
sale of some products and thus limit 
the movement of people in public 
areas. In a small number of countries 
these lists have also been used to 
restrict access to unhealthy products, 
like tobacco and nicotine products. 
Bans and restrictions on 
tobacco sales and use, 
applied in some countries
South Africa and Botswana, for 
example, took the opportunity to 
designate tobacco and nicotine 
products as non-essential goods, 
thereby imposing a temporary ban 
on their sale (155). Other countries 
restricted the use of tobacco in 
particular places, such as Spain, 
which extended smoking bans to 
outdoor areas (156), and 15 countries 
in the Middle East, where the use of 
waterpipes in indoor areas was banned 
(157). In India, spitting bans (an act 
associated with chewing tobacco) were 
imposed in many parts of the country 
(158). At the same time Bhutan, a 
country that has maintained a tobacco 
ban for over a decade, lifted the ban to 
discourage cross-border transmission 
and sold tobacco through state-owned 
retailers (159). 
Some of these actions provided 
important lessons for tobacco control 
going forward. A study conducted 
on the South African ban, for 
example, suggested that without 
implementing other coordinated 
tobacco control measures, sales bans 
may not successfully reduce tobacco 
use (160) and the noncompliance of 
“vape” shops to non-essential item 
closure orders in the United States 
meant that as many e-cigarette users 
stockpiled these products as those that 
tried to reduce or quit them (161). 
Impact of COVID-19  
on smoking behaviours  
is mixed 
These country actions represent 
unprecedented steps to mitigate the 
impact of tobacco on the vulnerability 
of populations and have likely had 
both positive and negative impacts 
on tobacco control. In South Africa 
for example, evidence compiled on 
the impact of the temporary tobacco 
sales ban suggests that many smokers 
attempted to quit smoking or reduced 
the number of cigarettes smoked per 
day (162). Globally, the impact of the 
pandemic on smoking behaviour seems 
to have varied greatly for different 
populations. Some people have 
reported smoking more than usual to 
reduce stress or loneliness at home 
(163, 164). At the same time, some 
studies show that there has been a 
record number of smokers trying to quit 
as a result of the COVID-19 pandemic 
and awareness of the link between 
tobacco use and developing worse 
symptoms of COVID-19 (165). 
Cessation services vital as 
COVID-19 prompts people 
to quit 
As a result of the COVID-19 pandemic, 
more people may be thinking about 
their health and potentially thinking 
about quitting tobacco. Cessation 
services – already insufficient or 
unavailable in much of the world – 
have been further neglected during 
the pandemic and are unlikely to be 
prioritized for funding during the 
COVID-19 economic recovery. For 
this reason, WHO and partners have 
aimed to focus more attention on 
helping people quit. In 2021, WHO 
launched several innovative initiatives 
including the World No Tobacco Day 
campaign “Commit to Quit” to help 
encourage people to give up tobacco.
While the COVID-19 pandemic highlighted the 
vulnerability of the world’s population, the 
tobacco and e-cigarette industries exploited 
the context for their own commercial ends. 
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Tobacco industry tactics during COVID-19 
While the COVID-19 pandemic 
highlighted the vulnerability of the 
world’s population to severe respiratory 
infection, the tobacco and e-cigarette 
industries found a number of ways 
to get around public health measures 
that restricted access to non-essential 
products and exploited the context for 
their own commercial ends. The STOP 
initiative at the University of Bath has 
systematically documented cases of 
industry interference since the start of 
the COVID-19 pandemic. Here is a list of 
some of the tactics they have identified:
■	 Donations to countries portrayed 
as corporate social responsibility 
(CSR). In Greece, for example, amid 
findings that smoking predisposes 
people to more severe outcomes of 
COVID-19, Philip Morris International 
donated several ventilators to ICUs. 
The industry further promoted 
these actions as socially responsible 
actions on their websites and in 
presentations to their shareholders, 
while remaining silent on the direct 
harms of using their products.
■	 Attempting to gain a voice in 
scientific debates. For example, 
involvement in research 
conducted on tobacco-plant 
vaccine development positions 
the tobacco industry as being 
“part of the solution”. 
■	 Producing promotional material that 
appears almost identical to official 
public health communications from 
health authorities.
■	 Widely distributing promotional 
merchandise such as masks with 
industry logos. 
■	 Offering significant discounts 
and promotions for e-cigarette 
“contactless delivery” and kerbside 
drop-off locations.
■	 The use of contactless delivery, 
which can undermine “minimum 
age of purchase” restrictions, 
and the waiver of ID validation 
requirements at the point of delivery 
of HTPs in at least one country. 
■	 Appropriation of the “Stay at 
home” social media hashtag (which 
was used by government and public 
health officials) to promote heated 
tobacco products and ENDS. 
■	 Using social media posts to promote 
the use of ENDS and other products 
as ideal companions for those 
working from home. 
■	 Making claims about the health 
benefits of ENDS. For instance, US 
Bidi Vapor claimed on Instagram 
that “A bidi stick a day keeps the 
pulmonologist away”. 
■	 Policy interference by challenging 
classifications of “essential” 
businesses to ensure their businesses 
were not negatively impacted.
■	 Policy interference by lobbying 
governments to reopen tobacco/
cigarette factories early in the 
pandemic in countries including 
Bangladesh, Indonesia, Pakistan and 
Russian Federation. This resulted 
in the deaths of two workers in 
Indonesia from COVID-19. 
■	 The tobacco industry has also been 
using the impact of the pandemic  
to undermine pending tobacco 
control measures. In Europe, 
for example, tobacco industry 
representatives have used the 
pandemic to postpone a ban on  
the sale of menthol cigarettes. 
Sources: (154, 166–168)
Commit to Quit!  
The World No Tobacco Day Campaign
Recognizing that many smokers who want to quit do not have 
access to appropriate support and that the pandemic has given more 
people a reason to try quitting, WHO has developed a number of 
new initiatives to help encourage people to successfully quit tobacco. 
These initiatives include smoker’s diaries, innovative chatbots and 
“Meet Florence”, the first artificial intelligence quit-tobacco initiative. 
The World No Tobacco Day Campaign, typically a 24-hour effort to 
increase awareness about a particular aspect of tobacco control, was 
adapted into a year-long campaign in 2021 to reach out globally and 
help get 100 million people to try to quit tobacco.
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The tobacco control community can learn a number of lessons from the COVID-19 
pandemic experience 
Here are just some examples of lessons learned:
■	 The importance of providing 
reliable and evidence-based 
information on harms to the 
public: Smoking is a known risk 
factor for lung and heart health 
and it is important to warn people 
of the potential harm it may cause 
in a new, infectious disease that 
affects these organs. Where the 
relationship between tobacco 
use and COVID-19 is under 
investigation, it is imperative that 
robust methodologies and analytical 
approaches are applied to ensure 
that strong and reliable evidence are 
used to guide appropriate action.
■	 The need to “build back better”: 
COVID-19 has taken a huge  
toll on health and economic  
well-being and we now know that 
many NCDs make people more 
vulnerable to its most serious 
consequences. Tobacco control 
 is a cost-effective way to improve 
population health. As countries  
go through economic challenges 
and health systems struggle to 
address the pandemic, tobacco 
control remains an important 
investment that can help prevent 
millions of deaths and much  
illness. Tobacco is a key risk factor 
for many NCDs, but stronger 
tobacco control measures can  
help to meaningfully protect  
people from its adverse effects 
in the future. In particular, higher 
tobacco taxes could play a  
central role as a potential way to 
generate much-needed revenue  
for governments during the  
post-pandemic economic recovery. 
■	 The importance of promoting 
responsible journalism and 
countering misinformation: 
The media must take responsibility 
for ensuring that trustworthy and 
reliable information is made readily 
available to the public. Given the 
many unknowns, the pandemic 
has seen a big increase in the rapid 
online publication of research 
studies highlighting research results 
that have not been adequately 
peer-reviewed. This must be 
avoided. Policies and legislation 
should also be developed to 
manage information on social media 
platforms and counter the impact 
of misinformation and information 
overload (“infodemics”).
■	 The need to stay alert to 
tobacco industry interference: 
The tobacco industry and related 
nicotine industries are relentlessly 
opportunistic. Even at a time of 
crisis they have found ways to 
market their products and get 
around restrictions intended to 
protect people’s health. Countries, 
corporations and individuals 
must remain vigilant against the 
industries’ tactics. 
■	 The importance of 
strengthening cessation 
services: The COVID-19 pandemic 
has heightened awareness of health 
issues and this may encourage 
some people to try to quit tobacco 
use. Potential quitters will be more 
likely to succeed if they have the 
appropriate support. Nicotine 
replacement therapies, such as gum 
and patches, and proven cessation 
services such as brief advice 
administered by trained health-care 
workers, toll-free quit lines and 
mobile text-messaging programmes 
should be made available to all, and 
strengthened globally.
Botswana intensifies tobacco control during COVID-19 pandemic
Botswana issued landmark 
emergency COVID-19 regulations 
in 2020 to prohibit the import and 
sale of tobacco and tobacco-related 
products during the pandemic. 
Parliament’s approval of Statutory 
Instrument No. 61 of 2020 made 
Botswana the second country 
in Africa (after South Africa) to 
prohibit the sale of tobacco and 
tobacco products during the 
COVID-19 pandemic emergency 
lockdown – a move that has been 
lauded by many as a bold step 
in placing the interests of public 
health above those of business 
and trade. It also affirms the 
commitment of the government of 
Botswana to make health a right 
for every citizen.
Through social media, Facebook 
and Twitter, the President of 
Botswana asked citizens to take 
care of their health during the 
COVID-19 emergency, saying: “Do 
not drink or smoke and keep at 
least two meters away from others 
and avoid handshakes.” He also 
advised people to stay at home, 
wash their hands regularly with 
soap and water, cough or sneeze 
into the inner flexed elbow and 
keep their families safe.
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Fifteen Eastern Mediterranean Region countries ban waterpipe use
Curbing waterpipe use became 
a major focus of tobacco-control 
experts and advocates in the 
Eastern Mediterranean Region 
after mounting research showed 
the links between tobacco use and 
increased vulnerability to COVID-19. 
The communal nature of waterpipe 
smoking (in which a single 
mouthpiece and hose are often 
shared between users in social 
gatherings) clearly counteracts the 
social distancing measures essential 
to limiting the spread of COVID-19. 
In response, the WHO Office for 
the Eastern Mediterranean Region 
worked closely with Ministries of 
Health of countries in the Region 
to encourage bans on waterpipe 
use in all indoor and outdoor public 
places. By April 2021, 15 countries 
and territories (Bahrain, Egypt, 
Iraq, Jordan, Kuwait, Lebanon, 
occupied Palestinian territory, 
including east Jerusalem1, Oman, 
Qatar, Saudi Arabia, Sudan, Syrian 
Arab Republic, Tunisia, United Arab 
Emirates, and Yemen) adopted 
temporary bans on waterpipe use 
in all indoor and outdoor public 
places, joining two countries 
that had already implemented 
permanent waterpipe bans (Iran 
(Islamic Republic of) and Pakistan). 
The ban represents a unique 
and important success for global 
tobacco control. It shows that 
tobacco control policies, in this 
case smoke-free laws, are feasible 
and effective, even with strong 
resistance from governments and 
the tobacco industry. 
1 “occupied Palestinian territory”  is also employed throughout the report to refer to  “occupied Palestinian territory,  including east Jerusalem”
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Monitor tobacco use and prevention policies
Protect people from tobacco smoke
Offer help to quit tobacco use
Warn about the dangers of tobacco
Enforce bans on tobacco advertising, promotion and sponsorship
Raise taxes on tobacco
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Monitoring strengthens tobacco control
Monitoring patterns and trends in 
tobacco use and exposure are key to 
combatting the tobacco epidemic and 
strengthening the WHO FCTC – one 
of the Sustainable Development Goals 
(SDG 3.a). Reliable, timely data is 
critical to understand both the unmet 
need for tobacco control measures 
and the effects of tobacco control 
measures already in place. Data gives 
policy-makers the evidence they need 
to advocate for more tobacco control 
efforts and implementation resources. 
Key products to track include: 
■	 cigarettes and other forms of 
smoked tobacco (e.g. cigar,  
pipe, bidis, water pipe, heated 
tobacco products); 
■	 smokeless tobacco products  
(oral or nasal tobacco); 
■	 novel and emerging tobacco 
products such as tobacco vaporizers; 
and 
■	 non-tobacco forms of nicotine  
(e.g. ENDS). 
In addition to monitoring the impact 
of tobacco control policy interventions 
(169), it is important that tobacco 
industry activities are monitored 
and tracked when feasible (170, 
171). Such data can help adjust and 
enhance tobacco control strategies.
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Monitor the prevalence of tobacco use
Countries with the highest level of achievement: Armenia, Australia, Austria, Azerbaijan, Bahamas, Bangladesh, Belgium, Bhutan, Brazil, Brunei Darussalam, 
Bulgaria, Cambodia, Canada, Chile, *China, Cook Islands, Costa Rica, Croatia, Cyprus, Czechia, Denmark, Ecuador, Egypt, Estonia, Finland, France, Georgia, 
Germany, Greece, Hungary, Iceland, Indonesia, Iran (Islamic Republic of), Ireland, Italy, Japan, Kazakhstan, Kuwait, Lao People’s Democratic Republic, Latvia, 
Lebanon, Lithuania, Luxembourg, Malaysia, Malta, Mongolia, Montenegro, Myanmar, Netherlands, New Zealand, Norway, Pakistan, Palau, Panama, Peru, 
P ilippi es, Poland, Portugal, Qatar, Republic of Korea, Republic of Moldova, Romania, Russian Federation, e bia, Singapore, Slovakia, Slovenia, Spain, Sweden, 
Swi zerland, *Tajikistan, Thailand, Turkey, Ukraine, United Kingdom, Unit d States of America, Uruguay, Viet Nam. 
* Country newly at the highest level since 31 December 2018.
MONITOR TOBACCO USE  
AND PREVENTION POLICIES
Article 20 of the WHO FCTC states: 
“…Parties shall establish …surveillance of the magnitude, patterns, determinants and 
consequences of tobacco consumption and exposure to tobacco smoke… Parties should integrate 
tobacco surveillance programmes into national, regional and global health surveillance programmes 
so that data are comparable and can be analysed at the regional and international levels…” (174)
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Half the world is covered 
by strong tobacco use 
monitoring systems 
Over half of the world’s population 
– 4.4 billion people in 78 countries 
– live in countries with strong 
monitoring systems that include 
recent, representative and periodic 
population-based surveys and school-
based surveys which ask adults and 
adolescents about tobacco use. Most 
of these countries (46 out of 78) with 
comprehensive monitoring are high-
income countries. Despite having 
adequate resources, 25% of high-
income countries have not completed 
monitoring of tobacco use within their 
population over the last 5 years. For 
the first time in this report, however, 
one low-income country has joined 
the group of countries that monitor at 
best-practice level (Tajikistan). No recent 
surveys (since 2014) were completed 
in a total 37 of the world’s countries. 
Ongoing monitoring of 
tobacco use is a challenge  
for some countries
Since 2018, the number of countries 
monitoring at best-practice level 
has increased from 76 to 78. The 
population living in countries who 
monitor at best-practice level increased 
from 3 billion to 4.4 billion. The two 
countries joining the best-practice 
group were China and Tajikistan.
Owing to the challenges of running 
national population-based surveys 
during the COVID-19 pandemic, 
many surveys planned in 2020 were 
delayed or cancelled. Further, the 
results from some surveys undertaken 
in 2019 were not released in time 
for this report. This situation led to 
11 countries at best-practice level in 
2018 being unable to maintain the 
achievement. Consequently, these 
11 countries (Bahamas, Bangladesh, 
Bhutan, Cambodia, Costa Rica, Egypt, 
Kuwait, Myanmar, Pakistan, Panama, 
Qatar), with 577 million people, have 
exceptionally been retained in the  
best-practice group in this report.
Increases in global coverage of MPOWER measures since 2007 has helped 
reduce the global rate of tobacco smoking from 22.7% to 17.5% in 2019.
Investing in regular surveys and other measures reduce tobacco use, Tajikistan 
Since 2004, Tajikistan has 
conducted several national surveys 
to monitor progress on tobacco 
control, including Demographic and 
Health surveys in 2012 and 2017; 
a Global Adult Tobacco Survey in 
2016; the WHO STEPwise Approach 
to Noncommunicable Disease 
Risk Factor Surveillance (STEPS) in 
2016–17; a Global School-Based 
Student Health Survey in 2006 
and Global Youth Tobacco Survey 
(GYTS) in 2004, 2014 and 2019. 
The results of the adult surveys 
conducted throughout this 
period show that the tobacco use 
prevalence rate is moderate to 
high among men and very low in 
women (13.5% in total – 25.7% 
among men and 0.2% among 
women). The smokeless forms of 
tobacco appear to be the main 
area of concern requiring attention, 
with 10.3% of the population 
overall and 19.7% of men using 
smokeless tobacco (172).
The second round of the STEPS 
survey is being planned and will 
provide an opportunity to monitor 
in-country trends in tobacco use 
among adults. Furthermore, the 
fourth round of GYTS is planned 
for 2024, demonstrating Tajikistan’s 
strong commitment to monitor 
tobacco use by collecting recent, 
representative and periodic data 
for both adults and youth. 
To address the issue of tobacco use, 
the National Strategy for Prevention 
and Control of Noncommunicable 
diseases and Injuries in the Republic 
of Tajikistan 2013–2023 includes 
the target of a 20% reduction in 
smoking and nasvai tobacco use (a 
form of smokeless tobacco) by 2023. 
Reaffirming the country’s 
commitment to tobacco control 
and benefiting from the political 
will generated by the evidence 
from prevalence surveys, Tajikistan 
became a Party to the WHO FCTC 
in 2013, and in 2018 passed a 
strong new tobacco control law. 
The new law applies to all tobacco 
products, including cigarettes 
and cigars as well as hookahs, 
smokeless tobacco, cigarettes and 
electronic cigarettes, and contains 
effective tobacco control measures 
in line with the WHO FCTC.
Students in Tajikistan fill out the Global Youth Tobacco Survey in 2019
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Since 2007, 2.9 billion people in 40 
additional countries have become 
newly covered by tobacco use 
monitoring at best-practice level.
Ninety-five percent of high-income 
countries and 80% of middle-income 
countries have completed at least 
one national survey among adults or 
adolescents in the past 5 years. However, 
only 40% of low-income countries 
(12 countries) have done so. In 2020, 
there was a total of 117 countries not 
monitoring their tobacco epidemic at the 
highest level, however, 29 were just one 
step away from a comprehensive level of 
monitoring. If those 29 countries closed 
the gap to meet best-practice level there 
would be an addition 1.8 billion people 
(23% of the world’s population) living in 
countries that ensure effective monitoring 
of the tobacco epidemic to better inform 
policy measures going forward.
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Tobacco use survey reports from China
Over one billion people 
smoke, less than 100 million 
fewer than in 2007 
In total, there are almost one billion 
tobacco smokers aged 15 years and 
above worldwide. This number has 
changed little since 2007 when there 
were just over one billion tobacco 
smokers. Currently, 847 million men 
smoke tobacco (46 million fewer than 
in 2007) and 153 million women (36 
million fewer than in 2007).
Despite three out of four countries 
banning sales to minors under the age 
of 18 years – and another 10 countries 
setting an even higher age limit for 
tobacco purchases – an estimated 24 
million children aged 13–15 around 
the world smoke, and 13 million use 
smokeless tobacco (91). 
Smoking rates are  
declining globally 
Between 2007 and 2019, smoking 
rates decreased from a global average 
of 22.7% to 17.5%, showing a relative 
reduction of 23% over 12 years. 
Smoking rates in low-income countries 
are about half the rate of rates in 
high-income countries, and this ratio 
has changed little over the period. 
The relative reduction of the smoking 
rate between 2007 and 2019 in high-
income countries was 20%, and in 
low-income countries 19%. In middle-
income countries (in which three-
quarters of the world’s population lives) 
the relative reduction was only 12%.
While smoking rates are declining 
fastest on average in high-income 
countries, these countries collectively 
still have the highest average smoking 
rate of all income groups in 2019 
(21.6%). During this same decade, 
smoking among men decreased from 
37.5% to 29.6%, and smoking among 
women decreased from 8.0% to 
5.3%. In 2019, smoking rates among 
women in high-income countries are 
still the highest of all country income 
groups (16.4%) – more than four 
times the average rate in low- and 
middle-income countries (3.5%). In 
contrast, the highest rates among 
men are seen in middle-income 
countries (35.3%), where it is almost 
double the average rate found in 
low-income countries (20.2%).
Currently there is no global estimate 
of ENDS use because the data are still 
scant in many regions of the world. 
Surveys play a strong role in informing tobacco policy development, China
China is the world’s largest producer 
and consumer of tobacco products 
and is home to more than 300 
million smokers (a quarter of the 
global total). Each year more 
than 1 million people in China die 
from diseases caused by tobacco 
(91, 173). To monitor the tobacco 
epidemic, China regularly conducts 
nationally representative tobacco 
use surveys.
China undertook the Global Adult 
Tobacco Survey in 2010. The survey 
results provided important data to 
promote tobacco control policies 
in China, such as raising tobacco 
taxes and tobacco advertising, 
promotion and sponsorship bans. 
The results were also used to raise 
awareness in the general public 
through news stories and social 
media content, and to inform policy 
proposals highlighting the urgency 
for tobacco control. 
To determine the seriousness of 
the tobacco problem among young 
people, China conducted the first 
round of a Global Youth Tobacco 
Survey (GYTS) in 2013–2014. At 
the time of the survey, China’s 
national Advertising Law was being 
amended, and the results provided 
strong evidence for the promotion 
of relevant provisions to strengthen 
the regulation of tobacco 
advertising in public places. In 2019, 
China implemented a second round 
of GYTS, which showed that the 
use of ENDS among adolescents 
was increasing. The data from 
these surveys were used by public 
health organizations to advocate in 
the National People’s Congress for 
provisions related to e-cigarettes in 
the “Minors Protection Law”.
Because of its vastness and diversity, 
national surveillance in China is 
challenging: data collectors have 
struggled to reach households in 
remote areas and sometimes spend 
several days visiting people’s homes 
to complete the questionnaires. 
However, robust research design has 
ensured that data are successfully 
gathered and are nationally 
representative. With China achieving 
the MPOWER best-practice level 
for monitoring tobacco use, 1.4 
billion more people are now covered 
by nationally representative and 
periodically collected data that 
help fight the tobacco epidemic. 
China aims to continue to improve 
its tobacco surveillance system to 
strengthen tobacco control and 
reduce tobacco use.
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PROTECT PEOPLE  
FROM TOBACCO SMOKE
The harms of  
second-hand smoke
There is no safe level of exposure 
to second-hand smoke, and even 
brief exposure can cause harm (175). 
Severe or fatal diseases, including 
heart disease, respiratory disease, and 
cancer (41, 176, 177) can result from 
exposure to second-hand smoke – and 
non-smokers living with smokers are 
at greater risk of such diseases, and 
premature death (178). Children and 
infants are particularly susceptible and 
at increased risk for respiratory disease, 
middle-ear disease, and sudden infant 
death syndrome (179–184). Pregnant 
women exposed to second-hand smoke 
are more likely to experience stillbirths, 
and their fetuses are more likely to have 
congenital malformations and lower 
birth weights (184). The only way to 
adequately protect both smokers and 
non-smokers from second-hand smoke 
is to fully eliminate indoor smoking 
(178). For example, an analysis based 
on data from Brazil suggested that, 
over a period of 16 years, up to 15 000 
infant deaths may have been averted by 
the implementation of comprehensive 
smoke-free laws (185).
Smoke-free must mean 
completely smoke-free
It is a misconception that smoke-free 
places that allow designated smoking 
rooms are indeed smoke-free and 
protect non-smokers from second-hand 
smoke. Such exceptions – designated 
smoking areas or rooms, ventilation 
systems, air exchanges, and filtration 
devices – are not protective, and 
cannot eliminate all second-hand 
smoke (41, 186, 187). Indeed, such 
accommodations weaken the impact 
of smoke-free laws. The only way to 
fully protect people from second-
hand smoke is to permit no exceptions 
(187–189). This is because, when fully 
implemented, smoke-free laws are 
highly effective in decreasing exposure 
and enhancing indoor air quality for 
both smokers and non-smokers  
(186, 190, 191).
The wider benefits of 
smoke-free laws are  
far-reaching
There is robust evidence that public 
spaces with smoke-free laws see 
reduced hospital admissions for acute 
coronary syndrome and reduced 
mortality from smoking-related illnesses 
(187). Smoke-free laws make smoking 
less acceptable, less visible to children 
and youth, and encourage healthier 
behaviours such as not smoking in the 
home or in the car (192–194). Smoke-
free environments may also encourage 
smokers to reduce their tobacco use, 
make a quit attempt, and remain 
tobacco-free in the long-term (191, 195). 
Smoke-free laws do not 
hurt business
In spite of tobacco industry assertions 
to the contrary, the best-designed 
studies report that smoke-free 
laws have no adverse economic 
consequences for businesses, including 
the hospitality industry (196–198). In 
fact, when applied, smoke-free laws 
invariably receive overwhelming public 
support (191, 199) and encourage 
families with children to visit and 
consume in places previously avoided 
by them. Smoke-free laws are relatively 
easy to pass and economically and 
politically feasible to enforce, and 
an increasing number of countries 
continue to adopt comprehensive 
smoke-free legislation at national and 
subnational level. 
Still, only 34% of countries 
and 24% of the world’s 
population are protected 
by complete smoking bans
There has been sustained progress in 
the adoption of smoke-free laws since 
2007, when only 10 countries in the 
world had a comprehensive smoking 
ban in place, covering just 3% of the 
world’s population. Since then, 1.6 
billion additional people in 57 additional 
countries are now covered by best-
practice smoke-free laws. This means 
Article 8 of the WHO FCTC states: 
“… [S]cientific evidence has unequivocally established that exposure to tobacco smoke causes death, disease and 
disability … [Parties] shall adopt and implement … measures providing for protection from exposure to tobacco 
smoke in indoor workplaces, public transport, indoor public places and, as appropriate, other public places”. 
WHO FCTC Article 8 guidelines are intended to assist Parties in meeting their obligations under Article 8 of the  
WHO FCTC and provide a clear timeline for Parties to adopt appropriate measures (within 5 years after entry  
into force of the WHO FCTC for a given Party) (174).
 WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC 2021 | 65
that there are now 1.8 billion people (a 
quarter of the world’s population) living 
in 67 countries where the smoking bans 
are at best-practice level.
While around one third of countries 
in each income group are covered by 
comprehensive smoke-free bans, more 
than half of these countries (39 of 67 
countries) with comprehensive smoking 
bans in 2020 were middle-income 
countries. The complete absence of 
smoking bans, or minimal bans that are 
not comprehensive enough to protect 
people from the harms of second-hand 
smoke, are remarkably common in 
high-income countries. In fact, 18 high-
income countries (30%) are leave their 
populations exposed to second-hand 
smoke in public places. The same is true 
for 25 middle-income countries (22%) 
and 13 low-income countries (45%). 
In the past 2 years, five countries have 
joined the group of countries providing 
protection at best-practice level, with 
all public places completely smoke-free. 
One of these countries (Saint Lucia) 
went from a minimal law covering 
only health care and governmental 
facilities to a complete ban covering all 
public places and workplaces. Three 
countries (Bolivia (Plurinational State 
of), Ethiopia and Jordan) advanced 
from three to five public places covered 
by comprehensive smoke-free bans, 
and one country (Paraguay) extended 
the smoke-free ban to two additional 
places (restaurants and cafés/pubs/
bars) to reach best-practice level. 
37% of countries, and  
38% of the world’s 
population, have partial 
smoking bans that fall  
short of best practice
There are 12 countries, representing 
124 million people, that only need to 
cover one more place with a smoking 
ban to join the 67 other countries 
with comprehensive smoke free laws: 
Tonga (universities); Democratic 
People’s Republic of Korea (government 
facilities); Cook Islands, Mauritius, 
Ukraine and Zambia (indoor offices); 
Senegal (restaurants); Bhutan (cafés, 
pubs, bars); and Armenia, Cyprus, 
Georgia and Hungary (public transport). 
A further 17 countries with 1.6 billion 
people only need to cover two more 
places with a smoke-free ban to reach 
best-practice adoption.
Six countries (with 260 million people 
in total) improved their smoke-free law 
since 2018 but did not reach best-
practice level in 2020. Fourteen countries 
(with 1.6 billion people in total) would 
achieve a comprehensive ban by simply 
removing the allowance of designated 
smoke rooms under the law.
Of the 524 million people (6.7% of  
the world’s population) who live in one 
of the world’s 100 largest cities, only 
299 million (in 47 cities) are protected 
by a comprehensive smoke-free law. 
Five of these cities (Bandung, Beijing, 
Hong Kong SAR, Jakarta and Medan) 
are covered by city-level smoke-free 
laws; seven are covered by state- or 
province-level smoke-free laws; and the 
remaining 35 are covered by national 
laws. Instead of waiting for national 
legislation to be adopted, the remaining 
52 of the world’s largest cities not 
currently protected by a national best-
practice law could move ahead with a 
city, state or provincial level law to more 
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Smoke-free environments
SMOKE-FREE ENVIRONMENTS – HIGHEST ACHIEVING COUNTRIES, 2020
Countries and areas with the highest level of achievement: Afghanistan, Albania, Antigua and Barbuda, Argentina, Australia, Barbados, Benin, *Bolivia 
(Plurinational State of), Brazil, Brunei Darussalam, Bulgaria, Burkina Faso, Burundi, Cambodia, Canada, Chad, Chile, Colombia, Congo, Costa Rica, Ecuador, Egypt, 
El Salvador, *Ethiopia, Gambia, Greece, Guatemala, Guyana, Honduras, Iran (Islamic Republic of), Ireland, Jamaica, *Jordan, Lao People’s Democratic Republic, 
Lebanon, Libya, Madagascar, Malta, Marshall Islands, Namibia, Nauru, Nepal, New Zealand, Niue, North Macedonia, Norway, occupied Palestinian territory, 
Pakistan, Panama, Papua New Guinea, *Paraguay, Peru, Romania, Russian Federation, *Saint Lucia, Seychelles, Spain, Suriname, Tajikistan, Thailand, Trinidad  
and Tobago, Turkey, Turkmenistan, Uganda, United Kingdom, Uruguay, Venezuela (Bolivarian Republic of).
* Country newly at the highest level since 31 December 2018.
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Total population: 7.8 billion Total number of countries: 195
Comprehensive smoke-free legislation 
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Ethiopia hospitality sector goes smoke-free
In February 2019, Ethiopia passed a 
law requiring public buildings and 
workplaces (including hotels) to be 
100% smoke-free (Proclamation No. 
1112/2019). The law bans smoking 
or tobacco use in any indoor and 
outdoor space within 10 metres of 
any doorway, operable window, or 
air-intake mechanism of any public 
place or workplace. 
The hospitality sector has some 
of the greatest levels of exposure 
to second-hand smoke, which 
means that if Ethiopia’s smoke-free 
law enforcement and compliance 
is to be effective, this sector 
needs to be fully on board. In 
2019, the Ethiopian Food and 
Drug Administration Authority 
(EFDA) – mandated to enforce 
and coordinate implementation of 
tobacco control activities in Ethiopia 
– undertook measures to scale up 
enforcement of the smoke-free 
regulation nationwide. EFDA raised 
awareness of the new law among 
staff nationally and locally, and 
introduced and promoted the new 
law among stakeholders, including 
hotels and resorts in Addis Ababa. 
Orientation workshops outlining the 
roles and responsibilities of hotel 
or resort owners were organized. 
More than 15 000 “No smoking” 
stickers and 3000 posters were 
printed and disseminated. These 
capacity-building activities were 
followed by compliance inspections. 
More than 16 000 inspections by 
regulators of a variety of public 
places across the country have been 
reported since 2019. 
After the new proclamation, 
many hotels made huge efforts to 
implement the 100% smoke-free 
law. Customers are informed by “no 
smoking” signs and verbally during 
reservation and at check-in that that 
smoking is prohibited within the 
hotel and its premises. No designated 
smoking rooms or areas, or ashtrays, 
are available. Hotel staff have 
welcomed the new law because it 
protects both customers and staff.
No Smoking sign in hotel lobby, Addis Ababa
Paraguay bans smoking in indoor public spaces spurred by COVID-19 evidence
An estimated 5000 people died 
from tobacco-related diseases in 
2019 in Paraguay, with almost 700 
of these deaths associated with 
exposure to second-hand smoke 
(200). The impact of tobacco use on 
the health of Paraguay’s population 
has been further highlighted 
during the COVID-19 pandemic, as 
evidence showed that tobacco users 
were more likely to suffer severe 
consequences of the disease. In fact, 
the link between COVID-19 and 
tobacco use was part of the rationale 
behind strengthening tobacco 
control in Paraguay during 2020.
Since Paraguay ratified the WHO 
FCTC in 2006 the country has 
embarked on ensuring that its 
tobacco control policies align with 
the Convention. After several failed 
attempts to adopt a complete 
smoke-free law, the passing of 
Decree 4624 in December 2020 
established that smoking traditional 
(cigars, cigarettes), heated, or 
electronic tobacco products would 
be permitted only in uncrowded 
open-air public spaces that are 
not transit areas for non-smokers. 
This closed the country’s previously 
remaining gap, which allowed 
smoking areas in enclosed, 
hospitality spaces. 
By making all indoor public spaces 
and workplaces, as well as public 
transport completely smoke-free, 
the decree brings Paraguay into 
compliance with a central mandate 
of the WHO FCTC: to protect 
populations from the harmful 
effects of tobacco. Simultaneously, 
the passage of this regulation made 
South America the first sub-region 
in the Americas to become entirely 
100% smoke-free. No smoking and no e-cigarette use signs 
in Paraguay
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OFFER HELP TO QUIT TOBACCO USE
The desire to quit is strong, 
but help is too scarce
Tobacco control policies in many 
countries have successfully motivated 
people to make quit attempts. On 
average, across countries where the 
Global Adult Tobacco Survey has been 
conducted, over 60% of smokers 
indicated that they intend to quit, and 
over 40% had attempted to quit in the 
12 months preceding the survey. While 
this is encouraging, support for quitting 
remains low (91).
Quitting tobacco has  
instant benefits
The health benefits of quitting smoking 
can be felt within hours or even minutes. 
In just one day, quitting tobacco can help 
reduce a person’s heart rate and blood 
pressure, and blood carbon monoxide 
levels can be expected to return to normal 
(201). Within 3 months of quitting, 
circulation and lung function improves, 
and within 1–9 months, coughing and 
shortness of breath generally decrease 
(201). The risk of death due to tobacco 
use also begins to decrease soon after 
quitting. The risk of death from lung 
cancer is reduced by 30–50% within 
10 years of quitting smoking (201), with 
current evidence suggesting that the risk 
of death from ischemic heart disease is 
halved within 5 years of quitting, and the 
risk of stroke returns to that of a never 
smoker within 5–15 years. 
Support is vital to quitting
Nicotine is so addictive that a quarter 
of teenagers can become dependent 
upon it after smoking just three or 
four cigarettes, and after smoking 
five packs, nearly 60% are dependent 
(202). Most people who use tobacco 
regularly do so because they are 
addicted to nicotine. This means they 
can therefore benefit greatly from a 
range of effective tobacco cessation 
interventions. Without cessation 
assistance, only around 4% of attempts 
to quit tobacco are successful (203).
Proven cessation medications and 
professional support can double a 
tobacco user’s chance of successfully 
quitting (204) and a number of 
different approaches have been 
developed to help people succeed. 
These can broadly be categorized 
as behavioural or pharmacological 
interventions, and differ in terms of 
their intensity, cost and effectiveness. 
Combining both behavioural and 
pharmacotherapy interventions is 
more effective and can double the 
chances of successfully quitting (a 70% 
to 100% relative increase compared 
to brief advice or support) (205). 
Behavioural interventions  
are efficient and present  
an opportunity to reach 
potential quitters
When a tobacco user visits a primary 
or specialized care service it presents 
an opportunity for the health-care 
worker to offer or provide them with 
personalized counselling. This “brief 
advice” from health professionals – 
given as part of a routine consultation 
or interaction – makes efficient use of 
the existing health-care system (205). 
Toll-free quit lines are another 
convenient way for potential tobacco 
quitters to access brief and potentially 
intensive behavioural counselling. 
Those that use quit lines increase their 
absolute quit rate by 4 percentage 
points, which represents a doubling 
of success compared to those who 
attempt to quit without assistance 
(204). This rate can be further increased 
if the quit line is “proactive” and 
counsellors make follow-up calls to 
potential tobacco quitters. Recent 
app-based interventions for cessation 
are promising, with text message 
interventions increasing the absolute 
quit rate by 4% (206).
Pharmacological interventions 
are diverse and can work  
better in combination
The effectiveness of pharmacotherapies 
to assist quitting tobacco is generally 
higher compared to people who did 
not use an intervention. The quit 
rate increase ranges from 6% for a 
single type of NRT to almost 15% for 
Varenicline. Pharmacotherapy cessation 
interventions include NRTs, as well as 
medications that do not contain nicotine 
but act to alleviate tobacco withdrawal 
symptoms. Combining more than one 
NRT (patches and a faster-acting form) 
can also increase NRT effectiveness.
Article 14 of the WHO FCTC states: 
“Each Party shall … take effective measures to promote cessation of tobacco use and adequate treatment for 
tobacco dependence… . Each Party shall … design and implement effective programmes aimed at promoting 
the cessation of tobacco use”. WHO FCTC Article 14 guidelines are intended to assist Parties in meeting their 
obligations under Article 14 of the WHO FCTC) (174).
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Over 30% of the world’s 
population are covered  
by comprehensive  
cessation services
As of 2020, comprehensive tobacco 
cessation services are in place for 2.5 
billion people in 26 countries – or 32% 
of the world’s population. The number 
of countries adopting comprehensive 
tobacco cessation measures lags behind 
the other MPOWER measures, with 
only 17 high-income countries and 
nine middle-income countries offering 
comprehensive cessation support. No 
low-income countries currently offer 
best-practice services.
Globally, almost all high-income 
countries (89%) offer at least partial 
coverage of the cost of cessation 
services. Most middle-income countries 
(72%) do the same, while 18% of 
low-income countries offer some 
cost-coverage for services. There are 
32 countries that provide no cessation 
support at all. These numbers show 
that while work has begun, there is still 
much more to be done.
Demand for cessation 
services is high and  
this must be met 
Since 2018, the number of countries 
offering comprehensive cessation 
services increased from 24 to 26, 
and the proportion of the world’s 
population covered by comprehensive 
cessation services increased from 31% 
to 32%. Five countries with a combined 
population of 129 million (Austria, 
Cook Islands, Jordan, Philippines and 
Tonga) began offering comprehensive 
cessation services in the past 2 years. 
Disappointingly, however, the number  
of people protected by this has been 
offset by three countries (Australia,  
El Salvador and Senegal, representing  
48 million people) dropping out of the  
best-practice group in the same period. 
Only four high-income countries (7% 
of the 61 high-income countries) offer 
no support to help users quit, while 12 
middle-income countries (11%) and 16 
low-income countries (55%) offer no 
support to tobacco users.
While progress has been slower in 
“O” than other MPOWER measures 
since 2007, best-practice adoption of 
cessation services nonetheless increased 
from 10 countries (5% of the world’s 
population) in 2007 to 26 countries 
(32% of the world’s population) in 
2020 – meaning 2.1 billion additional 
people are now protected by this 
measure. The population offered  
best-practice cessation services in 2020 
is six times what it was in 2007 (when  
it was only 406 million people). 
Sixty-seven countries – home to 2.2 
billion people – provide cessation 
support packages that are missing only 
one element to achieve best-practice 
implementation: (i) a national toll-free 
quit line; (ii) cost-coverage of NRT; or 
(iii) cost-coverage of cessation services 
in clinical settings or in the community. 
Of these 67 countries, 26 need to add 
a national toll-free quit line in order to 
bring comprehensive tobacco cessation 
support to an additional 827 million 
people, while 38 need to offer cost-
covered NRTs to cover an additional 
1.3 billion people. Three countries 
need to cost-cover one or more of its 
cessation services in clinical settings or 
the community so that an additional 50 
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Tobacco dependence treatment
TOBACCO DEPENDENCE TREATMENT – HIGHEST ACHIEVING COUNTRIES, 2020
Countries with the highest level of achievement: *Austria, Brazil, Canada, *Cook Islands, Costa Rica, Czechia, Denmark, India, Ireland, Jamaica, *Jordan, Kuwait, 
Luxembourg, Mexico, Netherlands, New Zealand, *Philippines, Republic of Korea, Saudi Arabia, Singapore, Slovakia, Sweden, *Tonga, Turkey, United Arab 
Emirates, United States of America.
* Country newly at the highest level since 31 December 2018.
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Of the 524 million people (6.7% of the 
world’s population) who live in one of 
the world’s 100 largest cities, only 252 
million (in 48 cities) are protected by a 
comprehensive cessation service. Two 
of these cities are covered by city-level 
policies (Hong Kong SAR and London) 
and the remaining 46 are covered by 
national policies. Instead of waiting for 
a national policy to be put in place, the 
remaining 52 large cities not currently 
protected by a national best-practice 
policy could move ahead with a city, 
state or provincial level policy to help 
their large populations sooner.
Amid significant health-care service disruptions during the COVID-19 
pandemic, 120 million additional people now have access to toll-free  
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Total population: 7.8 billion Total number of countries: 195
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Tonga becomes first Pacific Island Country to offer comprehensive  
cessation support 
Tonga’s smoking prevalence is among 
the highest in the world, with 40% of 
males and 16% of females smoking 
in 2017 (aged 18 to 69) (207). To 
address this, Tonga has implemented 
laws and policies to reduce the 
affordability of tobacco; prevent 
tobacco advertising, promotion 
and sponsorship; expand smoke-
free public places; and strengthen 
enforcement. These actions have 
increased the demand for cessation 
services, with 53.9% of male smokers 
and 62.9% of women smokers 
trying to quit smoking at least once 
in the past 12 months (207). 
The Ministry of Health’s “Quit 
Smoking Now”campaign, launched 
in 2016, and delivered through TV, 
radio, social media and outdoor 
signage, focuses on increasing 
motivation to quit, providing 
support to people who want to quit, 
and advocating for stronger policies 
to restrict the sale, distribution and 
use of tobacco products in Tonga.
A national toll-free quit line, the 
first of its kind in the South Pacific, 
was launched in 2016 as part of the 
campaign. Trained quit line advisors 
answer calls Monday to Friday 
during business hours to provide 
brief counselling support. One in 
three tobacco users supported 
through the quit line successfully 
quit for at least six months. 
Also as part of the government’s 
comprehensive programme on 
cessation, regular brief tobacco 
intervention trainings are 
conducted for primary health-
care workers throughout Tonga, 
and the government has also 
partially covered the cost of 
nicotine replacement therapies. 
An evaluation in 2017 revealed that 
95% of Tongans between the ages 
of 18 and 64 were aware of the 
campaign and awareness of the quit 
line increased from 40% to 74% 
(208). Tonga’s case highlights that 
strong government commitment 
and dedicated resources are key to 
tobacco cessation. These efforts 
received international recognition 
when the Ministry of Health and the 
Tonga Health Promotion Foundation 
won the World No Tobacco Day 
Award in 2018. 
Quit line advertisement in Tonga 
Scaling up cessation services in Jordan
With a 41% smoking rate, tobacco 
is the leading risk factor for 
noncommunicable diseases (NCDs) 
in Jordan, causing nearly 17% of all 
deaths in 2019 (200). According to 
the country’s 2019 STEPS Survey, 
about 50% of adult smokers in 
Jordan had tried to quit smoking 
in the past 12 months, yet only 
a small percentage of them had 
access to support to do it (209). 
In response, the Jordanian Ministry 
of Health greatly scaled up national 
tobacco cessation services through 
its partnership with the Access 
Initiative for Quitting Tobacco, a 
joint initiative between WHO, the 
UN Interagency Task Force on NCD 
Prevention and Control, and PATH, 
with support from the Coalition 
for Access to NCD Medicines and 
Products. The initiative is designed to 
help countries deliver comprehensive 
tobacco cessation services during the 
COVID-19 pandemic. In 2020, Jordan 
became the fourth country in the 
WHO Eastern Mediterranean Region 
to provide comprehensive tobacco 
cessation services, achieving this 
through a newly established national 
toll-free quit line, strengthened 
tobacco cessation support in primary 
care, and free access to NRT.
Jordan also received donated NRT 
products to help 5400 frontline 
workers, patients with NCDs, and 
refugees quit smoking, greatly 
expanding cessation services in 
the country’s primary health-care 
centres. In addition to this support, 
tobacco users can also freely access 
WHO’s first virtual health worker, 
Florence, who helps people develop 
a personalized plan to quit and can 
refer them to cessation services 
such as the quit line. 
Tobacco cessation consultation in Jordan
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WARN ABOUT THE DANGERS 
OF TOBACCO
Graphic health warning 
labels are critical 
Many tobacco users still do not know, 
or do not fully understand, the dangers 
to which they expose themselves and 
others by consuming tobacco (210). In 
this context, consumers have a right to 
be warned about the health impacts 
of the products they buy and use 
(210–212). Graphic health warnings 
provide accurate information about 
the risks associated with tobacco use 
and can help encourage tobacco users 
to reduce their consumption and quit 
(213, 214). Effective health warnings 
can also communicate the risks of 
exposing others to second-hand smoke 
(215). There is significant evidence that 
accurate, prominent warnings prompt 
tobacco users to think about quitting, 
and can result in decreased tobacco  
use (216, 217). 
The power of packaging
Packaging allows companies to “sell” 
their product by manipulating people’s 
perception of taste, strength, and the 
health impacts associated with it (218). 
Marketing terms suggesting reduced 
health risks including “light”,  
“ultra-light”, and “low tar” are 
deceptive and should be banned (216). 
However, this may not be sufficient to 
decrease the misperceptions of reduced 
risk associated with these cigarette types 
(219, 220). Other requirements, such as 
plain packaging, may help to transform 
people’s perceptions.
Graphic health warnings on tobacco 
product packaging are a reliable way 
of reaching users with important 
information (221) and are a relatively 
cheap public communication method 
for governments (221). Graphic health 
warnings are well-supported by the 
public – more than most other tobacco 
control measures (215, 222).
These warnings are most effective when 
pictorial, graphic, comprehensive, and 
strongly worded (223, 224), and are 
particularly effective in deterring youth 
and young adults from cigarette and 
smokeless tobacco use (225). To be 
effective they should be large, cover at 
least half of a package’s surface (front 
and back) (221), and should refer to 
specific health effects from tobacco use. 
To maintain their impact, labels should 
be rotated on a regular basis (226). Over 
time, strengthening the warnings can 
increase knowledge about the harms of 
tobacco, and can increase quit attempts 
and reduce cigarette consumption (227). 
Strong graphic package warnings are 
in place for almost 4.7 billion people 
in 101 countries – covering over 
half of the global population (60%) 
and over half of all countries. More 
people are protected by this MPOWER 
measure than any other, with 52% of 
countries adopting graphic warning 
requirements at the highest level: 69% 
of high-income countries, 50% of 
middle-income countries and 24% of 
low-income countries. Only 43 countries 
(six high-income, 24 middle-income and 
13 low-income) adopted warnings that 
cover less than 30% of the pack or have 
not adopted any warning labels, and 51 
others have issued warnings that cover 
30% but less than 50% of the principal 
package display areas (below the 
minimum required by the WHO FCTC). 
HEALTH WARNING LABELS
Article 11 of the WHO FCTC states: 
Each Party shall … adopt and implement … effective measures to ensure that … tobacco product packaging  
and labelling do not promote a tobacco product by any means that are false, misleading, deceptive or likely  
to create an erroneous impression about its characteristics, health effects, hazards or emissions”. 
WHO FCTC Article 11 guidelines are intended to help Parties meet their obligations under Article 11 of the  
WHO FCTC, which provides a clear timeline for Parties to adopt appropriate measures (within 3 years after  
entry into force of the WHO FCTC for a given Party) (174).
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Health warning labels
HEALTH WARNING LABELS – HIGHEST ACHIEVING COUNTRIES, 2020
In the past 2 years, eight additional 
countries, with 9% of the world’s 
population, have joined the 93 countries 
that require large graphic warning 
labels on tobacco products. Two are 
high-income countries (United States 
and Qatar), three are middle-income 
countries (Mauritania, Montenegro 
and Nigeria), and three are low-income 
countries (Ethiopia, Gambia and Niger). 
All eight countries strengthened existing 
laws to meet best-practice level.
Of all MPOWER measures, large graphic 
pack warnings on cigarettes have 
seen the most progress since 2007 
both in terms of countries acting and 
population covered by a best-practice 
policy. Since 2007, when only nine 
countries (5% of the world’s population) 
had large graphic pack warnings on 
cigarettes, an additional 92 countries 
(with 55% of the world’s population) 
have acted to meet comprehensive 
graphic warning requirements. 
More countries have 
adopted strong graphic 
health warnings than any 
other MPOWER measure
Twenty-three countries, representing 
658 million people, are only one step 
away from best-practice graphic  
health warnings.
Eight countries, with a total of 435 
million people, need only increase the 
size of the graphic health warnings 
to cover up to another 20% of the 
packages to meet all best-practice 
criteria for large graphic warnings. 
An additional six countries, with a 
total population of 20 million, need 
only add a requirement for a graphic 
image (instead of text only) to meet 
best-practice. Nine other countries, 
with a total population of 203 million, 
have mandated large graphic warnings 
covering at least 50% of the pack, and 
need only add one criterion to achieve 
best practice – eight of these need only 
mandate that the warnings appear 
on each package and any outside 
packaging used in the retail sale, and 
one country needs only to stipulate 
rotation of warnings.
Seven countries (Iraq, Israel, Japan, 
Maldives, Niue, Uganda, Uzbekistan), 
with 255 million people, improved their 
legislation since 2018 but did not reach 
best-practice level in 2020.
Of the 524 million people (6.7% of the 
world’s population) who live in one of 
the world’s 100 largest cities, only 379 
million (in 67 cities) are informed about 
the dangers of tobacco use by the display 
of large graphic warning labels on their 
cigarette packs. One of these cities is 
covered by city-level legislation (Hong 
Kong SAR) and the remaining 66 are 
covered by national laws. 
More than half of all countries are now covered by graphic 
health warnings on tobacco packaging at best-practice level
Countries with the highest level of achievement: Argentina, Armenia, Australia, Austria, Bangladesh, Barbados, Belarus, Belgium, Bolivia (Plurinational State of), 
Brazil, Brunei Darussalam, Bulgaria, Burkina Faso, Cambodia, Cameroon, Canada, Chad, Chile, Costa Rica, Croatia, Cyprus, Czechia, Denmark, Djibouti, Ecuador, 
Egypt, El Salvador, Estonia, *Ethiopia, Fiji, Finland, France, *Gambia, Georgia, Germany, Ghana, Greece, Guyana, Honduras, Hungary, India, Iran (Islamic Republic 
of), Ireland, Italy, Jamaica, Kazakhstan, Kyrgyzstan, Lao People’s Democratic Republic, Latvia, Lithuania, Luxembourg, Madagascar, Malaysia, Malta, *Mauritania, 
Mau itius, Mexico, Mongolia, *Montenegro, Nam bia, Nepal, Netherlands, New Zealand, *Niger, *Nigeri , akistan, Panama, Peru, Philippines, Poland, Portugal, 
*Qatar, Republic of Moldova, Romania, Russian Federation, Saint Lucia, Samoa, Saudi Arabia, Senegal, Seychelles, Singapore, Slovakia, Slovenia, Solomon Islands, 
Spain, Sri Lanka, Suriname, Sweden, Tajikistan, Thailand, Timor-Leste, Trinidad and Tobago, Turkey, Turkmenistan, Ukraine, *United Kingdom, United States of 
America, Uruguay, Vanuatu, Venezuela (Bolivarian Republic of), Viet Nam.
* Country newly at the highest level since 31 December 2018.
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An increasing number of countries require plain packaging of tobacco products
Several countries are moving forward with plain packaging. By the end of 2020, 17 countries had adopted legislation 

























































No warning or small warnings
Medium size warnings missing 
some or many appropriate 
characteristics OR large warnings 
missing many appropriate 
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Medium size warnings with all 
appropriate characteristics OR 
large warnings missing some 
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Large warnings with all 
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Mauritania goes from no health warnings to large graphic health warnings 
packaging requirements
Mauritania has been Party to 
the WHO FCTC since 2005, and 
in June 2018 introduced its first 
tobacco control legislation – the 
culmination of a long-running effort 
that included the involvement of 
dedicated parliamentarians, civil 
society (including the Centre for 
Tobacco Control in Africa), and the 
WHO Country Office. 
A 2018 law concerning the 
Production, Importation, Distribution, 
Sale, Advertising, Promotion and 
Consumption of Tobacco and its 
Products, stated that packages or 
cartridges, and all forms of outer 
packaging of tobacco products, must 
include a health warning covering 
at least 70% of the surface on both 
sides. These warnings must include 
pictures and text, and be written 
in Mauritania’s official languages. 
Since then the Minister of Health 
has issued a decree in February of 
2020, regulating the warnings. This 
came into force on May 30, 2021. 
The decree prohibits the inclusion 
of descriptive terms or other signs 
that directly or indirectly give the 
impression that a particular tobacco 
product is less harmful than others, 
including terms such 
as “low tar”, “light”, 
“ultralight” or “soft”, 
etc, or other terms that 
have a similar meaning 
in other languages. The 
requirements apply to packs 
and any external packaging, 
including cartons. 
Mauritania is one of the 
rare examples of a country 
that has gone from no 
warning requirements to 
large pictorial warnings required, 
with all appropriate characteristics  
and more. The country is now one of 
the 14 highest achieving countries of 
the African Region in 2020 in terms 
of health warning labels (joined 
recently by Ethiopia and Gambia), 
and has already banned smoking in 
public places and on public transport.
Graphic health warnings mark the biggest change in labelling in four decades  
in the United States
Cigarette smoking remains the 
leading cause of preventable 
disease, disability, and death in the 
United States,1 and authorities have 
therefore taken steps to strengthen 
measures to warn the public of the 
risks associated with tobacco use.
After several attempts to issue 
and implement regulations that 
align with the Family Smoking 
Prevention and Tobacco Control Act 
2009 (attempts that were met by 
legal challenges from the tobacco 
industry), a new rule issued by the 
FDA in March 2020 has mandated 
11 new warnings on various health 
conditions to occupy the top 50% 
of the front and rear of tobacco 
packages and at least 20% of the 
top of cigarette advertisements. The 
warnings include a broad selection 
of text as well as graphic images.
This move is considered the most 
significant change in cigarette 
labelling in the United States 
since 1984. It reflects successive 
governments’ commitment to 
protect the population from the 
harms caused by tobacco and to 
close the gaps in public awareness 
about the adverse effects of 
tobacco. It is anticipated that the 
proposed rule will take effect in July 
2022,1 and will place the United 
States as the 22nd country in the 
Region of the Americas to attain 
the highest achievement for “W”  
as per the MPOWER measures.
One of 13 proposed warning label featuring 
text statements accompanied by photo-
realistic colour images depicting lesser known 
health risks of cigarette smoking (228).
1 US Food and Drug Administration. See https://www.fda.gov/regulatory-information/search-fda-guidance-documents/required-warnings-cigarette-packages-and-
advertisements-small-entity-compliance-guide-revised for more information.
Graphic health warning label, Mauritania
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ANTI-TOBACCO MASS MEDIA CAMPAIGNS
Article 12 of the WHO FCTC states: 
“Each Party shall promote and strengthen public awareness of tobacco control issues, using all available 
communication tools, as appropriate. … each Party shall … promote … broad access to effective and 
comprehensive educational and public awareness programmes on the health risks including the addictive 
characteristics of tobacco consumption and exposure to tobacco smoke; … [Each party shall promote]  
public awareness about the risks of tobacco consumption and exposure to tobacco smoke, and about the 
 benefits of the cessation of tobacco use and tobacco-free lifestyles; … [each party shall promote] public  
awareness of and access to information regarding the adverse health, economic, and environmental  
consequences of tobacco production and consumption”. WHO FCTC Article 12 guidelines are intended  
to assist Parties in meeting their obligations under Article 12 of the WHO FCTC (174).
Hard-hitting mass media 
campaigns are effective  
and essential
Mass media anti-tobacco campaigns are 
commonly used in high-income countries 
but have been shown to be effective in 
low- and middle-income countries as 
well (229). There is strong evidence that 
if well-designed and hard-hitting, they 
can reduce tobacco use, increase quit 
attempts, lower youth initiation rates and 
reduce second-hand smoke exposure 
(230–235). As such it is imperative that 
these campaigns form an important part 
of all comprehensive tobacco control 
strategy or programmes (236). 
Television campaigns using graphic 
imagery are especially effective in 
motivating quit attempts (234, 236). 
Sustained campaigns involving multiple 
communication channels (i.e. TV, radio 
and the Internet) are more likely to 
have a longer-term impact on tobacco 
use behaviour, but campaigns with a 
duration of as little as 3 weeks can also 
have a positive impact (231, 237–239). 
While expensive, mass media 
campaigns can quickly and efficiently 
reach large populations (234) with 
messages and information on how 
to quit, and can include toll-free quit 
line numbers on campaign products, 
e.g. at the bottom of posters or at 
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Anti-tobacco mass media campaigns
ANTI-TOBACCO MASS MEDIA CAMPAIGNS – HIGHEST ACHIEVING COUNTRIES, 2020
Countries with the highest level of achievement: *Angola, Belarus, *Cabo Verde, *China, Costa Rica, *Cuba, El Salvador, Estonia, *Ethiopia, France, Georgia, 
G rmany, *Ghana, *Guyana, Indo esia, Ireland, *Japan, *Kazakhstan, *Latvia, *Malaysia, *Monaco, *Morocco, Myanmar, *Namibia, New Zealand, Norway, 
*Palau, Qatar, Republic of Korea, *Russian Federation, *Rwanda, Saint Lucia, *Saudi Arabia, *Thailand, Timor-Leste, Togo, Tonga, *Tunisia, Turkey, Turkmenistan, 
*Tuvalu, *Ukraine, United Kingdom, United States of America, Viet Nam.
* Country newly at the highest level since 31 December 2018.
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More than half of the 
world’s population  
were not exposed to a 
best-practice mass media 
campaign in 2020
Almost half of the world’s population 
(3.3 billion people) live in a country  
that has aired at least one national  
anti-tobacco mass media campaign at 
best-practice level in the past 2 years. 
Another 39% of the population lived 
in countries that conducted mass 
media campaigns of at least 3 weeks’ 
duration, with some but not all  
best-practice criteria.
Of the 45 countries that ran a  
best-practice anti-tobacco campaign 
during that time, 15 were high-income 
countries (25% of high-income 
countries); 27 were middle-income 
countries (26% of middle-income 
countries); and three were low-income  
countries (10% of low-income 
countries). More than half of the 
countries in the world (103) have not 
run any kind of sustained campaign in 
the past 2 years, leaving about 17% of 
the world’s population unreached by 
any national campaign.
National mass media  
efforts continue to lag 
People in low-income countries are 
the least exposed to anti-tobacco mass 
media: over 64% of the population 
of low-income countries, living in 21 
countries, have not been exposed 
to any kind of national campaign in 
the past 2 years. The first period for 
which mass media campaigns were 
monitored was 2009-10. Since then, 
the total number of people exposed to 
a best-practice mass media campaign 
rose until 2013-14, when 4.3 billion 
people lived in countries airing such 
campaigns. Regrettably, this number 
dropped to 1.8 billion people in 2018. 
In 2020, the campaign implemented in 
China brings the total population back 
up to 3.3 billion. 
Most countries that run campaigns  
do not repeat the effort every 2 years. 
Since 2009-10, only three countries 
have run a best-practice campaign 
every 2 years (Turkey, United Kingdom 
and Viet Nam). Seven countries ran a 
best-practice campaign five times over 
the six 2-year periods, missing only 
one opportunity to sustain the series 
of campaigns (Australia, El Salvador, 
Ireland, Malaysia, Norway, Republic  
of Korea and United States).
Mass media campaigns have been neglected  
for too long – more than half of countries ran  
no recent national campaign.
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Population (billions) Countries



























































































No national campaign conducted 
between July 2018 and June 
2020 with a duration of at east 
three weeks
National campaign implemented 
with 1-4 appropriate characteristics
National campaign implemented 
with 5-8 appropriate characteristics, 
or with 7 characteristics excluding 
airing on TV and/or radio
National campaign implemented 
with at least 7 appropriate 
characteristics including airing 
on TV and/or radio
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Bringing “smoke-free” home: a mass media campaign in Thailand
Tobacco use is responsible for over 70 000 deaths 
annually in Thailand, and tobacco-related illness 
is the country’s leading cause of death (including 
approximately 9000 from second-hand smoke (200). 
While the Non-Smokers’ Health Protection Act B.E. 
2535 (1992) made all public places non-smoking 
areas, it was recognized that homes are the places 
that families, and especially children, spend most of 
their time, and where they are likely to be exposed to 
second-hand smoke. Notably, a survey by Thailand’s 
National Statistical Office in 2017 found that as many  
as 17.3 million people across the country were exposed 
to second-hand smoke in their homes. 
In 2019, partners from across sectors worked together 
to develop a mass media campaign to prevent young 
children from exposure to second-hand smoke at 
home, which was the theme of the established Action 
on Smoking and Health (ASH Thailand) “Smokefree 
Home” project. The campaign was strategically 
developed collaboratively by partners from across 
sectors employing the findings of focus group 
discussions with the target audience, and media such 
as television, radio, print, outdoor billboards, online 
advertising, and transit advertising to maximize the 
impact of the campaign. The main objectives of the 
campaign titled “Stop destroying your child’s dream” 
were to promote social awareness of the dangers 
of second-hand smoke in homes and to encourage 
smokers to quit for the benefits of the family, especially 
young children. The campaign is currently being 
evaluated for reach and impact.
Since 2010, when mass media data was first  
collected for this report, Thailand has consistently run 
anti-tobacco mass media campaigns with at least six of 
the eight criteria used to assess level of achievement. 
The “Stop destroying your child’s dream” anti-tobacco campaign, Thailand
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ENFORCE BANS ON TOBACCO 
ADVERTISING, PROMOTION 
AND SPONSORSHIP
TAPS bans help protect 
the population against the 
tobacco industry
Despite tobacco companies’ insistence 
that the billions of dollars they spend 
annually on advertising is only to 
increase their market share at the 
expense of competitors, there is 
indisputable evidence that TAPS 
activities also increase or sustain 
tobacco use by both the effective 
recruitment of new tobacco users or 
by discouraging tobacco users from 
quitting (231, 240, 241). 
Tobacco companies use a mix of 
marketing techniques tailored to 
different groups and target specific 
populations through new products that 
circumvent regulations and maintain 
social acceptability (242). Youth and 
women are especially targeted in  
low- and middle-income countries (234). 
Tobacco advertising and promotion 
increases the likelihood that adolescents 
will start to use tobacco which may lead 
to a higher prevalence of adult tobacco 
users in the future (241, 244, 245). 
Promotional and sponsorship activities 
can also influence businesses that may 
benefit from the billions of dollars 
invested in TAPS themselves. 
And, wherever possible, the tobacco 
industry attempts to avoid regulation 
by adopting weak voluntary advertising 
codes, discrediting the evidence base for 
restrictions, and using both lobbyists and 
litigation to avoid TAPS bans (231, 246). 
TAPS bans reduce  
tobacco use
TAPS bans are effective in reducing 
tobacco sales and tobacco consumption 
in all parts of the world (246–249) 
and their impact may be even more 
dramatic in low- and middle-income 
countries than in high-income countries 
(249). Comprehensive bans on all TAPS 
activities are a key tobacco control 
strategy and policy measure (174, 247) 
and are one of only two WHO FCTC 
provisions with a mandatory timeframe 
for implementation (the other one is 
Article 11 of the Convention). 
TAPS bans must be 
comprehensive and  
well-enforced
TAPS bans must be comprehensive 
because partial bans have little or no 
effect (231, 247, 250). When bans 
are not comprehensive, tobacco 
companies exploit legal loopholes or 
simply shift their investments to forms 
of promotion that are not banned 
(247, 251, 252). Bans must therefore 
cover all TAPS activities, including 
direct promotion (e.g. TV advertising, 
radio, print publications and billboards 
as well as advertising at points of 
sale); and indirect promotion (e.g. 
brand stretching and brand sharing, 
free distribution, price discounts, 
product placement on TV/films and 
sponsorships including “corporate 
social responsibility” programmes) 
(253). Bans must also include point of 
sale product displays that “normalize” 
the products, prompt people to 
smoke, encourage impulse purchases, 
interfere with quitting, and increase the 
susceptibility of children and youth to 
see and try the products (254–259). 
Article 13 of the WHO FCTC states: 
“... [A] comprehensive ban on advertising, promotion and sponsorship would reduce the consumption 
of tobacco products. Each Party shall ... undertake a comprehensive ban of all tobacco advertising, 
promotion and sponsorship. … [W]ithin the period of 5 years after entry into force of this Convention 
for that Party, each Party shall undertake appropriate legislative, executive, administrative and/or other 
measures and report accordingly in conformity with Article 21”(41). WHO FCTC Article 13 guidelines are 
intended to assist Parties in meeting their obligations under Article 13 of the WHO-FCTC (174).
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Bans must also encompass the financial 
or in-kind contributions that tobacco 
companies may make to another entity 
for deserving or socially responsible 
causes. These contributions fall within 
the definition of tobacco sponsorship 
in article 1(g) of the WHO FCTC and 
should therefore be banned (253). 
Corporate social responsibility activities 
are typically employed to convince 
governments to delay and refrain 
from implementing tobacco control 
programmes and should also be 
included in TAPS bans (259).
Legislation should use clear, 
uncomplicated language and 
unambiguous definitions, and avoid 
providing lists of prohibited activities 
that are, or could be understood 
to be, exhaustive (249). Moreover, 
legislation must be coupled with strong 
enforcement and monitoring, with high 
financial penalties for violations (174). 
TAPS bans should apply  
to digital media
The growth in communications 
technology and the use of Internet-based 
mobile phones means TAPS activities 
can appear via multiple social media 
platforms – and children and adolescents 
are particularly exposed (260), not 
least through social media influencers, 
spokespeople, and brand-sponsored 
contests that are used to promote 
tobacco products (261, 262). Countries’ 
existing legislation banning TAPS may not 
necessarily clearly or explicitly include a 
ban on advertisements on the Internet, 
so ensuring that bans are inclusive of 
Internet-based media is crucial (263, 
264). In some cases, enforcing TAPS  
bans on social media sites may require 
cross-border legislation, and for this 
reason, countries will need to cooperate 
and coordinate efforts (262).
The number of countries 
covered by TAPS bans 
continues to steadily rise
Although TAPS bans remain an 
under-adopted measure, 57 countries 
(21% of the world’s population) have 
comprehensive bans on TAPS. In 2007 
there were only eight countries – 4% 
of the world’s population – with best-
practice TAPS bans in place. Since then, 
an additional 49 countries (including 
five since 2018 – Côte d’Ivoire, Ethiopia, 
Iraq, Jordan, and Venezuela (Bolivarian 
Republic of)) have introduced TAPS 
bans effectively, increasing global 
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Enforce bans on tobacco advertising
ENFORCE BANS ON TOBACCO ADVERTISING, PROMOTION AND SPONSORSHIP  
– HIGHEST ACHIEVING COUNTRIES, 2020
Countries with the highest level of achievement: Afghanistan, Albania, Algeria, Antigua and Barbuda, Azerbaijan, Bahrain, Benin, Brazil, Chad, Colombia, Congo, 
*Côte d’Ivoire, Democratic Republic of the Congo, Djibouti, Eritrea, *Ethiopia, Finland, Gambia, Ghana, Guinea, Guyana, Iceland, Iran (Islamic Republic of), 
*Iraq, *Jordan, Kenya, Kiribati, Kuwait, Libya, Madagascar, Maldives, Mauritania, Mauritius, Mongolia, Nepal, Niger, Nigeria, Niue, Panama, Qatar, Republic of 
Moldova, Russian Federation, Saudi Arabia, Senegal, Seychelles, Slovenia, Spain, Suriname, Togo, Turkey, Tuvalu, Uganda, United Arab Emirates, Uruguay, Vanuatu, 
*Venezuela (Bolivarian Republic of), Yemen.
* Country newly at the highest level since 31 December 2018.








































Complete absence of ban, or ban 
that does not cover national TV, 
radio and print media
Ban on national TV, radio and 
print media only
Ban on national TV, radio and 
print media as well as on some 
but not all other forms of direct 
and/or indirect advertising
Ban on all forms of direct and/or 
indirect advertising (or at least 
90% of the population covered 
by complete subnational bans)

































































Total population: 7.8 billion Total number of countries: 195
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More than a third of  
low-income countries  
have complete TAPS bans
In 2020, of the 57 countries with 
comprehensive TAPS bans, 12 are  
low-income countries (40%), 31  
are middle-income countries (30%)  
and 14 are high-income (23%). In  
a further 10 low-income countries  
TAPS bans are either minimal (do not 
include advertising on national TV, 
radio and print media) or completely 
absent. The same is true in 19 middle-
income countries and 11 high-income 
countries. Seven countries (Armenia, 
Belgium, Bolivia (Plurinational State of), 
Denmark, Israel, Pakistan and Samoa) 
– with a total 262 million people – 
improved their laws since 2018 but did 
not reach best practice in 2020. 
An additional 2.1 billion 
people could easily be 
covered by TAPS bans 
A best-practice TAPS ban has 10 
appropriate characteristics. In 2020, 
26 countries covering 2.1 billion 
people had mandated nine of these 
10 characteristics and thus were only 
one provision away from achieving 
a best-practice TAPS ban. The most 
common missing provision is banning 
advertising at point of sale (eight 
countries), followed by banning brand 
stretching (seven countries). Forty 
countries, with 1.2 billion people, 
have a complete absence of TAPS 
bans, or very minimal restrictions.
Seven countries need only to ban 
brand-stretching (Croatia, France, 
Georgia, Lithuania, Sri Lanka, Thailand, 
Turkmenistan). Eight need only to ban 
advertising of tobacco products at point 
of sale (Argentina, Bolivia (Plurinational 
State of), Cook Islands, India, Mali, 
Montenegro, Netherlands, South 
Africa). Five countries and territories 
need only to ban industry sponsorship 
(Egypt, Sudan, Syrian Arab Republic, 
United Kingdom, Viet Nam). Three 
need only ban promotional discounts 
(Cyprus, Lebanon, Papua New Guinea). 
Norway need only ban brand-sharing, 
Tonga need only ban the appearance of 
tobacco products or brands in TV and/
or films, and one territory -  occupied 
Palestinian territory, including east 
Jerusalem -  need only ban the free 
distribution of tobacco products.
Over a quarter of the 524 million 
people who live in 29 of the world’s 
100 largest cities are protected by a 
TAPS ban. All of these cities are covered 
by national laws. Instead of waiting 
for a national law to be put in place, 
the remaining 71 of the world’s largest 
cities not currently protected by a 
national best-practice law could move 
ahead with city, state or provincial 
level legislation to protect their large 
populations sooner.
The Bolivarian Republic of Venezuela institutes complete ban on tobacco 
advertising, promotion, and sponsorship 
In 2019 The Bolivarian Republic 
of Venezuela achieved full 
implementation of its third 
MPOWER measure with the 
adoption of a Ministry of 
Health Resolution completely 
banning tobacco advertising, 
promotion, and sponsorship, 
including the display of tobacco 
products at points of sale. The 
regulation also explicitly bans 
social corporate responsibility 
by tobacco industry actors.
Although some restrictions on TAPS 
existed before this regulation was 
passed, they did not cover points 
of sale. This was a particularly 
problematic gap, as the country’s 
Global Youth Tobacco Survey 
in 2019 revealed that 44.3% 
of students noticed tobacco 
advertisements or promotions 
when visiting points of sale (265). 
Establishing the ban required 
close coordination between the 
ministries of health and culture, as 
one of the strategies used by the 
tobacco industry in The Bolivarian 
Republic of Venezuela involved its 
promotion of cultural activities. 
The Bolivarian Republic of 
Venezuela’s TAPS ban now joins 
the country’s two other measures 
at the highest level – large pictorial 
health warnings on packages, 
and smoke-free regulation. The 
Bolivarian Republic of Venezuela’s 
work to implement the WHO 
FCTC highlights the importance 
of Ministry of Health leadership, 
and shows that adopting measures 
need not be a costly exercise. 
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Effective collaboration between WHO and key government partners results  
in a comprehensive TAPS ban in Iraq
Following the release of the WHO 
report on the global tobacco 
epidemic 2019, the Tobacco Free 
Initiative in the WHO Eastern 
Mediterranean Region worked 
with country-level stakeholders 
to identify key gaps in policy 
implementation and how to 
support policy progress.
Twelve Eastern Mediterranean 
Region countries had not adopted a 
comprehensive ban in line with the 
WHO FCTC and thus strengthening 
bans on tobacco advertising, 
promotion and sponsorship (TAPS) 
was recognized as a priority. The 
WHO team developed needed 
resources to support countries in 
this area, including formulating 
a draft ministerial decree that 
could be adapted across countries’ 
various legal contexts.
Country teams in ministries of 
health and in WHO Country Offices 
used these technical resources to 
advocate for stronger rules to ban 
TAPS. With commitment from 
senior leaders, Iraq demonstrated 
particular success. WHO worked 
with the legal and executive 
departments of the Iraqi Ministry 
of Health to support coordinated 
efforts for policy change through 
a ministerial decree. Ultimately, a 
decision banning all forms of TAPS 
was introduced by the Minister 
for Health and Environment in 
Iraq, taking the country to the 
highest level of achievement 
of this MPOWER measure.
Almost a third of middle and  
low-income countries are covered  
by comprehensive TAPS bans.
Bulldozer takes down a billboard advertising a cigarette brand
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Enforcing TAPS bans through local action: Brazil, Indonesia and the Republic of Korea
Comprehensive bans on tobacco 
advertising, promotion and 
sponsorship (TAPS) are effective 
in reducing tobacco sales and 
consumption. However, TAPS bans 
must be well enforced in order to 
deliver these benefits. 
Through the Partnership for 
Healthy Cities, three cities have 
shown how local policies and 
activities can strengthen TAPS 
enforcement. In Rio de Janeiro, 
Brazil, the city has enhanced the 
implementation of a national TAPS 
ban by monitoring compliance. City 
authorities have assessed points 
of sale and provided training for 
inspection agents, and have also 
run a communications campaign to 
raise awareness about the ban and 
its restrictions. 
Meanwhile in Seoul, Republic 
of Korea, a plan has been 
developed to support stronger 
enforcement of TAPS regulations 
across the city using the National 
Health Promotion Act’s Article 
9-4 (Prohibition of, or Restriction 
on, Advertisements of Tobacco). 
The city’s approach has included 
a key informant survey (adapted 
for city-level use from a national 
model provided by WHO) to 
assess public knowledge of, and 
approaches to, compliance. 
Finally, local authorities in Jakarta, 
Indonesia, have strengthened 
enforcement of a local TAPS policy 
banning outdoor advertisements 
by building capacity among 
local government officials and 
conducting regular enforcement 
drives. They also developed a 
simple, phone-based application 
to support enforcement of the 
outdoor ban. The city aims to 
achieve 90% compliance with both 
indoor and existing outdoor bans 
on tobacco advertising. 
Inspectors training for TAPS enforcement in 
Rio de Janeiro
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RAISE TAXES ON TOBACCO
Raising taxes to increase the 
price of tobacco products 
is the single most effective 
tobacco control measure
Increased taxes are highly cost-effective 
in reducing tobacco use (22, 198). In 
fact, a recent report published by the 
Task Force on Fiscal Policy for Health 
estimated that tax increases that would 
lead to a 50% tobacco price increase 
worldwide could avert 27.2 million 
premature deaths over the next 50 
years (266). Tobacco taxation is also 
inexpensive to implement, costing  
low- and middle-income countries as 
little as US$ 0.05 per capita each year 
to administer (267). 
On average, a 10% price increase will 
reduce consumption by 5% in low- 
and middle-income countries (up to 
8% in some instances), and by about 
4% in high-income countries (198). 
Approximately half of this reduction 
is due to tobacco users quitting, with 
the other half the result of existing 
users smoking less (268). Tobacco 
taxation is rightly considered as a highly 
cost-effective “best-buy” intervention, 
meaning that the returns and economic 
benefits of this measure are several 
times higher than its cost (269, 270). 
Increased taxes can fund 
expanded government 
health programmes
Tax increases not only reduce tobacco 
use and improve health, they also 
generate more government revenues 
(22, 198). The report of the Task Force 
on Fiscal Policy for Health also estimated 
that a 50% tobacco price increase in 
2017 would raise an additional US$ 3 
trillion (US$ 2016 discounted) worldwide 
over the next 50 years (266). Additional 
funding generated by increased 
taxation at country level could be used 
for tobacco control programmes as 
well as other important health and 
social initiatives, which have now been 
successfully demonstrated in some 
countries (271, 272). Using tax revenues 
in this way will further increase public 
support for higher taxes.
Taxes should be raised 
significantly and periodically 
Governments must monitor tobacco 
tax rates and prices relative to real 
income and significantly raise tax rates 
at regular intervals to ensure that 
tobacco products do not become more 
affordable – a trend common in many 
countries where income and purchasing 
power are growing rapidly (22). Despite 
some of these countries raising tobacco 
tax rates, they have not offset inflation 
and income growth, causing an erosion 
of the tax’s value and effectiveness 
in reducing consumption (22, 273). 
Nominal tax increases that do not 
make tobacco products less affordable 
are unlikely to reduce consumption or 
encourage cessation. 
Tobacco tax policies need 
strong tax administration 
Tax administration can be made easier if 
the right tax policies are applied. Of the 
different types of tax levied on tobacco 
products, excise taxes are the most 
effective at raising prices and triggering 
significant health impact (22, 274). 
Simpler tax structures are likewise easier 
to administer – complex structures and 
tiered excise taxes should be avoided 
to diminish incentives for companies 
to price tobacco products in ways that 
can undermine the health and revenue 
impact of tobacco taxes (22).
Strengthening tax and customs 
administration, as well as improving 
enforcement capacity, enhances 
the impact of raised tobacco taxes 
(22). Key interventions to improve 
tax administration include ensuring 
compliance (through licensing, detailed 
tax declaration requirements and 
advanced information technology), 
ensuring control and enforcement on 
the supply chain (through, for example, 
the use of risk-based approaches for 
enforcement targets, tax stamps, 
track and trace systems, implementing 
anti-forestalling methods), and 
using clearly defined procedures to 
follow after detecting illicit trade of 
tobacco (including high penalties) 
(22). Experiences from numerous 
countries show that illicit trade of 
tobacco products can be successfully 
addressed even when taxes and prices 
are increased, hence the threat of tax 
evasion should not be used as a reason  
to forgo tax increases (22, 275).
Article 6 of the WHO FCTC states:
“...[P]rice and tax measures are an effective and important means of reducing tobacco consumption...
[Parties should adopt]...measures which may include:...tax policies and...price policies on tobacco products 
so as to contribute to the health objectives aimed at reducing tobacco consumption” (174).
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Raise taxes on tobacco
RAISE TAXES ON TOBACCO – HIGHEST ACHIEVING COUNTRIES, 2020
Gaining political buy-in is key 
to adopting key tax reforms
The concerns around the political 
economy of tobacco taxation are 
effectively exploited by the tobacco 
industry to block any major tobacco 
tax reforms. Pre-emptively addressing 
those concerns can greatly help the 
smooth adoption of important tobacco 
tax reforms. Those concerns can be 
summarized in the SCARE tactics (22): 
S Smuggling and illicit trade
C Court and legal challenges
A Anti-poor rhetoric or regressivity
R Revenue reduction
E Employment impact  
Experience from countries around the 
world shows that these arguments 
are either unfounded or greatly 
exaggerated and that tax increases 
are in fact good for health, for equity, 
for revenues and for the economy 
overall, with very little risk of facing 
legal threats, especially when laws are 
carefully designed and enacted (22). 
One billion people are 
covered by high tobacco 
taxes 
The evidence on tobacco interventions 
indicates that the most effective and 
efficient way to reduce tobacco use is 
to raise the price of tobacco through 
tobacco taxes. However, tobacco tax is 
the least-adopted MPOWER measure. 
In 2020 only 13% of the world’s 
population living in 40 countries were 
protected by tax rates at 75% or more 
of the price of the most popular brand 
of cigarettes. 
The total number of countries that 
raised tobacco taxes to a level at or 
above 75% of the price of the most 
sold brand of cigarettes increased 
from 38 in 2018 to 40 in 2020, but the 
number of people protected by this 
level of tax remained at 1 billion. The 
addition of two countries to the total 
number of countries at the highest level 
of achievement represents a net gain 
after six countries (Denmark, Georgia, 
Morocco, Netherlands, Portugal and 
Sri Lanka) increased their taxes to 
best-practice levels, while another four 
countries lost their position in this top 
group (Australia, Austria, Colombia 
and Niue). The most significant tax 
share increase seen in these six new 
best-practice countries was made by 
Sri Lanka, whose 2018 rate of 66.17% 
was raised to 77.02% by 2020. No 
low-income countries have raised taxes 
to 75% or above since 2018. Sixteen 
countries, including eight low-income 
countries, increased taxes enough since 
2018 to move one category closer to 
best-practice level. 
In 2008, 23 countries in the world had 
tax rates at 75% or more of the price, 
covering only half a million people or 
7% of the world’s population. Since 
then, an additional half a billion people 
in 17 additional countries are covered 
by best-practice taxation levels. While 
21 countries raised taxes sufficiently to 
reach the highest group, four others 
dropped out of the group since 2008.
Today, middle-income countries 
constitute more than half of the 
population (61%) protected by the 
raised-taxes measure. Less than 3% of 
protected people live in low-income 
countries. 
Countries and areas with the highest level of achievement: Andorra, Argentina, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Chile, Croatia, Czechia, 
*Denmark, Egypt, Estoni , Finland, Fra ce, *Georgia, Greece, Ireland, Israel, Italy, Jordan, Latvia, Madag scar, Malta, Mauri ius, Montenegro, *Morocco, 
*Netherlands, New Zealand, North Macedonia, occupied Palestinian territory, Poland, *Portugal, Serbia, Slovakia, Slovenia, Spain, *Sri Lanka, Thailand,  
Turkey, United Kingdom.
* Country newly at the highest level since 31 December 2018.
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In 2020, 24 (40%) high income 
countries and 15 (15%) of middle-
income countries levied taxes at 
best-practice level. Only one low-
income country – Madagascar – had 
taxes at the highest level. However, 
15 countries (10 high-income, four 
middle-income and one low-income) 
are just five percentage points or less 
away from the best practice level, 
having tax rates between 70% and 
75% of retail price. If these countries 
increased their tax rates to 75%, an 
additional 465 million people would 
be covered by the most effective 
measure to reduce tobacco use. 
Furthermore, 4% of high-income 
countries, 16% of middle-income 
countries and 20% of low-income 
countries do not tax tobacco even at 
a minimal level (i.e. under 25% of the 
retail price is tax). All 23 countries are 
missing the opportunity to save lives  
by raising taxes to this basic level. 
Population (billions) Countries
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Low- and middle-income countries have much progress to make to raise taxes and prices 
Price and tax levels are highest in  
high-income countries, even when 
adjusting for differences in purchasing 
power. Cigarette pack prices, total taxes 
and the tobacco excise component as 
a share of pack prices are all lower in 
low- and middle-income countries, with 
average total tax as a proportion of 
price amounting to 51.2% in  
low-income countries and 59.1% 
in middle-income countries. This 
proportion reaches 67.4% in high-
income countries, even though the 
non-tax portion of cigarette prices is 
fairly similar throughout the world. 
There is a strong case for all countries, 
particularly low- and middle-income 
countries, to increase their excise taxes 
further, which will have the effect of 
making cigarettes less affordable.
WEIGHTED AVERAGE RETAIL PRICE AND TAXATION (EXCISE AND TOTALS) 






















= PPP $3.49 
(61.5% of pack price)
Total taxes 
= PPP $1.21 
(50.1% of pack price)
Total taxes 
= PPP $2.88 
(58.7% of pack price)
Total taxes 
= PPP $6.04 
(67.6% of pack price)
Price minus taxes
Other taxes






















Note: Averages are weighted by WHO estimates of number of current cigarette smokers ages 15+ in each country in 2019. Prices are expressed in Purchasing  
Power Parity (PPP) adjusted dollars or international dollars to account for differences in the purchasing power across countries. Based on 54 high-income,  
99 middle-income and 23 low-income countries with data on prices of most sold brand, excise and other taxes, and PPP conversion factors.
One in five countries are now  
protected by high tobacco taxes.
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Affordability should be 
continuously monitored  
and decreased
To measure whether cigarettes have 
become more or less affordable over 
time in a given country, price data from 
previous editions of this report were 
used to compute the per capita GDP 
required to purchase 2000 cigarettes 
of the most sold brand reported in 
each year. The average change over the 
period 2010–2020 was then calculated 
for this current report. Using this 
measure, cigarettes have become less 
affordable in 84 countries and did not 
significantly change in 68 countries, 
while they became more affordable in 
20 countries. Of those 20 countries, 17 
were low- and middle-income countries.
Affordability can change rapidly and 
monitoring these changes can give 
governments an indicator of when 
to best apply higher tobacco taxes. 
Automatic adjustments in taxes can 
be applied, which can account for 
fluctuations in national economies.
Of the 524 million people (6.7% of the 
world’s population) who live in one 
of the world’s 100 largest cities, only 
130 million (in 24 cities) are protected 
by tobacco taxation. No city has yet, 
independently of national government, 
introduced taxes on tobacco products 
that have resulted in raising the share  
of total taxes to 75% or more of the 
retail price.
Cigarettes have become less affordable 
since 2010 in 84 countries globally, equally 
distributed between high-income and  
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Raising taxes is key to comprehensive tobacco control, Morocco
After its manufactured tobacco 
sector was liberalized in 2011, 
Morocco embarked on a 3-year 
journey to reform its tobacco 
taxation structure. Inspired by how 
other countries had implemented 
tobacco control measures, this 
reform aimed mainly at protecting 
public health and consolidating 
state revenue. 
Morocco’s previous excise tobacco 
tax system had comprised an 
ad valorem tax with a fixed 
minimum price on all new brands 
introduced to the market – a 
system that incentivized companies 
to introduce low-cost brands 
and encouraged consumers to 
buy cheap tobacco products. 
To address this, in 2013 Morocco 
introduced, in addition to the 
existing ad valorem system, a 
specific tax, along with a minimum 
tax collection amount for tobacco 
products. A minimum tax burden 
was also instated, where collected 
taxes could not represent less  
than 53.6% of the retail price  
of cigarettes. 
And in 2017, as part of efforts to 
further simplify Morocco’s tobacco 
tax structure, the consumption 
(excise) tax rate on dark tobacco 
cigarettes was applied to gradually 
reach (over a period of 3 years) a 
uniform tax rate across all types  
of cigarettes, moving away from 
the two-tiered system previously  
in place. 
Morocco further increased its 
minimum excise tax on cigarettes  
in 2019, as well as its minimum  
tax burden, which rose from  
53.6% to 58%. Thanks to these 
increases, total tax now represents 
76.1% of the price of the most  
sold brand of cigarettes, reaching 
the highest level of achievement 
of the “R” component of the 
MPOWER package. The tax reforms 
and increases in rates resulted in 
increases in revenues which went 
up from 10.4 billion Moroccan 
Dirham in 2013 to 12.8 billion 
Moroccan Dirham in 2018.
And 2021 saw another increase 
in the consumption tax on cigars, 
cigarillos and water-pipe tobacco. 
The country aims to continue 
raising tobacco taxes on a regular 
basis to compensate for inflation. 
These gradual tax increases are 
expected to increase prices and 
reduce demand for tobacco, 
thus decreasing their harmful 
consumption and burden of disease. 
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Georgia’s comprehensive tax policy reduces tobacco consumption
Tobacco tax rates in Georgia rose 
significantly between 2013 and 
2019. After separate rises in the 
specific excise tax on filter cigarettes 
and on non-filter cigarettes, by 2018 
both rates were equalized, leading 
to a uniform tax on all types of 
cigarettes. The excise tax on one 
pack of filtered cigarettes increased 
from 0.6 Georgian Lari per pack of 
20 sticks (in 2013) to 1.7 Georgian 
Lari (in 2017). For unfiltered 
cigarettes, the specific excise was 
increased from 0.15 Georgian Lari 
per pack of 20 sticks (2013) to 1.7 
Georgian Lari (2017). In 2015, all 
cigarettes were subject to a new 
additional ad valorem tax of 5% on 
the retail price – a figure that rose to 
10% in 2016 and further increased 
to 30% of the retail price in 2019.
To avoid substitution to other 
tobacco products, tax increases 
were also applied to roll-your own 
(RYO) tobacco. In 2013, the excise 
tax on 1 kg of imported raw tobacco 
was 20 Georgian Lari, and by 2018 
it had risen to 35 Georgian Lari. In 
2019, the excise tax on raw tobacco 
had almost doubled to 60 Georgian 
Lari per kilogram.
By 2019, demand for unfiltered 
cigarettes decreased by 96% 
compared to the previous year. 
For RYO, 2019 also seems 
to be a turning point – the 
excise tax hike from 35 to 60 
Georgian Lari (an increase of 
71%) reduced raw tobacco 
consumption by 260% in 2020. 
The evolution of Georgia’s total 
tobacco tax burden, which consists 
of excise, ad-valorem and VAT, can 
be seen in the graph 1 below. By 
2021 the tax burden represented 
71% of the price of the most sold 
brand – up from just 15% in 2012. 
The price also increased by 2.75 
times between 2012 and 2021.
As shown in graph 2 below, there 
is a clear downward trend in total 
tobacco use thanks to sustained 
increases in tobacco taxation and 
the increase in tax across products, 
reducing risks for substitution.
Graph 1:
REAL PRICE AND TAX BURDEN, PACK OF MOST SOLD BRAND 


























2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
72% 71%74%
TOTAL MARKET OF LOCALLY PRODUCED FILTERED AND 
UNFILTERED CIGARETTES, AND RYO TOBACCO 2015–2020







REAL PRICE AND TAX BURDEN, PACK OF MOST SOLD BRAND 


























2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
72% 71%74%
TOTAL MARKET OF LOCALLY PRODUCED FILTERED AND 
UNFILTERED CIGARETTES, AND RYO TOBACCO 2015–2020






 WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC 2021 | 93
94 | WORLD HEALTH ORGANIZATION
NATIONAL TOBACCO  
CONTROL PROGRAMMES:
Every country should have 
a national tobacco control 
programme to lead tobacco 
control efforts
The WHO FCTC strongly suggests 
that countries set up a national, 
decentralized tobacco control 
programme (NTCP) to lead their 
tobacco control efforts. Adequately 
financed, clearly focused NTCPs or 
coordination mechanisms are critical 
for developing and maintaining the 
sustainable policies that can reverse 
the tobacco epidemic (108). Ministries 
of health, or equivalent government 
agencies, should take the lead on 
strategic tobacco control planning and 
policy setting, with other ministries or 
agencies reporting to this centralized 
authority (251). Tobacco control 
programmes should also be integrated 
into countries’ broad health and 
development agendas (276).
In large countries or those with federal 
political systems, decentralizing NTCP 
authority to subnational level can allow 
more flexibility in policy development 
and programme implementation. 
Public health and government leaders 
at appropriate subnational levels 
must be given adequate resources 
to build implementation capacity 
that can be sustained over time (171) 
and enable policies and programmes 
to reach as wide a population as 
possible (277). On this note, NTCPs 
should ensure that population 
subgroups with disproportionately 
high rates of tobacco use are 
reached by policies and programmes 
tailored to their needs (277).
Tobacco control requires  
an actively involved  
civil society 
NTCPs require the involvement 
of appropriate nongovernmental 
organizations and other civil society 
groups to maintain progress on national 
as well as global tobacco control efforts 
(108). NTCPs must specifically exclude 
the tobacco industry and its allies, which 
cannot be legitimate stakeholders in 
tobacco control efforts (171). 
Almost a third of countries globally 
(60 countries) have a national agency 
with responsibility for tobacco control 
objectives staffed by at least five 
full-time equivalent people, meaning 
that 66% of the world’s population 
are served by such an agency. An 
additional 113 countries (with another 
one third of the world’s population) are 
working on tobacco control objectives 
with fewer staff (80 countries), or 
with an unknown number of staff (33 
countries). Only 18 countries (with 152 
million people) do not have a national 
agency for tobacco control, 13 of which 
are low- and middle-income countries. 
In the past 2 years, four countries 
enhanced their national tobacco control 
programmes sufficiently to reach the 
highest level of adoption (Ghana, 
Hungary, Spain and Trinidad and 
Tobago), adding 89 million people to 
the population covered. At the same 
time, two countries dropped below 
best-practice level: Cuba reduced the 
number of staff dedicated full-time to 
tobacco control, and Switzerland did 
not report the number of staff. 
Over the more than a decade since 
2008, substantial progress has 
been achieved with a total of 18 
countries, home to 598 million people, 
establishing a well-staffed national 
team working full time on tobacco 
control. It is worth noting that this 
measure may underestimate the true 
extent of NTCPs in countries because 
information on tobacco control 
programme staffing at the national 
level is incomplete, and there is no 
formal mechanism for collecting this 
information from countries.
The WHO Framework Convention on Tobacco Control strongly suggests that countries set up  
a national tobacco control programme (NTCP) to lead their tobacco control efforts. To this  
end, WHO FCTC Article 5 states that:
“Each Party shall develop, implement, periodically update and review comprehensive 
multisectoral national tobacco control strategies, plans and programmes … [and] establish or 
reinforce and finance a national coordinating mechanism or focal points for tobacco control.” 
In addition, WHO FCTC Article 26.2 sets out that: “Each Party shall provide financial support in 
respect of its national activities intended to achieve the objective of the Convention” (174).
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Population (billions) Countries



























































































No national agency for 
tobacco control
Existence of national agency with 
responsibilty for tobacco control 
objectives with less than 5 staff 
or staff not reported









Existence of national agency 
with responsibilty for tobacco 
control objectives and at least 
5 staff members
223
Almost a third of countries globally have a national agency  
with responsibility for tobacco control objectives staffed  
by at least five full-time equivalent people.
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National Tobacco Control Programme, India 
Strong, nationally funded 
tobacco control programmes are 
the cornerstone of WHO FCTC 
implementation. India established 
one of the world’s largest public-
funded NTCPs in 2007 – within 2 
years of the WHO FCTC coming 
into force. India’s vast NTCP is 
now implemented in all 700 of the 
country’s districts.
Key pillars of the programme 
(funded and staffed at national, 
state, and district level) include: (a) 
training and capacity building for 
stakeholders, including law enforcers; 
(b) education and communication 
activities; (c) school programmes; (d) 
monitoring tobacco control laws; and 
(e) provision of cessation support, 
including pharmacological treatment. 
Activities and interventions are 
adapted and designed according to 
local needs. 
The Indian government has 
strategically invested in scaling 
up tobacco cessation through 
mCessation services and the toll-free 
National Tobacco Quitline, which has 
four hubs servicing different regions 
of the country. The Quitline is staffed 
by 100 trained counsellors providing 
services in over 15 languages to 
address the needs of 267 million 
adult tobacco users in India. 
And to support tobacco product 
regulation, the government has 
established three tobacco testing 
laboratories – the first of their 
kind in the WHO South East Asia 
Region. To track key tobacco 
control indicators, robust tobacco 
surveillance (in the form of regular 
GATS and GYTS surveys) have been 
dovetailed with the programme, 
with subnational level estimates. 
The three-tiered NTCP framework 
(consisting of national, state and 
district tobacco control cells) enables 
the government to take strong, 
evidence-based policy measures such 
as banning ENDS, implementing 
large pack warnings, a tobacco-
free films policy, and tobacco-free 
educational institution guidelines. 
These policies and initiatives have 
reduced the prevalence of adult 
tobacco use by 17% (relative 
reduction) between 2009 and 
2016 – proof that that adequate 
commitment and public investment 
in comprehensive tobacco control 
policies results in substantial public 
health gains, even in high prevalence, 
tobacco-producing countries.
Awareness generation among school/college going youth on the harmful effects of tobacco use through street play (nukkad natak) 
in Uttar Pradesh, India
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ELECTRONIC NICOTINE  
DELIVERY SYSTEMS
As discussed in the background chapter on ENDS, MPOWER measures as well as age restrictions on sales 
and flavour bans can be applied to ENDS. Here we assess the status of these measures as they are applied 
to ENDS globally.
Almost half of countries monitor 
adolescent e-cigarette use
Most surveys that ask about ENDS 
use focus on e-cigarette use and not 
on broader ENDS use. Eighty-seven 
countries monitor e-cigarette use among 
adolescents through national school-
based surveys. This means that 45% of 
countries with 3.5 billion people have 
data on e-cigarettes use among children 
and adolescents that can be used to 
guide local policy decisions. Not all 
survey a consistent age group however, 
making global comparisons challenging.
Forty-four of the countries that monitor 
adolescents’ e-cigarette use are  
middle-income countries, while 42 
are high-income countries. Only one 
low-income country (Yemen) currently 
conducts surveys on adolescents that 
incorporate questions about current 
e-cigarette use.
E-cigarette use among 
adults should be routinely 
incorporated into nationally 
representative surveys 
Currently, 56 countries representing 
a population of 4.9 billion people 
capture e-cigarette use among adults 
in nationally representative surveys 
that – of which are low-income 
countries. Meanwhile, a total of 139 
countries, representing a population 
of 2.8 billion people (of which 4.1 
billion live in 113 low- and middle-
income countries) have no data on 
adult current e-cigarette use at all.
E-cigarette use among adolescents 
is monitored by national
school-based surveys
E-cigarette use among adolescents 
is not monitored by national 
school-based surveys
Not applicable
© WHO 2021. All rights reserved.
Data Source: WHO
Map Production: WHO GIS Centre
for Health, DNA/DDI
The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on
the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its
frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.
Monitoring e-cigarette use among adolescents
Countries that monitor ENDS use among adolescents: Albania, Antigua and Barbuda, Argentina, Australia, Austria, Belize, Bolivia (Plurinational State of), Brazil, 
Brunei Darussalam, Bulgaria, Can da, China, Colombi , Croatia, Cuba, Cyprus, Czechia, Denmark, Dominican Republic, Ecuador, El Salvador, Estonia, Fiji, Finland, 
France, Germany, Ghana, Greece, Grenada, Guatemala, Guyana, Hungary, Iceland, Iraq, Ireland, Italy, Jamaica, Japan, Kazakhstan, Kiribati, Kyrgyzstan, Lao 
People’s Democratic Republic, Latvia, Lithuania, Luxembourg, Malaysia, Malta, Marshall Islands, Mauritius, Monaco, Mongolia, Montenegro, Netherlands, New 
Zealand, Nicaragua, Niue, North Macedonia, Norway, Panama, Papua New Guinea, Paraguay, Peru, Poland, Portugal, Qatar, Republic of Korea, Romania, Russian 
Federation, Saint Lucia, Saint Vincent and the Grenadines, San Marino, Serbia, Slovakia, Slovenia, Spain, Suriname, Sweden, Switzerland, Thailand, Trinidad and 
Tobago, Ukraine, Unites States of America, Uruguay, Vanuatu, Venezuela, Viet Nam, Yemen.
MONITORING E-CIGARETTE USE AMONG ADOLESCENTS USING NATIONAL 
 SCHOOL-BASED SURVEYS COMPLETED IN 2020 OR EARLIER
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E-cigarette use among adults
is monitored by national 
population-based surveys
E-cigarette use among adults 
is not monitored by national 
population-based surveys
Not applicable
© WHO 2021. All rights reserved.
Data Source: WHO
Map Production: WHO GIS Centre
for Health, DNA/DDI
The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on
the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its
frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.
Monitoring e-cigarette use among adults
Countries that monitor ENDS use among adults: Argentina, Australia, Austria, Bolivia (Plurinational State of), Brunei Darussalam, Bulgaria, Canada, Chile China, 
Colombia, Costa Rica, Cyprus, Czechia, Denmark, Ecuador, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Indonesia, Ireland, Italy, Kazakhstan, 
Latvia, Lithuania, Luxembourg, Malaysia, Malta, Marshall Islands, Mexico, Nepal, N therlands, New Zealand, Panama, Philippines, Poland, Qatar, Republic of Korea, 
Romania, Russian Federation, Senegal, Serbia, Slovenia, Spain, Sweden, Switzerland, Ukraine, United Arab Emirates, Unites States of America, Uruguay, Viet Nam. 
ENDS should not be left unregulated.
Too many countries do not 
regulate ENDS
Globally, 111 countries have adopted 
measures addressing ENDS. Thirty-two 
of these countries ban the sale of ENDS. 
Seventy-nine countries (over 40% of all 
countries), allow the sale of ENDS but 
have adopted one or more measures 
either fully or partially to regulate them. 
These measures include bans on the 
use of ENDS in public indoor areas; 
bans on advertising, promotion and 
sponsorship; and the application of 
graphic health warnings on packaging 
as well as age restrictions on the sale of 
ENDS and flavoring bans or restrictions. 
The remaining 84 countries, home to 
27% of the world’s population, have no 
regulations in place addressing ENDS. 
While 84% of high-income countries 
have either a regulation or a sales 
ban in effect, half of middle-income 
countries and three-quarters of 
low-income countries have taken no 
regulatory action concerning ENDS.
Measures that ban ENDS use 
in public indoor places, apply 
health warnings on ENDS  
and ban on ENDS advertising, 
promotion and sponsorship 
should all be applied
Excluding countries that ban sale of 
ENDS, 30 countries completely ban 
the use of ENDS in all public places, 
workplaces and public transport; an 
additional 45 countries partially ban their 
use in these places. The remaining 120 
countries have either no smoke-free place 
measures (37 countries), or ENDS are 
not explicitly covered by such measures 
where they exist (83 countries). 
Only eight countries mandate the use of 
large graphic health warnings on ENDS 
packaging meeting full criteria, two of 
which apply these requirements only 
to ENDS devices and not to e-liquids. 
Another 45 countries mandate some 
form of health warning on either 
ENDS devices, e-liquids or both. And 
110 countries either have no graphic 
tobacco health warning measures in 
place (24 countries), or where they do 
exist, ENDS are not explicitly covered 
by them (86 countries). Thirty-two 
countries ban the sale of ENDS and 
therefore do not mandate health 
warnings for them.
Twenty-two countries completely ban 
advertising, promotion and sponsorship 
of ENDS devices, e-liquids or both (15 
ban these activities for both devices and 
e-liquids; four ban them only for ENDS 
devices; and three ban them only for 
e-liquids). An additional 53 countries 
have partial advertising, promotion 
and sponsorship measures in place 
that cover ENDS. The remaining 120 
countries either have no such measures 
in place (16 countries), or where they 
do exist, ENDS are not explicitly covered 
by them (104 countries).
MONITORING E-CIGARETTE USE AMONG ADULTS USING NATIONAL  SCHOOL-
BASED SURVEYS COMPLETED IN 2020 OR EARLIER
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Sale is banned Full or partial measures No measures
HIGH-INCOME COUNTRIES MIDDLE-INCOME COUNTRIES LOW-INCOME COUNTRIES
Measures include: 
1. Prohibiting the use of ENDS in public indoor areas
2. Graphic health warnings applied to packaging
3. Prohibiting the advertisement, promotion and sponsorship of ENDS
4. Minimum age restrictions applied to sale of ENDS
5. Ban on flavours
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Full or partial measure adopted
Sale is banned
No measure or ban
No data
Not applicable
© WHO 2021. All rights reserved.
Data Source: WHO
Map Production: WHO GIS Centre
for Health, DNA/DDI
The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on
the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its
frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.
Measures applied to ENDS
Note: 13 countries have both a sales ban and additional ENDS regulation in place, and these are classified here as sales-ban countries. Please see Annex II Table 2.1 
for further details.
ENDS are regulated in the following countries: Albania, Algeria, Andorra, Armenia, Australia, Austria, Azerbaijan, Barbados, Belarus, Belgium, Bulgaria, Cameroon, 
Canada, Chile, China, Congo, Costa Rica, Cote d’Ivoire, Croatia, Cyprus, Czechia, Denmark, Ecuador, El Salvador, Estonia, Fiji, Finland, France, Georgia, Germany, 
Greece, Guyana, Honduras, Hungary, Iceland, Ireland, Israel, Italy, Jamaica, Kazakhstan, Kenya, Lao People’s Democratic Republic, Latvia, Lithuania, Luxembourg,  
Malta, Montenegro, Nepal, Netherlands, New Zealand, Niue, Norway, Palau, Papua New Guinea, Paraguay, Philippines, Poland, Portugal, Republic of Korea, 
Republic of Moldova, Romania, Russian Federation, Saint Lucia, San Marino, Saudi Arabia, Serbia, Slovakia, Slovenia, Spain, Sweden, Tajikistan, Togo, Turkey, 
Tuvalu, Ukraine, United Arab Emirates, United Kingdom, United States of America, Uzbekistan.
Sale of ENDS is banned in the following countries and territories: Argentina, Bahrain, Brazil, Brunei Darussalam, Cambodia, Democratic People’s Republic of 
Korea, Egypt, Ethiopia, Gambia, India, Iran (Islamic Republic of), Iraq, Jordan, Kuwait, Lebanon, Malaysia, Mauritius, Mexico, occupied Palestinian territory, Oman, 
Panama, Qatar, Singapore, Sri Lanka, Suriname, Syrian Arab Republic, Thailand, Timor-Leste, Turkmenistan, Uganda, Uruguay, Venezuela (Bolivarian Republic of).
SELECTED LEGISLATIVE MEASURES APPLIED TO ENDS, 2020
COUNTRIES APPLYING MINIMUM AGE OF SALES RESTRICTIONS 












No measures for tobacco or ENDS
Criteria* fully or partially met for 
tobacco but no measures for ENDS
Criteria* partially met for ENDS
Criteria* fully met for ENDS
* for a list of the criteria, refer to Technical Note I


























# 32 countries with a ban on sale of ENDS are 
excluded from this indicator
1 In 2 countries this measure applies to ENDS 
devices only, and in 9 countries this measure 
applies to e-liquids only
2 In 2 countries this measure applies to ENDS 
devices only, not e-liquids
3 In 2 countries this measure applies to ENDS 
devices only, and in 1 country this measure 
applies to e-liquids only
4 In 4 countries this measure applies to ENDS 
devices only, and in 3 countries this measure 
applies to e-liquids only
MEASURES APPLIED TO ENDS, 2020
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Finland’s ban on flavours and aromas in e-cigarettes liquids 
In 2016, Finland introduced pioneering e-cigarette regulations that banned use of flavourings, set minimum-age 
limits for buyers, provided import restrictions, banned the use of e-cigarettes in non-smoking areas and prohibited 
e-cigarette marketing, display and distance-selling. Following these revisions to Finland’s Tobacco Act, liquids used in 
e-cigarettes are available exclusively in tobacco flavour in Finland. Through a combination of swift action and stringent 
regulation, Finland achieved further declines in smoking prevalence (from 15% in 2016 to 14% in 2018) without seeing 
a contingent rise in daily e-cigarette use (less than 1% in 2018). The country has set an ambitious goal of bringing both 
tobacco and nicotine products below a prevalence rate of 5% within the next decade.
Flavours should be banned  
to reduce the appeal of  
ENDS products to children  
and adolescents
Excluding countries that ban the sale of 
ENDS, only 3 countries have adopted 
a ban all flavours in ENDS, except for 
“tobacco” flavour (Finland, Hungary 
and Montenegro). Six other countries 
ban only selected flavours or permit 
specific flavours (Denmark, Estonia, 
Germany, New Zealand, Philippines, 
Saudi Arabia). 
Age restrictions on the sale  
of ENDS has been adopted  
by only 69 countries
Of the 163 countries that permit the 
sale of ENDS, 69 countries limit their 
sale to a minimum age (18 years in 
62 countries, 19 years in one country 
and 21 years in six countries), while 
the other 94 countries do not. This 
means 42% of countries restrict access 
to ENDS by age compared to 90% of 
countries which apply these restrictions 
to tobacco.
There is no consistency in  
taxing ENDS
As they are often priced and taxed 
differently, data was collected for 
e-liquids used in both open and closed 
systems. Open systems are devices 
that allow the user to buy e-liquids 
and fill their device with the mixtures 
they want (with no nicotine, different 
nicotine concentrations and/or 
flavours). Closed systems are products 
that come with a prefilled container 
(called a cartridge, pod or tank) and 
where own mixes are not possible.
Of the 51 countries where data are 
available for open-systems ENDS, 28 
countries (55%) impose no excise tax 
on open systems e-liquids. And of the 
44 countries where data are available 
for closed systems, 57% (25 countries) 
impose no excise tax on closed systems 
e-liquids (commonly sold as pods).
In countries where an excise tax is 
imposed on ENDS e-liquids, the tax is 
generally low, with only three countries 
levying taxes equal to, or above, 75% 
of the price of the cheapest brand 
for open systems e-liquids (Portugal, 
Russian Federation and Slovenia). For 
closed systems e-liquids, no country 
applies taxes as high as 75% of the 
price of the cheapest brand of closed 
system ENDS. 
SELECTED LEGISLATIVE MEASURES APPLIED TO ENDS, 2020
COUNTRIES APPLYING MINIMUM AGE OF SALES RESTRICTIONS 












No measures for tobacco or ENDS
Criteria* fully or partially met for 
tobacco but no measures for ENDS
Criteria* partially met for ENDS
Criteria* fully met for ENDS
* f r a list of the criteri , refer to Tech ical Note I


























# 32 countries with a ban on sale of ENDS are 
excluded from this indicator
1 In 2 countries this measure applies to ENDS 
devices only, and in 9 countries this measure 
applies to e-liquids only
2 In 2 countries this measure applies to ENDS 
devices only, not e-liquids
3 In 2 countries this measure applies to ENDS 
devices only, and in 1 country this measure 
applies to e-liquids only
4 In 4 countries this measure applies to ENDS 
devices only, and in 3 countries this measure 
applies to e-liquids only
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Excise on closed-system e-liquids
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ENDS closed-system e-liquids tax policy
Countries with a tax on clos d system e-liquids: Armenia, Austria, Az rbaija , Bahrain, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, China, Croatia, 
Czechia, Denmark Estonia, France, Georgia, Germany, Greece, Hungary, Iceland, Indonesia, Ireland, Israel, Italy, Kazakhstan, Kyrgyzstan, Lithuania, Luxembourg, 
Malta, Netherlands, Pakistan, Peru, Poland, Portugal, Republic of Korea, Republic of Moldova, Romania, Russian Federation, Serbia, Spain, Sweden, Tonga, 
Ukraine, United Arab Emirates, United Kingdom, Uzbekistan.
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ENDS open-system e-liquids tax policy
Note: Jordan also has both a ban on the sale of ENDS and an excise
C untries with a tax on open systems e-liquids: Albania, Armenia, Austria, Azerbaijan, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, 
Czechia, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Iceland, Indonesia, Ireland, Israel, Italy, Jordan, Kazakhstan, Kyrgyzstan, Lao People’s 
Democratic Republic, Latvia, Lithuania, Luxembourg, Malta, Montenegro, Morocco, Netherlands, North Macedonia, Peru, Poland, Portugal, Republic of Moldova, 
Romania, Russian Federation, Serbia, Slovakia, Slovenia, Spain, Sweden, Tonga, Ukraine, United Kingdom, Uzbekistan, Yemen.
ENDS CLOSED SYSTEM E-LIQUIDS TAX POLICY, 2020
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Countries should consider 
including ENDS cessation in  
their cessation strategies
Many ENDS users wanting to quit use 
tools such as toll-free quit lines, text 
message programmes and specialized 
tobacco dependence treatments. Data 
from the largest quit line operator in 
the United States (serving 23 states 
and over 700 employers and health 
plans) showed that among the 74 
646 quit line participants enrolled 
between January 2017 and June 2020, 
14% were using e-cigarettes and 2% 
of them were exclusive e-cigarette 
users. Therefore, the country’s national 
tobacco cessation services should 
consider providing support for ENDS 
users to quit (1).
Tobacco control must anticipate 
nicotine and tobacco products 
will evolve rapidly and plan for 
their regulation
In recent years, there have been 
newer nicotine and tobacco products 
introduced to several markets. These 
are rapidly evolving and may have 
implications for regulation. Therefore, 
the availability, characteristics and use 
of these and other emerging products 
should be closely monitored going 
forward and regulations should be 
future-proofed as much as possible to 
cover these products. This report did 
not collect data on nicotine pouches or 
other novel nicotine products. 
Measures applied to ENNDS are 
often not consistent with those 
applied to ENDS
Data collected on ENNDS indicate 
that although 14 countries regulate 
(or ban the sale of) ENNDS in the 
same way they regulate ENDS, others 
have differing approaches for these 
products, including banning the 
sale of one when allowing the sale 
of the other. Twenty-nine countries 
ban the sale of ENNDS and only one 
country explicitly bans both ENNDS 
and ENDS (Iraq). Apart from sale 
bans, 35 countries regulate ENNDS 
but in ways that are inconsistent with 
measures applied to ENDS. A total of 
117 countries with 4 billion people 
are not covered by any measures that 
specifically address ENNDS. See Annex 
II for further details.
Note on Heated Tobacco Products 
The Eighth Conference of the Parties to the WHO FCTC recognized HTPs as tobacco products and noted that they 
should therefore be subject to the provisions of the WHO FCTC, and monitored and regulated like other tobacco 
products. Data collected for this report indicate that HTPs are banned (sales ban or another type of ban that restricts 
their availability) in 11 countries, (Brazil, Democratic People’s Republic of Korea, Ethiopia, India, Iran (Islamic Republic 
of), Mexico, Norway, Panama, Singapore, Syrian Arab Republic, Timor-Leste). In the remaining 184 countries, 
HTPs are either implicitly or explicitly regulated as tobacco products, or explicitly regulated in other categories. 
Further analysis will be made in the future to understand better how these products are addressed by countries.
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Ukraine imposes taxes on ENDS and HTPs 
Ukraine has committed itself to implementation  
of the WHO FCTC COP-8 decision on regulating  
novel and emerging nicotine and tobacco products 
with a similar approach to that used for conventional 
tobacco products. Thus, in 2019 the Ukraine parliament 
adopted Law Nº 466-IX that imposes taxes on the 
liquids used in ENDS, ENNDS and HTPs starting from 
January 1, 2021.
At the same time Ukraine worked to increase public 
knowledge about ENDS. From November 2020 to 
January 2021, an NGO called Life, together with the 
Public Health Center, conducted a national information 
campaign titled “There is no safe smoking” with the 
support of global health organization Vital Strategies. 
Social videos and public service announcements 
(broadcast on television, on the Internet, on subway 
and train stations) were aimed at raising young people’s 
awareness of the health risks of using electronic 
smoking devices. Residents of Kyiv, the capital of 
Ukraine, also saw social advertising on the city streets. 
The campaign reached around 25 million people and 
evaluations showed that 73% of people received new 
information via the campaign, and that 47% of ENDS 
and HTP users were motivated to quit as a result of it. 
Ukraine MPs, doctors, experts and activists unite to defend equal taxation rates for all tobacco products
Examples of country actions applied to ENDS
106 | WORLD HEALTH ORGANIZATION
Pictorial health warnings mandated on ENDS, Republic of Korea 
In the Republic of Korea, ENDS have been regulated as 
tobacco products under the Tobacco Business Act since 
January 2014. Although the ENDS industry strongly 
opposed displaying health warnings on ENDS products, 
pictorial health warnings on all nicotine and tobacco 
products have become mandatory.
The Tobacco Pictorial Health Warning Committee, 
composed of representatives from the Ministry of 
Health and Welfare, the Ministry of Finance, the 
Ministry of Gender Equality and Family, academia 
and experts from public health, youth education, 
communication, and civil society organizations, 
reviewed the most recent available scientific evidence 
on tobacco products to draw up a list of topics for 
the warnings. In addition, the Ministry of Health and 
Welfare conducted focus group interviews and online 
public surveys to identify the most powerful text and 
images for health warnings, and evaluated existing 
health warnings from around the world. 
Since December 2016, three rounds of health warnings 
have been issued by the Ministry of Health and Welfare, 
and images for the warnings on ENDS have changed 
every 2 years to deliver the message more effectively 
on the harm of ENDS use. The Republic of Korea was 
the first country in the world to make pictorial health 
warnings obligatory on ENDS, and its experience 
of doing so provides a valuable example of how to 
consultatively develop and implement health warnings 
on emerging and novel nicotine and tobacco products 
based on scientific evidence. 
23 December 2018 to  
22 December 2020
23 December 2016 to  
22 December 2018
23 December 2020 to  
22 December 2022
Changes in the pictorial health warning on e-cigarettes in Republic of Korea
Sri Lanka bans ENDS 
Sri Lanka was one of the first countries in the South-East Asia Region to ban electronic cigarettes. As per 
“Prohibited Tobacco Products” regulations of 2016, no person in the country shall manufacture, import, sell or 
offer for sale any electronic cigarette that contains tobacco. This initiative shows the commitment of the country to 
effectively address the ongoing tobacco epidemic as electronic cigarettes could put people, specially youth, at risk  
of nicotine addiction.
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In the 13 years during which MPOWER 
has been monitored, there have been 
tremendous strides made in tobacco 
control. At the same time there have 
been countless challenges – perhaps the 
greatest of which was faced in 2020 in 
the shape of the COVID-19 pandemic. 
Despite these hurdles, there are now 5.3 
billion people who are protected by at 
least one best-practice tobacco control 
measure – 4.2 billion more than were 
covered in 2007. Conversely, 2.4 billion 
people remain unprotected by evidence-
based tobacco control best practices, 
leaving them at risk from the health and 
economic harms caused by tobacco.
There has been inspiring progress in 
tobacco control since the adoption of 
the WHO FCTC and the introduction 
of MPOWER. Billions of lives are now 
better protected and millions of lives 
have been saved over the years. This 
has come about through the collective 
and coordinated efforts of a global 
community dedicated to tobacco 
control. But there is still so much work 
ahead of us. Only two countries in 
the world (Brazil and Turkey) have put 
all MPOWER measures in place at a 
comprehensive level. And although the 
prevalence of smoking has declined 
across most of the world, as the total 
population grows, the total number of 
people smoking remains high. 
Every country has an obligation to 
protect the health of its people, and all 
Parties to the WHO FCTC have made 
a commitment to implement strong 
tobacco control policies as an important 
means of fulfilling their obligation to 
protect the health of their people. 
The SDGs have also underscored the 
importance of this commitment and 
call to “strengthen the implementation 
of the WHO FCTC in all countries, as 
appropriate”, measured by the reduction 
of tobacco use in adults. Tobacco use 
reduction is also one of the 16 trace 
indicators to measure (and is a major 
contributor to) the Healthier Billion 
component of the WHO Triple Billion 
Targets, an initiative to help countries 
deliver on the SDGs.
The focus of this report, addressing 
new and emerging products, charts 
a new threat to tobacco control. 
ENDS are increasingly available in 
many countries along with other 
novel products like heated tobacco 
products and nicotine pouches. As 
they emerge and rapidly evolve, these 
products can be difficult to characterize 
and therefore bring with them many 
regulatory challenges. At the same 
time, the tobacco and related industries 
behind these newer products pedal 
misinformation campaigns, marketing 
them as “clean”, “smoke-free” or 
CONCLUSION
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“safer”, and claim they are effective 
cessation aids. By doing so, these 
industries attempt to appear part of  
the solution to the tobacco epidemic,  
as opposed to instigators and 
perpetrators of the epidemic. These 
industries also target children and 
adolescents by using marketing 
strategies and thousands of flavours 
that make ENDS and other nicotine 
and tobacco products appealing. When 
children use ENDS, or even try them, 
they are more than twice as likely 
to use conventional cigarettes. The 
tobacco industry gains new customers.
The evidence from this report indicates 
that 32 countries currently ban the 
sale of ENDS, taking a strong stance 
on preventing the potential harms 
they pose to their populations. A 
further 79 countries have adopted 
bans on use in public indoor areas, 
advertising, promotion or sponsorship 
bans or graphic health warnings for 
ENDS; however, 39 of these are only 
partially adopted. This leaves a total 84 
countries with no legislation addressing 
ENDS in any of these domains. 
The data also show that only a handful 
of countries ban flavours in ENDS, and 
a few more regulate them. In parallel to 
this, 94 countries do not limit the sale of 
ENDS to a minimum age, making these 
products freely available to minors.
And where data are available on tax 
rates, these rates are generally low, 
with only three countries taxing ENDS 
e-liquids at 75% or more of the retail 
price. Too many countries remain 
vulnerable to the tactics used by the 
tobacco and related industries to expand 
their markets. Countries should protect 
their populations, and in particular 
their children and adolescents, from 
unregulated novel and emerging 
tobacco and nicotine products. 
There has been inspiring progress in the 
13 years since MPOWER monitoring 
began, but still there are many challenges 
to overcome in order to achieve the 
commitments countries have made 
through the WHO FCTC, the SDGs and 
the Noncommunicable Diseases Global 
Action Plan to reduce tobacco use and 
bring a swift end the tobacco epidemic. 
Countries should remain vigilant and 
maintain focus on implementing 
evidence-based measures that are 
proven to reduce tobacco use, and avoid 
distractions caused by the proliferation of 
newer products. As the world emerges 
from the COVID-19 pandemic, the call 
to build back better should be central to 
tobacco control. We must all recommit 
to strengthening implementation 
of the WHO FCTC, strive to adopt 
MPOWER measures at the highest level 
of achievement, and ensure that all the 
people of the world are protected from 
the harms of tobacco and nicotine.
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COVID-19 and the WHO report on the global tobacco epidemic, 2021
The WHO report on the global 
tobacco epidemic, 2021 requires 
the coordinated inputs of hundreds 
of public health specialists. It is 
important to note, therefore, that 
production of this report faced 
unique limitations. Many country-
level focal points in tobacco 
control faced significant capacity 
challenges over the period of 
data collection and validation 
because they had to take on 
additional COVID-19 response 
functions, therefore some valuable 
information or refinements of our 
analyses may have been missed. 
We also note that comparisons of 
the latest data to previous years 
will need to take into account the 
exceptional circumstances during 
2020 that have both accelerated 
progress in tobacco control in some 
parts and slowed it down in others. 
For instance, a number of countries 
have managed to strengthen their 
tobacco control legislation during 
that time. It is beyond the scope of 
this report to analyse the unique 
context of each country. 
We want to take this opportunity 
to thank all those who offered 
their valuable time and resources 
to ensuring this report could be 
published on time. Many people 
involved in the report have suffered 
from COVID-19 directly, had to 
care for family or friends during 
this difficult time, and/or have lost 
loved ones. 
We dedicate this report to all those 
we lost to COVID-19.
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This report provides summary indicators 
of country achievements for each 
of the MPOWER measures, and the 
methodology used to calculate each 
indicator is described in this Technical 
Note. To ensure consistency and 
comparability, the data collection and 
analysis methodology used in this 
report are largely based on previous 
editions of the report. Some details of 
the methodology employed in earlier 
reports, however, have been revised 
and strengthened for the present 
report. Where revisions have been 
made, data from previous reports have 
been re-analysed so that results are 
comparable across years.
This edition of the report includes for 
the first time data on ENDS and ENNDS, 
therefore the methodology used for 
the data related to these products was 
added throughout the Technical Notes.
Data sources
Data were collected using the  
following sources:
■	 For all areas: official reports from 
WHO FCTC Parties to the Conference 
of the Parties (COP) and their 
accompanying documentation.1
■	 For M (monitoring): tobacco 
prevalence surveys not reported 
under the COP reporting mechanism 
were collected mainly through  
WHO Regional and WHO Country 
Offices. Technical Note II provides 
further details.
■	 For P (protect people from tobacco 
smoke), W (warn about the dangers 
of tobacco) and E (enforce bans 
on tobacco advertising, promotion 
and sponsorship): original tobacco 
control legislation (including 
regulations) adopted in all Member 
States that relate to smoke-free 
environments, packaging and 
labelling measures and tobacco 
advertising, promotion and 
sponsorship. Tobacco control laws 
and regulations as well as product 
regulations are also the sources  
of data for ENDS and ENNDS. 
In cases where a law had been 
adopted by 31 December 2020  
but had not yet entered into force, 
the respective law was assessed  
and data were reported with 
an asterisk denoting “Provision 
adopted but not implemented  
by 31 December 2020”. In 
cases where a law had been 
adopted but not yet the 
implementing regulations, data 
were reported with the asterisk 
“Regulations are pending”.
■	 For W (mass media): data on  
anti-tobacco mass media campaigns 
were obtained from Member States. 
In order to avoid unnecessary 
data collection, WHO conducted 
a screening for anti-tobacco mass 
media campaigns in all WHO Country 
Offices. In countries where potentially 
eligible mass media campaigns 
were identified, focal points in each 
country were contacted for further 
information on these campaigns, 
and data on eligible campaigns were 
gathered and systematically recorded.
■	 For O (offer help to quit tobacco 
use): data not reported under the 
COP reporting mechanism were 
collected mainly through WHO 
Regional and WHO Country Offices. 
■	 For R (raise taxes on tobacco): the 
prices of the most sold brand of 
cigarettes, the cheapest brand and 
a premium brand were collected 
through regional data collectors. 
Information on the taxation of 
cigarettes (and when possible, most 
commonly used other smoked and 
smokeless tobacco products) and 
revenues from tobacco taxation was 
collected from ministries of finance. 
Technical Note III provides the 
detailed methodology used.
Based on these sources of information, 
WHO assessed each indicator as of 
31 December 2020. Exceptions to this 
cut-off date were tobacco product 
prices and taxes (cut-off date 31 July 
2020) and anti-tobacco mass media 
campaigns (cut-off date 30 June 2020). 
Data validation
For each country, every data point for 
which legislation was the source was 
assessed by two expert staff from 
two different WHO offices, generally 
one from WHO headquarters and 
the other from the respective WHO 
Regional Office. Any inconsistencies 
were reviewed by the two WHO expert 
staff involved and, if needed, by a third 
expert staff member not yet involved 
in the appraisal of the legislation. 
Disagreements in the interpretation 
of the legislation were resolved by: 
(i) checking the original texts of the 
legislation; (ii) trying to obtain consensus 
from the two expert staff involved in 
the data collection; (iii) trying to obtain 
clarification from judges or lawyers in 
the concerned country; and (iv) the 
decision of the third expert in cases 
where differences remained. Data were 
also checked for completeness and 
logical consistency across variables.
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Data sign-off
Final, validated data for each country 
were sent to the respective governments 
for review and sign-off. To facilitate 
review by governments, a summary 
sheet was generated for each country 
and was sent for review prior to the 
close of the report database. In cases 
where national authorities requested 
data changes, the requests were 
assessed by WHO expert staff according 
to both the legislation/materials and 
the clarification shared by the national 
authorities, and data were updated or 
left unchanged. In cases where national 
authorities explicitly did not agree with 
the data assessment, this is specifically 
noted in the annex tables. Further details 
about the data processing procedure are 
available from WHO.
Data analysis
It is important to note that data about 
laws reflect the status of legislation 
adopted by 31 December 2020 that 
has a stated date of effect and is not 
undergoing a legal challenge that could 
impact the date of implementation. 
Data from laws not in effect by 31 
December 2020 have a footnote stating 
this. The summary measures developed 
for this report are the same as those 
used for the 2019 report.
The report provides analysis of progress 
made between 2018 and 2020, and 
between 2007 and 2020 using the latest 
assessment of the status of measures 
in each year so that the results are 
comparable across years. For R, the 
earliest comparable data are 2008 and 
for mass media, data are available only 
from 2010. To calculate the change 
in the percentage of the population 
covered by each policy or measure over 
time, population estimates for the year 
20192 were used. Using a static year 
eliminates the effect of population 
growth when measuring change over 
time. Indicators from previous years 
have been recalculated, according to 
legislation/materials received after the 
assessment period of the respective 
report or according to changes in the 
indicator methodology. All income 
groups used for this report derive 
from the World Bank income-group 
classification published on 1 July 2020 
by the World Bank.3 Upper-middle 
and lower-middle income groups are 
combined into one group for this report.
When country or population totals for 
MPOWER measures are referred to 
collectively in the analysis section of 
this report, only the implementation 
of tobacco control policies (smoke-free 
legislation, cessation services, warning 
labels, advertising, promotion and 
sponsorship bans, and tobacco taxes)  
is included in these totals. 
Monitoring of tobacco use and  
anti-tobacco mass media campaigns  
are reported separately. 
Correction to previously 
published data
The 2018 data published in the last 
report were reviewed, and about 3% of 
data points were corrected. The full set 
of MPOWER data revised for all years 
back to 2007 is available in the WHO 
Global Health Observatory at https://
www.who.int/data/gho/data/themes/
theme-details/GHO/tobacco-control.
Monitoring of tobacco use 
and prevention policies
The strength of a national tobacco 
surveillance system is assessed by the 
frequency and periodicity of nationally 
representative youth and adult surveys 
in countries. Countries are grouped in 
the top Monitoring category when all 
criteria listed below are met for both 
youth and adult surveys:
■	 whether a survey was carried  
out recently;
■	 whether the survey was representative 
of the country’s population;
■	 whether a similar survey was repeated 
within 5 years (periodic); and
■	 whether the youth and adult 
populations were surveyed through 
school-based and household 
population-based surveys respectively.
Surveys were considered recent if 
conducted in the past 5 years. For 
this report, this means 2015 or later. 
Surveys were considered representative 
only if a scientific random sampling 
method was used to ensure nationally 
representative results. (Although they 
provide useful information, subnational 
surveys or national surveys of specific 
population groups provide insufficient 
information to enable tobacco control 
action for the total population.) Surveys 
were considered periodic if the same 
survey or a survey using the same or 
similar questions was repeated at least 
once every 5 years. The following 
definitions were applied for youth and 
adult surveys:
Youth surveys: school-based surveys 
of students aged 13–15 years or 
other age range encountered during 
secondary-level school. The questions 
asked in the surveys should provide 
indicators that are consistent with those 
specified in the Global Youth Tobacco 
Survey questionnaires and manuals.
Adult surveys: population-based 
surveys that can provide indicators 
for adults aged 15 years and over (or 
another age range starting around 
15 and including people older than 
15), consistent with those specified 
in the Global Adult Tobacco Survey 
questionnaires and manuals.
The groupings for the Monitoring 
indicator are listed below. 
No known data or no recent* data or 
data that are not both recent* and 
representative**
Recent* and representative**  
data for either adults or youth
Recent* and representative**  
data for both adults and youth
Recent*, representative** and 
periodic*** data for both adults  
and youth
* Data from 2015 or later.
**  Survey sample representative of the national 
population.
*** Collected at least every 5 years.
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Owing to the difficulty of running 
population or school-based national 
surveys during the COVID-19 pandemic, 
countries who were at the highest  
level of achievement in the previous 
report have not been downgraded in 
this report.
Smoke-free legislation
There is a wide range of places and 
institutions that can be made  
smoke-free by law. Smoke-free 
legislation can be in place at the 
national or subnational level. The 
report includes data based on national 
legislation, and legislation in subnational 
jurisdictions where available and where 
national laws are incomplete. The 
assessment of subnational smoke-
free legislation includes first-level 
administrative subdivisions of a country, 
as listed in ISO3166. Subnational data 
reported in Annex VI only reflect 
the content of the subnational laws. 
Provisions covered by national legislation 
are indicated by an informative note  
next to the subnational data. In 
cases where the status of smoke-free 
legislation is not reported for some or 
all subnational jurisdictions, we assume 
the existing national law applies. 
Legislation was assessed to determine 
whether smoke-free laws provided 
for a complete4 indoor smoke-free 
environment at all times, in all the 
facilities of each of the following 
 eight places:
■	 health-care facilities;




■	 indoor offices and workplaces not 
considered in any other category;
■	 restaurants or facilities that serve 
mostly food;
■	 cafés, pubs and bars or facilities  
that serve mostly beverages;
■	 public transport.
Groupings for the smoke-free 
legislation indicator are based on 
the number of places where indoor 
smoking is completely prohibited. 
Countries with no complete smoking 
ban at national level but where at least 
90% of the population is covered by 
complete subnational smoke-free laws 
are grouped in the top category.
The groupings for the smoke-free 
legislation indicator are listed below.
Not reported
Complete absence of bans, or up to two 
public places completely smoke-free
Three to five public places completely 
smoke-free
Six to seven public places completely 
smoke-free
All public places completely smoke-
free (or at least 90% of the population 
covered by complete subnational 
smoke-free legislation)
In addition to the data used for the 
above groupings of the smoke-free 
legislation indicator, other related 
data such as information on fines and 
enforcement were collected and are 
reported in Annex VI.
A number of countries include 
exceptions to their smoke-free law that 
allow for the provision of designated 
smoking rooms (DSRs) in certain 
public places and workplaces. This 
is reported as a “No”. For the small 
number of countries where DSRs are 
allowed under “very strict technical 
requirements”,5 this is reported in the 
Annex tables as an asterisk instead of 
a “Yes”. If DSRs are allowed but the 
very strict requirements are missing or 
not mentioned in the legislation, this 
is reported as a “No”. The groupings 
for smoke-free laws treat an asterisk 
the same as a “No”, because a law 




The indicator of achievement in 
treatment for tobacco dependence  
is based on whether the country  
has available:
■	 nicotine replacement therapy (NRT);
■	 smoking cessation support; 
■	 reimbursement for any of the above; 
and
■	 a national toll-free quit line.
Despite the low cost of quit lines, 
few low- or middle-income countries 
have implemented such programmes. 
Thus, national toll-free quit lines are 
included as a qualification only for 
the highest category. Reimbursement 
for tobacco dependence treatment 
is considered only for the top two 
categories to take restricted national 
budgets of many lower-income 
countries into consideration.
The top three categories reflect varying 
levels of government commitment to 
the provision of nicotine replacement 
therapy and cessation support.
The groupings for the tobacco 




NRT* and/or some cessation 
services** (neither cost-covered) 
NRT* and/or some cessation services** 
(at least one of which is cost-covered)
National quit line, and both NRT*  
and some cessation services**  
(cost-covered)
* Nicotine replacement therapy.
**  Smoking cessation support available in any of the 
following places: health clinics or other primary care 
facilities, hospitals, office of a health professional, the 
community or other settings.
In addition to data used for the grouping 
of the tobacco dependence treatment 
indicator, other related data such as 
information on countries’ essential 
medicines lists, etc. were collected and 
are reported in Annex VI. 
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Warning labels on  
tobacco packaging
The section of the report that 
assesses each country’s legislation 
on health warnings includes the 
following information about 
cigarette package warnings:
■	 whether specific health warnings 
are mandated;
■	 the mandated size of the warnings, 
as a percentage of the front and 
back of the cigarette package;
■	 whether the warnings appear on 
individual packages as well as on 
any outside packaging and labelling 
used in retail sale;
■	 whether the warnings describe 
specific harmful effects of tobacco 
use on health;
■	 whether the warnings are large, 
clear, visible and legible (e.g. 
specific colours and font styles 
and sizes are mandated);
■	 whether the warnings rotate;
■	 whether the warnings are written  
in (all) the principal language(s)  
of the country;
■	 whether the warnings include 
pictures or pictograms.
The size of the warnings on both 
the front and back of the cigarette 
pack were averaged to calculate 
the percentage of the total pack 
surface area covered by warnings. 
This information was combined 
with the warning characteristics 
to construct the groupings for 
the health warnings indicator.
The groupings for the health warnings 
indicator are listed below.
Data not reported
No warnings or small warnings 1
Medium size warnings 2 missing some3 
or many 4 appropriate characteristics5 
OR large warnings 6 missing many 4 
appropriate characteristics5
Medium size warnings 2 with all 
appropriate characteristics5 OR large 
warnings6 missing some 3 appropriate 
characteristics 5
Large warnings 6 with all appropriate 
characteristics5
1  Average of front and back of package is less  
than 30%.
2  Average of front and back of package is between  
30 and 49%.
3 One to three.
4 Four or more.
5  Appropriate characteristics:
■	 specific health warnings mandated;
■	 appearing on individual packages as well as  
on any outside packaging and labelling used  
in retail sale;
■	 describing specific harmful effects of tobacco 
use on health;
■	 are large, clear, visible and legible  
(e.g. specific colours and font style 
 and sizes are mandated);
■	 rotate;
■	 include pictures or pictograms;
■	 written in (all) the principal language(s)  
of the country.
6  Average of front and back of the package is  
at least 50%.
In addition to the data about cigarettes 
used for the grouping of the health 
warnings indicator, data about 
other smoked tobacco products and 
smokeless tobacco products, as well 
as other related data such as the 
appearance of the quit line number,  
the requirement for plain packaging, 
etc. were collected and are reported  
in Annex VI. 
Plain packaging (also called 
standardized packaging) is defined by 
WHO FCTC Article 11 guidelines as 
a measure “to restrict or prohibit the 
use of logos, colours, brand images or 
promotional information on packaging 
other than brand names and product 
names displayed in a standard colour 
and font style”. 
In order for a country to appear in 
this report as having introduced plain 
packaging, the following criteria 
(established by WHO FCTC Article 13 
guidelines) are requested by a law and 
the implementing rules: 
■	 black and white or two other 
contrasting colours, as prescribed  
by national authorities;
■	 nothing other than a brand 
name, a product name and/or 
manufacturer’s name, contact 
details and the quantity of product 
in the packaging, without any logos 
or other features apart from health 
warnings, tax stamps and other 
government-mandated information 
or markings; 
■	 prescribed font style and size for the 
above elements; 
■	 standardized shape, size and 
materials:
■	 there should be no advertising or 
promotion inside or attached to the 
package or on individual cigarettes 
or other tobacco products.
Countries with a law requiring plain 
packaging but with no implementing 
rules or regulations yet adopted, will 
not be reported as having introduced 
plain packaging but will have the 
footnote “Regulations are pending” 
added in the report. This is also the 
case for countries that have required 
health warnings by law without having 
yet issued the proper texts and/or 
images by decree, rule, regulation, etc.
Anti-tobacco mass  
media campaigns
Countries undertake communication 
activities for many reasons, including 
improving public relations, creating 
attention for an issue, building support 
for public policies, and prompting 
behaviour change. Anti-tobacco 
communication campaigns, which are 
a core tobacco control intervention, 
must have specified features in order 
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to be minimally effective: they must 
be of sufficient duration and must 
be designed to effectively support 
tobacco control priorities, including 
increasing knowledge, changing social 
norms, promoting cessation, preventing 
tobacco uptake, and increasing support 
for good tobacco control policies.
With this in mind, and consistent with 
the definition of “anti-tobacco mass 
media campaigns” in the last report, 
only mass media campaigns that were: 
(i) designed to support tobacco control; 
(ii) at least 3 weeks in duration and 
(iii) implemented between 1 July 2018 
and 30 June 2020 were considered 
eligible for analysis. For the sake of 
logistical feasibility and cross-country 
comparability, only national-level 
campaigns were considered eligible. 
Consistent with the last report and to 
enable greater accuracy, materials from 
campaigns had to be submitted and 
verified based on the eligibility criteria 
for all countries.
Eligible campaigns were assessed 
according to the following characteristics, 
which signify the use of a comprehensive 
communication approach:
1. The campaign was part of a 
comprehensive tobacco control 
programme.
2. Before the campaign, research was 
undertaken or reviewed to gain 
a thorough understanding of the 
target audience.
3. Campaign communication materials 
were pre-tested with the target 
audience and refined in line with 
campaign objectives. 
4. Air time (radio, television)  
and/or placement (billboards, print 
advertising, etc.) were obtained 
by purchasing or securing it using 
either the organization’s own 
internal resources or an external 
media planner or agency (this 
information indicates whether the 
campaign adopted a thorough 
media planning and buying process 
to effectively and efficiently reach  
its target audience).
5. The implementing agency worked 
with journalists to gain publicity or 
news coverage for the campaign.
6. Process evaluation was undertaken 
to assess how effectively the 
campaign had been implemented.
7. An outcome evaluation process  
was implemented to assess 
campaign impact.
8. The campaign was aired on 
television and/or radio.
The groupings for the mass media 
campaigns indicator are listed below.
Data not reported
No national campaign conducted 
between July 2018 and June 2020 
with a duration of at least 3 weeks
National campaign conducted with 
one to four appropriate characteristics
National campaign conducted with 
five to six appropriate characteristics, 
or with seven characteristics excluding 
airing on television and/or radio
National campaign conducted  
with at least seven appropriate 
characteristics including airing  
on television and/or radio
Bans on advertising, 
promotion and sponsorship
The report includes data on legislation 
in national as well as subnational 
jurisdictions. The assessment of 
subnational legislation on advertising, 
promotion and sponsorship bans 
includes first-level administrative 
subdivisions as listed in ISO3166. 
Subnational data reported in Annex VI 
only reflect the content of subnational 
laws. Provisions covered by national 
legislation are indicated by an 
informative note next to the subnational 
data. In cases where the status of 
advertising, promotion and sponsorship 
legislation is not reported for some or all 
subnational jurisdictions, we assume the 
existing national law applies.
Country-level achievements in banning 
tobacco advertising, promotion and 
sponsorship were assessed based on 
whether the bans covered the following 
types of advertising:
■	 national television and radio;
■	 local magazines and newspapers;
■	 billboards and outdoor advertising;
■	 point of sale (indoor);
■	 free distribution of tobacco products 
in the mail or through other means;
■	 promotional discounts;
■	 non-tobacco products identified 
with tobacco brand names  
(brand stretching);6
■	 brand names of non-tobacco 
products used for tobacco products 
(brand sharing);7
■	 appearance of tobacco brands 
(product placement) or tobacco 
products in television and/or films;
■	 sponsorship (contributions and/or 
publicity of contributions).
The first four types of advertising 
listed are termed “direct” advertising, 
and the remaining six are termed 
“indirect” advertising. Complete bans 
on tobacco advertising, promotion and 
sponsorship usually start with bans on 
direct advertising in national media and 
progress to bans on indirect advertising 
as well as promotion and sponsorship.
The basic distinction for the two 
lowest groups is whether bans cover 
national television, radio and print 
media or not, and the remaining 
groups were constructed based on 
how comprehensively the law covers 
bans of other forms of direct and 
indirect advertising included in the 
questionnaire. In cases where the 
law did not explicitly address cross-
border advertising, it was interpreted 
that advertising at both domestic and 
international levels was covered by 
the ban only if advertising was totally 
banned at national level.
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The groupings for the bans on 
advertising, promotion and sponsorship 
indicator are listed below. Countries 
where at least 90% of the population 
were covered by subnational 
legislation completely banning tobacco 
advertising, promotion and sponsorship 
are grouped in the top category.
Data not reported
Complete absence of ban, or ban that 
does not cover national television (TV), 
radio and print media
Ban on national TV, radio and print 
media only
Ban on national TV, radio and print 
media as well as on some (but not 
all) other forms of direct* and/or 
indirect** advertising
Ban on all forms of direct* and 
indirect**advertising (or at least 
90% of the population covered by 
subnational legislation completely 
banning tobacco advertising, 
promotion and sponsorship)
* Direct advertising bans:
■	 national television and radio;
■	 local magazines and newspapers;
■	 billboards and outdoor advertising;
■	 point of sale (indoor).
** Indirect advertising bans:
■	 free distribution of tobacco products in the mail 
or through other means;
■	 promotional discounts;
■	 non-tobacco goods and services identified with 
tobacco brand names (brand stretching);
■	 brand names of non-tobacco products used for 
tobacco products (brand sharing);
■	 appearance of tobacco brands (product 
placement) or tobacco products in television 
and/or films;
■	 sponsorship (contributions and/or publicity of 
contributions).
In addition to the data used for the 
grouping of the bans on advertising, 
promotion and sponsorship indicator, 
other related data, such as bans on 
internet sales or on display of tobacco 
products at points of sale were collected 
and are reported in Annex VI.
Tobacco taxes
Countries are grouped according to the 
percentage contribution of all tobacco 
taxes to the retail price of a pack of 20 
of the most popular brand of cigarettes. 
Taxes assessed include excise tax, value 
added tax (or sales taxes), import duty 
(when the cigarettes were imported) 
and any other taxes levied. In the case 
of countries where different levels of 
taxes applied to cigarettes are based  
on length, quantity produced, or type 
(e.g. filter vs. non-filter), only the rate 
that applied to the most popular brand 
is used in the calculation.
Given the lack of information on 
country and brand-specific profit 
margins of retailers and wholesalers, 
their profits were assumed to be  
zero (unless provided by the national 
data collector).
The groupings for the tobacco tax 
indicator are listed below. Please refer 
to Technical Note III for more details.
Data not reported
< 25% of retail price is tax 
≥ 25% and < 50% of retail price is tax 
≥ 50% and < 75% of retail price is tax 
≥ 75% of retail price is tax 
Trend in affordability of 
the most sold brand of 
cigarettes
The affordability of cigarettes was 
computed as the percentage of per 
capita GDP required to purchase 2000 
cigarettes of the most popular brand 
in each year of this report from 2010 
to present. The least-squares annual 
growth rate of affordability was 
computed by fitting a linear regression 
trend line to the logarithmic values of 
the affordability measure.
The groupings for the affordability 
indicator are listed below. Please refer 
to Technical Note III for more details. 
YES
Cigarettes less affordable – per capita 
GDP needed to buy 2000 cigarettes 
of the most sold brand increased on 
average between 2010 and 2020
NO
Cigarettes more affordable – per 
capita GDP needed to buy 2000 
cigarettes of the most sold brand 
declined on average between 2010 
and 2020
No trend change in affordability of 
cigarettes since 2010
... Insufficient data to conduct a trend analysis
National tobacco  
control programmes
Classification of countries’ national 
tobacco control programmes is based 
on the existence of a national agency 
with responsibility for tobacco control 
objectives. Countries with at least five 
full-time equivalent staff members 
working at the national agency with 
responsibility for tobacco control meet 
the criteria for the highest group.
The groupings for the national  
tobacco control programme indicator 
are listed below.
Data not reported
No national agency for tobacco control
Existence of national agency with 
responsibility for tobacco control 
objectives with no or fewer than five 
full-time equivalent staff members
Existence of national agency with 
responsibility for tobacco control 
objectives and at least five full-time 
equivalent staff members
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Data collected and reported 
for ENDS and ENNDS in 
relation to the P, W and E 
measures 
For the first time ever, this report 
includes PWE data collected about 
ENDS and ENNDS. For P, W and E 
related data, the methodology used to 
collect and validate the data as well as 
the criteria used, were identical to those 
described earlier in this Technical Note. 
However, no subnational legislation 
was assessed for these products (only 
national legislation) and no compliance 
data were collected. 
Specifications on data about 
ENDS and ENNDS
In terms of product regulation, ENDS 
and ENNDS were categorized based 
on provisions in national legislation 
or regulations. For countries where 
the sale of ENDS and ENNDS is 
banned, we have nonetheless 
reported on regulations relating to 
their use, advertising, promotion, and 
sponsorship. For W and E, a distinction 
was made between the regulation 
applicable to the electronic devices 
and the one applicable to the e-liquids. 
The questions used for the groupings 
of the P,W and E measures described 
earlier were all assessed, and other 
related data such as minimum sale 
age, or regulation of flavours, were 
also collected and some of these are 
reported in Annex II.
Compliance assessment
Compliance with national and 
comprehensive subnational  
smoke-free legislation as well as 
with advertising, promotion and 
sponsorship bans was assessed by up 
to five national experts, who scored 
the compliance in these two areas 
as “minimal”, “moderate” or “high”. 
These five experts were selected 
according to the following criteria:
■	 person in charge of tobacco 
prevention in the country’s 
ministry of health, or the most 
senior government official in 
charge of tobacco control or 
tobacco-related conditions;
■	 the head of a prominent 
nongovernmental organization 
dedicated to tobacco control;
■	 a health professional (e.g. physician, 
nurse, pharmacist or dentist) 
specializing in tobacco-related 
conditions;
■	 a staff member of a public health 
university department;
■	 the tobacco control focal point of 
the WHO Country Office.
The experts performed their assessments 
independently. Average scores were 
calculated by WHO from the five 
individual assessments by assigning two 
points for highly enforced policies, one 
point for moderately enforced policies 
and no points for minimally enforced 
policies, with a potential minimum of 0 
and maximum of 10 points in total from 
these five experts.
The compliance assessment was 
obtained for legislation adopted by 1 
April 2020. For countries with more 
recent legislation, compliance data are 
reported as “not applicable”. 
The compliance assessments are listed 
in Annex VI. Annex I summarizes 
this information. Compliance scores 
are represented separately from 
the grouping (i.e. compliance is not 
included in the calculation of the 
grouping categories).
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1 Parties report on the implementation of the WHO Framework Convention on Tobacco Control according to Article 21. The objective of reporting is to enable 
Parties to learn from each other’s experience in implementing the WHO FCTC. Parties’ reports are also the basis for review by the COP of the implementation 
 of the WHO FCTC. Parties submit their initial report 2 years after entry into force of the WHO FCTC for that Party, and then every subsequent 3 years,  
through the reporting instrument adopted by COP. Since 2012, all Parties report at the same time, once every 2 years. For more information please refer to  
https://www.who.int/fctc/reporting/en/.
2 United Nations Department of Economic and Social Affairs, Population Division in World population prospects: the revision (median fertility projection for the 
year 2020). For more information please refer to https://population.un.org/wpp/Download/Standard/Population/. 
3 The World Bank: World development indicators published July 1, 2020. For more information please refer to https://datahelpdesk.worldbank.org/
knowledgebase/. 
4 “Complete” is used in this report to mean that smoking is not permitted, with no exemptions allowed, except in residences and indoor places that serve as 
equivalents to long-term residential facilities, such as prisons and long-term health and social care facilities such as psychiatric units and nursing homes. 
Ventilation and any form of designated smoking rooms and/or areas do not protect from the harms of second-hand tobacco smoke, and the only laws that 
provide protection are those that result in the complete absence of smoking in all public places
5 When legislation did not explicitly ban the identification of non-tobacco products with tobacco brand names (brand stretching) and did not provide a definition 
of tobacco advertising and promotion, it was interpreted that brand stretching was covered by the existing ban of all forms of advertising and promotion when 
the country was a Party to the WHO FCTC, assuming that the WHO FCTC definitions apply. 
6 When legislation did not explicitly ban the use of brand names of non-tobacco products for tobacco products (brand sharing) and did not provide a definition of 
tobacco advertising and promotion, it was interpreted that brand sharing was covered by the existing ban of all forms of advertising and promotion when the 
country was a Party to the WHO FCTC, assuming that the WHO FCTC definitions apply.
7 Designated smoking room exceptions in the legislation that include at least three out of the six following characteristics, and include at least criteria 5 or 6,  
are denoted in the annex tables with an asterisk. The designated smoking room must:
■	 be a closed indoor environment;
■	 be furnished with automatic doors, generally kept closed;
■	 be non-transit premises for non-smokers;
■	 be furnished with appropriate forced- ventilation mechanical devices;
■	 have appropriate installations and functional openings installed, and air must be expelled from the premises;
■	 be maintained, with reference to surrounding areas, in a depression not lower than 5 Pascals. 
Background chapters
All background chapters were 
developed as brief summaries of 
the topic areas covered and are 
not intended to be comprehensive 
reviews of the existing literature.  
All recommendations presented  
are based upon pre-existing 
Member State agreements or 
published technical guidance. 
COVID-19 and tobacco:  
the links
This chapter is intended to provide 
a brief overview of the impact 
the COVID-19 pandemic has had 
on tobacco users and tobacco 
control. The chapter is based upon 
literature provided by partners 
working in tobacco control and a 
narrative review of the literature on 
COVID-19 and tobacco. Databases 
searched include PubMED and 
Scopus and search terms used 
included ‘tobacco’, “smoking”, 
“coronavirus”, “COVID”, “policies”, 
“tobacco control”, “law” and 
“interventions”. Three main 
questions were explored:
■	 What is the link between 
tobacco use and COVID-19? 
With regard to the question 
of the relationship between 
tobacco use and COVID-19 
outcomes, systematic reviews 
identified in the literature 
search were reviewed. WHO 
has commissioned an umbrella 
systematic review of this 
literature (see below) and the 
researchers leading this work 
reviewed this aspect closely.
■	 How did countries react to 
the emerging evidence on the 
link between smoking and 
COVID-19? This section of the 
chapter was informed by the 
literature review described 
above as well as the experience 
of the WHO supporting 
countries during the pandemic. 
This is not an exhaustive review 
of all country approaches and is 
not intended to provide policy 
guidance or recommendations. 
■	 How has the tobacco industry 
exploited the crisis to further 
their commercial ends? Our 
partners at the University 
of Bath, STOP Initiative, are 
continuously monitoring 
industry interference. Again,  
the information provided here 
is not exhaustive but provides 
a brief overview of the more 
prominent activities conducted 
by the industry.
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Monitoring the prevalence of tobacco 
use is central to efforts to control the 
global tobacco epidemic. Reliable 
prevalence data on the magnitude of 
the tobacco epidemic and its influencing 
factors provide the information needed 
to plan, adopt and evaluate the impact 
of tobacco control interventions. This 
report contains survey data for both 
smoking1 and smokeless tobacco use 
among young people and adults  
(Annex XI). It also presents WHO-
modelled, age-standardized prevalence 
estimates for tobacco use for people 
aged 15 years and over (Annex X). This 
technical note provides information on 
the method used to generate the WHO 
prevalence estimates.
Sources of information 
For the analysis, the following sources of 
information were explored (where official 
survey reports explaining the sampling, 
methodology and detailed results were 
not publicly available, Member States 
were asked to provide them):
■	 information on surveys provided 
by Parties to the WHO FCTC 
Secretariat;
■	 information collected through WHO 
tobacco-focused surveys conducted 
under the aegis of the Global 
Tobacco Surveillance System – in 
particular, the Global Adult Tobacco 
Survey (GATS);
■	 tobacco information collected 
through other WHO surveys 
including WHO STEPwise surveys 
and World Health Surveys;
■	 other systems-based surveys 
undertaken by other organizations, 
including surveys such as the 
Demographic and Health Surveys 
(DHS) and the Multiple Indicator 
Cluster Survey (MICS); and
■	 an extensive search through WHO 
regional offices and WHO country 
offices to identify country-specific 
surveys not part of international 
surveillance systems – such as the 
National Survey of Risk Factors in 
Argentina, or the Mauritius Non 
Communicable Diseases Survey.
For the analysis, information from surveys 
conducted since 1990 was used if it:
■	 was officially recognized by the 
national health authority;
■	 included randomly selected 
participants who were representative 
of the general population;
■	 provided data for one or more of 
six tobacco use definitions: daily 
tobacco user, current tobacco user, 
daily tobacco smoker, current tobacco 
smoker, daily cigarette smoker or 
current cigarette smoker; and
■	 presented prevalence values by age 
and sex.
The above indicators provide for the 
most complete representation of 
tobacco use across countries and at the 
same time help minimize attrition of 
countries from further analysis because 
of lack of adequate data. Although 
differences exist in the types of tobacco 
products used in different countries 
and grown or manufactured in different 
regions of the world, data on at least 
one of these six indicators are available 
in most countries, thereby permitting 
robust statistical analyses.2
The information identified above is 
stored in the WHO Tobacco Control 
Global DataBank and, along with the 
source code used for generating the 
WHO smoking prevalence estimates, 
is published alongside this report at 
https://www.who.int/health-topics/
tobacco/.
Analysis and presentation 
of tobacco use prevalence 
indicators
Estimation method
A statistical model based on a Bayesian 
negative binomial meta-regression 
was used to model crude adjusted 
and age-standardized estimates for 
countries for each indicator (current 
and daily tobacco use, current and daily 
tobacco smoking, and current and daily 
cigarette smoking) separately for men 
and women. A trend was considered to 
be statistically significant if the posterior 
probability of the increase or decrease 
was greater than 0.75. A full description 
of the method is available as a peer-
reviewed article in the Lancet, volume 
385, No. 9972, p966–976 (2015).
Once the prevalence rates from national 
surveys were compiled into a dataset, the 
model was fit to calculate trend estimates 
for the six indicators specified above.
The model has two main components:
(a) adjusting for missing indicators 
and age groups, and (b) running the 
regression to generate an estimate of 
trends over time as well as the credible 
interval around the estimate.
Depending on the completeness of 
survey data from a particular country, 
the model at times makes use of data 
from other countries to fill information 
gaps. Countries with data gaps “borrow 
information” from “priors” calculated 
from their data pooled with data from 
countries in the same UN subregion.3
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Differences in age groups 
covered by each survey
Survey results for any one country were 
sometimes reported for a variety of 
different age groups. Where data were 
missing for any age group in the range 
of 15 years and above, the model uses 
available data from a country’s other 
surveys to estimate the age pattern of 
tobacco use. For ages that the country 
has never surveyed, the average age 
pattern seen in countries in the same UN 
subregion is applied to the country’s data.
Differences in the indicators  
of tobacco use measured
Similarly, countries may report different 
indicators across surveys (e.g. current 
smoking in one survey and daily smoking 
in another, or tobacco smoking in one 
and cigarette smoking in another). Where 
data were missing for any indicator, 
the model uses available data from a 
country’s other surveys to estimate the 
missing information. For indicators on 
which the country has never reported, 
the average relationships seen in 
countries in the same UN subregion are 
applied to the country’s data.
Modelled results
The model was run for all countries with 
surveys that met the inclusion criteria. 
Results for countries with insufficient 
survey data (e.g. only one survey with a 
detailed age breakdown for prevalence 
for either sex) were not reported.
The output of the model is a set of trend 
lines for each country that summarize its 
prevalence history from 2000 to the year 
of the most recent survey. If the most 
recent survey was earlier than 2019, the 
trend is projected to 2019. The projection 
assumes that the pace and level of 
adoption of new policies during the 
period covered by the countries’ national 
surveys continued unchanged to 2019. 
Countries with few surveys will have 
more borrowed information blended into 
their trend line than countries with many 
surveys. To allow global comparability, 
the trend calculation is the same for all 
countries. No allowances are made for 
inflection points in the specific years 
when tobacco control policies were 
introduced or improved. Therefore, WHO 
estimates and projections may differ from 
countries’ own estimates and projections.
For this report, country-level trends have 
been summarized into average trends for 
high-income countries, middle-income 
countries, low-income countries and 
a global average. Trends from 2007 to 
2019 are presented.
In this report, comparable estimates 
of current tobacco use among people 
aged 15 years and over are presented 
at country-level for the year 2019. 
The rates are comparable because the 
model has standardized the survey 
results as described above, and then 
age-standardized as described below.
When calculating global and World 
Bank income group average prevalence 
rates, countries without estimates were 
included in the averages by assuming 
their prevalence rates are the average 




Comparison of crude rates between two 
or more countries at one point in time, or 
of one country at different points in time, 
can be misleading if the two populations 
being compared have significantly 
different age distributions or differences 
in tobacco use by sex. The method of 
age-standardization is commonly used 
to overcome this problem and allows for 
meaningful comparison of prevalence 
between countries, once all other 
comparison issues described have been 
addressed. The method involves applying 
the age-specific rates by sex in each 
population to one standard population 
(this report uses the WHO Standard 
Population, a fictitious population whose 
age distribution is largely reflective of 
the population age structure of low- 
and middle-income countries). The 
resulting age-standardized rates refer to 
the number of smokers per 100 WHO 
Standard Population. As a result, the rates 
generated using this process are only 
hypothetical numbers with no inherent 
meaning. They are only meaningful  
when comparing rates obtained from  
one country with those obtained in 
another country.
Comparison with smoking 
estimates in earlier editions 
of this report
The estimates in this report are 
consistent with each other but not with 
estimates produced for earlier editions 
of this report. While the method of 
estimation is the same, the updated 
data set for the period 1990–2020 is 
much more complete.
For example, since the WHO report on 
the global tobacco epidemic, 2019, 243 
national surveys from 100 countries 
have been added to the data set, and 
40 existing surveys have been updated 
with additional data points. Each round 
of WHO estimates is calculated using all 
available survey data back to 1990. The 
more data points available, the more 
robust the trend estimates are. Each 
estimation round therefore improves 
upon earlier published estimates, and 
only the latest round should be used. 
While country-level estimates in this 
report pertain only to 2019, the trend 
from 2000 to 2025 is published in the 
biennial WHO global report on trends 
in tobacco smoking 2000–2025.
1 Tobacco smoking includes cigarette, cigar, pipe, hookah, shisha, water-pipe, heated tobacco products and any other form of smoked tobacco.
2 For countries where prevalence of smokeless tobacco use is reported, we have published these data.
3 For a complete list of countries by UN subregion, please refer to pages ix to xiii of World population prospects: the 2019 revision, published by the UN 
Department of Economic and Social Affairs at https://population.un.org/wpp/Download/Standard/Population/ (accessed December 17, 2020). Please note 
that, for the purposes of tobacco use analysis, the following adjustments were made: (i) Eastern Africa subregion was divided into two regions: Eastern African 
Islands and Remainder of Eastern Africa; (ii) Armenia, Azerbaijan, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Tajikistan, Uzbekistan and 
Turkmenistan were classified with Eastern Europe; (iii) Cyprus, Israel and Turkey were classified with Southern Europe; (iv) Central Africa and Southern Africa 
were combined into one subregion; (v) Melanesia, Micronesia and Polynesia subregions were combined into one subregion; and (vi) Ireland and the United 
Kingdom were combined with Northern America. 
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This report includes appendices 
containing information on the 
share of total and excise taxes in 
the price of the most widely sold 
brand of cigarettes, based on tax 
policy information collected from 
each country. This note contains 
information on the methodology used 
by WHO to estimate the share of 
total and tobacco excise taxes in the 
price of a pack of 20 cigarettes using 
country-reported data. It also provides 
information on other data collected 
for this report in relation to tobacco 
taxation and price and tax data on 
heated tobacco products and nicotine 
and non-nicotine delivery systems.
1. Data collection
All data were collected between June 
2020 and February 2021 by WHO 
regional data collectors. The two main 
inputs into calculating the share of total 
and excise taxes were (1) prices and 
(2) tax rates and structure. Prices were 
collected for the most widely sold brand 
of cigarettes, the least-expensive brand 
and a premium brand for July 2020.
Data on tax structure were collected 
through contacts with ministries of 
finance. The validity of this information 
was checked against other sources. For 
many countries, this was done through 
the wealth of work and knowledge 
accumulated by WHO working directly 
with ministries of finance on tobacco 
taxation since 2009. Other sources, 
including tax law documents, decrees 
and official schedules of tax rates and 
structures and trade information, when 
available, were either provided by data 
collectors or were downloaded from 
ministerial websites. 
The tax data collected focus on indirect 
taxes levied on tobacco products (e.g. 
excise taxes of various types, import 
duties, value added taxes), which 
usually have the most significant impact 
on the price of tobacco products. 
Within indirect taxes, excise taxes are 
the most important because they are 
applied exclusively to tobacco and 
contribute the most to increasing 
the price of tobacco products and 
subsequently reducing consumption. 
Thus, rates, amounts and point of 
application of excise taxes are central 
components of the data collected.
Certain other taxes, in particular 
direct taxes such as corporate taxes, 
can potentially impact tobacco 
prices to the extent that producers 
pass them on to final consumers. 
However, because of the practical 
difficulty of obtaining information 
on these taxes and the complexity in 
estimating their potential impact on 
price in a consistent manner across 
countries, they are not considered.
TECHNICAL NOTE III
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1. Specific excise 
taxes
A specific excise tax is a tax on a selected good produced for sale within a country or 
imported and sold in that country. In general, the tax is collected from the manufacturer 
or at the point of entry into the country by the importer, in addition to import duties. 
These taxes come in the form of an amount per stick, pack, per 1000 sticks, or per 
kilogram. Example: US$ 1.50 per pack of 20 cigarettes.
2. Ad valorem  
excise taxes
An ad valorem excise tax is a tax on a selected good produced for sale within a  
country or imported and sold in that country. In general, the tax is collected from  
the manufacturer or at the point of entry into the country by the importer, in addition 
to import duties. These taxes come in the form of a percentage of the value of a 
transaction between two independent entities at some point of the production/
distribution chain; ad valorem taxes are generally applied to the value of the 
transactions between the manufacturer and the retailer/wholesaler. Example: 60%  
of the manufacturer’s price.
3. Import duties An import duty is a tax on a selected good imported into a country to be consumed 
in that country (i.e. the goods are not in transit to another country). In general, import 
duties are collected from the importer at the point of entry into the country. These 
taxes can be either specific or ad valorem. Specific import duties are applied in the 
same way as specific excise taxes (e.g. an amount per 1000 sticks). Ad valorem import 
duties are generally applied to the CIF (cost, insurance, freight) value, i.e. the value of 
the unloaded consignment that includes the cost of the product itself, insurance and 
transport and unloading. Example: 50% import duty levied on CIF.
4. Value added taxes 
and sales taxes
The value-added tax (VAT) is a “multi-stage” tax on all consumer goods and services 
applied proportionally to the price taxes the consumer pays for a product. Although 
manufacturers and wholesalers also participate in the administration and payment of 
the tax all along the manufacturing/distribution chain, they are all reimbursed through 
a tax credit system, so that the only entity who pays in the end is the final consumer. 
Most countries that impose a VAT do so on a base that includes any excise tax and 
customs duty. Example: VAT representing 10% of the retail price.
Some countries, however, impose sales taxes instead. Unlike VAT, sales taxes are 
generally levied at the point of retail on the total value of goods and services purchased. 
For the purposes of the report, care was taken to ensure the VAT and/or sales tax shares 
were computed in accordance with country-specific rules.
5. Other taxes Information was also collected on any other tax that is not called an excise tax, import 
duty, VAT or sales tax, but that applies to either the quantity of tobacco or to the value 
of a transaction of a tobacco product, with as much detail as possible regarding what is 
taxed and how the base is defined.
The table below describes the types of tax information collected.
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2. Data analysis
The price of the most sold brand 
of cigarettes was considered in the 
calculation of the tax as a share of the 
retail price reported in Annex table 
9.1 in online Annex IX. In the case 
of countries where different levels 
of taxes are applied on cigarettes 
based on length of cigarette, quantity 
produced, or type (e.g. filter vs. 
non-filter), only the relevant rate 
that applied to the most sold brand 
was used in the calculation.
In the case of Canada and the United 
States, national average estimates 
calculated for prices and taxes reflect 
the fact that different rates are applied 
by state/province over and above the 
applicable federal tax. In the case 
of Brazil, where state VATs vary, the 
highest rate, which is applied in most 
States, was applied. In the Federated 
States of Micronesia, which also has 
varying VAT rates across states, the VAT 
rate applicable to the state where price 
data was collected (Pohnpei) was used. 
A weighted average of retail price and 
tax were calculated for China given the 
very large array of brands sold in the 
market: the most sold brand changing 
almost every year and representing a 
very small share of the market was not 
representative.
The import duty was only used in the 
calculation of tax shares if the most 
sold brand of cigarettes was imported 
into the country. Import duty was 
not applied in total tax calculation for 
countries reporting that the most sold 
brand, even if an international brand, 
was produced locally. In cases where 
the imported cigarettes originated from 
a country with which a bilateral or 
multilateral trade agreement waived the 
duty, care was taken to ensure that the 
import duty was not taken into account 
in calculating taxes levied.
“Other taxes” are all other indirect 
taxes not reported as excise taxes, 
import duties or VAT. An example of 
such tax is the environmental levy. 
The next step of the exercise was to 
convert all taxes to the same base – in 
our case, the tax- inclusive retail sale price 
(hereafter referred to as P). Standardizing 
bases is important in calculating tax share 
correctly, as the example in the table 
shows. Country B apparently applies 
the same ad valorem tax rate (20%) as 
Country A, but in fact ends up with a 
higher tax rate and a higher final price 
because the tax is applied later in the 
distribution chain. Comparing reported 
statutory ad valorem tax rates without 
taking into account the stage at which 
the tax is applied could therefore lead  
to biased results.
A similar methodology was used to 
calculate the price and tax share of the 
most common type of smoked (other 
than cigarettes) and smokeless tobacco 
products, as reported by each country. 
The calculation was made for the 
price of a product for 20 grams of any 
smoked or smokeless tobacco product, 
20 sticks of cigarettes, bidis and heated 
tobacco products (HTPs) and one stick 
of cigars and cigarillos. For the e-liquid 
of closed electronic nicotine or non-
nicotine delivery systems (ENDS/ENNDS) 
the price and tax was calculated for 
1 ml while for open systems, it was 
calculated for 10 ml. Price and tax for 
smoked tobacco products (including 
bidis, cigarillos, cigars, pipe tobacco, 
roll-your-own or waterpipe tobacco) 
was calculated for 69 countries, while 
the calculation for smokeless tobacco 
products (chewing tobacco, dry snuff, 
moist snuff or nose tobacco ) was  
made for 21 countries. Price and tax 
was also calculated for HTPs for 51 
countries, for the e-liquid of closed 
ENDS/ENNDS for 45 countries and for 
the e-liquid of open ENDS/ENNDS for 






[A] Manufacturer’s price (same in both countries) 2.00 2.00
[B] Country A:  
ad valorem tax on manufacturer’s price (20%) = 20% x [A]
0.40 -
[C] Retailer’s and wholesaler’s profit margin (same in both countries) 0.20 0.20
[D] Country B: ad valorem tax on retailer’s price (20%) = 20% x [E] - 0.55
[E] Final price = P = [A]+[B]+[C] or [A]+[C]+[D] 2.60 2.75
Total tax share (as % of P) 0.40/2.60 = 15.4% 0.55/2.75 = 20%
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3. Calculation 
As an example of the calculations 
performed, denote Sts as the share of 
taxes in the price of a widely consumed 
brand of cigarettes (20-cigarette pack 
or equivalent). Then,
Sts = Sas + Sav + Sid + SVAT  1
Where:
Sts = Total share of taxes in the price 
of a pack of cigarettes;
Sas = Share of amount-specific excise 
taxes in the price of a pack of 
cigarettes;
Sav = Share of ad valorem excise  
taxes in the price of a pack  
of cigarettes;
Sid = Share of import duties in the price 
of a pack of cigarettes (if the most 
popular brand is imported);
SVAT = Share of the value added tax in 
the price of a pack of cigarettes.
Calculating Sas is straightforward 
and involves dividing the specific tax 
amount for a 20-cigarette pack by  
the total price. Unlike Sas, the share  
of ad valorem taxes, Sav, depending  
on the base it is applied on, can 
be much more difficult to calculate 
and would involve making some 
assumptions described below. Import 
duties are sometimes amount-specific,  
sometimes value-based. Sid is therefore 
calculated the same way as Sas if it is 
amount-specific and the same way 
as Sav if it is value-based. VAT rates 
reported for countries are usually 
applied on the VAT-exclusive retail  
sale price but are also sometimes 
reported on VAT-inclusive prices. SVAT  
is calculated to consistently reflect  
the share of the VAT in VAT-inclusive 
retail sale price.
The price of a pack of cigarettes can  
be expressed as the following:
P = [(M + M × ID) + (M + M×ID) ×  
Tav% + Tas + π] × (1 + VAT%), or
P =  [M × (1 × ID) × (1 + Tav%) + Tas + π]  
× (1 + VAT%)  2
Where: 
P =  Price per pack of 20 cigarettes 
of the most popular brand 
consumed locally;
M = Manufacturer’s/distributor’s 
price, or import price if the  
brand is imported;
ID = Import duty rate (where 
applicable) on a pack of 20 
cigarettes;1
Tav = Statutory rate of ad valorem tax;
Tas = Amount-specific excise tax on  
a pack of 20 cigarettes;
π = Retailer’s, wholesaler’s and 
importer’s profit per pack  
of 20 cigarettes (sometimes 
expressed as a mark-up);
VAT = Statutory rate of value added  
tax on VAT-exclusive price.
Changes to this formula were made 
based on country-specific considerations 
such as the base for the ad valorem 
tax and excise tax, the existence – or 
not – of ad valorem and specific excise 
taxes, and whether the most popular 
brand was locally produced or imported. 
In many cases (particularly in low- and 
middle-income countries) the base 
for ad valorem excise tax was the 
manufacturer’s price or CIF value. But in 
fact, the base of the ad valorem varies 
a lot around the world and can include 
other bases, such as retail price, retail 
price net of some taxes (and/or some 
predefined margins), retail price net of 
all taxes, etc.
Given knowledge of price (P) and 
amount-specific excise tax (Tas), the 
share Sas is easy to recover (=Tas/P). 
The case of ad valorem taxes 
(and, where applicable, Sid) is fairly 
straightforward when, by law, the 
base is retail price. The calculation 
is more complicated when the base 
is the manufacturer’s price (M) and 
needs to be recovered to calculate the 
amount of ad valorem tax. In most of 
the cases, M was not known (unless 
specifically reported by the country), 
and therefore had to be estimated.
Using equation (2), it is possible to 
recover M: 
                                                                                  
M =
1 + VAT%
–     – Tas
P
(1 + Tav%) x (1 + ID)
π
  
 3  
π, or wholesalers’ and retailers’ profit 
margins, are rarely publicly disclosed 
and will vary from country to country. 
For domestically produced most 
popular brands, we considered π to 
be nil (i.e. =0) in the calculation of M 
because the retailer’s and wholesaler’s 
margins are assumed to be small. 
Setting the margin to 0, however, 
would result in an overestimation of 
M and therefore of the base for the 
ad valorem tax. This will in turn result 
in an overestimation of the amount of 
ad valorem tax. Since the goal of this 
exercise is to measure how high the 
share of tobacco taxes is in the price of 
a typical pack of cigarettes, assuming 
that the retailer’s/wholesaler’s profit 
(π) is nil, therefore, does not penalize 
countries by underestimating their ad 
valorem taxes. Considering this, it was 
decided that unless country-specific 
information was made available to 
WHO, the retailer’s or wholesaler’s 
margin would be assumed to be nil for 
domestically produced brands. 
For countries where the most popular 
brand is imported, the import duty 
is applied on CIF values, and the 
consequent excise taxes are typically 
applied on a base that includes the 
CIF value and the import duty, but not 
the importer’s profit. For domestically 
produced cigarettes, the producer’s 
price includes its own profit, so 
it is automatically included in M. 
However, the importer’s profit can be 
relatively significant and setting it to 
zero (as in the case of domestically 
manufactured cigarettes) would 
substantially overestimate M, and 
thereby substantially overestimate 
the share of ad valorem tax in final 
price. For this reason, M had to be 
estimated differently for imported 
products: M* (or the CIF value) was 
calculated either based on information 
reported by countries or using 
secondary sources (data from the 
United Nations Comtrade database2). 
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M* was normally calculated as the 
import price of cigarettes in a country 
(value of cigarette imports divided by 
the quantity of cigarette imports for 
the importing country).3 However, 
in exceptional cases where no such 
data were available (Angola, Bhutan, 
Equatorial Guinea and Libya), the 
export price was considered instead. 
The ad valorem and other taxes were 
then calculated in the same way as for 
local cigarettes, using M* rather than  
M as the base, where applicable.
In the case of VAT, in most of the 
cases the base was P excluding the 
VAT (or, similarly, the manufacturer’s/
distributor’s price plus all excise taxes). 
In other words:
SVAT = VAT% × (1 - SVAT), equivalent to
SVAT = VAT% ÷ (1+ VAT%)(4)
In some cases, however, we were 
informed that the VAT was not 
effectively collected at all levels of the 
supply chain and was mainly levied at 
the importing or manufacturing gate. 
In this case, the VAT was calculated on 
the basis of M (or M*) and the different 
taxes collected at this stage, mainly 
import duties and excise taxes (Angola, 
Benin, Cabo Verde, Equatorial Guinea, 
Gabon, Gambia, Guinea, Kiribati, 
Malaysia, Mali, Mauritania, Tonga, 
Uganda and Vanuatu).
In sum, tax rates are calculated using 
the formula:
Sts = Sid + Sas + Sav + SVAT (5)
Sas = Tas ÷ P
Sav = (Tav % × M) ÷ P or  
(Tav % × M*× (1+ Sid)) ÷ P 
4  
if the most popular brand was 
imported
Sid = (TID % × M*) ÷ P (if the import 
duty is value-based) or  
ID ÷ P (if import duty is a  
specific amount per pack)
SVAT = VAT% ÷ (1+ VAT%) 
4. Prices
Primary collection of price data in this 
and previous reports involved surveying 
retail outlets. Price data were collected 
from two different types of outlets.
Questionnaires sent to data collectors 
were pre-populated with the names 
of the highest selling brand in each 
country. The popular brand was 
identified using data collected from the 
2018 questionnaires, through reports 
from data collectors in 2020 and 
through WHO’s close collaboration with 
ministries of finance. For the countries 
where such data were not available, 
data collectors were asked to indicate 
the names of the popular brands and 
provide their prices. 
The two types of retail outlets were 
defined as follows:
■	 Supermarket/hypermarket: chain 
or independent retail outlets 
with a selling space of over 2500 
square metres and a primary 
focus on selling food/beverages/
tobacco and other groceries. 
Hypermarkets also sell a range 
of non-grocery merchandise.
■	 Kiosk/newsagent/tobacconist/
independent food store: small 
convenience stores, retail outlets 
selling predominantly food, 
beverages and tobacco or a 
combination of these (e.g. kiosk, 
newsagent or tobacconist) or a wide 
range of predominantly grocery 
products (independent food stores 
or independent small grocers).
Most sold brands have been used 
consistently over time to gain a better 
reflection of the change in prices. 
However, in some cases where the 
market share of the brand initially 
used was considered to have changed 
substantially, a change was made to 
the new, more prevalent brand. In 
2020, changes in the brand were made 
for Benin, Brazil,5 Cambodia, Japan,6 
Madagascar, Micronesia (Federated 
States of),7 Venezuela (Bolivarian 
Republic of) (different brand but same 
price category), Chad, Democratic 
Republic of the Congo, New Zealand8, 
Panama, Peru, Portugal, Saint Vincent 
and the Grenadines (cheaper brand 
category), Angola, Ecuador, Iran 
(Islamic Republic of), Philippines, Sierra 
Leone, Yemen (more expensive brand 
category). In four other countries 
(Equatorial Guinea, Hungary, Iceland 
and India) the brand reported in 2020 
was a variant of the brand reported in 
2018, with similar price levels and these 
were treated as identical in both years 
for purposes of price comparisons.
As in 2012, 2014, 2016 and 2018, the 
price used for each of the 27 countries 
of the European Union (EU) was the 
most sold brand collected by WHO. 
Prior to 2012, price and tax information 
were taken entirely from the EU’s 
Taxation and Customs Union website. 
The price used by the EU in the past 
to calculate tax rates was the most 
popular price category (MPPC), which 
was assumed to be similar to the most 
sold brand price category collected in 
this report. However, since 2011, the 
EU calculates and reports tax rates 
based on the Weighted Average Price 
(WAP) and therefore information on 
the MPPC is no longer readily available 
for EU countries. Consequently, in 
order to be consistent with past years’ 
estimates and to ensure comparability 
with other countries, WHO decided in 
2012 to collect first hand prices of the 
most sold brand to calculate tax rates.9 
The most sold brand is determined 
based on brand market shares reported 
from secondary sources, which is 
then validated by countries. It is also 
worth noting that the EU tables use 
a WAP calculated from market data 
derived from the previous year (due 
to availability of data), which means 
that it would not reflect a price change 
that may have occurred following a tax 
increase in the next year. It also means 
that the estimated tax share may not be 
representative of the actual tax share 
since the WAP and the tax rates are 
from different years. Excise and VAT 
rates are still collected from the EU 
published tables. However, tax shares, 
as computed and presented in this 
report, will not necessarily be similar 
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to the rates published by the EU. This 
is mainly due to the calculation of the 
specific excise tax rates as a percentage 
of the retail price, which will vary 
depending on the price used. The most 
sold brand was used for all EU countries 
except for Finland, who reported to 
WHO its weighted average price (WAP) 
for 2008, 2010, 2012, 2014, 2016, 2018 
and 2020. 
5. Considerations in 
interpreting tax share 
changes
Changes in tax as a share of price are 
not only dependent on tax changes 
but also on price changes. Therefore, 
despite an increase in tax, the tax share 
could remain the same or go down; 
similarly, sometimes a tax share can 
increase even if there is no change/
increase in the tax.
In the current database, there are cases 
where taxes increased between 2018 
and 2020 but the share of tax as a 
percentage of the price went down. 
This is mainly due to the fact that, 
in absolute terms, the price increase 
was larger than the tax increase 
(particularly in the case of specific 
excise tax increases). For example, in 
Kenya, the specific excise tax increased 
from 2500 KES per 1000 cigarettes in 
2018 to 3,157 KES per 1000 cigarettes 
in 2020 (a 26.3% increase), while the 
price of the most sold brand increased 
from 130 to 250 KES per pack (a 92% 
increase). In terms of tax share the 
excise represented 38.5% of the price 
in 2018 and it went down to 25.3% of 
the price in 2020. This is because prices 
rose more than taxes. 
In the same way, there are cases where 
increases (decreases) in tax as a share 
of price were mitigated by factors 
not directly related to tax rates. In the 
current database, this was attributable 
to one or more of the following reasons:
■	 In some instances, the price increased 
without a tax change, leading to 
a decrease in the tax share for a 
specific or mixed excise structure 
(e.g. Andorra, Austria, Belize, Brazil, 
Bulgaria, Burundi, Dominica, Ecuador, 
El Salvador, Germany, Greece, 
Malaysia, Mauritius, Micronesia 
(Federated States of), Palau, Sao Tome 
and Principe, Switzerland, Tunisia, 
Uganda, United Republic of Tanzania).
■	 In other cases, prices increased 
above tax increases, leading to 
a decrease in tax share for a 
specific or mixed excise structure 
(e.g. Australia, Belgium, Bolivia 
(Plurinational State of), Canada, 
Chile, Colombia, Costa Rica, 
Dominican Republic, Fiji, Iceland, 
Japan, Jordan, Kenya, Latvia, 
Lesotho, Luxembourg, Mongolia, 
Namibia, Nepal, New Zealand, 
North Macedonia, Norway, Papua 
New Guinea, Russian Federation, 
Samoa, Serbia, Seychelles, Slovakia, 
Slovenia, South Africa, Sweden, 
Tajikistan, Ukraine, the United 
Kingdom, Uruguay, Zambia, 
Zimbabwe).
■	 In the case of imported products, 
the CIF value is an external variable 
that also influences the calculation 
of tax share. This has implications 
in countries where ad valorem 
is based on the CIF value, when 
import duties are applicable on 
the CIF value or when the VAT is 
calculated on the base of CIF value 
+ excise rather than VAT exclusive 
retail price. For example, if the CIF 
value increases, the base for the 
application of the tax is higher, 
leading to a higher tax percentage 
if nothing else changes. Countries 
that have seen changes in their 
tax share mainly due to changes 
in CIF value include Gabon, 
Ghana, Niger, and Vanuatu. 
Care should also be taken in relation 
to countries where the most sold 
brand changed between 2018 
and 2020. This also has had an 
impact on the tax proportion of 
the affected countries which had a 
specific or mixed excise structure. 
In some cases, because the new 
brand reported was more expensive 
and despite tax increases, the 
total tax share decreased (Angola, 
Yemen and the Philippines). In the 
case of Ecuador the tax proportion 
decreased despite no tax change, 
because of the apparent increase 
in prices due to the new, more 
expensive brand reported as the 
most sold brand. 
Finally, when new, improved information 
was provided in terms of taxation and 
prices for some countries, corrections 
were made in the calculations of tax 
rates for 2008, 2010, 2012, 2014, 2016, 
and 2018 estimates, as needed.
6. Taxation of novel and 
emerging nicotine and 
tobacco products  
(see Table 9.3 for HTPs  
and 9.7 for ENDS/ENNDS, 
online Annex IX)
Heated tobacco products (HTPs)
Similar to cigarettes, the price of the 
most sold brand of sticks (not the 
devices) has been collected and where 
applicable, taxes applied. The same 
methodology used for calculating 
the tax of cigarettes was followed for 
HTPs. Only two notable differences 
were applied: when specific excise tax 
was applied on the weight of tobacco 
contained in the sticks, the assumption 
was made that each stick contained 
0.3 grams of tobacco (or 6 grams 
per pack of 20). This assumption was 
made based on an average estimate 
published by the e-cigarettes market 
data provider ECigIntelligence10. The 
second assumption was made on the 
value of the CIF for countries that 
applied a tax based on the CIF value. 
Given the lack available data on the 
import value of HTPs, an extrapolation 
was made assuming the CIF value of 
HTPs would be about double the CIF 
value of cigarettes. This was based on 
the assumption that the cost of HTP 
production was higher than cigarettes 
production. Estimates of the CIF value 
as a proportion of retail price of the 
most sold brand of cigarette in 2018 
and 2020 ranged from 10–15%. Based 
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on this, a standard CIF value of 20% 
of the retail price of the most sold 
brand of HTPs was applied for countries 
where a CIF value was needed to 
calculate the tax burden of HTPs.
Electronic nicotine and  
non-nicotine delivery systems 
(ENDS/ENNDS)
Given the heterogeneity of the ENDS/
ENNDS market and the difficulty in 
identifying a most sold brand that is 
representative enough of the market 
in a given country, data were collected 
on the price of the cheapest brand 
available for a nicotine or non-nicotine 
containing e-liquid (whichever was the 
cheapest available). Data were also 
collected for two types of e-liquids, 
those used for open systems and 
those for closed systems.11 The tax was 
calculated in the same manner as for 
cigarettes with a notable difference 
being the base quantity. For e-liquid, 
the base reported is in volume, per ml. 
Because of differences in prices and 
packaging, the price was standardized 
per 10 ml for open systems e-liquids 
and per 1 ml for closed systems 
e-liquids. Similar to the case of HTPs 
and where a CIF value was needed 
to calculate the tax burden on ENDS/
ENNDS e-liquids, given the lack of data, 
assumptions were made regarding the 
CIF value as a proportion of the retail 
price of the cheapest brand reported. 
Assuming the CIF value was a proxy for 
the cost of production and, based on 
information from ECigIntelligence that 
mark-ups at the wholesale and retail 
levels could represent up to 100% of 
the cost at each level, it was assumed 
that the CIF value would be a bit less 
than a third of the price, at around 
20% of the final retail price. A base of 
20% of the retail price was assigned 
for countries where the ad valorem 
excise or import duty was calculated 
on CIF value (except for Morocco and 
Peru where a CIF value was reported by 
national authorities).
7. Supplementary tax 
information (see Table 9.5, 
online Annex IX)
An important consideration highlighted 
in this report is that many aspects of 
tobacco taxation need to be taken 
into account in order to assess if a 
tax policy is well designed. Tax as a 
proportion of price does not tell the 
whole story about the effectiveness of a 
tax policy. To explore other dimensions 
of tax policy, since 2015 the report has 
been collecting additional information 
on tobacco (cigarette) taxation and 
compiles it into data that can inform 
researchers and policy-makers further  
on tax policy in different countries.
The information is compiled and 
classified in this report according to 
two main themes: tax structure/level 
and tax administration. Information was 
also collected in relation to countries 
that earmark tobacco taxes to fund 
health programmes and/or tobacco 
control activities. The different sets of 
data/indicators reported under each 
of the themes were developed and are 
justified based on evidence provided  
in past reports.
Tax structure/level
■	 Excise tax proportion of price: 
higher tax rates and greater reliance 
on excise is better.
■	 Type of excise applied: if excise tax 
is specific, ad valorem, a mix of the 
two, or if no excise is applied.
■	 Uniform vs. tiered excise tax 
system: a uniform excise is easier 
to administer than a tiered system 
where variable rates apply based  
on selected criteria within one 
tobacco product (not applicable  
in countries where no excise tax  
is implemented).
■	 Whether a country applies a specific 
excise or a mixed system relying more 
on the specific tax component (>50% 
of total excise is specific): specific 
excises typically lead to higher prices 
and a smaller price gap between 
different brands, which is better (not 
applicable in countries where only ad 
valorem excise is applicable or where 
no excise tax is implemented).
■	 If the excise applied is ad valorem or 
if it is mixed, and whether there is a 
minimum specific tax. A minimum tax 
provides protection against products 
being undervalued. It also forces 
prices up since the price will not be 
lower than the tax paid (this category 
does not apply to countries where 
only specific excise tax is applicable or 
where no excise tax is implemented). 
■	 Base of the ad valorem tax in 
countries that apply an ad valorem 
or a mixed excise system. Ad 
valorem taxes applied to the retail 
price or the retail price excluding 
VAT are administratively simpler.  
The retail price is easier to determine 
than producer price or CIF value, 
and therefore there is less risk of 
undervaluation (not applicable in 
countries where only specific excise 
is applicable, or where no excise tax 
is implemented).
■	 If the excise tax applied is specific 
or if it is mixed, and whether 
the specific tax component is 
automatically adjusted for inflation 
(or other). If the specific tax is not 
adjusted for inflation (or another 
indicator such as income) over time, 
its impact will be eroded. It is good 
to have it adjusted automatically 
(this category does not apply to 
countries where only ad valorem 
excise tax is applicable or where no 
excise tax is implemented).
■	 Price dispersion: share of cheapest 
brand price in premium brand price 
(cheapest brand price ÷ premium 
brand price × 100). The higher the 
proportion, the smaller the gap and 
the fewer are the opportunities for 
substitution to cheaper brands.
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Tax administration
Sales of duty free cigarettes: In most 
countries tobacco products are found 
to be sold without excise (and other 
indirect taxes such as VAT and import 
duties) in duty-free shops in airports, on 
international transport vehicles and/or 
other tax-free shops. Duty-free tobacco 
products are usually made available to 
travellers going out of the country, but 
they are now also made available for 
travellers entering a country. Banning 
the sale of duty-free cigarettes for 
personal consumption reduces the 
chance that these products end up in 
the illicit market. Additionally, there 
is no justification for selling a deadly 
product duty-free; those foregone taxes 
are a revenue loss for the government. 
Some countries have already acted 
and have banned the sale of duty-free 
tobacco products. Those products 
may still be found in airport and other 
tax-free shops, but they are sold with 
(excise) taxes included. 
Earmarking (portion of taxes or 
revenues from taxes dedicated to  
health and/or tobacco control).
Taxes can generate substantial 
revenues. Earmarking all or a part of 
tobacco tax revenues can be a useful 
tool for improving the political economy 
of tobacco tax increases. Setting 
aside portions of tax revenue to fund 
tobacco control efforts or relevant 
health programmes can help convince 
the public, politicians and officials of 
the value of significant tobacco tax 
increases, the ultimate goal of which  
is to reduce tobacco use (see Table 9.4 
in online Annex IX).
8. Estimates of the 
affordability of cigarettes 
(see Table 9.6, online  
Annex IX)
The affordability of cigarettes for each 
of the years 2010, 2012, 2014, 2016, 
2018 and 2020 was measured by the 
per capita GDP required to purchase 
2000 cigarettes of the most sold  
brand reported in that year. Analysis  
of affordability in this report informs 
the following:
■	 Affordability index (% of GDP per 
capita to buy 2000 cigarettes): across 
countries, a higher value indicates 
cigarettes are relatively more 
expensive in relation to income.
■	 Whether cigarettes have become 
relatively more affordable between 
2010 and 2020 (change in the 
affordability index as measured 
above, between 20010 and 
2020): as affordability decreases, 
consumption is discouraged.
Estimates of GDP per capita in local 
currency units were sourced from the 
IMF’s World Economic Outlook (WEO) 
database which provides a complete 
series of estimates for most of the 195 
countries reported on. Where GDP 
per capita data were not available in 
the WEO database, the World Bank’s 
GDP per capita data series was used. 
Countries for which no relevant data 
were available in the IMF WEO database 
or World Bank’s GDP per capita series 
were dropped from the affordability 
analysis (Andorra, Cook Islands, Cuba, 
Democratic People’s Republic of Korea, 
Monaco, Niue, Somalia, Syrian Arab 
Republic and Venezuela (Bolivarian 
Republic of)). For each country–year 
pair, the currency reported for the 
most sold brand was tallied with the 
corresponding currency for the GDP 
series, and exchange rate conversions 
and adjustments were performed as 
needed (Belarus, Cambodia, Estonia, 
Mauritania, Latvia, Liberia, Lithuania, Sao 
Tome and Principe, Venezuela (Bolivarian 
Republic of), Zambia, Zimbabwe). 
To assess whether affordability 
changed on average since 2010, the 
average annual percentage change in 
affordability was calculated as the least 
squares growth rate for all countries 
with 4 or more years of data. This 
criterion automatically excluded Bhutan, 
Malawi and South Sudan, as less than 
4 years of price data were available for 
analysis. Additionally, countries that did 
not report price data for the most sold 
brand in 2020 were excluded (Barbados, 
Brunei Darussalam, Central African 
Republic, Cook Islands, Cuba, Djibouti, 
Eritrea, Grenada, Guinea-Bissau, Haiti, 
Saint Kitts and Nevis, San Marino, and 
Solomon Islands).
The affordability of cigarettes was 
judged to have been unchanged if the 
least squares trend in the per capita GDP 
required to purchase 2000 cigarettes 
(that is, 100 packs of 20 cigarettes) 
was not significant at the 5% level. 
Cigarettes were judged to have become 
less (more) affordable on average if the 
least squares trend in the per capita GDP 
required to purchase 2000 cigarettes 
was positive (negative) and significantly 
different from zero at the 5% level.
1 Import duties may vary depending on the 
country of origin in cases of preferential trade 
agreements. WHO tried to determine the origin 
of the pack and relevance of using such rates 
where possible.
2 https://comtrade.un.org/ 
3 When quantity was reported in weight (kg) 
rather than number of sticks, the conversion 
was made assuming one stick contained one 
gram of tobacco.
4 Or Sav = (Tav % × M*) ÷ P, if the ad valorem 
tax was applied only on the CIF value, not the 
CIF value + the import duty.
5 Brand change within the same price category 
but price also increased compared to 2018.
6 Brand change within the same price category 
but price also increased compared to 2018.
7 Brand change within the same price category 
but price also increased compared to 2018.
8 Brand change to a cheaper price category but 
price also increased compared to 2018
9 Due to a lack of capacity, the price is collected 
for cigarettes only while calculations for other 
smoked or smokeless tobacco products are 
made using the EU tables when available, 
including the WAP and tax rates.
10 ECigIntelligence.com (restricted access).
11 Open systems are devices that allow the user 
to buy e-liquids and fill their device with the 
mixtures they want (with no nicotine, different 
nicotine concentrations and/or flavours). Closed 
systems are products that come with a prefilled 
container (called a cartridge, pod or tank).
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Annex I provides an overview of 
selected tobacco control policies 
in countries. For each WHO region 
an overview table is presented that 
includes information on monitoring 
and prevalence, smoke-free 
environments, treatment of tobacco 
dependence, health warnings and 
packaging, anti-tobacco mass media 
campaigns, advertising, promotion 
and sponsorship bans, taxation 
levels, and affordability of cigarettes, 
based on the methodology outlined 
in Technical Notes I, II and III.
Country-level data were generally but 
not always provided with supporting 
documents such as laws, regulations, 
policy documents, etc. Available 
documents were assessed by WHO and 
this Annex provides summary measures 
or indicators of country achievements 
for each of the MPOWER measures. 
Detailed information, including detailed 
footnotes on each of the indicators, 
is available in Annex II for electronic 
nicotine delivery systems, in Annex VI 
for smokefree environments, health 
warnings and packaging, anti-tobacco 
mass media campaigns, advertising, 
promotion and sponsorship bans, 
and in Annex IX for tobacco taxation 
and affordability. It is important to 
note that data about laws reflect the 
status of legislation adopted by 31 
December 2020 which has a stated 
date of effect and is not undergoing 
a legal challenge that could impact 
the date of implementation.
The summary measures reported for 
the WHO report on the Global Tobacco 
Epidemic, 2021 are the same as those 
in the 2019 report. The methodology 
used to calculate each indicator is 
described in Technical Note I. This 
review, however, does not constitute a 
thorough and complete legal analysis 
of each country’s legislation. Except 
for smoke-free environments and bans 
on tobacco advertising, promotion 
and sponsorship, data were collected 
at the national/ federal level only 
and therefore provide incomplete 
information about Member States 
where subnational governments play 
an active role in tobacco control. 
Daily smoking prevalence for the 
population aged 15 years and over 
in 2019 is an indicator modelled 
by WHO from tobacco use surveys 
published by Member States. Tobacco 
smoking is one of the most widely 
reported indicators in country surveys. 
The calculation of WHO estimates 
to allow international comparison 
is described in Technical Note II.
ANNEX I
REGIONAL SUMMARY  
OF MPOWER MEASURES
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2020 INDICATOR AND COMPLIANCE  CHANGE SINCE 2018













































CHANGE IN POWER INDICATOR GROUP, UP OR DOWN, SINCE 2018
Algeria 14% IIIII IIIIIIIIII 35.5% Yes
Angola . . . IIIIIIIII IIIIIIIIII 12.1% Yes
Benin 4% IIIII IIIIIIIII 9.5% No
Botswana 13% — IIIIIIIIII 52.2% Yes p
Burkina Faso 9% IIII IIIIIII 43.5%
Burundi 7% IIII 37.3% Yes
Cabo Verde 6% IIIII IIIIIIII 19.5% q
Cameroon 5% . . . . . . 43.2%
Central African Republic . . . — — . . . . . .
Chad 6% IIII IIIIIIIII 51.6% p
Comoros 10% IIIIII IIIII 73.8%
Congo 10% IIIIIIIIII 26.9% Yes q
Côte d'Ivoire 9% — IIIIII 34.5% No p
Democratic Republic  
of the Congo 9% III IIIIIII 52.1% No q p
Equatorial Guinea . . . — — 24.2% Yes q
Eritrea 4% — . . . . . . . . .
Eswatini 6% — . . . 53.5% No
Ethiopia 3% IIIIIII IIIIIII 51.2% p p p p
Gabon . . . III IIIIIIIIII 21.6% q
Gambia 9% IIIII 8 IIIIIIIIII 48.7% Yes p
Ghana 2% — IIIIIII 31.8%
Guinea . . . IIIIIIIIII 37.0%
Guinea-Bissau 7% — — . . . . . .
Kenya 7% — IIIIIIII 39.0% q
Lesotho 18% IIIII — 50.6%
Liberia 6% — — 56.8% p
Madagascar 13% IIIII IIIIIIIII 80.4%
Malawi 7% — — 56.3% . . .
Mali 6% — IIIIII 27.7% No
Mauritania 7% IIIII IIII 5.9% p p
Mauritius 15% IIIIII IIIIIIIII 81.2% Yes
Mozambique 11% IIIII IIIII 28.5% Yes
Namibia 14% IIIII IIIII 42.0%
Niger 4% IIIIIII 31.8% q p
Nigeria 3% III 8 IIII 35.1% p
Rwanda 9% — IIIII 64.3%
Sao Tome and Principe 4% — 33.7%
Senegal 5% IIIIIII IIIIIIIIII 38.2% Yes q
Seychelles 15% IIIIIIIIII IIIIIIIIII 69.5%
Sierra Leone 12% — — 22.6% Yes
South Africa 17% — IIIIIIII 52.7%
South Sudan . . . — — 66.1% . . .
Togo 4% IIIIII IIIIIIIIII 41.4% Yes p
Uganda 5% IIIIII IIIIIIIII 34.6% Yes
United Republic of Tanzania 6% — . . . 30.0% No
Zambia 10% IIII — 38.8%
Zimbabwe 8% IIIII — 29.3%
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2020 INDICATOR AND COMPLIANCE  CHANGE SINCE 2018













































CHANGE IN POWER INDICATOR GROUP, UP OR DOWN, SINCE 2018
Algeria 14% IIIII IIIIIIIIII 35.5% Yes
Angola . . . IIIIIIIII IIIIIIIIII 12.1% Yes
Benin 4% IIIII IIIIIIIII 9.5% No
Botswana 13% — IIIIIIIIII 52.2% Yes p
Burkina Faso 9% IIII IIIIIII 43.5%
Burundi 7% IIII 37.3% Yes
Cabo Verde 6% IIIII IIIIIIII 19.5% q
Cameroon 5% . . . . . . 43.2%
Central African Republic . . . — — . . . . . .
Chad 6% IIII IIIIIIIII 51.6% p
Comoros 10% IIIIII IIIII 73.8%
Congo 10% IIIIIIIIII 26.9% Yes q
Côte d'Ivoire 9% — IIIIII 34.5% No p
Democratic Republic  
of the Congo 9% III IIIIIII 52.1% No q p
Equatorial Guinea . . . — — 24.2% Yes q
Eritrea 4% — . . . . . . . . .
Eswatini 6% — . . . 53.5% No
Ethiopia 3% IIIIIII IIIIIII 51.2% p p p p
Gabon . . . III IIIIIIIIII 21.6% q
Gambia 9% IIIII 8 IIIIIIIIII 48.7% Yes p
Ghana 2% — IIIIIII 31.8%
Guinea . . . IIIIIIIIII 37.0%
Guinea-Bissau 7% — — . . . . . .
Kenya 7% — IIIIIIII 39.0% q
Lesotho 18% IIIII — 50.6%
Liberia 6% — — 56.8% p
Madagascar 13% IIIII IIIIIIIII 80.4%
Malawi 7% — — 56.3% . . .
Mali 6% — IIIIII 27.7% No
Mauritania 7% IIIII IIII 5.9% p p
Mauritius 15% IIIIII IIIIIIIII 81.2% Yes
Mozambique 11% IIIII IIIII 28.5% Yes
Namibia 14% IIIII IIIII 42.0%
Niger 4% IIIIIII 31.8% q p
Nigeria 3% III 8 IIII 35.1% p
Rwanda 9% — IIIII 64.3%
Sao Tome and Principe 4% — 33.7%
Senegal 5% IIIIIII IIIIIIIIII 38.2% Yes q
Seychelles 15% IIIIIIIIII IIIIIIIIII 69.5%
Sierra Leone 12% — — 22.6% Yes
South Africa 17% — IIIIIIII 52.7%
South Sudan . . . — — 66.1% . . .
Togo 4% IIIIII IIIIIIIIII 41.4% Yes p
Uganda 5% IIIIII IIIIIIIII 34.6% Yes
United Republic of Tanzania 6% — . . . 30.0% No
Zambia 10% IIII — 38.8%
Zimbabwe 8% IIIII — 29.3%
Please refer to Technical Note I for definitions of categories
ADULT DAILY SMOKING PREVALENCE*:  
AGE-STANDARDIZED PREVALENCE RATES FOR ADULT DAILY 
SMOKERS OF TOBACCO (BOTH SEXES COMBINED), 2019
. . . Estimates not available
30% or more 
From 20% to 29.9% 
From 15% to 19.9% 
Less than 15% 
* The figures should be used strictly for the purpose of drawing 
comparisons across countries and must not be used to estimate 
absolute number of daily tobacco smokers in a country.
MONITORING: PREVALENCE DATA
No known data or no recent data or data 
that are not both recent and representative
Recent and representative data for either 
adults or youth
Recent and representative data for both 
adults and youth
Recent, representative and periodic data 
for both adults and youth
SMOKE-FREE ENVIRONMENTS: SMOKING BANS
Data not reported
Complete absence of ban, or up to two public 
places completely smoke-free
Three to five public places completely smoke-free
Six to seven public places completely smoke-free
All public places completely smoke-free (or 
at least 90% of the population covered by 
complete subnational smoke-free legislation)
CESSATION PROGRAMMES:  
TREATMENT OF TOBACCO DEPENDENCE
Data not reported
None
NRT and/or some cessation services (neither 
cost-covered)
NRT and/or some cessation services (at least 
one of which is cost-covered)
National quit line, and both NRT and some 
cessation services cost-covered
HEALTH WARNINGS:  
HEALTH WARNINGS ON CIGARETTE PACKAGES
Data not reported
No warnings or small warnings
Medium size warnings missing some 
appropriate characteristics OR large warnings 
missing many appropriate characteristics
Medium size warnings with all appropriate 
characteristics OR large warnings missing 
some appropriate characteristics
Large warnings with all appropriate 
characteristics
MASS MEDIA: ANTI-TOBACCO CAMPAIGNS
Data not reported
No national campaign conducted between 
July 2018 and June 2020 with a duration of at 
least 3 weeks
National campaign conducted with one to four 
appropriate characteristics
National campaign conducted with five to six 
appropriate characteristics
National campaign conducted with at least 
seven appropriate characteristics including 
airing on television and/or radio
ADVERTISING BANS:  
BANS ON ADVERTISING, PROMOTION AND SPONSORSHIP
Data not reported
Complete absence of ban, or ban that does not 
cover national television, radio and print media
Ban on national television, radio and print 
media only
Ban on national television, radio and print 
media as well as on some but not all other 
forms of direct and/or indirect advertising
Ban on all forms of direct and indirect 
advertising (or at least 90% of the population 
covered by subnational legislation completely 
banning tobacco advertising, promotion  
and sponsorship)
TAXATION: SHARE OF TOTAL TAXES IN THE RETAIL PRICE  
OF THE MOST WIDELY SOLD BRAND OF CIGARETTES
Data not reported
< 25% of retail price is tax 
≥ 25% and <50% of retail price is tax 
≥ 50% and <75% of retail price is tax 
≥ 75% of retail price is tax 
AFFORDABILITY OF CIGARETTES
YES
Cigarettes less affordable - Trend in per capita 
GDP needed to buy cigarettes increased since 
2010 at a rate over 1.45% per year
NO
Cigarettes more affordable - Trend in per capita 
GDP needed to buy cigarettes decreased since 
2010 at a rate over 1.45% per year
No significant change in affordability of 
cigarettes since 2010
... Insufficient data to conduct a trend analysis
COMPLIANCE: COMPLIANCE WITH BANS ON ADVERTISING, 











Moderate compliance (3/10 to 7/10)
||
| Minimal compliance (0/10 to 2/10)
SYMBOLS LEGEND
Plain packaging is mandated.
8 Law adopted but not implemented by 
31 December 2020.
qp Change in POWER indicator group, up or down, 
between 2018 and 2020. Some 2018 data were 
revised in 2020. 2020 grouping rules were applied 
to both years.
... Data not reported/not available
– Data not required/not applicable





2020 INDICATOR AND COMPLIANCE  CHANGE SINCE 2018













































CHANGE IN POWER INDICATOR GROUP, UP OR DOWN, SINCE 2018
Antigua and Barbuda . . . III IIIIIIIII 13.1% q
Argentina 18% IIIIIIII IIIIIIIII 76.6% Yes
Bahamas 8% — IIIIIII 43.2% Yes
Barbados 5% IIIIIIIIII — . . . . . .
Belize 5% — — 34.7%
Bolivia  
(Plurinational State of) . . . III II 35.7% Yes p
Brazil 11% IIIIIIIIII IIIIII 81.5%
Canada 9% IIIIIIIII IIIIIIIII 61.7% Yes
Chile 19% IIIIIIIIII IIIIIIIII 80.0% Yes
Colombia 5% IIIIIIII IIIIIIII 73.1% Yes q
Costa Rica 5% IIIIIIIII IIIIII 53.6% Yes
Cuba 13% IIII — . . . . . .
Dominica . . . — — 22.7%
Dominican Republic 8% IIIII — 44.3% q
Ecuador 4% IIIIIIII IIIIII 66.9% Yes
El Salvador 5% IIIII IIIIIIII 46.5% Yes q
Grenada . . . — — . . . . . . q
Guatemala 5% IIIII IIII 49.0%
Guyana 9% IIIIII IIIIIIIII 27.5% No
Haiti 5% — — . . . . . .
Honduras . . . IIIIIII IIIIIIIII 42.6% Yes
Jamaica 7% IIIIII IIIIIIIII 42.6% Yes
Mexico 7% IIIII IIIII 67.6%
Nicaragua . . . III IIIII 69.4% p
Panama 2% IIIIIIII IIIIIIIII 56.5% No
Paraguay 8% — IIII 18.3% p
Peru 6% IIIIII IIIIIII 67.7% Yes p
Saint Kitts and Nevis . . . — — . . . . . .
Saint Lucia . . . IIIII — 51.3% p
Saint Vincent and the 
Grenadines . . . — — 23.1% Yes
Suriname . . . IIIII IIIIIIIII 26.5% Yes q
Trinidad and Tobago . . . IIIIIII IIIIIII 25.7% Yes
United States of America 14% . . . 8 . . . 40.0% p
Uruguay 18% IIIIIIIIII IIIIIIIII 65.9%
Venezuela  
(Bolivarian Republic of) . . . IIIIIIII IIIIIIII 73.4% . . . p
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Please refer to Technical Note I for definitions of categories
ADULT DAILY SMOKING PREVALENCE*:  
AGE-STANDARDIZED PREVALENCE RATES FOR ADULT DAILY 
SMOKERS OF TOBACCO (BOTH SEXES COMBINED), 2019
. . . Estimates not available
30% or more 
From 20% to 29.9% 
From 15% to 19.9% 
Less than 15% 
* The figures should be used strictly for the purpose of drawing 
comparisons across countries and must not be used to estimate 
absolute number of daily tobacco smokers in a country.
MONITORING: PREVALENCE DATA
No known data or no recent data or data 
that are not both recent and representative
Recent and representative data for either 
adults or youth
Recent and representative data for both 
adults and youth
Recent, representative and periodic data 
for both adults and youth
SMOKE-FREE ENVIRONMENTS: SMOKING BANS
Data not reported
Complete absence of ban, or up to two public 
places completely smoke-free
Three to five public places completely smoke-free
Six to seven public places completely smoke-free
All public places completely smoke-free (or 
at least 90% of the population covered by 
complete subnational smoke-free legislation)
CESSATION PROGRAMMES:  
TREATMENT OF TOBACCO DEPENDENCE
Data not reported
None
NRT and/or some cessation services (neither 
cost-covered)
NRT and/or some cessation services (at least 
one of which is cost-covered)
National quit line, and both NRT and some 
cessation services cost-covered
HEALTH WARNINGS:  
HEALTH WARNINGS ON CIGARETTE PACKAGES
Data not reported
No warnings or small warnings
Medium size warnings missing some 
appropriate characteristics OR large warnings 
missing many appropriate characteristics
Medium size warnings with all appropriate 
characteristics OR large warnings missing 
some appropriate characteristics
Large warnings with all appropriate 
characteristics
MASS MEDIA: ANTI-TOBACCO CAMPAIGNS
Data not reported
No national campaign conducted between 
July 2018 and June 2020 with a duration of at 
least 3 weeks
National campaign conducted with one to four 
appropriate characteristics
National campaign conducted with five to six 
appropriate characteristics
National campaign conducted with at least 
seven appropriate characteristics including 
airing on television and/or radio
ADVERTISING BANS:  
BANS ON ADVERTISING, PROMOTION AND SPONSORSHIP
Data not reported
Complete absence of ban, or ban that does not 
cover national television, radio and print media
Ban on national television, radio and print 
media only
Ban on national television, radio and print 
media as well as on some but not all other 
forms of direct and/or indirect advertising
Ban on all forms of direct and indirect 
advertising (or at least 90% of the population 
covered by subnational legislation completely 
banning tobacco advertising, promotion  
and sponsorship)
TAXATION: SHARE OF TOTAL TAXES IN THE RETAIL PRICE  
OF THE MOST WIDELY SOLD BRAND OF CIGARETTES
Data not reported
< 25% of retail price is tax 
≥ 25% and <50% of retail price is tax 
≥ 50% and <75% of retail price is tax 
≥ 75% of retail price is tax 
AFFORDABILITY OF CIGARETTES
YES
Cigarettes less affordable - Trend in per capita 
GDP needed to buy cigarettes increased since 
2010 at a rate over 1.45% per year
NO
Cigarettes more affordable - Trend in per capita 
GDP needed to buy cigarettes decreased since 
2010 at a rate over 1.45% per year
No significant change in affordability of 
cigarettes since 2010
... Insufficient data to conduct a trend analysis
COMPLIANCE: COMPLIANCE WITH BANS ON ADVERTISING, 











Moderate compliance (3/10 to 7/10)
||
| Minimal compliance (0/10 to 2/10)
SYMBOLS LEGEND
Plain packaging is mandated.
8 Law adopted but not implemented by 
31 December 2020.
qp Change in POWER indicator group, up or down, 
between 2018 and 2020. Some 2018 data were 
revised in 2020. 2020 grouping rules were applied 
to both years.
... Data not reported/not available
– Data not required/not applicable
2020 INDICATOR AND COMPLIANCE  CHANGE SINCE 2018













































CHANGE IN POWER INDICATOR GROUP, UP OR DOWN, SINCE 2018
Antigua and Barbuda . . . III IIIIIIIII 13.1% q
Argentina 18% IIIIIIII IIIIIIIII 76.6% Yes
Bahamas 8% — IIIIIII 43.2% Yes
Barbados 5% IIIIIIIIII — . . . . . .
Belize 5% — — 34.7%
Bolivia  
(Plurinational State of) . . . III II 35.7% Yes p
Brazil 11% IIIIIIIIII IIIIII 81.5%
Canada 9% IIIIIIIII IIIIIIIII 61.7% Yes
Chile 19% IIIIIIIIII IIIIIIIII 80.0% Yes
Colombia 5% IIIIIIII IIIIIIII 73.1% Yes q
Costa Rica 5% IIIIIIIII IIIIII 53.6% Yes
Cuba 13% IIII — . . . . . .
Dominica . . . — — 22.7%
Dominican Republic 8% IIIII — 44.3% q
Ecuador 4% IIIIIIII IIIIII 66.9% Yes
El Salvador 5% IIIII IIIIIIII 46.5% Yes q
Grenada . . . — — . . . . . . q
Guatemala 5% IIIII IIII 49.0%
Guyana 9% IIIIII IIIIIIIII 27.5% No
Haiti 5% — — . . . . . .
Honduras . . . IIIIIII IIIIIIIII 42.6% Yes
Jamaica 7% IIIIII IIIIIIIII 42.6% Yes
Mexico 7% IIIII IIIII 67.6%
Nicaragua . . . III IIIII 69.4% p
Panama 2% IIIIIIII IIIIIIIII 56.5% No
Paraguay 8% — IIII 18.3% p
Peru 6% IIIIII IIIIIII 67.7% Yes p
Saint Kitts and Nevis . . . — — . . . . . .
Saint Lucia . . . IIIII — 51.3% p
Saint Vincent and the 
Grenadines . . . — — 23.1% Yes
Suriname . . . IIIII IIIIIIIII 26.5% Yes q
Trinidad and Tobago . . . IIIIIII IIIIIII 25.7% Yes
United States of America 14% . . . 8 . . . 40.0% p
Uruguay 18% IIIIIIIIII IIIIIIIII 65.9%
Venezuela  
(Bolivarian Republic of) . . . IIIIIIII IIIIIIII 73.4% . . . p






2020 INDICATOR AND COMPLIANCE  CHANGE SINCE 2018













































CHANGE IN POWER INDICATOR GROUP, UP OR DOWN, SINCE 2018
Bangladesh 17% IIIIII IIIIIII 73.0% Yes
Bhutan . . . IIIIIIII IIIIIIIIII 8.1% . . .
Democratic People's  
Republic of Korea 15% IIIIIIII — 0.0% . . .
India 7% IIIIIIII IIIII 57.6% Yes
Indonesia 33% II IIII 62.3%
Maldives 19% IIIII IIIII 65.7% Yes p
Myanmar 15% IIIII IIIIII 49.9% No
Nepal 13% I IIIIIIIIII 27.0% q
Sri Lanka 10% IIIIII IIIII 77.0% Yes p
Thailand 17% IIIIII IIIIIIII 78.6%
Timor-Leste 23% IIIIII IIIIIIIII 21.8%
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Please refer to Technical Note I for definitions of categories
ADULT DAILY SMOKING PREVALENCE*:  
AGE-STANDARDIZED PREVALENCE RATES FOR ADULT DAILY 
SMOKERS OF TOBACCO (BOTH SEXES COMBINED), 2019
. . . Estimates not available
30% or more 
From 20% to 29.9% 
From 15% to 19.9% 
Less than 15% 
* The figures should be used strictly for the purpose of drawing 
comparisons across countries and must not be used to estimate 
absolute number of daily tobacco smokers in a country.
MONITORING: PREVALENCE DATA
No known data or no recent data or data 
that are not both recent and representative
Recent and representative data for either 
adults or youth
Recent and representative data for both 
adults and youth
Recent, representative and periodic data  
for both adults and youth
SMOKE-FREE ENVIRONMENTS: SMOKING BANS
Data not reported
Complete absence of ban, or up to two public 
places completely smoke-free
Three to five public places completely smoke-free
Six to seven public places completely smoke-free
All public places completely smoke-free (or 
at least 90% of the population covered by 
complete subnational smoke-free legislation)
CESSATION PROGRAMMES:  
TREATMENT OF TOBACCO DEPENDENCE
Data not reported
None
NRT and/or some cessation services (neither 
cost-covered)
NRT and/or some cessation services (at least 
one of which is cost-covered)
National quit line, and both NRT and some 
cessation services cost-covered
HEALTH WARNINGS:  
HEALTH WARNINGS ON CIGARETTE PACKAGES
Data not reported
No warnings or small warnings
Medium size warnings missing some 
appropriate characteristics OR large warnings 
missing many appropriate characteristics
Medium size warnings with all appropriate 
characteristics OR large warnings missing 
some appropriate characteristics
Large warnings with all appropriate 
characteristics
MASS MEDIA: ANTI-TOBACCO CAMPAIGNS
Data not reported
No national campaign conducted between 
July 2018 and June 2020 with a duration of at 
least 3 weeks
National campaign conducted with one to four 
appropriate characteristics
National campaign conducted with five to six 
appropriate characteristics
National campaign conducted with at least 
seven appropriate characteristics including 
airing on television and/or radio
ADVERTISING BANS:  
BANS ON ADVERTISING, PROMOTION AND SPONSORSHIP
Data not reported
Complete absence of ban, or ban that does not 
cover national television, radio and print media
Ban on national television, radio and print 
media only
Ban on national television, radio and print 
media as well as on some but not all other 
forms of direct and/or indirect advertising
Ban on all forms of direct and indirect 
advertising (or at least 90% of the population 
covered by subnational legislation completely 
banning tobacco advertising, promotion  
and sponsorship)
TAXATION: SHARE OF TOTAL TAXES IN THE RETAIL PRICE  
OF THE MOST WIDELY SOLD BRAND OF CIGARETTES
Data not reported
< 25% of retail price is tax 
≥ 25% and <50% of retail price is tax 
≥ 50% and <75% of retail price is tax 
≥ 75% of retail price is tax 
AFFORDABILITY OF CIGARETTES
YES
Cigarettes less affordable - Trend in per capita 
GDP needed to buy cigarettes increased since 
2010 at a rate over 1.45% per year
NO
Cigarettes more affordable - Trend in per capita 
GDP needed to buy cigarettes decreased since 
2010 at a rate over 1.45% per year
No significant change in affordability of 
cigarettes since 2010
... Insufficient data to conduct a trend analysis
COMPLIANCE: COMPLIANCE WITH BANS ON ADVERTISING, 











Moderate compliance (3/10 to 7/10)
||
| Minimal compliance (0/10 to 2/10)
SYMBOLS LEGEND
Plain packaging is mandated.
8 Law adopted but not implemented by 
31 December 2020.
qp Change in POWER indicator group, up or down, 
between 2018 and 2020. Some 2018 data were 
revised in 2020. 2020 grouping rules were applied 
to both years.
... Data not reported/not available
– Data not required/not applicable
2020 INDICATOR AND COMPLIANCE  CHANGE SINCE 2018













































CHANGE IN POWER INDICATOR GROUP, UP OR DOWN, SINCE 2018
Bangladesh 17% IIIIII IIIIIII 73.0% Yes
Bhutan . . . IIIIIIII IIIIIIIIII 8.1% . . .
Democratic People's  
Republic of Korea 15% IIIIIIII — 0.0% . . .
India 7% IIIIIIII IIIII 57.6% Yes
Indonesia 33% II IIII 62.3%
Maldives 19% IIIII IIIII 65.7% Yes p
Myanmar 15% IIIII IIIIII 49.9% No
Nepal 13% I IIIIIIIIII 27.0% q
Sri Lanka 10% IIIIII IIIII 77.0% Yes p
Thailand 17% IIIIII IIIIIIII 78.6%
Timor-Leste 23% IIIIII IIIIIIIII 21.8%





2020 INDICATOR AND COMPLIANCE  CHANGE SINCE 2018













































CHANGE IN POWER INDICATOR GROUP, UP OR DOWN, SINCE 2018
Albania 18% . . . . . . 66.7% Yes
Andorra 28% IIIIIII — 78.4% . . .
Armenia 25% IIIIIIII 8 IIIIIIII 44.2% No p p
Austria 21% IIIIIIIII IIIIIIIIII 74.5% Yes p p q
Azerbaijan 18% . . . . . . 49.7%
Belarus 23% IIIIII IIIIIII 55.6% Yes
Belgium 19% IIIIIIII IIIIIIIII 76.9% Yes
Bosnia and Herzegovina 30% — IIIIIII 84.0% Yes
Bulgaria 32% IIIII IIIIII 85.3% No
Croatia 31% . . . . . . 83.6%
Cyprus 29% IIIIIII IIIIIIIIII 74.4% Yes
Czechia 24% IIIIIIIII IIIIIIII 77.2% Yes
Denmark 15% IIIIIIIII — 78.0% p
Estonia 21% IIIIIIIIII IIIIIIIII 87.6%
Finland 15% IIIIIIIIII IIIIIIIIII 88.2% Yes
France 28% IIIIIIII IIIIIIIIII 83.2% Yes
Georgia 27% IIIIIIII IIIIIIII 81.2% p
Germany 18% — IIIIIIIII 63.5% Yes
Greece 27% . . . . . . 80.8% Yes
Hungary 28% . . . . . . 72.7% Yes
Iceland 10% IIIIIIIIII IIIIIIIIII 55.0%
Ireland 18% IIIIIIIIII IIIIIIIIII 78.9% No
Israel 18% . . . . . . 83.2% Yes p
Italy 20% — IIIIIII 76.6% Yes
Kazakhstan 16% — IIIIIII 55.7% Yes p
Kyrgyzstan 22% III IIIII 52.9% Yes p
Latvia 30% IIIIIIII IIIIIIIIII 79.9%
Lithuania 22% III IIIIIIIIII 74.0%
Luxembourg 17% . . . . . . 68.3%
Malta 19% . . . . . . 77.6% No
Monaco . . . . . . — . . . . . .
Montenegro 27% . . . . . . 77.5% Yes p
Netherlands 17% . . . IIIIIIII 77.2% Yes p
North Macedonia . . . . . . . . . 80.3%
Norway 12% IIIIIIIIII IIIIIIIIII 61.6% Yes
Poland 21% IIIIIIII IIIIII 78.4%
Portugal 20% IIIIIIII IIIIIII 78.6% p
Republic of Moldova 24% . . . . . . 62.4% Yes
Romania 27% IIIIIII IIIIIIII 69.6%
Russian Federation 27% IIIIIIIII IIIIIIII 56.1% Yes
San Marino . . . . . . . . . . . . . . .
Serbia 33% III IIIIII 76.5% Yes
Slovakia 24% IIIIIIIIII IIIIIIIIII 76.3% Yes
Slovenia 20% . . . . . . 78.7%
Spain 25% IIIIIIII IIIIIIII 78.2%
Sweden 9% — IIIIIIIIII 68.1% Yes
Switzerland 21% — . . . 59.6% Yes
Tajikistan . . . III IIIIIIIII 41.9%
Turkey 26% IIIIIII IIIIIIII 84.9%
Turkmenistan 4% IIIIIIIII IIIIIIIIII 42.2% Yes
Ukraine 24% IIIIIIII IIIIIIII 69.3% Yes
United Kingdom of Great 
Britain and Northern Ireland 13% IIIIIIIIII IIIIIIIIII 79.3% Yes
Uzbekistan 9% . . . . . . 56.3% p
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Please refer to Technical Note I for definitions of categories
ADULT DAILY SMOKING PREVALENCE*:  
AGE-STANDARDIZED PREVALENCE RATES FOR ADULT DAILY 
SMOKERS OF TOBACCO (BOTH SEXES COMBINED), 2019
. . . Estimates not available
30% or more 
From 20% to 29.9% 
From 15% to 19.9% 
Less than 15% 
* The figures should be used strictly for the purpose of drawing 
comparisons across countries and must not be used to estimate 
absolute number of daily tobacco smokers in a country.
MONITORING: PREVALENCE DATA
No known data or no recent data or data 
that are not both recent and representative
Recent and representative data for either 
adults or youth
Recent and representative data for both 
adults and youth
Recent, representative and periodic data  
for both adults and youth
SMOKE-FREE ENVIRONMENTS: SMOKING BANS
Data not reported
Complete absence of ban, or up to two public 
places completely smoke-free
Three to five public places completely smoke-free
Six to seven public places completely smoke-free
All public places completely smoke-free (or 
at least 90% of the population covered by 
complete subnational smoke-free legislation)
CESSATION PROGRAMMES:  
TREATMENT OF TOBACCO DEPENDENCE
Data not reported
None
NRT and/or some cessation services (neither 
cost-covered)
NRT and/or some cessation services (at least 
one of which is cost-covered)
National quit line, and both NRT and some 
cessation services cost-covered
HEALTH WARNINGS:  
HEALTH WARNINGS ON CIGARETTE PACKAGES
Data not reported
No warnings or small warnings
Medium size warnings missing some 
appropriate characteristics OR large warnings 
missing many appropriate characteristics
Medium size warnings with all appropriate 
characteristics OR large warnings missing 
some appropriate characteristics
Large warnings with all appropriate 
characteristics
MASS MEDIA: ANTI-TOBACCO CAMPAIGNS
Data not reported
No national campaign conducted between 
July 2018 and June 2020 with a duration of at 
least 3 weeks
National campaign conducted with one to four 
appropriate characteristics
National campaign conducted with five to six 
appropriate characteristics
National campaign conducted with at least 
seven appropriate characteristics including 
airing on television and/or radio
ADVERTISING BANS:  
BANS ON ADVERTISING, PROMOTION AND SPONSORSHIP
Data not reported
Complete absence of ban, or ban that does not 
cover national television, radio and print media
Ban on national television, radio and print 
media only
Ban on national television, radio and print 
media as well as on some but not all other 
forms of direct and/or indirect advertising
Ban on all forms of direct and indirect 
advertising (or at least 90% of the population 
covered by subnational legislation completely 
banning tobacco advertising, promotion  
and sponsorship)
TAXATION: SHARE OF TOTAL TAXES IN THE RETAIL PRICE  
OF THE MOST WIDELY SOLD BRAND OF CIGARETTES
Data not reported
< 25% of retail price is tax 
≥ 25% and <50% of retail price is tax 
≥ 50% and <75% of retail price is tax 
≥ 75% of retail price is tax 
AFFORDABILITY OF CIGARETTES
YES
Cigarettes less affordable - Trend in per capita 
GDP needed to buy cigarettes increased since 
2010 at a rate over 1.45% per year
NO
Cigarettes more affordable - Trend in per capita 
GDP needed to buy cigarettes decreased since 
2010 at a rate over 1.45% per year
No significant change in affordability of 
cigarettes since 2010
... Insufficient data to conduct a trend analysis
COMPLIANCE: COMPLIANCE WITH BANS ON ADVERTISING, 











Moderate compliance (3/10 to 7/10)
||
| Minimal compliance (0/10 to 2/10)
SYMBOLS LEGEND
Plain packaging is mandated.
8 Law adopted but not implemented by 
31 December 2020.
qp Change in POWER indicator group, up or down, 
between 2018 and 2020. Some 2018 data were 
revised in 2020. 2020 grouping rules were applied 
to both years.
... Data not reported/not available
– Data not required/not applicable
2020 INDICATOR AND COMPLIANCE  CHANGE SINCE 2018













































CHANGE IN POWER INDICATOR GROUP, UP OR DOWN, SINCE 2018
Albania 18% . . . . . . 66.7% Yes
Andorra 28% IIIIIII — 78.4% . . .
Armenia 25% IIIIIIII 8 IIIIIIII 44.2% No p p
Austria 21% IIIIIIIII IIIIIIIIII 74.5% Yes p p q
Azerbaijan 18% . . . . . . 49.7%
Belarus 23% IIIIII IIIIIII 55.6% Yes
Belgium 19% IIIIIIII IIIIIIIII 76.9% Yes
Bosnia and Herzegovina 30% — IIIIIII 84.0% Yes
Bulgaria 32% IIIII IIIIII 85.3% No
Croatia 31% . . . . . . 83.6%
Cyprus 29% IIIIIII IIIIIIIIII 74.4% Yes
Czechia 24% IIIIIIIII IIIIIIII 77.2% Yes
Denmark 15% IIIIIIIII — 78.0% p
Estonia 21% IIIIIIIIII IIIIIIIII 87.6%
Finland 15% IIIIIIIIII IIIIIIIIII 88.2% Yes
France 28% IIIIIIII IIIIIIIIII 83.2% Yes
Georgia 27% IIIIIIII IIIIIIII 81.2% p
Germany 18% — IIIIIIIII 63.5% Yes
Greece 27% . . . . . . 80.8% Yes
Hungary 28% . . . . . . 72.7% Yes
Iceland 10% IIIIIIIIII IIIIIIIIII 55.0%
Ireland 18% IIIIIIIIII IIIIIIIIII 78.9% No
Israel 18% . . . . . . 83.2% Yes p
Italy 20% — IIIIIII 76.6% Yes
Kazakhstan 16% — IIIIIII 55.7% Yes p
Kyrgyzstan 22% III IIIII 52.9% Yes p
Latvia 30% IIIIIIII IIIIIIIIII 79.9%
Lithuania 22% III IIIIIIIIII 74.0%
Luxembourg 17% . . . . . . 68.3%
Malta 19% . . . . . . 77.6% No
Monaco . . . . . . — . . . . . .
Montenegro 27% . . . . . . 77.5% Yes p
Netherlands 17% . . . IIIIIIII 77.2% Yes p
North Macedonia . . . . . . . . . 80.3%
Norway 12% IIIIIIIIII IIIIIIIIII 61.6% Yes
Poland 21% IIIIIIII IIIIII 78.4%
Portugal 20% IIIIIIII IIIIIII 78.6% p
Republic of Moldova 24% . . . . . . 62.4% Yes
Romania 27% IIIIIII IIIIIIII 69.6%
Russian Federation 27% IIIIIIIII IIIIIIII 56.1% Yes
San Marino . . . . . . . . . . . . . . .
Serbia 33% III IIIIII 76.5% Yes
Slovakia 24% IIIIIIIIII IIIIIIIIII 76.3% Yes
Slovenia 20% . . . . . . 78.7%
Spain 25% IIIIIIII IIIIIIII 78.2%
Sweden 9% — IIIIIIIIII 68.1% Yes
Switzerland 21% — . . . 59.6% Yes
Tajikistan . . . III IIIIIIIII 41.9%
Turkey 26% IIIIIII IIIIIIII 84.9%
Turkmenistan 4% IIIIIIIII IIIIIIIIII 42.2% Yes
Ukraine 24% IIIIIIII IIIIIIII 69.3% Yes
United Kingdom of Great 
Britain and Northern Ireland 13% IIIIIIIIII IIIIIIIIII 79.3% Yes
Uzbekistan 9% . . . . . . 56.3% p






< “Occupied Palestinian territory” 
should be understood to refer to 
the “occupied Palestinian territory, 
including east Jerusalem”
2020 INDICATOR AND COMPLIANCE  CHANGE SINCE 2018













































CHANGE IN POWER INDICATOR GROUP, UP OR DOWN, SINCE 2018
Afghanistan 7% I IIIIIIIII 20.7% Yes
Bahrain 13% — . . . 72.2% Yes
Djibouti . . . . . . . . . . . . . . .
Egypt 21% III IIIIIIII 78.5%
Iran (Islamic Republic of) 9% IIIIIIIII IIIIIIIIII 15.5% Yes
Iraq 17% III IIIIIII 7.6% p p
Jordan 30% — IIIIIII 78.0% Yes p p p
Kuwait 17% . . . . . . 18.9% Yes
Lebanon 24% IIIIIII IIIIIIIII 9.9%
Libya . . . II IIIIIIIIII 9.4% Yes
Morocco 11% IIIII IIIIIIIII 76.1% p
occupied Palestinian 
territory <
. . . IIIIII 92.8% Yes
Oman 7% — IIIIIIIIII 63.6% Yes q p
Pakistan 12% IIIII IIIIIIIII 60.8%
Qatar 10% — IIIIIIIIII 68.2% Yes p p
Saudi Arabia 11% IIIII IIIIIIIIII 73.8% Yes
Somalia . . . — — 7.1% . . .
Sudan . . . — IIIIIIII 73.4% No p
Syrian Arab Republic . . . . . . . . . 41.8% . . . q
Tunisia 21% — IIIIIII 69.6%
United Arab Emirates 9% IIIIIIII IIIIIIIII 72.6% Yes
Yemen 14% III IIIIII 50.7% Yes
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Please refer to Technical Note I for definitions of categories
ADULT DAILY SMOKING PREVALENCE*:  
AGE-STANDARDIZED PREVALENCE RATES FOR ADULT DAILY 
SMOKERS OF TOBACCO (BOTH SEXES COMBINED), 2019
. . . Estimates not available
30% or more 
From 20% to 29.9% 
From 15% to 19.9% 
Less than 15% 
* The figures should be used strictly for the purpose of drawing 
comparisons across countries and must not be used to estimate 
absolute number of daily tobacco smokers in a country.
MONITORING: PREVALENCE DATA
No known data or no recent data or data 
that are not both recent and representative
Recent and representative data for either 
adults or youth
Recent and representative data for both 
adults and youth
Recent, representative and periodic data  
for both adults and youth
SMOKE-FREE ENVIRONMENTS: SMOKING BANS
Data not reported
Complete absence of ban, or up to two public 
places completely smoke-free
Three to five public places completely smoke-free
Six to seven public places completely smoke-free
All public places completely smoke-free (or 
at least 90% of the population covered by 
complete subnational smoke-free legislation)
CESSATION PROGRAMMES:  
TREATMENT OF TOBACCO DEPENDENCE
Data not reported
None
NRT and/or some cessation services (neither 
cost-covered)
NRT and/or some cessation services (at least 
one of which is cost-covered)
National quit line, and both NRT and some 
cessation services cost-covered
HEALTH WARNINGS:  
HEALTH WARNINGS ON CIGARETTE PACKAGES
Data not reported
No warnings or small warnings
Medium size warnings missing some 
appropriate characteristics OR large warnings 
missing many appropriate characteristics
Medium size warnings with all appropriate 
characteristics OR large warnings missing 
some appropriate characteristics
Large warnings with all appropriate 
characteristics
MASS MEDIA: ANTI-TOBACCO CAMPAIGNS
Data not reported
No national campaign conducted between 
July 2018 and June 2020 with a duration of at 
least 3 weeks
National campaign conducted with one to four 
appropriate characteristics
National campaign conducted with five to six 
appropriate characteristics
National campaign conducted with at least 
seven appropriate characteristics including 
airing on television and/or radio
ADVERTISING BANS:  
BANS ON ADVERTISING, PROMOTION AND SPONSORSHIP
Data not reported
Complete absence of ban, or ban that does not 
cover national television, radio and print media
Ban on national television, radio and print 
media only
Ban on national television, radio and print 
media as well as on some but not all other 
forms of direct and/or indirect advertising
Ban on all forms of direct and indirect 
advertising (or at least 90% of the population 
covered by subnational legislation completely 
banning tobacco advertising, promotion  
and sponsorship)
TAXATION: SHARE OF TOTAL TAXES IN THE RETAIL PRICE  
OF THE MOST WIDELY SOLD BRAND OF CIGARETTES
Data not reported
< 25% of retail price is tax 
≥ 25% and <50% of retail price is tax 
≥ 50% and <75% of retail price is tax 
≥ 75% of retail price is tax 
AFFORDABILITY OF CIGARETTES
YES
Cigarettes less affordable - Trend in per capita 
GDP needed to buy cigarettes increased since 
2010 at a rate over 1.45% per year
NO
Cigarettes more affordable - Trend in per capita 
GDP needed to buy cigarettes decreased since 
2010 at a rate over 1.45% per year
No significant change in affordability of 
cigarettes since 2010
... Insufficient data to conduct a trend analysis
COMPLIANCE: COMPLIANCE WITH BANS ON ADVERTISING, 











Moderate compliance (3/10 to 7/10)
||
| Minimal compliance (0/10 to 2/10)
SYMBOLS LEGEND
Plain packaging is mandated.
8 Law adopted but not implemented by 
31 December 2020.
qp Change in POWER indicator group, up or down, 
between 2018 and 2020. Some 2018 data were 
revised in 2020. 2020 grouping rules were applied 
to both years.
... Data not reported/not available
– Data not required/not applicable
2020 INDICATOR AND COMPLIANCE  CHANGE SINCE 2018













































CHANGE IN POWER INDICATOR GROUP, UP OR DOWN, SINCE 2018
Afghanistan 7% I IIIIIIIII 20.7% Yes
Bahrain 13% — . . . 72.2% Yes
Djibouti . . . . . . . . . . . . . . .
Egypt 21% III IIIIIIII 78.5%
Iran (Islamic Republic of) 9% IIIIIIIII IIIIIIIIII 15.5% Yes
Iraq 17% III IIIIIII 7.6% p p
Jordan 30% — IIIIIII 78.0% Yes p p p
Kuwait 17% . . . . . . 18.9% Yes
Lebanon 24% IIIIIII IIIIIIIII 9.9%
Libya . . . II IIIIIIIIII 9.4% Yes
Morocco 11% IIIII IIIIIIIII 76.1% p
occupied Palestinian 
territory <
. . . IIIIII 92.8% Yes
Oman 7% — IIIIIIIIII 63.6% Yes q p
Pakistan 12% IIIII IIIIIIIII 60.8%
Qatar 10% — IIIIIIIIII 68.2% Yes p p
Saudi Arabia 11% IIIII IIIIIIIIII 73.8% Yes
Somalia . . . — — 7.1% . . .
Sudan . . . — IIIIIIII 73.4% No p
Syrian Arab Republic . . . . . . . . . 41.8% . . . q
Tunisia 21% — IIIIIII 69.6%
United Arab Emirates 9% IIIIIIII IIIIIIIII 72.6% Yes
Yemen 14% III IIIIII 50.7% Yes






2020 INDICATOR AND COMPLIANCE  CHANGE SINCE 2018













































CHANGE IN POWER INDICATOR GROUP, UP OR DOWN, SINCE 2018
Australia 12% . . . IIIIIIIIII 73.9% Yes q q
Brunei Darussalam 12% IIIIIII IIIIIIIII – –
Cambodia 15% IIIIIII IIIIIIII 26.4% No p
China 23% IIIIIIII IIIIIII 54.5% No
Cook Islands 17% IIIIIII IIIIIIIIII . . . . . . p
Fiji 15% IIIIIII IIIIII 36.9% Yes
Japan 17% — — 61.0% Yes p
Kiribati 37% IIIIIIII IIIIIIIII 41.4% No
Lao People's  
Democratic Republic 24% IIIIII IIIIIIIIII 11.7% No
Malaysia 17% — IIIIIIII 51.5% Yes
Marshall Islands 19% IIIIIII IIIIIIII 54.1% No
Micronesia 
(Federated States of) . . . IIIIIII IIIII 46.7% Yes
Mongolia 23% IIIII IIIIII 45.4%
Nauru 37% IIIIIIII IIIIIIIIII 42.2% Yes q
New Zealand 13% IIIIIIIIII IIIIIIIIII 82.0% Yes
Niue . . . . . . . . . 57.8% . . . q
Palau 14% IIIIIIIIII IIIIIIIIII 71.4% Yes
Papua New Guinea 35% II III 53.1% q
Philippines 18% IIIII IIIIII 55.7% Yes p
Republic of Korea 20% IIIII IIIII 73.9% Yes
Samoa 20% . . . . . . 49.2% Yes
Singapore 14% IIIIIIII IIIIIIIIII 67.1%
Solomon Islands 29% III IIIIII . . . . . .
Tonga 26% . . . . . . 67.3% Yes p
Tuvalu 29% IIIIIIII IIIIIIII 38.7%
Vanuatu 12% – IIIIIIII 52.7%
Viet Nam 20% IIIII IIIIII 38.8% No
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Please refer to Technical Note I for definitions of categories
ADULT DAILY SMOKING PREVALENCE*:  
AGE-STANDARDIZED PREVALENCE RATES FOR ADULT DAILY 
SMOKERS OF TOBACCO (BOTH SEXES COMBINED), 2019
. . . Estimates not available
30% or more 
From 20% to 29.9% 
From 15% to 19.9% 
Less than 15% 
* The figures should be used strictly for the purpose of drawing 
comparisons across countries and must not be used to estimate 
absolute number of daily tobacco smokers in a country.
MONITORING: PREVALENCE DATA
No known data or no recent data or data 
that are not both recent and representative
Recent and representative data for either 
adults or youth
Recent and representative data for both 
adults and youth
Recent, representative and periodic data  
for both adults and youth
SMOKE-FREE ENVIRONMENTS: SMOKING BANS
Data not reported
Complete absence of ban, or up to two public 
places completely smoke-free
Three to five public places completely smoke-free
Six to seven public places completely smoke-free
All public places completely smoke-free (or 
at least 90% of the population covered by 
complete subnational smoke-free legislation)
CESSATION PROGRAMMES:  
TREATMENT OF TOBACCO DEPENDENCE
Data not reported
None
NRT and/or some cessation services (neither 
cost-covered)
NRT and/or some cessation services (at least 
one of which is cost-covered)
National quit line, and both NRT and some 
cessation services cost-covered
HEALTH WARNINGS:  
HEALTH WARNINGS ON CIGARETTE PACKAGES
Data not reported
No warnings or small warnings
Medium size warnings missing some 
appropriate characteristics OR large warnings 
missing many appropriate characteristics
Medium size warnings with all appropriate 
characteristics OR large warnings missing 
some appropriate characteristics
Large warnings with all appropriate 
characteristics
MASS MEDIA: ANTI-TOBACCO CAMPAIGNS
Data not reported
No national campaign conducted between 
July 2018 and June 2020 with a duration of at 
least 3 weeks
National campaign conducted with one to four 
appropriate characteristics
National campaign conducted with five to six 
appropriate characteristics
National campaign conducted with at least 
seven appropriate characteristics including 
airing on television and/or radio
ADVERTISING BANS:  
BANS ON ADVERTISING, PROMOTION AND SPONSORSHIP
Data not reported
Complete absence of ban, or ban that does not 
cover national television, radio and print media
Ban on national television, radio and print 
media only
Ban on national television, radio and print 
media as well as on some but not all other 
forms of direct and/or indirect advertising
Ban on all forms of direct and indirect 
advertising (or at least 90% of the population 
covered by subnational legislation completely 
banning tobacco advertising, promotion  
and sponsorship)
TAXATION: SHARE OF TOTAL TAXES IN THE RETAIL PRICE  
OF THE MOST WIDELY SOLD BRAND OF CIGARETTES
Data not reported
< 25% of retail price is tax 
≥ 25% and <50% of retail price is tax 
≥ 50% and <75% of retail price is tax 
≥ 75% of retail price is tax 
AFFORDABILITY OF CIGARETTES
YES
Cigarettes less affordable - Trend in per capita 
GDP needed to buy cigarettes increased since 
2010 at a rate over 1.45% per year
NO
Cigarettes more affordable - Trend in per capita 
GDP needed to buy cigarettes decreased since 
2010 at a rate over 1.45% per year
No significant change in affordability of 
cigarettes since 2010
... Insufficient data to conduct a trend analysis
COMPLIANCE: COMPLIANCE WITH BANS ON ADVERTISING, 











Moderate compliance (3/10 to 7/10)
||
| Minimal compliance (0/10 to 2/10)
SYMBOLS LEGEND
Plain packaging is mandated.
8 Law adopted but not implemented by 
31 December 2020.
qp Change in POWER indicator group, up or down, 
between 2018 and 2020. Some 2018 data were 
revised in 2020. 2020 grouping rules were applied 
to both years.
... Data not reported/not available
– Data not required/not applicable
2020 INDICATOR AND COMPLIANCE  CHANGE SINCE 2018













































CHANGE IN POWER INDICATOR GROUP, UP OR DOWN, SINCE 2018
Australia 12% . . . IIIIIIIIII 73.9% Yes q q
Brunei Darussalam 12% IIIIIII IIIIIIIII – –
Cambodia 15% IIIIIII IIIIIIII 26.4% No p
China 23% IIIIIIII IIIIIII 54.5% No
Cook Islands 17% IIIIIII IIIIIIIIII . . . . . . p
Fiji 15% IIIIIII IIIIII 36.9% Yes
Japan 17% — — 61.0% Yes p
Kiribati 37% IIIIIIII IIIIIIIII 41.4% No
Lao People's  
Democratic Republic 24% IIIIII IIIIIIIIII 11.7% No
Malaysia 17% — IIIIIIII 51.5% Yes
Marshall Islands 19% IIIIIII IIIIIIII 54.1% No
Micronesia 
(Federated States of) . . . IIIIIII IIIII 46.7% Yes
Mongolia 23% IIIII IIIIII 45.4%
Nauru 37% IIIIIIII IIIIIIIIII 42.2% Yes q
New Zealand 13% IIIIIIIIII IIIIIIIIII 82.0% Yes
Niue . . . . . . . . . 57.8% . . . q
Palau 14% IIIIIIIIII IIIIIIIIII 71.4% Yes
Papua New Guinea 35% II III 53.1% q
Philippines 18% IIIII IIIIII 55.7% Yes p
Republic of Korea 20% IIIII IIIII 73.9% Yes
Samoa 20% . . . . . . 49.2% Yes
Singapore 14% IIIIIIII IIIIIIIIII 67.1%
Solomon Islands 29% III IIIIII . . . . . .
Tonga 26% . . . . . . 67.3% Yes p
Tuvalu 29% IIIIIIII IIIIIIII 38.7%
Vanuatu 12% – IIIIIIII 52.7%
Viet Nam 20% IIIII IIIIII 38.8% No
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Annex II provides an overview of 
selected tobacco control measures 
applied to ENDS.
For each WHO region an overview table 
is presented that includes information  
on monitoring and prevalence, ENDS 
use in public indoor areas, health 
warnings and packaging, advertising, 
promotion and sponsorship bans, 
taxation levels, age restrictions on sales 
and regulations applied to flavours, 
based on the methodology outlined in 
Technical Notes I, II and III.
Annex II provides detailed information 
on selected regulatory aspects of ENDS 
and ENNDS, for each WHO region.  
The following data are reported in  
this Annex: 
Regulation of ENDS/ENNDS: 
■	 Bans applied to ENDS/ENNDS
■	 P, W and E measures applied to 
ENDS/ENNDS
■	 Minimum age of sale
■	 How flavours are regulated.
Monitoring and taxation of  
ENDS/ENNDS:
■	 Data on prevalence of ENDS use 
available from national population-
based surveys of adults and/or 
school-based surveys of adolescents
■	 Excise tax applied on ENDS/ENNDS 
e-liquids (closed systems and/or 
open systems)
ANNEX II
REGIONAL SUMMARY OF 
MEASURES APPLIED TO ENDS
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Table 2.1.1 
Africa
Regulation of ENDS/ENNDS 
*  ENNDS are treated the same as ENDS
— Not applicable because sale is banned
COUNTRY BANS P – MEASURE W – HEALTH  
WARNINGS MEASURE
E – MEASURE MINIMUM AGE OF SALE HOW ARE FLAVOURS 
REGULATED
Algeria None Partial Partial (e-liquids only) Full (e-liquids only) 18 Not regulated
Angola None None None None None Not regulated
Benin None None None None None Not regulated
Botswana None None None None None Not regulated
Burkina Faso None None None None None Not regulated
Burundi None None None None None Not regulated
Cabo Verde None None None None None Not regulated
Cameroon None None None None None Not regulated
Central African Republic None None None None None Not regulated
Chad None None None None None Not regulated
Comoros None None None None None Not regulated
Congo None Full* Partial (e-liquids only)* Full* 18* Not regulated
Côte d'Ivoire None None Partial (devices only)* Full (devices only)* 18* Not regulated
Democratic Republic of the Congo None None None None None Not regulated
Equatorial Guinea None None None None None Not regulated
Eritrea None None None None None Not regulated
Eswatini None None None None None Not regulated
Ethiopia Sales, manufacture, wholesale, distribution, offer for sale, import to trade None — None — —
Gabon None None None None None Not regulated
Gambia Sales, import, manufacture, distribution, possession, offer for sale* None — None — —
Ghana None None None None None Not regulated
Guinea None None None None None Not regulated
Guinea-Bissau None None None None None Not regulated
Kenya None None Partial (e-liquids only) Full (e-liquids only) 18 Not regulated
Lesotho None None None None None Not regulated
Liberia None None None None None Not regulated
Madagascar None None None None None Not regulated
Malawi None None None None None Not regulated
Mali None None None None None Not regulated
Mauritania None None None None None Not regulated
Mauritius Sales, offer for sale, distribution* None — None — —
Mozambique None None None None None Not regulated
Namibia None None None None None Not regulated
Niger None None None None None Not regulated
Nigeria None None None None None Not regulated
Rwanda None None None None None Not regulated
Sao Tome and Principe None None None None None Not regulated
Senegal None None None None None Not regulated
Seychelles None None None None None Not regulated
Sierra Leone None None None None None Not regulated
South Africa None None None None None Not regulated
South Sudan None None None None None Not regulated
Togo None Partial Partial (e-liquids only) Full (e-liquids only) 18 Not regulated
Uganda Sales, import, manufacture, distribution, process, offer for sale, bring into the country* None — None — —
United Republic of Tanzania None None None None None Not regulated
Zambia None None None None None Not regulated
Zimbabwe None None None None None Not regulated
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COUNTRY BANS P – MEASURE W – HEALTH  
WARNINGS MEASURE
E – MEASURE MINIMUM AGE OF SALE HOW ARE FLAVOURS 
REGULATED
Algeria None Partial Partial (e-liquids only) Full (e-liquids only) 18 Not regulated
Angola None None None None None Not regulated
Benin None None None None None Not regulated
Botswana None None None None None Not regulated
Burkina Faso None None None None None Not regulated
Burundi None None None None None Not regulated
Cabo Verde None None None None None Not regulated
Cameroon None None None None None Not regulated
Central African Republic None None None None None Not regulated
Chad None None None None None Not regulated
Comoros None None None None None Not regulated
Congo None Full* Partial (e-liquids only)* Full* 18* Not regulated
Côte d'Ivoire None None Partial (devices only)* Full (devices only)* 18* Not regulated
Democratic Republic of the Congo None None None None None Not regulated
Equatorial Guinea None None None None None Not regulated
Eritrea None None None None None Not regulated
Eswatini None None None None None Not regulated
Ethiopia Sales, manufacture, wholesale, distribution, offer for sale, import to trade None — None — —
Gabon None None None None None Not regulated
Gambia Sales, import, manufacture, distribution, possession, offer for sale* None — None — —
Ghana None None None None None Not regulated
Guinea None None None None None Not regulated
Guinea-Bissau None None None None None Not regulated
Kenya None None Partial (e-liquids only) Full (e-liquids only) 18 Not regulated
Lesotho None None None None None Not regulated
Liberia None None None None None Not regulated
Madagascar None None None None None Not regulated
Malawi None None None None None Not regulated
Mali None None None None None Not regulated
Mauritania None None None None None Not regulated
Mauritius Sales, offer for sale, distribution* None — None — —
Mozambique None None None None None Not regulated
Namibia None None None None None Not regulated
Niger None None None None None Not regulated
Nigeria None None None None None Not regulated
Rwanda None None None None None Not regulated
Sao Tome and Principe None None None None None Not regulated
Senegal None None None None None Not regulated
Seychelles None None None None None Not regulated
Sierra Leone None None None None None Not regulated
South Africa None None None None None Not regulated
South Sudan None None None None None Not regulated
Togo None Partial Partial (e-liquids only) Full (e-liquids only) 18 Not regulated
Uganda Sales, import, manufacture, distribution, process, offer for sale, bring into the country* None — None — —
United Republic of Tanzania None None None None None Not regulated
Zambia None None None None None Not regulated
Zimbabwe None None None None None Not regulated
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Table 2.1.2 
The Americas
Regulation of ENDS/ENNDS 
*  ENNDS are treated the same as ENDS
— Not applicable because sale is banned
COUNTRY BANS P – MEASURE W – HEALTH  
WARNINGS MEASURE
E – MEASURE MINIMUM AGE OF SALE HOW ARE FLAVOURS 
REGULATED
Antigua and Barbuda None None None None None Not regulated
Argentina Sales, import, distribution, commercialization, advertising, promotion Full — Partial — —
Bahamas None None None None None Not regulated
Barbados None Full None None 18 Not regulated
Belize None None None None None Not regulated
Bolivia (Plurinational State of) None None None None None Not regulated
Brazil Sales, import* Full* — Full* — —
Canada None Partial* Partial (e-liquids only) Partial* 18 Not regulated
Chile None None None None None Not regulated
Colombia None None None None None Not regulated
Costa Rica None Full Full Partial 18 Not regulated
Cuba None None None None None Not regulated
Dominica None None None None None Not regulated
Dominican Republic None None None None None Not regulated
Ecuador None Full Full Partial 18 Not regulated
El Salvador None Full None None None Not regulated
Grenada None None None None None Not regulated
Guatemala None None None None None Not regulated
Guyana None Full* None Full* 18* Not regulated
Haiti None None None None None Not regulated
Honduras None Full* Full (devices only)* Partial 21* Not regulated
Jamaica None Full Full Partial 18 Not regulated
Mexico Sales, import, distribution, display,  promotion, production* None — None — —
Nicaragua None None None None None Not regulated
Panama Sales, import* Full* — None — —
Paraguay None Full* None Partial* 18* Not regulated
Peru None None None None None Not regulated
Saint Kitts and Nevis None None None None None Not regulated
Saint Lucia None Full Full None 18 Not regulated
Saint Vincent and the Grenadines None None None None None Not regulated
Suriname Sales, import, distribution* None — None — —
Trinidad and Tobago None None None None None Not regulated
United States of America None None Partial (e-liquids only) Partial 21 Not regulated
Uruguay Sales, commercialisation, importation, registration as a trademark or patent* Full* — Full* — —
Venezuela (Bolivarian Republic of) Sales, promotion, commercialisation* None — None — —
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COUNTRY BANS P – MEASURE W – HEALTH  
WARNINGS MEASURE
E – MEASURE MINIMUM AGE OF SALE HOW ARE FLAVOURS 
REGULATED
Antigua and Barbuda None None None None None Not regulated
Argentina Sales, import, distribution, commercialization, advertising, promotion Full — Partial — —
Bahamas None None None None None Not regulated
Barbados None Full None None 18 Not regulated
Belize None None None None None Not regulated
Bolivia (Plurinational State of) None None None None None Not regulated
Brazil Sales, import* Full* — Full* — —
Canada None Partial* Partial (e-liquids only) Partial* 18 Not regulated
Chile None None None None None Not regulated
Colombia None None None None None Not regulated
Costa Rica None Full Full Partial 18 Not regulated
Cuba None None None None None Not regulated
Dominica None None None None None Not regulated
Dominican Republic None None None None None Not regulated
Ecuador None Full Full Partial 18 Not regulated
El Salvador None Full None None None Not regulated
Grenada None None None None None Not regulated
Guatemala None None None None None Not regulated
Guyana None Full* None Full* 18* Not regulated
Haiti None None None None None Not regulated
Honduras None Full* Full (devices only)* Partial 21* Not regulated
Jamaica None Full Full Partial 18 Not regulated
Mexico Sales, import, distribution, display,  promotion, production* None — None — —
Nicaragua None None None None None Not regulated
Panama Sales, import* Full* — None — —
Paraguay None Full* None Partial* 18* Not regulated
Peru None None None None None Not regulated
Saint Kitts and Nevis None None None None None Not regulated
Saint Lucia None Full Full None 18 Not regulated
Saint Vincent and the Grenadines None None None None None Not regulated
Suriname Sales, import, distribution* None — None — —
Trinidad and Tobago None None None None None Not regulated
United States of America None None Partial (e-liquids only) Partial 21 Not regulated
Uruguay Sales, commercialisation, importation, registration as a trademark or patent* Full* — Full* — —
Venezuela (Bolivarian Republic of) Sales, promotion, commercialisation* None — None — —
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Table 2.1.3 
South-East Asia
Regulation of ENDS/ENNDS 
*  ENNDS are treated the same as ENDS
— Not applicable because sale is banned
COUNTRY BANS P – MEASURE W – HEALTH  
WARNINGS MEASURE
E – MEASURE MINIMUM AGE OF SALE HOW ARE FLAVOURS 
REGULATED
Bangladesh None None None None None Not regulated
Bhutan None None None None None Not regulated
Democratic People's Republic of Korea Sales, import, export* None — None — —
India Sales, production, manufacture, import,  export, transport, distribution, storage* None — Partial* — —
Indonesia None None None None None Not regulated
Maldives None None None None None Not regulated
Myanmar None None None None None Not regulated
Nepal Manufacture, import, distribute, promote  (bans restricted to some places only) Full* None Full (devices only)* 18* Not regulated
Sri Lanka Sales, manufacture, import, offer for sale None — None — —
Thailand Sales, import* None — None — —
Timor-Leste Sales, import* None — None — —
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COUNTRY BANS P – MEASURE W – HEALTH  
WARNINGS MEASURE
E – MEASURE MINIMUM AGE OF SALE HOW ARE FLAVOURS 
REGULATED
Bangladesh None None None None None Not regulated
Bhutan None None None None None Not regulated
Democratic People's Republic of Korea Sales, import, export* None — None — —
India Sales, production, manufacture, import,  export, transport, distribution, storage* None — Partial* — —
Indonesia None None None None None Not regulated
Maldives None None None None None Not regulated
Myanmar None None None None None Not regulated
Nepal Manufacture, import, distribute, promote  (bans restricted to some places only) Full* None Full (devices only)* 18* Not regulated
Sri Lanka Sales, manufacture, import, offer for sale None — None — —
Thailand Sales, import* None — None — —
Timor-Leste Sales, import* None — None — —
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Table 2.1.4 
Europe
Regulation of ENDS/ENNDS 
*  ENNDS are treated the same as ENDS
8 Provision adopted but not implemented by 31 December 2020
— Not applicable because sale is banned
COUNTRY BANS P – MEASURE W – HEALTH  
WARNINGS MEASURE
E – MEASURE MINIMUM AGE OF SALE HOW ARE FLAVOURS 
REGULATED
Albania None Full* None None 18* Not regulated
Andorra None Partial None None 18* Not regulated
Armenia None Partial Full Partial 18 Not regulated
Austria None Partial* Partial Partial* 18* Not regulated
Azerbaijan None Partial* None Full (devices only)* 18* Not regulated
Belarus None Partial* None Partial* 18* Not regulated
Belgium None Partial* Partial Partial 18* Not regulated
Bosnia and Herzegovina None None None None None Not regulated
Bulgaria None None Partial Partial 18 Not regulated
Croatia None Partial Partial Partial 18 Not regulated
Cyprus None Partial* Partial Partial* 18* Not regulated
Czechia None Partial* Partial Partial* 18* Not regulated
Denmark None Partial* Partial Partial* 18* Some specific flavours are allowed*8
Estonia None Partial* Partial Partial* 18* Some specific flavours  are allowed
Finland None Partial* Partial (e-liquids only) Full* 18* All flavours are banned*
France None Partial* Partial Partial* 18 Not regulated
Georgia None Partial None Partial 18 Not regulated
Germany None None Partial Partial 18 Some specific flavours  are banned 
Greece None Full* Partial Partial* 18* Not regulated
Hungary None Partial* Partial Partial 18* All flavours are banned*
Iceland None Partial* None Full* 18* Not regulated
Ireland None None Partial Partial None Not regulated
Israel None Partial Partial Partial 18 Not regulated
Italy None Partial Partial Partial 18 Not regulated
Kazakhstan None Partial* None None 21* Not regulated
Kyrgyzstan None None None None None Not regulated
Latvia None Partial* Partial Partial* 18* Not regulated
Lithuania None Partial Partial Partial 18 Not regulated
Luxembourg None Partial* Partial* Partial* 18* Not regulated
Malta None Full* Partial Partial* 18* Not regulated
Monaco None None None None None Not regulated
Montenegro None Partial* Partial Partial* None All flavours are banned*
Netherlands None Partial* Partial* Partial* 18* Not regulated
North Macedonia None None None None None Not regulated
Norway None Full* Partial Partial* 18* Not regulated
Poland None Partial Partial Partial 18 Not regulated
Portugal None Partial Partial Partial 18 Not regulated
Republic of Moldova None Partial Partial Full 18 Not regulated
Romania None Partial Partial Partial None Not regulated
Russian Federation None Full* None Full* 18* Not regulated
San Marino None Partial* None None 18* Not regulated
Serbia None None None Partial* None Not regulated
Slovakia None None Partial Partial 18 Not regulated
Slovenia None Partial* Partial Full 18* Not regulated
Spain None Partial Partial Partial 18 Not regulated
Sweden None None Partial Partial 18 Not regulated
Switzerland None None None None None Not regulated
Tajikistan None Full Full Partial 18 Not regulated
Turkey Import (except for personal consumption) Full* Full (devices only)* Full (devices only)* 18* Not regulated
Turkmenistan Sales* None — None — —
Ukraine None Partial* None None None Not regulated
United Kingdom of Great Britain  
and Northern Ireland None None Partial Partial None Not regulated
Uzbekistan None Partial* None Partial (devices only)* None Not regulated
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COUNTRY BANS P – MEASURE W – HEALTH  
WARNINGS MEASURE
E – MEASURE MINIMUM AGE OF SALE HOW ARE FLAVOURS 
REGULATED
Albania None Full* None None 18* Not regulated
Andorra None Partial None None 18* Not regulated
Armenia None Partial Full Partial 18 Not regulated
Austria None Partial* Partial Partial* 18* Not regulated
Azerbaijan None Partial* None Full (devices only)* 18* Not regulated
Belarus None Partial* None Partial* 18* Not regulated
Belgium None Partial* Partial Partial 18* Not regulated
Bosnia and Herzegovina None None None None None Not regulated
Bulgaria None None Partial Partial 18 Not regulated
Croatia None Partial Partial Partial 18 Not regulated
Cyprus None Partial* Partial Partial* 18* Not regulated
Czechia None Partial* Partial Partial* 18* Not regulated
Denmark None Partial* Partial Partial* 18* Some specific flavours are allowed*8
Estonia None Partial* Partial Partial* 18* Some specific flavours  are allowed
Finland None Partial* Partial (e-liquids only) Full* 18* All flavours are banned*
France None Partial* Partial Partial* 18 Not regulated
Georgia None Partial None Partial 18 Not regulated
Germany None None Partial Partial 18 Some specific flavours  are banned 
Greece None Full* Partial Partial* 18* Not regulated
Hungary None Partial* Partial Partial 18* All flavours are banned*
Iceland None Partial* None Full* 18* Not regulated
Ireland None None Partial Partial None Not regulated
Israel None Partial Partial Partial 18 Not regulated
Italy None Partial Partial Partial 18 Not regulated
Kazakhstan None Partial* None None 21* Not regulated
Kyrgyzstan None None None None None Not regulated
Latvia None Partial* Partial Partial* 18* Not regulated
Lithuania None Partial Partial Partial 18 Not regulated
Luxembourg None Partial* Partial* Partial* 18* Not regulated
Malta None Full* Partial Partial* 18* Not regulated
Monaco None None None None None Not regulated
Montenegro None Partial* Partial Partial* None All flavours are banned*
Netherlands None Partial* Partial* Partial* 18* Not regulated
North Macedonia None None None None None Not regulated
Norway None Full* Partial Partial* 18* Not regulated
Poland None Partial Partial Partial 18 Not regulated
Portugal None Partial Partial Partial 18 Not regulated
Republic of Moldova None Partial Partial Full 18 Not regulated
Romania None Partial Partial Partial None Not regulated
Russian Federation None Full* None Full* 18* Not regulated
San Marino None Partial* None None 18* Not regulated
Serbia None None None Partial* None Not regulated
Slovakia None None Partial Partial 18 Not regulated
Slovenia None Partial* Partial Full 18* Not regulated
Spain None Partial Partial Partial 18 Not regulated
Sweden None None Partial Partial 18 Not regulated
Switzerland None None None None None Not regulated
Tajikistan None Full Full Partial 18 Not regulated
Turkey Import (except for personal consumption) Full* Full (devices only)* Full (devices only)* 18* Not regulated
Turkmenistan Sales* None — None — —
Ukraine None Partial* None None None Not regulated
United Kingdom of Great Britain  
and Northern Ireland None None Partial Partial None Not regulated
Uzbekistan None Partial* None Partial (devices only)* None Not regulated




Regulation of ENDS/ENNDS 
*  ENNDS are treated the same as ENDS
— Not applicable because sale is banned
< “occupied Palestinian territory” should be understood to refer  
 to the “occupied Palestinian territory, including east Jerusalem”
COUNTRY OR TERRITORY BANS P – MEASURE W – HEALTH  
WARNINGS MEASURE
E – MEASURE MINIMUM AGE OF SALE HOW ARE FLAVOURS 
REGULATED
Afghanistan None None None None None Not regulated
Bahrain Sales, import, distribution* None — None — —
Djibouti None None None None None Not regulated
Egypt Sales, import, trade* None — None — —
Iran (Islamic Republic of) Sales, import, production, supply, export* None — None — —
Iraq Sales, import, trade, manufacture* None — Full* — —
Jordan Sales, import, distribution, manufacture* Full* — None — —
Kuwait Sales, trade, import* Partial* — Full* — —
Lebanon Sales, import* Full* — Partial* — —
Libya None None None None None Not regulated
Morocco None None None None None Not regulated
occupied Palestinian territory < Sales, import, manufacture * None — None — —
Oman Sales, import* None — None — —
Pakistan None None None None None Not regulated
Qatar Sales, import, trade, display, distribution, manufacture* None — None — —
Saudi Arabia None Partial* Partial* None None Flavours are restricted*
Somalia None None None None None Not regulated
Sudan None None None None None Not regulated
Syrian Arab Republic Sales, manufacture, distribution, trade* Partial* — None — —
Tunisia None None None None None Not regulated
United Arab Emirates None None Partial (e-liquids only)* Full* 18* Not regulated
Yemen None None None None None Not regulated
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COUNTRY OR TERRITORY BANS P – MEASURE W – HEALTH  
WARNINGS MEASURE
E – MEASURE MINIMUM AGE OF SALE HOW ARE FLAVOURS 
REGULATED
Afghanistan None None None None None Not regulated
Bahrain Sales, import, distribution* None — None — —
Djibouti None None None None None Not regulated
Egypt Sales, import, trade* None — None — —
Iran (Islamic Republic of) Sales, import, production, supply, export* None — None — —
Iraq Sales, import, trade, manufacture* None — Full* — —
Jordan Sales, import, distribution, manufacture* Full* — None — —
Kuwait Sales, trade, import* Partial* — Full* — —
Lebanon Sales, import* Full* — Partial* — —
Libya None None None None None Not regulated
Morocco None None None None None Not regulated
occupied Palestinian territory < Sales, import, manufacture * None — None — —
Oman Sales, import* None — None — —
Pakistan None None None None None Not regulated
Qatar Sales, import, trade, display, distribution, manufacture* None — None — —
Saudi Arabia None Partial* Partial* None None Flavours are restricted*
Somalia None None None None None Not regulated
Sudan None None None None None Not regulated
Syrian Arab Republic Sales, manufacture, distribution, trade* Partial* — None — —
Tunisia None None None None None Not regulated
United Arab Emirates None None Partial (e-liquids only)* Full* 18* Not regulated
Yemen None None None None None Not regulated
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Table 2.1.6 
Western Pacific
Regulation of ENDS/ENNDS 
*  ENNDS are treated the same as ENDS
8 Provision adopted but not implemented by 31 December 2020
— Not applicable because sale is banned
COUNTRY BANS P – MEASURE W – HEALTH  
WARNINGS MEASURE
E – MEASURE MINIMUM AGE OF SALE HOW ARE FLAVOURS 
REGULATED
Australia None Partial None None 18 Not regulated
Brunei Darussalam Sales, import* Full* — None — —
Cambodia Sales, import* None — None — —
China None None None None 18* Not regulated
Cook Islands None None None None None Not regulated
Fiji None Partial* None Partial* 18* Not regulated
Japan None None None None None Not regulated
Kiribati None None None None None Not regulated
Lao People's Democratic Republic None Full* None Partial* 18* Not regulated
Malaysia Sales None — None — —
Marshall Islands None None None None None Not regulated
Micronesia (Federated States of) None None None None None Not regulated
Mongolia None None None None None Not regulated
Nauru None None None None None Not regulated
New Zealand None Full* None Partial* 18* Flavours are restricted*8
Niue None Full* Partial* Full* 21* Not regulated
Palau None Partial None Partial 21 Not regulated
Papua New Guinea None Full Partial (devices only) Partial (devices only) 18 Not regulated
Philippines None Partial* None Full* 21* Some specific flavours  are allowed*
Republic of Korea None Partial Partial (e-liquids only) Partial (e-liquids only) 19* Not regulated
Samoa None None None None None Not regulated
Singapore Sales, import, distribute, offer for sale, possession* Full* — Partial* — —
Solomon Islands None None None None None Not regulated
Tonga None None None None None Not regulated
Tuvalu None Partial* Partial* Full* 18* Not regulated
Vanuatu None None None None None Not regulated
Viet Nam None None None None None Not regulated
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COUNTRY BANS P – MEASURE W – HEALTH  
WARNINGS MEASURE
E – MEASURE MINIMUM AGE OF SALE HOW ARE FLAVOURS 
REGULATED
Australia None Partial None None 18 Not regulated
Brunei Darussalam Sales, import* Full* — None — —
Cambodia Sales, import* None — None — —
China None None None None 18* Not regulated
Cook Islands None None None None None Not regulated
Fiji None Partial* None Partial* 18* Not regulated
Japan None None None None None Not regulated
Kiribati None None None None None Not regulated
Lao People's Democratic Republic None Full* None Partial* 18* Not regulated
Malaysia Sales None — None — —
Marshall Islands None None None None None Not regulated
Micronesia (Federated States of) None None None None None Not regulated
Mongolia None None None None None Not regulated
Nauru None None None None None Not regulated
New Zealand None Full* None Partial* 18* Flavours are restricted*8
Niue None Full* Partial* Full* 21* Not regulated
Palau None Partial None Partial 21 Not regulated
Papua New Guinea None Full Partial (devices only) Partial (devices only) 18 Not regulated
Philippines None Partial* None Full* 21* Some specific flavours  are allowed*
Republic of Korea None Partial Partial (e-liquids only) Partial (e-liquids only) 19* Not regulated
Samoa None None None None None Not regulated
Singapore Sales, import, distribute, offer for sale, possession* Full* — Partial* — —
Solomon Islands None None None None None Not regulated
Tonga None None None None None Not regulated
Tuvalu None Partial* Partial* Full* 18* Not regulated
Vanuatu None None None None None Not regulated
Viet Nam None None None None None Not regulated
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Table 2.2.1 
Africa
Monitoring and taxation  
of ENDS/ENNDS 
*  ENNDS are taxed the same as ENDS
… Data not available
DATA ON PREVALENCE OF ENDS USE ARE AVAILABLE  
FROM NATIONAL SURVEYS
EXCISE TAX IS APPLIED ON ENDS/ENNDS E-LIQUIDS
 
COUNTRY
POPULATION-BASED SURVEYS  
OF ADULTS
SCHOOL-BASED SURVEYS  
OF ADOLESCENTS
CLOSED SYSTEMS OPEN SYSTEMS
Algeria No No … …
Angola No No … …
Benin No No … …
Botswana No No … …
Burkina Faso No No … …
Burundi No No … …
Cabo Verde No No … …
Cameroon No No … …
Central African Republic No No … …
Chad No No … …
Comoros No No … …
Congo No No … …
Côte d'Ivoire No No … …
Democratic Republic of the Congo No No … …
Equatorial Guinea No No … …
Eritrea No No … …
Eswatini No No … …
Ethiopia No No Sale is banned Sale is banned
Gabon No No … …
Gambia No No Sale is banned Sale is banned
Ghana No Yes … …
Guinea No No … …
Guinea-Bissau No No … …
Kenya No No … …
Lesotho No No … …
Liberia No No … …
Madagascar No No … …
Malawi No No … …
Mali No No … …
Mauritania No No … …
Mauritius No Yes Sale is banned Sale is banned
Mozambique No No … …
Namibia No No … …
Niger No No … …
Nigeria No No … …
Rwanda No No … …
Sao Tome and Principe No No … …
Senegal Yes No … …
Seychelles No No … …
Sierra Leone No No … …
South Africa No No … …
South Sudan No No … …
Togo No No … …
Uganda No No Sale is banned Sale is banned
United Republic of Tanzania No No … …
Zambia No No … …
Zimbabwe No No … …
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DATA ON PREVALENCE OF ENDS USE ARE AVAILABLE  
FROM NATIONAL SURVEYS
EXCISE TAX IS APPLIED ON ENDS/ENNDS E-LIQUIDS
 
COUNTRY
POPULATION-BASED SURVEYS  
OF ADULTS
SCHOOL-BASED SURVEYS  
OF ADOLESCENTS
CLOSED SYSTEMS OPEN SYSTEMS
Algeria No No … …
Angola No No … …
Benin No No … …
Botswana No No … …
Burkina Faso No No … …
Burundi No No … …
Cabo Verde No No … …
Cameroon No No … …
Central African Republic No No … …
Chad No No … …
Comoros No No … …
Congo No No … …
Côte d'Ivoire No No … …
Democratic Republic of the Congo No No … …
Equatorial Guinea No No … …
Eritrea No No … …
Eswatini No No … …
Ethiopia No No Sale is banned Sale is banned
Gabon No No … …
Gambia No No Sale is banned Sale is banned
Ghana No Yes … …
Guinea No No … …
Guinea-Bissau No No … …
Kenya No No … …
Lesotho No No … …
Liberia No No … …
Madagascar No No … …
Malawi No No … …
Mali No No … …
Mauritania No No … …
Mauritius No Yes Sale is banned Sale is banned
Mozambique No No … …
Namibia No No … …
Niger No No … …
Nigeria No No … …
Rwanda No No … …
Sao Tome and Principe No No … …
Senegal Yes No … …
Seychelles No No … …
Sierra Leone No No … …
South Africa No No … …
South Sudan No No … …
Togo No No … …
Uganda No No Sale is banned Sale is banned
United Republic of Tanzania No No … …
Zambia No No … …
Zimbabwe No No … …
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Table 2.2.2 
The Americas
Monitoring and taxation  
of ENDS/ENNDS 
*  ENNDS are taxed the same as ENDS
… Data not available
DATA ON PREVALENCE OF ENDS USE ARE AVAILABLE  
FROM NATIONAL SURVEYS
EXCISE TAX IS APPLIED ON ENDS/ENNDS E-LIQUIDS
 
COUNTRY
POPULATION-BASED SURVEYS  
OF ADULTS
SCHOOL-BASED SURVEYS  
OF ADOLESCENTS
CLOSED SYSTEMS OPEN SYSTEMS
Antigua and Barbuda No Yes … …
Argentina Yes Yes Sale is banned Sale is banned
Bahamas No No … …
Barbados No No … …
Belize No Yes … …
Bolivia (Plurinational State of) Yes Yes … …
Brazil No Yes Sale is banned Sale is banned
Canada Yes Yes … …
Chile Yes No … …
Colombia Yes Yes … …
Costa Rica Yes No … …
Cuba No Yes … …
Dominica No No … …
Dominican Republic No Yes … …
Ecuador Yes Yes … …
El Salvador No Yes … …
Grenada No Yes … …
Guatemala No Yes … …
Guyana No Yes … …
Haiti No No … …
Honduras No No … …
Jamaica No Yes … …
Mexico Yes No Sale is banned Sale is banned
Nicaragua No Yes … …
Panama Yes Yes Sale is banned Sale is banned
Paraguay No Yes … …
Peru No Yes No No
Saint Kitts and Nevis No No … …
Saint Lucia No Yes … …
Saint Vincent and the Grenadines No Yes … …
Suriname No Yes Sale is banned Sale is banned
Trinidad and Tobago No Yes … …
United States of America Yes Yes … …
Uruguay Yes Yes Sale is banned Sale is banned
Venezuela (Bolivarian Republic of) No Yes Sale is banned Sale is banned
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DATA ON PREVALENCE OF ENDS USE ARE AVAILABLE  
FROM NATIONAL SURVEYS
EXCISE TAX IS APPLIED ON ENDS/ENNDS E-LIQUIDS
 
COUNTRY
POPULATION-BASED SURVEYS  
OF ADULTS
SCHOOL-BASED SURVEYS  
OF ADOLESCENTS
CLOSED SYSTEMS OPEN SYSTEMS
Antigua and Barbuda No Yes … …
Argentina Yes Yes Sale is banned Sale is banned
Bahamas No No … …
Barbados No No … …
Belize No Yes … …
Bolivia (Plurinational State of) Yes Yes … …
Brazil No Yes Sale is banned Sale is banned
Canada Yes Yes … …
Chile Yes No … …
Colombia Yes Yes … …
Costa Rica Yes No … …
Cuba No Yes … …
Dominica No No … …
Dominican Republic No Yes … …
Ecuador Yes Yes … …
El Salvador No Yes … …
Grenada No Yes … …
Guatemala No Yes … …
Guyana No Yes … …
Haiti No No … …
Honduras No No … …
Jamaica No Yes … …
Mexico Yes No Sale is banned Sale is banned
Nicaragua No Yes … …
Panama Yes Yes Sale is banned Sale is banned
Paraguay No Yes … …
Peru No Yes No No
Saint Kitts and Nevis No No … …
Saint Lucia No Yes … …
Saint Vincent and the Grenadines No Yes … …
Suriname No Yes Sale is banned Sale is banned
Trinidad and Tobago No Yes … …
United States of America Yes Yes … …
Uruguay Yes Yes Sale is banned Sale is banned
Venezuela (Bolivarian Republic of) No Yes Sale is banned Sale is banned
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Table 2.2.3 
South-East Asia
Monitoring and taxation  
of ENDS/ENNDS 
*  ENNDS are taxed the same as ENDS
… Data not available
1 Data refer to ENNDS.
DATA ON PREVALENCE OF ENDS USE ARE AVAILABLE  
FROM NATIONAL SURVEYS
EXCISE TAX IS APPLIED ON ENDS/ENNDS E-LIQUIDS
 
COUNTRY
POPULATION-BASED SURVEYS  
OF ADULTS
SCHOOL-BASED SURVEYS  
OF ADOLESCENTS
CLOSED SYSTEMS OPEN SYSTEMS
Bangladesh No No … …
Bhutan No No … …
Democratic People's Republic of Korea No No Sale is banned Sale is banned
India No No Sale is banned Sale is banned
Indonesia Yes No Yes No1
Maldives No No … …
Myanmar No No … …
Nepal Yes No … …
Sri Lanka No No Sale is banned Sale is banned
Thailand No Yes Sale is banned Sale is banned
Timor-Leste No No Sale is banned Sale is banned
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DATA ON PREVALENCE OF ENDS USE ARE AVAILABLE  
FROM NATIONAL SURVEYS
EXCISE TAX IS APPLIED ON ENDS/ENNDS E-LIQUIDS
 
COUNTRY
POPULATION-BASED SURVEYS  
OF ADULTS
SCHOOL-BASED SURVEYS  
OF ADOLESCENTS
CLOSED SYSTEMS OPEN SYSTEMS
Bangladesh No No … …
Bhutan No No … …
Democratic People's Republic of Korea No No Sale is banned Sale is banned
India No No Sale is banned Sale is banned
Indonesia Yes No Yes No1
Maldives No No … …
Myanmar No No … …
Nepal Yes No … …
Sri Lanka No No Sale is banned Sale is banned
Thailand No Yes Sale is banned Sale is banned
Timor-Leste No No Sale is banned Sale is banned
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Table 2.2.4 
Europe
Monitoring and taxation  
of ENDS/ENNDS 
*  ENNDS are taxed the same as ENDS
… Data not available
DATA ON PREVALENCE OF ENDS USE ARE AVAILABLE  
FROM NATIONAL SURVEYS
EXCISE TAX IS APPLIED ON ENDS/ENNDS E-LIQUIDS
 
COUNTRY
POPULATION-BASED SURVEYS  
OF ADULTS
SCHOOL-BASED SURVEYS  
OF ADOLESCENTS
CLOSED SYSTEMS OPEN SYSTEMS
Albania No Yes … Yes
Andorra No No … …
Armenia No No No No
Austria Yes Yes No No
Azerbaijan No No Yes* Yes*
Belarus No No No No
Belgium No No No No
Bosnia and Herzegovina No No No No
Bulgaria Yes Yes No No
Croatia No Yes No No
Cyprus Yes Yes … Yes*
Czechia Yes Yes No No
Denmark Yes Yes No No
Estonia Yes Yes Yes* Yes*
Finland Yes Yes … Yes*
France Yes Yes No No
Georgia No Yes Yes* Yes*
Germany Yes Yes No No
Greece Yes Yes Yes* Yes*
Hungary Yes Yes Yes* …
Iceland Yes Yes No No
Ireland Yes Yes No No
Israel No No No No
Italy Yes Yes Yes Yes
Kazakhstan Yes Yes Yes Yes
Kyrgyzstan No Yes Yes Yes
Latvia Yes Yes … Yes*
Lithuania Yes Yes Yes* Yes*
Luxembourg Yes No No No
Malta Yes Yes No No
Monaco No Yes … …
Montenegro No Yes … Yes*
Netherlands Yes Yes No No
North Macedonia No Yes … Yes*
Norway No Yes … …
Poland Yes Yes No No
Portugal No Yes Yes Yes
Republic of Moldova No No No No
Romania Yes Yes Yes Yes
Russian Federation Yes Yes Yes Yes
San Marino No Yes … …
Serbia Yes Yes Yes* Yes*
Slovakia No Yes … No
Slovenia Yes Yes … Yes
Spain Yes Yes No No
Sweden Yes Yes Yes Yes
Switzerland Yes Yes … …
Tajikistan No No … …
Turkey No No … …
Turkmenistan No No Sale is banned Sale is banned
Ukraine Yes Yes No No
United Kingdom of Great Britain and Northern Ireland No No No No
Uzbekistan No No No No
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DATA ON PREVALENCE OF ENDS USE ARE AVAILABLE  
FROM NATIONAL SURVEYS
EXCISE TAX IS APPLIED ON ENDS/ENNDS E-LIQUIDS
 
COUNTRY
POPULATION-BASED SURVEYS  
OF ADULTS
SCHOOL-BASED SURVEYS  
OF ADOLESCENTS
CLOSED SYSTEMS OPEN SYSTEMS
Albania No Yes … Yes
Andorra No No … …
Armenia No No No No
Austria Yes Yes No No
Azerbaijan No No Yes* Yes*
Belarus No No No No
Belgium No No No No
Bosnia and Herzegovina No No No No
Bulgaria Yes Yes No No
Croatia No Yes No No
Cyprus Yes Yes … Yes*
Czechia Yes Yes No No
Denmark Yes Yes No No
Estonia Yes Yes Yes* Yes*
Finland Yes Yes … Yes*
France Yes Yes No No
Georgia No Yes Yes* Yes*
Germany Yes Yes No No
Greece Yes Yes Yes* Yes*
Hungary Yes Yes Yes* …
Iceland Yes Yes No No
Ireland Yes Yes No No
Israel No No No No
Italy Yes Yes Yes Yes
Kazakhstan Yes Yes Yes Yes
Kyrgyzstan No Yes Yes Yes
Latvia Yes Yes … Yes*
Lithuania Yes Yes Yes* Yes*
Luxembourg Yes No No No
Malta Yes Yes No No
Monaco No Yes … …
Montenegro No Yes … Yes*
Netherlands Yes Yes No No
North Macedonia No Yes … Yes*
Norway No Yes … …
Poland Yes Yes No No
Portugal No Yes Yes Yes
Republic of Moldova No No No No
Romania Yes Yes Yes Yes
Russian Federation Yes Yes Yes Yes
San Marino No Yes … …
Serbia Yes Yes Yes* Yes*
Slovakia No Yes … No
Slovenia Yes Yes … Yes
Spain Yes Yes No No
Sweden Yes Yes Yes Yes
Switzerland Yes Yes … …
Tajikistan No No … …
Turkey No No … …
Turkmenistan No No Sale is banned Sale is banned
Ukraine Yes Yes No No
United Kingdom of Great Britain and Northern Ireland No No No No
Uzbekistan No No No No




Monitoring and taxation  
of ENDS/ENNDS 
*  ENNDS are taxed the same as ENDS
… Data not available
< “occupied Palestinian territory” should be understood to refer  
 to the “occupied Palestinian territory, including east Jerusalem”
1 Estimates made are for e-shisha
2 Jordan has both a ban on sale of ENDS and an excise
3 Data refer to ENNDS
DATA ON PREVALENCE OF ENDS USE ARE AVAILABLE  
FROM NATIONAL SURVEYS
EXCISE TAX IS APPLIED ON ENDS/ENNDS E-LIQUIDS
 
COUNTRY OR TERRITORY
POPULATION-BASED SURVEYS  
OF ADULTS
SCHOOL-BASED SURVEYS  
OF ADOLESCENTS
CLOSED SYSTEMS OPEN SYSTEMS
Afghanistan No No … …
Bahrain No No Yes1 …
Djibouti No No … …
Egypt No No Sale is banned Sale is banned
Iran (Islamic Republic of) No No Sale is banned Sale is banned
Iraq No Yes Sale is banned Sale is banned
Jordan No No … Yes2
Kuwait No No Sale is banned Sale is banned
Lebanon No No Sale is banned Sale is banned
Libya No No … …
Morocco No No … Yes3
occupied Palestinian territory < No No Sale is banned Sale is banned
Oman No No Sale is banned Sale is banned
Pakistan No No Yes …
Qatar Yes Yes Sale is banned Sale is banned
Saudi Arabia No No … …
Somalia No No … …
Sudan No No … …
Syrian Arab Republic No No Sale is banned Sale is banned
Tunisia No No … …
United Arab Emirates Yes No Yes* …
Yemen No Yes … Yes
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DATA ON PREVALENCE OF ENDS USE ARE AVAILABLE  
FROM NATIONAL SURVEYS
EXCISE TAX IS APPLIED ON ENDS/ENNDS E-LIQUIDS
 
COUNTRY OR TERRITORY
POPULATION-BASED SURVEYS  
OF ADULTS
SCHOOL-BASED SURVEYS  
OF ADOLESCENTS
CLOSED SYSTEMS OPEN SYSTEMS
Afghanistan No No … …
Bahrain No No Yes1 …
Djibouti No No … …
Egypt No No Sale is banned Sale is banned
Iran (Islamic Republic of) No No Sale is banned Sale is banned
Iraq No Yes Sale is banned Sale is banned
Jordan No No … Yes2
Kuwait No No Sale is banned Sale is banned
Lebanon No No Sale is banned Sale is banned
Libya No No … …
Morocco No No … Yes3
occupied Palestinian territory < No No Sale is banned Sale is banned
Oman No No Sale is banned Sale is banned
Pakistan No No Yes …
Qatar Yes Yes Sale is banned Sale is banned
Saudi Arabia No No … …
Somalia No No … …
Sudan No No … …
Syrian Arab Republic No No Sale is banned Sale is banned
Tunisia No No … …
United Arab Emirates Yes No Yes* …
Yemen No Yes … Yes
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Table 2.2.6 
Western Pacific
Monitoring and taxation  
of ENDS/ENNDS 
*  ENNDS are taxed the same as ENDS
… Data not available
DATA ON PREVALENCE OF ENDS USE ARE AVAILABLE  
FROM NATIONAL SURVEYS
EXCISE TAX IS APPLIED ON ENDS/ENNDS E-LIQUIDS
 
COUNTRY
POPULATION-BASED SURVEYS  
OF ADULTS
SCHOOL-BASED SURVEYS  
OF ADOLESCENTS
CLOSED SYSTEMS OPEN SYSTEMS
Australia Yes Yes … …
Brunei Darussalam Yes Yes Sale is banned Sale is banned
Cambodia No No Sale is banned Sale is banned
China Yes Yes … …
Cook Islands No No … …
Fiji No Yes … …
Japan No Yes … …
Kiribati No Yes … …
Lao People's Democratic Republic No Yes … No
Malaysia Yes Yes Sale is banned Sale is banned
Marshall Islands Yes Yes … …
Micronesia (Federated States of) No No … …
Mongolia No Yes … …
Nauru No No … …
New Zealand Yes Yes … …
Niue No Yes … …
Palau No No … …
Papua New Guinea No Yes … …
Philippines Yes No … …
Republic of Korea Yes Yes Yes …
Samoa No No … …
Singapore No No Sale is banned Sale is banned
Solomon Islands No No … …
Tonga No No No No
Tuvalu No No … …
Vanuatu No Yes … …
Viet Nam Yes Yes … …
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DATA ON PREVALENCE OF ENDS USE ARE AVAILABLE  
FROM NATIONAL SURVEYS
EXCISE TAX IS APPLIED ON ENDS/ENNDS E-LIQUIDS
 
COUNTRY
POPULATION-BASED SURVEYS  
OF ADULTS
SCHOOL-BASED SURVEYS  
OF ADOLESCENTS
CLOSED SYSTEMS OPEN SYSTEMS
Australia Yes Yes … …
Brunei Darussalam Yes Yes Sale is banned Sale is banned
Cambodia No No Sale is banned Sale is banned
China Yes Yes … …
Cook Islands No No … …
Fiji No Yes … …
Japan No Yes … …
Kiribati No Yes … …
Lao People's Democratic Republic No Yes … No
Malaysia Yes Yes Sale is banned Sale is banned
Marshall Islands Yes Yes … …
Micronesia (Federated States of) No No … …
Mongolia No Yes … …
Nauru No No … …
New Zealand Yes Yes … …
Niue No Yes … …
Palau No No … …
Papua New Guinea No Yes … …
Philippines Yes No … …
Republic of Korea Yes Yes Yes …
Samoa No No … …
Singapore No No Sale is banned Sale is banned
Solomon Islands No No … …
Tonga No No No No
Tuvalu No No … …
Vanuatu No Yes … …
Viet Nam Yes Yes … …
178 | WORLD HEALTH ORGANIZATION
Annex III provides information 
on the year in which respective 
countries attained the highest level of 
achievement for five of the MPOWER 
measures. Data are shown separately 
for each WHO region.
For Monitoring tobacco use the earliest 
year assessed is 2007. However, it is 
possible that while 2007 is reported 
as the year of highest achievement for 
some countries, they actually may have 
reached this level earlier.
Years of highest level achievement 
of the MPOWER measure Raise taxes 
on tobacco are not included in this 
Annex. The share of taxes in product 
price depends both on tax policy and 
on demand and supply factors that 
affect manufacturing and retail prices. 
Countries with tax increases might have 
seen the share of tax remain unchanged 
or even decline if the non-tax share of 
price rose at the same, or a higher rate, 
complicating the interpretation of the 
year of highest level of achievement. 
See Technical Note III for details on the 
calculation of tax shares.
ANNEX III
YEAR OF HIGHEST LEVEL OF 
ACHIEVEMENT IN SELECTED 
TOBACCO CONTROL MEASURES
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Table 3.1.1 
Africa
Year of highest level of 
achievement in selected 
tobacco control measures 
Note: an empty cell indicates that the population  
is not covered by the measure at the highest level  
of achievement.
* or earlier year
COUNTRY MONITOR TOBACCO USE AND 
PREVENTION POLICIES
PROTECT PEOPLE FROM 
TOBACCO SMOKE
OFFER HELP TO QUIT  
TOBACCO USE
WARN ABOUT THE  
DANGERS OF TOBACCO




















Ethiopia 2019 2019 2019
Gabon

















Sao Tome and Principe
Senegal 2016 2016






United Republic of Tanzania
Zambia
Zimbabwe
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COUNTRY MONITOR TOBACCO USE AND 
PREVENTION POLICIES
PROTECT PEOPLE FROM 
TOBACCO SMOKE
OFFER HELP TO QUIT  
TOBACCO USE
WARN ABOUT THE  
DANGERS OF TOBACCO




















Ethiopia 2019 2019 2019
Gabon

















Sao Tome and Principe
Senegal 2016 2016






United Republic of Tanzania
Zambia
Zimbabwe
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Table 3.1.2 
Americas
Year of highest level of 
achievement in selected 
tobacco control measures 
Note: an empty cell indicates that the population  
is not covered by the measure at the highest level  
of achievement.
8 Provision adopted but not implemented by  
31 December 2020
* or earlier year
COUNTRY MONITOR TOBACCO USE AND 
PREVENTION POLICIES
PROTECT PEOPLE FROM 
TOBACCO SMOKE
OFFER HELP TO QUIT  
TOBACCO USE
WARN ABOUT THE  
DANGERS OF TOBACCO
ENFORCE BANS ON TOBACCO 
ADVERTISING, PROMOTION 
AND SPONSORSHIP





Bolivia (Plurinational State of) 2020 2009
Brazil  2015 2011 2002 2003 2011
Canada 2007* 2007 2008 2011
Chile 2007* 2013 2006
Colombia 2008 2009




Ecuador  2016 2011 2012
El Salvador 2015 2011
Grenada
Guatemala 2008
Guyana 2017 2018 2017
Haiti
Honduras 2010 2017
Jamaica 2013 2016 2013
Mexico 2014 2009
Nicaragua
Panama 2008 2005 2008
Paraguay 2020
Peru  2010 2010 2011
Saint Kitts and Nevis
Saint Lucia 2020 2017
Saint Vincent and the Grenadines
Suriname 2013 2016 2013
Trinidad and Tobago 2009 2013
United States of America 2007* 2008  2020  8	
Uruguay  2008 2005 2005 2014
Venezuela (Bolivarian Republic of) 2011 2004 2019
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COUNTRY MONITOR TOBACCO USE AND 
PREVENTION POLICIES
PROTECT PEOPLE FROM 
TOBACCO SMOKE
OFFER HELP TO QUIT  
TOBACCO USE
WARN ABOUT THE  
DANGERS OF TOBACCO
ENFORCE BANS ON TOBACCO 
ADVERTISING, PROMOTION 
AND SPONSORSHIP





Bolivia (Plurinational State of) 2020 2009
Brazil  2015 2011 2002 2003 2011
Canada 2007* 2007 2008 2011
Chile 2007* 2013 2006
Colombia 2008 2009




Ecuador  2016 2011 2012
El Salvador 2015 2011
Grenada
Guatemala 2008
Guyana 2017 2018 2017
Haiti
Honduras 2010 2017
Jamaica 2013 2016 2013
Mexico 2014 2009
Nicaragua
Panama 2008 2005 2008
Paraguay 2020
Peru  2010 2010 2011
Saint Kitts and Nevis
Saint Lucia 2020 2017
Saint Vincent and the Grenadines
Suriname 2013 2016 2013
Trinidad and Tobago 2009 2013
United States of America 2007* 2008  2020  8	
Uruguay  2008 2005 2005 2014
Venezuela (Bolivarian Republic of) 2011 2004 2019
184 | WORLD HEALTH ORGANIZATION
Table 3.1.3 
South-East Asia
Year of highest level of 
achievement in selected 
tobacco control measures 
Note: an empty cell indicates that the population  
is not covered by the measure at the highest level  
of achievement.
* or earlier year
COUNTRY MONITOR TOBACCO USE AND 
PREVENTION POLICIES
PROTECT PEOPLE FROM 
TOBACCO SMOKE
OFFER HELP TO QUIT  
TOBACCO USE
WARN ABOUT THE  
DANGERS OF TOBACCO










Nepal 2011 2011 2014
Sri Lanka 2012
Thailand 2008 2010 2005
Timor-Leste 2018
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COUNTRY MONITOR TOBACCO USE AND 
PREVENTION POLICIES
PROTECT PEOPLE FROM 
TOBACCO SMOKE
OFFER HELP TO QUIT  
TOBACCO USE
WARN ABOUT THE  
DANGERS OF TOBACCO










Nepal 2011 2011 2014
Sri Lanka 2012
Thailand 2008 2010 2005
Timor-Leste 2018
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Table 3.1.4 
Europe
Year of highest level of 
achievement in selected 
tobacco control measures 
Note: an empty cell indicates that the population  
is not covered by the measure at the highest level  
of achievement.
* or earlier year
COUNTRY MONITOR TOBACCO USE AND 
PREVENTION POLICIES
PROTECT PEOPLE FROM 
TOBACCO SMOKE
OFFER HELP TO QUIT  
TOBACCO USE
WARN ABOUT THE  
DANGERS OF TOBACCO






Austria 2007* 2020 2016




Bulgaria  2008 2012 2016
Croatia  2012 2017
Cyprus  2016 2017
Czechia  2010 2018 2016
Denmark 2007* 2011 2016
Estonia 2007* 2016
Finland 2007* 2016 2016
France 2007* 2016
Georgia  2014 2018
Germany 2007* 2016
Greece 2007* 2010 2016
Hungary  2012 2016
Iceland 2007* 2006
Ireland 2007* 2004 2003 2016
Israel
Italy 2007* 2016
Kazakhstan  2010 2014
Kyrgyzstan 2014
Latvia 2007* 2016
Lithuania  2008 2016
Luxembourg  2010 2016 2017
Malta  2008 2010 2016
Monaco
Montenegro  2016 2019





Republic of Moldova  2013 2015 2015
Romania  2010 2015 2016
Russian Federation  2012 2013 2014 2013
San Marino
Serbia  2012 
Slovakia  2008 2018 2016
Slovenia  2008 2017 2017
Spain 2007* 2010 2017 2010
Sweden 2007* 2018 2016
Switzerland 2007*
Tajikistan  2020 2018 2018
Turkey 2007* 2008 2010 2012 2012
Turkmenistan 2000 2014
Ukraine 2007* 2009
United Kingdom of Great Britain and Northern Ireland 2007* 2006 2016
Uzbekistan
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COUNTRY MONITOR TOBACCO USE AND 
PREVENTION POLICIES
PROTECT PEOPLE FROM 
TOBACCO SMOKE
OFFER HELP TO QUIT  
TOBACCO USE
WARN ABOUT THE  
DANGERS OF TOBACCO






Austria 2007* 2020 2016




Bulgaria  2008 2012 2016
Croatia  2012 2017
Cyprus  2016 2017
Czechia  2010 2018 2016
Denmark 2007* 2011 2016
Estonia 2007* 2016
Finland 2007* 2016 2016
France 2007* 2016
Georgia  2014 2018
Germany 2007* 2016
Greece 2007* 2010 2016
Hungary  2012 2016
Iceland 2007* 2006
Ireland 2007* 2004 2003 2016
Israel
Italy 2007* 2016
Kazakhstan  2010 2014
Kyrgyzstan 2014
Latvia 2007* 2016
Lithuania  2008 2016
Luxembourg  2010 2016 2017
Malta  2008 2010 2016
Monaco
Montenegro  2016 2019





Republic of Moldova  2013 2015 2015
Romania  2010 2015 2016
Russian Federation  2012 2013 2014 2013
San Marino
Serbia  2012 
Slovakia  2008 2018 2016
Slovenia  2008 2017 2017
Spain 2007* 2010 2017 2010
Sweden 2007* 2018 2016
Switzerland 2007*
Tajikistan  2020 2018 2018
Turkey 2007* 2008 2010 2012 2012
Turkmenistan 2000 2014
Ukraine 2007* 2009
United Kingdom of Great Britain and Northern Ireland 2007* 2006 2016
Uzbekistan




Year of highest level of 
achievement in selected 
tobacco control measures 
Note: an empty cell indicates that the population  
is not covered by the measure at the highest level  
of achievement.
* or earlier year
< “occupied Palestinian territory” should be understood to refer  
 to the “occupied Palestinian territory, including east Jerusalem”
COUNTRY OR TERRITORY MONITOR TOBACCO USE AND 
PREVENTION POLICIES
PROTECT PEOPLE FROM 
TOBACCO SMOKE
OFFER HELP TO QUIT  
TOBACCO USE
WARN ABOUT THE  
DANGERS OF TOBACCO







Iran (Islamic Republic of) 2008 2007 2008 2007
Iraq 2020














United Arab Emirates 2008 2013
Yemen 2013
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Iran (Islamic Republic of) 2008 2007 2008 2007
Iraq 2020














United Arab Emirates 2008 2013
Yemen 2013
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Table 3.1.6 
Western Pacific
Year of highest level of 
achievement in selected 
tobacco control measures 
Note: an empty cell indicates that the population  
is not covered by the measure at the highest level  
of achievement.
* or earlier year
COUNTRY MONITOR TOBACCO USE AND 
PREVENTION POLICIES
PROTECT PEOPLE FROM 
TOBACCO SMOKE
OFFER HELP TO QUIT  
TOBACCO USE
WARN ABOUT THE  
DANGERS OF TOBACCO
ENFORCE BANS ON TOBACCO 
ADVERTISING, PROMOTION 
AND SPONSORSHIP
Australia 2007* 2005 2004
Brunei Darussalam  2016 2012 2007
Cambodia 2016 2016
China  2019 




Lao People's Democratic Republic  2015 2016 2016
Malaysia  2012 2008
Marshall Islands 2006
Micronesia (Federated States of)
Mongolia  2009 2012 2012
Nauru 2009
New Zealand 2007* 2003 2000 2007
Niue 2018 2018
Palau  2012 
Papua New Guinea 2012
Philippines 2007* 2020 2014
Republic of Korea 2007* 2006
Samoa 2013





Viet Nam  2014 2013
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ENFORCE BANS ON TOBACCO 
ADVERTISING, PROMOTION 
AND SPONSORSHIP
Australia 2007* 2005 2004
Brunei Darussalam  2016 2012 2007
Cambodia 2016 2016
China  2019 




Lao People's Democratic Republic  2015 2016 2016
Malaysia  2012 2008
Marshall Islands 2006
Micronesia (Federated States of)
Mongolia  2009 2012 2012
Nauru 2009
New Zealand 2007* 2003 2000 2007
Niue 2018 2018
Palau  2012 
Papua New Guinea 2012
Philippines 2007* 2020 2014
Republic of Korea 2007* 2006
Samoa 2013





Viet Nam  2014 2013
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Annex IV provides information on 
whether the populations of the world’s 
100 biggest cities are covered by 
selected tobacco control measures at 
the highest level of achievement. 
Cities are listed alphabetically. There 
are many ways to define geographically 
and measure the size of “a city”. For 
the purposes of this report, we focused 
on the jurisdictional boundaries of 
cities, since subnational laws will apply 
to populations within jurisdictions. 
Where a large “city” includes several 
jurisdictions or parts of jurisdictions, 
it is possible that not everyone in the 
entire “city” is covered by the same 
laws. We therefore use the list of cities 
and their populations published in 
the United Nations Statistics Division 
Demographic Yearbook, since these 
are defined jurisdictionally. Please refer 
to Table 8 at https://unstats.un.org/
unsd/demographic-social/products/dyb/
dyb_2018/ for the source data.
A number of countries do not appear in 
Table 8 of the Demographic Yearbook 
because they did not report data. 
Countries missing from the list because 
they did not report data, but large 
enough to potentially qualify for the 
100 biggest cities list are: Angola, 
Chad, Democratic Republic of the 
Congo, Nigeria, Sudan and Viet Nam. 
Refer to Technical Note I for definitions 
of highest level of achievement.
ANNEX IV
Highest level of achievement in selected 
tobacco control measures in the 100 
biggest cities in the world
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Table 4.1 
Highest level of 
achievement in selected 
tobacco control measures 
in the 100 biggest cities*  
in the world 
*  Only cities which appear among the top 100 cities sorted by 
population size, according to the United Nations Statistics Division 
Demographic Yearbook 2018 (available at: https://unstats.un.org/
unsd/demographic/products/dyb/dyb2018/Table08.xls).
N
City’s population covered by national 
legislation or policy at the highest level of 
achievement
S
City’s population covered by state-level 
legislation or policy at the highest level of 
achievement
C
City’s population covered by city-level 
legislation or policy at the highest level of 
achievement
Notes: An empty cell indicates that the population in 
the respective city is not covered by the measure at 
the highest level of achievement. Refer to Technical 
Note I for definitions of highest level of achievement 
of the respective measure. 
8 Privision adopted but not implemented by 31 
December 2020
…  Data not available
CITY POPULATION COVERAGE AT THE HIGHEST LEVEL OF ACHIEVEMENT COVERAGE AT THE HIGHEST LEVEL OF ACHIEVEMENT COUNTRY
PROTECT PEOPLE FROM 
TOBACCO SMOKE
OFFER HELP TO QUIT 
TOBACCO USE
WARN ABOUT THE 
DANGERS OF TOBACCO




RAISE TAXES ON 
TOBACCO
Abidjan 4 395 243 N Côte d'Ivoire
Adana 2 216 475 N N N N N Turkey
Addis Ababa 4 215 965 N N N Ethiopia
Ahmedabad 5 633 927 N N India
Aleppo 4 450 000 Syrian Arab Republic
Alexandria 5 163 750 N N N Egypt
Algiers 2 712 944 N N Algeria
Amman 3 728 346 N N Jordan
Ankara 5 445 026 N N N N N Turkey
Antalya 2 364 396 N N N N N Turkey
Baku 2 254 175 N Azerbaijan
Bandung 2 525 220 C Indonesia
Bangalore 8 495 492 N N India
Bangkok 8 305 218 N N N Thailand
Beijing 18 796 000 C China
Belo Horizonte 2 513 451 N N N N N Brazil
Berlin 3 613 495 N Germany
Bogor 5 162 044 Indonesia
Bogotá 8 181 047 N N Colombia
Brasília 2 977 216 N N N N N Brazil
Buenos Aires 13 879 707 N N N Argentina
Bursa 2 936 803 N N N N N Turkey
Busan 3 428 923 N Republic of Korea
Cairo 9 539 673 N N N Egypt
Cali 2 445 405 N N Colombia
Casablanca 3 352 399 N Morocco
Chennai 4 646 732 N N India
Chicago 2 704 958 N   N 8	 United States of America
Chittagong 2 591 681 N Bangladesh
Daegu 2 465 268 N Republic of Korea
Damasus Rural (Rif Dimashq) 2 529 000 Syrian Arab Republic
Dar es Salaam 5 147 070 United Republic of Tanzania
Delhi 11 034 555 N N India
Dhaka 8 906 035 N Bangladesh
Douala 2 948 464 N Cameroon
Faisalabad 3 203 846 N N Pakistan
Fortaleza 2 609 716 N N N N N Brazil
Guadalajara 5 060 750 N N Mexico
Guayaquil 2 581 884 N N Ecuador
Havana 2 130 517 . . . . . . . . . . . . Cuba
Hong Kong SAR 7 451 000 C C C China, Hong Kong SAR
Houston 2 303 482 N   N 8	 United States of America
Hyderabad 6 993 262 S N N India
Incheon 2 923 047 N Republic of Korea
Istanbul 15 029 231 N N N N N Turkey
Izmir 4 279 677 N N N N N Turkey
Jaipur 3 046 163 N N India
Jakarta 10 428 001 C Indonesia
Jiddah 3 430 697 N N N Saudi Arabia
Kabul 3 817 241 N N Afghanistan
Kanpur 2 768 057 N N India
Karachi 14 910 352 N N Pakistan
Kiev 2 893 215 N Ukraine
Kolkata 4 496 694 N N India
Konya 2 180 149 N N N N N Turkey
Lahore 11 126 285 N N Pakistan
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RAISE TAXES ON 
TOBACCO
Abidjan 4 395 243 N Côte d'Ivoire
Adana 2 216 475 N N N N N Turkey
Addis Ababa 4 215 965 N N N Ethiopia
Ahmedabad 5 633 927 N N India
Aleppo 4 450 000 Syrian Arab Republic
Alexandria 5 163 750 N N N Egypt
Algiers 2 712 944 N N Algeria
Amman 3 728 346 N N Jordan
Ankara 5 445 026 N N N N N Turkey
Antalya 2 364 396 N N N N N Turkey
Baku 2 254 175 N Azerbaijan
Bandung 2 525 220 C Indonesia
Bangalore 8 495 492 N N India
Bangkok 8 305 218 N N N Thailand
Beijing 18 796 000 C China
Belo Horizonte 2 513 451 N N N N N Brazil
Berlin 3 613 495 N Germany
Bogor 5 162 044 Indonesia
Bogotá 8 181 047 N N Colombia
Brasília 2 977 216 N N N N N Brazil
Buenos Aires 13 879 707 N N N Argentina
Bursa 2 936 803 N N N N N Turkey
Busan 3 428 923 N Republic of Korea
Cairo 9 539 673 N N N Egypt
Cali 2 445 405 N N Colombia
Casablanca 3 352 399 N Morocco
Chennai 4 646 732 N N India
Chicago 2 704 958 N   N 8	 United States of America
Chittagong 2 591 681 N Bangladesh
Daegu 2 465 268 N Republic of Korea
Damasus Rural (Rif Dimashq) 2 529 000 Syrian Arab Republic
Dar es Salaam 5 147 070 United Republic of Tanzania
Delhi 11 034 555 N N India
Dhaka 8 906 035 N Bangladesh
Douala 2 948 464 N Cameroon
Faisalabad 3 203 846 N N Pakistan
Fortaleza 2 609 716 N N N N N Brazil
Guadalajara 5 060 750 N N Mexico
Guayaquil 2 581 884 N N Ecuador
Havana 2 130 517 . . . . . . . . . . . . Cuba
Hong Kong SAR 7 451 000 C C C China, Hong Kong SAR
Houston 2 303 482 N   N 8	 United States of America
Hyderabad 6 993 262 S N N India
Incheon 2 923 047 N Republic of Korea
Istanbul 15 029 231 N N N N N Turkey
Izmir 4 279 677 N N N N N Turkey
Jaipur 3 046 163 N N India
Jakarta 10 428 001 C Indonesia
Jiddah 3 430 697 N N N Saudi Arabia
Kabul 3 817 241 N N Afghanistan
Kanpur 2 768 057 N N India
Karachi 14 910 352 N N Pakistan
Kiev 2 893 215 N Ukraine
Kolkata 4 496 694 N N India
Konya 2 180 149 N N N N N Turkey
Lahore 11 126 285 N N Pakistan
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CITY POPULATION COVERAGE AT THE HIGHEST LEVEL OF ACHIEVEMENT COVERAGE AT THE HIGHEST LEVEL OF ACHIEVEMENT COUNTRY
PROTECT PEOPLE FROM 
TOBACCO SMOKE
OFFER HELP TO QUIT 
TOBACCO USE
WARN ABOUT THE 
DANGERS OF TOBACCO




RAISE TAXES ON 
TOBACCO
Lima 10 350 721 N N Peru
London 8 135 667 S C N N United Kingdom of Great Britain and Northern Ireland
Los Angeles 3 976 322 S N   N 8	 United States of America
Luanda 2 487 444 N Angola
Lucknow 2 817 105 N N India
Madrid 3 203 157 N N N N Spain
Mashhad 3 001 184 N N N Iran (Islamic Republic of)
Medan 2 269 588 C Indonesia
Medellín 2 529 403 N N Colombia
Mexico City 21 800 320 S N N Mexico
Monterrey 4 834 971 S N N Mexico
Moscow 11 918 057 N N N Russian Federation
Mumbai 12 442 373 N N India
Nagoya 2 295 638 Japan
Nagpur 2 405 665 N N India
Nairobi 3 109 861 N Kenya
New York 8 537 673 N   N 8	 United States of America
Osaka 2 691 185 Japan
Paris 2 206 488 N N France
Puebla-Tlaxcala 3 046 766 N N Mexico
Pune 3 124 458 N N India
Pyongyang 2 581 076 Democratic People's Republic of Korea
Quezon City 2 936 116 N N Philippines
Rawalpindi 2 098 231 N N Pakistan
Rio De Janeiro 6 498 837 N N N N N Brazil
Riyadh 5 188 286 N N N Saudi Arabia
Rome 2 873 147 N N Italy
Saint Petersburg 4 990 602 N N N Russian Federation
Salvador 2 938 092 N N N N N Brazil
Santiago 5 613 962 N N N Chile
São Paulo 12 038 175 N N N N N Brazil
Seoul 9 776 305 N Republic of Korea
Singapore 5 638 676 N N Singapore
Surabaya 2 885 245 Indonesia
Surat 4 501 610 N N India
Tangerang 3 050 758 Indonesia
Tashkent 2 464 933 Uzbekistan
Tehran 8 693 706 N N N Iran (Islamic Republic of)
Tokyo 9 272 740 Japan
Toluca 2 386 157 S N N Mexico
Toronto 2 956 024 S N N Canada
Yangon 5 211 431 Myanmar
Yaounde 2 873 567 N Cameroon
Yokohama 3 724 844 Japan
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RAISE TAXES ON 
TOBACCO
Lima 10 350 721 N N Peru
London 8 135 667 S C N N United Kingdom of Great Britain and Northern Ireland
Los Angeles 3 976 322 S N   N 8	 United States of America
Luanda 2 487 444 N Angola
Lucknow 2 817 105 N N India
Madrid 3 203 157 N N N N Spain
Mashhad 3 001 184 N N N Iran (Islamic Republic of)
Medan 2 269 588 C Indonesia
Medellín 2 529 403 N N Colombia
Mexico City 21 800 320 S N N Mexico
Monterrey 4 834 971 S N N Mexico
Moscow 11 918 057 N N N Russian Federation
Mumbai 12 442 373 N N India
Nagoya 2 295 638 Japan
Nagpur 2 405 665 N N India
Nairobi 3 109 861 N Kenya
New York 8 537 673 N   N 8	 United States of America
Osaka 2 691 185 Japan
Paris 2 206 488 N N France
Puebla-Tlaxcala 3 046 766 N N Mexico
Pune 3 124 458 N N India
Pyongyang 2 581 076 Democratic People's Republic of Korea
Quezon City 2 936 116 N N Philippines
Rawalpindi 2 098 231 N N Pakistan
Rio De Janeiro 6 498 837 N N N N N Brazil
Riyadh 5 188 286 N N N Saudi Arabia
Rome 2 873 147 N N Italy
Saint Petersburg 4 990 602 N N N Russian Federation
Salvador 2 938 092 N N N N N Brazil
Santiago 5 613 962 N N N Chile
São Paulo 12 038 175 N N N N N Brazil
Seoul 9 776 305 N Republic of Korea
Singapore 5 638 676 N N Singapore
Surabaya 2 885 245 Indonesia
Surat 4 501 610 N N India
Tangerang 3 050 758 Indonesia
Tashkent 2 464 933 Uzbekistan
Tehran 8 693 706 N N N Iran (Islamic Republic of)
Tokyo 9 272 740 Japan
Toluca 2 386 157 S N N Mexico
Toronto 2 956 024 S N N Canada
Yangon 5 211 431 Myanmar
Yaounde 2 873 567 N Cameroon
Yokohama 3 724 844 Japan
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Annex V shows the status of the  
WHO Framework Convention on 
Tobacco Control (WHO FCTC) and  
of the Protocol to Eliminate Illicit  
Trade in Tobacco Products. 
Ratification is the international act 
by which countries that have already 
signed a convention formally state their 
consent to be bound by it. Accession 
is the international act by which 
countries that have not signed a treaty/
convention formally state their consent 
to be bound by it. Acceptance and 
approval are the legal equivalent to 
ratification. Signature of a convention 
indicates that a country is not legally 
bound by the treaty but is committed 
not to undermine its provisions.
The WHO FCTC entered into force on 
27 February 2005. The treaty remains 
open for ratification, acceptance, 
approval, formal confirmation and 
accession indefinitely for States and 
eligible regional economic integration 
organizations wishing to become 
Parties to it.
The Protocol to Eliminate Illicit Trade 
in Tobacco Products entered into force 
on 25 September 2018. It is subject 
to ratification, acceptance, approval 
or accession by States and to formal 
confirmation or accession by regional 
economic integration organizations 
that are Party to the WHO Framework 
Convention on Tobacco Control.
ANNEX V
STATUS OF THE WHO FRAMEWORK 
CONVENTION ON TOBACCO CONTROL 
AND OF THE PROTOCOL TO ELIMINATE 
ILLICIT TRADE IN TOBACCO PRODUCTS
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Table 5.1 
Status of the WHO 
Framework Convention  
on Tobacco Control as  
at 1 June 2021
*  Ratification is the international act by which countries that 
have already signed a treaty or convention formally state their 
consent to be bound by it.
a  Accession is the international act by which countries that have 
not signed a treaty/convention formally state their consent to 
be bound by it.
A  Acceptance is the international act, similar to ratification, by 
which countries that have already signed a treaty/convention 
formally state their consent to be bound by it.
AA  Approval is the international act, similar to ratification, by 
which countries that have already signed a treaty/convention 
formally state their consent to be bound by it.
c  Formal confirmation is the international act corresponding to 
ratification by a State, whereby an international organization 
(in the case of the WHO FCTC, competent regional economic 
integration organizations) formally state their consent to be 
bound by a treaty/convention.
d  Succession is the international act, however phrased or 
named, by which successor States formally state their consent 
to be bound by treaties/conventions originally entered.
COUNTRY DATE OF SIGNATURE DATE OF RATIFICATION* 
(OR LEGAL EQUIVALENT)
Afghanistan 29 Jun 2004 13 Aug 2010 
Albania 29 Jun 2004 26 Apr 2006 
Algeria 20 Jun 2003 30 Jun 2006 
Andorra 11 May 2020 a
Angola 29 Jun 2004 20 Sep 2007 
Antigua and Barbuda 28 Jun 2004 5 Jun 2006 
Argentina 25 Sep 2003 
Armenia 29 Nov 2004 a
Australia 5 Dec 2003 27 Oct 2004 
Austria 28 Aug 2003 15 Sep 2005 
Azerbaijan 1 Nov 2005 a
Bahamas 29 Jun 2004 3 Nov 2009 
Bahrain 20 Mar 2007 a
Bangladesh 16 Jun 2003 14 Jun 2004 
Barbados 28 Jun 2004 3 Nov 2005 
Belarus 17 Jun 2004 8 Sep 2005 
Belgium 22 Jan 2004 1 Nov 2005 
Belize 26 Sep 2003 15 Dec 2005 
Benin 18 Jun 2004 3 Nov 2005 
Bhutan 9 Dec 2003 23 Aug 2004 
Bolivia (Plurinational State of) 27 Feb 2004 15 Sep 2005 
Bosnia and Herzegovina 10 Jul 2009 a
Botswana 16 Jun 2003 31 Jan 2005 
Brazil 16 Jun 2003 3 Nov 2005 
Brunei Darussalam 3 Jun 2004 3 Jun 2004 
Bulgaria 22 Dec 2003 7 Nov 2005 
Burkina Faso 22 Dec 2003 31 Jul 2006 
Burundi 16 Jun 2003 22 Nov 2005 
Cabo Verde 17 Feb 2004 4 Oct 2005 
Cambodia 25 May 2004 15 Nov 2005 
Cameroon 13 May 2004 3 Feb 2006 
Canada 15 Jul 2003 26 Nov 2004 
Central African Republic 29 Dec 2003 7 Nov 2005 
Chad 22 Jun 2004 30 Jan 2006 
Chile 25 Sep 2003 13 Jun 2005 
China 10 Nov 2003 11 Oct 2005 
Colombia 10 Apr 2008 a
Comoros 27 Feb 2004 24 Jan 2006 
Congo 23 Mar 2004 6 Feb 2007 
Cook Islands 14 May 2004 14 May 2004 
Costa Rica 3 Jul 2003 21 Aug 2008 
Côte d'Ivoire 24 Jul 2003 13 Aug 2010 
Croatia 2 Jun 2004 14 Jul 2008 
Cuba 29 Jun 2004 
Cyprus 24 May 2004 26 Oct 2005 
Czechia 16 Jun 2003 1 Jun 2012 
Democratic People's Republic of Korea 17 Jun 2003 27 Apr 2005 
Democratic Republic of the Congo 28 Jun 2004 28 Oct 2005 
Denmark 16 Jun 2003 16 Dec 2004 
Djibouti 13 May 2004 31 Jul 2005 
Dominica 29 Jun 2004 24 Jul 2006 
Ecuador 22 Mar 2004 25 Jul 2006 
Egypt 17 Jun 2003 25 Feb 2005 
El Salvador 18 Mar 2004 21 Jul 2014 
Equatorial Guinea 17 Sep 2005 a
Estonia 8 Jun 2004 27 Jul 2005 
Eswatini 29 Jun 2004 13 Jan 2006 
Ethiopia 25 Feb 2004 25 Mar 2014 
Fiji 3 Oct 2003 3 Oct 2003 
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COUNTRY DATE OF SIGNATURE DATE OF RATIFICATION* 
(OR LEGAL EQUIVALENT)
Finland 16 Jun 2003 24 Jan 2005 
France 16 Jun 2003 19 Oct 2004 AA
Gabon 22 Aug 2003 20 Feb 2009 
Gambia 16 Jun 2003 18 Sep 2007 
Georgia 20 Feb 2004 14 Feb 2006 
Germany 24 Oct 2003 16 Dec 2004 
Ghana 20 Jun 2003 29 Nov 2004 
Greece 16 Jun 2003 27 Jan 2006 
Grenada 29 Jun 2004 14 Aug 2007 
Guatemala 25 Sep 2003 16 Nov 2005 
Guinea 1 Apr 2004 7 Nov 2007 
Guinea-Bissau 7 Nov 2008 a
Guyana 15 Sep 2005 a
Haiti 23 Jul 2003 
Honduras 18 Jun 2004 16 Feb 2005 
Hungary 16 Jun 2003 7 Apr 2004 
Iceland 16 Jun 2003 14 Jun 2004 
India 10 Sep 2003 5 Feb 2004 
Iran (Islamic Republic of) 16 Jun 2003 6 Nov 2005 
Iraq 29 Jun 2004 17 Mar 2008 
Ireland 16 Sep 2003 7 Nov 2005 
Israel 20 Jun 2003 24 Aug 2005 
Italy 16 Jun 2003 2 Jul 2008 
Jamaica 24 Sep 2003 7 Jul 2005 
Japan 9 Mar 2004 8 Jun 2004 A
Jordan 28 May 2004 19 Aug 2004 
Kazakhstan 21 Jun 2004 22 Jan 2007 
Kenya 25 Jun 2004 25 Jun 2004 
Kiribati 27 Apr 2004 15 Sep 2005 
Kuwait 16 Jun 2003 12 May 2006 
Kyrgyzstan 18 Feb 2004 25 May 2006 
Lao People's Democratic Republic 29 Jun 2004 6 Sep 2006 
Latvia 10 May 2004 10 Feb 2005 
Lebanon 4 Mar 2004 7 Dec 2005 
Lesotho 23 Jun 2004 14 Jan 2005 
Liberia 25 Jun 2004 15 Sep 2009 
Libya 18 Jun 2004 7 Jun 2005 
Lithuania 22 Sep 2003 16 Dec 2004 
Luxembourg 16 Jun 2003 30 Jun 2005 
Madagascar 24 Sep 2003 22 Sep 2004 
Malaysia 23 Sep 2003 16 Sep 2005 
Maldives 17 May 2004 20 May 2004 
Mali 23 Sep 2003 19 Oct 2005 
Malta 16 Jun 2003 24 Sep 2003 
Marshall Islands 16 Jun 2003 8 Dec 2004 
Mauritania 24 Jun 2004 28 Oct 2005 
Mauritius 17 Jun 2003 17 May 2004 
Mexico 12 Aug 2003 28 May 2004 
Micronesia (Federated States of) 28 Jun 2004 18 Mar 2005 
Mongolia 16 Jun 2003 27 Jan 2004 
Montenegro 23 Oct 2006 d
Morocco 16 Apr 2004 
Mozambique 18 Jun 2003 14 Jul 2017
Myanmar 23 Oct 2003 21 Apr 2004 
Namibia 29 Jan 2004 7 Nov 2005 
Nauru 29 Jun 2004 a
Nepal 3 Dec 2003 7 Nov 2006 
Netherlands 16 Jun 2003 27 Jan 2005 A
New Zealand 16 Jun 2003 27 Jan 2004 
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COUNTRY DATE OF SIGNATURE DATE OF RATIFICATION* 
(OR LEGAL EQUIVALENT)
Nicaragua 7 Jun 2004 9 Apr 2008 
Niger 28 Jun 2004 25 Aug 2005 
Nigeria 28 Jun 2004 20 Oct 2005 
Niue 18 Jun 2004 3 Jun 2005 
North Macedonia 30 Jun 2006 a
Norway 16 Jun 2003 16 Jun 2003 AA
Oman 9 Mar 2005 a
Pakistan 18 May 2004 3 Nov 2004 
Palau 16 Jun 2003 12 Feb 2004 
Panama 26 Sep 2003 16 Aug 2004 
Papua New Guinea 22 Jun 2004 25 May 2006 
Paraguay 16 Jun 2003 26 Sep 2006 
Peru 21 Apr 2004 30 Nov 2004 
Philippines 23 Sep 2003 6 Jun 2005 
Poland 14 Jun 2004 15 Sep 2006 
Portugal 9 Jan 2004 8 Nov 2005 AA
Qatar 17 Jun 2003 23 Jul 2004 
Republic of Korea 21 Jul 2003 16 May 2005 
Republic of Moldova 29 Jun 2004 3 Feb 2009 
Romania 25 Jun 2004 27 Jan 2006 
Russian Federation 3 Jun 2008 a
Rwanda 2 Jun 2004 19 Oct 2005 
Samoa 25 Sep 2003 3 Nov 2005 
San Marino 26 Sep 2003 7 Jul 2004 
Sao Tome and Principe 18 Jun 2004 12 Apr 2006 
Saudi Arabia 24 Jun 2004 9 May 2005 
Senegal 19 Jun 2003 27 Jan 2005 
Serbia 28 Jun 2004 8 Feb 2006 
Seychelles 11 Sep 2003 12 Nov 2003 
Sierra Leone 22 May 2009 a
Singapore 29 Dec 2003 14 May 2004 
Slovakia 19 Dec 2003 4 May 2004 
Slovenia 25 Sep 2003 15 Mar 2005 
Solomon Islands 18 Jun 2004 10 Aug 2004 
South Africa 16 Jun 2003 19 Apr 2005 
Spain 16 Jun 2003 11 Jan 2005 
Sri Lanka 23 Sep 2003 11 Nov 2003 
Saint Kitts and Nevis 29 Jun 2004 21 Jun 2011 
Saint Lucia 29 Jun 2004 7 Nov 2005 
Saint Vincent and the Grenadines 14 Jun 2004 29 Oct 2010 
Sudan 10 Jun 2004 31 Oct 2005 
Suriname 24 Jun 2004 16 Dec 2008 
Sweden 16 Jun 2003 7 Jul 2005 
Switzerland 25 Jun 2004 
Syrian Arab Republic 11 Jul 2003 22 Nov 2004 
Tajikistan 21 Jun 2013 a
Thailand 20 Jun 2003 8 Nov 2004 
Timor-Leste 25 May 2004 22 Dec 2004 
Togo 12 May 2004 15 Nov 2005 
Tonga 25 Sep 2003 8 Apr 2005 
Trinidad and Tobago 27 Aug 2003 19 Aug 2004 
Tunisia 22 Aug 2003 7 Jun 2010 
Turkey 28 Apr 2004 31 Dec 2004 
Turkmenistan 13 May 2011 a
Tuvalu 10 Jun 2004 26 Sep 2005 
Uganda 5 Mar 2004 20 Jun 2007 
Ukraine 25 Jun 2004 6 Jun 2006 
United Arab Emirates 24 Jun 2004 7 Nov 2005 
Table 5.1 
Status of the WHO 
Framework Convention  
on Tobacco Control as  
at 1 June 2021 (continued)
*  Ratification is the international act by which countries that 
have already signed a treaty or convention formally state their 
consent to be bound by it.
a  Accession is the international act by which countries that have 
not signed a treaty/convention formally state their consent to 
be bound by it.
A  Acceptance is the international act, similar to ratification, by 
which countries that have already signed a treaty/convention 
formally state their consent to be bound by it.
AA  Approval is the international act, similar to ratification, by 
which countries that have already signed a treaty/convention 
formally state their consent to be bound by it.
c  Formal confirmation is the international act corresponding to 
ratification by a State, whereby an international organization 
(in the case of the WHO FCTC, competent regional economic 
integration organizations) formally state their consent to be 
bound by a treaty/convention.
d  Succession is the international act, however phrased or 
named, by which successor States formally state their consent 
to be bound by treaties/conventions originally entered.
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COUNTRY DATE OF SIGNATURE DATE OF RATIFICATION* 
(OR LEGAL EQUIVALENT)
United Kingdom of Great Britain  
and Northern Ireland
16 Jun 2003 16 Dec 2004 
United Republic of Tanzania 27 Jan 2004 30 Apr 2007 
United States of America 10 May 2004 
Uruguay 19 Jun 2003 9 Sep 2004 
Uzbekistan 15 May 2012 a
Vanuatu 22 Apr 2004 16 Sep 2005 
Venezuela (Bolivarian Republic of) 22 Sep 2003 27 Jun 2006 
Viet Nam 3 Sep 2003 17 Dec 2004 
Yemen 20 Jun 2003 22 Feb 2007 
Zambia 23 May 2008 a
Zimbabwe 4 Dec 2014 a
Source: United Nations Treaty Collection web site https://treaties.un.org/pages/ViewDetails.aspx?src=TREATY&mtdsg_no=IX-
4&chapter=9&clang=_en, accessed 11 June 2021).
Though not a Member State of WHO, as a Member State of the United Nations, Liechtenstein is also eligible to become Party to the WHO 
FCTC, though it has taken no action to do so.
On submitting instruments to become Party to the WHO FCTC, some Parties have included notes and/or declarations. All notes can be viewed 
at https://treaties.un.org/pages/ViewDetails.aspx?src=TREATY&mtdsg_no=IX-4&chapter=9&clang=_en
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Table 5.2 
Status of the Protocol to 
Eliminate Illicit Trade in 
Tobacco Products as at  
1 June 2021
*  Ratification is the international act by which countries that 
have already signed a treaty or convention formally state their 
consent to be bound by it.
a  Accession is the international act by which countries that have 
not signed a treaty/convention formally state their consent to 
be bound by it.
A  Acceptance is the international act, similar to ratification, by 
which countries that have already signed a treaty/convention 
formally state their consent to be bound by it.
AA  Approval is the international act, similar to ratification, by 
which countries that have already signed a treaty/convention 
formally state their consent to be bound by it.
c  Formal confirmation is the international act corresponding to 
ratification by a State, whereby an international organization 
(in the case of the WHO FCTC, competent regional economic 
integration organizations) formally state their consent to be 
bound by a treaty/convention.
d  Succession is the international act, however phrased or 
named, by which successor States formally state their consent 
to be bound by treaties/conventions originally entered.
COUNTRY DATE OF SIGNATURE DATE OF RATIFICATION* 
(OR LEGAL EQUIVALENT)
Austria 9 Jan 2014 28 Oct 2014
Belgium 17 May 2013 22 Feb 2019
Benin 24 Sep 2013 6 Jul 2018
Botswana 1 Oct 2013
Brazil 14 Jun 2018 a
Burkina Faso 8 Mar 2013 30 Mar 2016
Cabo Verde 16 Oct 2019 a
Chad 13 Jun 2018 a
China 10 Jan 2013
Colombia 21 Feb 2013
Comoros 14 Oct 2016 a
Congo 14 May 2015 a
Costa Rica 21 Mar 2013 7 Mar 2017
Côte d'Ivoire 24 Sep 2013 25 May 2016
Croatia 10 Jun 2019 a
Cyprus 23 Oct 2013 29 Aug 2017
Czechia 12 Jul 2019 a
Democratic Republic of the Congo 9 Dec 2013
Denmark 7 Jan 2014
Ecuador 25 Sep 2013 15 Oct 2015
Egypt 10 Sep 2020 a
Eswatini 21 Sep 2016 a
Fiji 11 Jul 2013 24 Apr 2019
Finland 25 Sep 2013
France 10 Jan 2013 30 Nov 2015
Gabon 10 Jan 2013 1 Oct 2014 A
Gambia 26 Sep 2016 a
Germany 1 Oct 2013 31 Oct 2017
Ghana 24 Sep 2013
Greece 9 Jul 2013 24 May 2021
Guinea 9 May 2017 a
Guinea-Bissau 24 Sep 2013
Hungary 23 Jun 2020 a
India 5 Jun 2018 a
Iran (Islamic Republic of) 7 Jan 2014 27 Aug 2018
Iraq 2 Dec 2015 a
Ireland 20 Dec 2013
Israel 23 Dec 2013
Kenya 29 May 2013  4 May 2020
Kuwait 11 Nov 2013 21 Feb 2019
Latvia 4 Feb 2016 a
Libya 10 Jan 2013
Lithuania 6 Sep 2013 14 Dec 2016
Luxembourg 25 Jul 2019 a
Madagascar 25 Sep 2013 21 Sep 2017
Mali 8 Jan 2014 17 Jun 2016
Malta 2 Aug 2018 a
Mauritius 26 Jun 2018 a
Mongolia 1 Nov 2013 8 Oct 2014
Montenegro 1 Jul 2013 11 Oct 2017
Myanmar 10 Jan 2013
Netherlands 6 Jan 2014 3 Jul 2020 A
Nicaragua 10 Jan 2013 20 Dec 2013
Niger 12 Jul 2017 a
Nigeria 8 Mar 2019 a
North Macedonia 8 Jan 2014
Norway 16 Oct 2013 29 Jun 2018
Pakistan 29 Jun 2018 a
Panama 10 Jan 2013 23 Sep 2016
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COUNTRY DATE OF SIGNATURE DATE OF RATIFICATION* 
(OR LEGAL EQUIVALENT)
Portugal 8 Jan 2014 22 Jul 2015
Qatar 18 Jun 2013 2 Jul 2018
Republic of Korea 10 Jan 2013
Samoa 29 Jun 2018 a
Saudi Arabia 9 Oct 2015 a
Senegal 31 Aug 2016 a
Serbia 30 Jun 2017 a
Seychelles 7 Jan 2020 a
Slovakia 25 Sep 2017 a
Slovenia 6 Jan 2014
South Africa 10 Jan 2013
Spain 23 Dec 2014 a
Sri Lanka 8 Feb 2016 a
Sudan 30 Sep 2013
Sweden 6 Jan 2014 9 Jul 2019
Syrian Arab Republic 10 Jan 2013
Togo  9 Jan 2014 31 Jan 2018
Tunisia 11 Jan 2013
Turkey 10 Jan 2013 26 Apr 2018
Turkmenistan 30 Mar 2015 a
United Kingdom of Great Britain  
and Northern Ireland
17 Dec 2013 27 Jun 2018
United Republic of Tanzania 24 Sep 2013
Uruguay 10 Jan 2013 24 Sep 2014
Yemen 7 Jan 2014
Source: United Nations Treaty Collection web site https://treaties.un.org/pages/ViewDetails.aspx?src=IND&mtdsg_no=IX-4-
a&chapter=9&clang=_en, accessed 11 June 2021).
On submitting instruments to become Party to the Protocol to Eliminate Illicit Trade in Tobacco Products, some Parties have included 
notes and/or declarations. All notes can be viewed at https://treaties.un.org/pages/ViewDetails.aspx?src=IND&mtdsg_no=IX-4-
a&chapter=9&clang=_en 
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